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1GENERAL INTRODUCTION
Breast cancer patients are faced with several, often complex, treatment decisions shortly after 
diagnosis. Decisions that are of great impact on a woman her life course. The cornerstone of the 
treatment of breast cancer is surgery. Although high survival rates are achieved in breast cancer 
surgery, irrespective of the type of surgery performed, breast cancer surgery can adversely affect 
women’s psychological health and health-related quality of life outcomes. Anticipation of long-
term physical, sexual, and psychosocial outcomes is therefore vitally important in treatment deci-
sion-making. In the heat of the healthcare evolution into a more value-based healthcare, this thesis 
provides insight into obtaining, measuring and improving outcomes that matters most to breast 
cancer patients. To explain the title of this thesis; the ‘bril’ (Dutch for glasses) in brilliance is a met-
aphor for the look at the care delivered from the patient’s perspective, striving for patient-centred 
care and more tailor-made treatment, and is furthermore a nod to the three-dimensional glasses 
that were used in the trials described in this thesis. 
Breast cancer 
The breast, a mass of lobes, ducts, glandular, adipose and fibrous tissues, is an organ whose 
structures reflect the special function of lactation. Moreover is the breast part of the female body 
image and serves as a female sexual characteristic. The breast contour, shape, density, volume, 
and symmetry varies substantially between individuals. Breast cancer is the most common cancer 
affecting women worldwide1. Even so in the Netherlands, where 1 in 8 women are diagnosed with 
breast cancer during her lifetime2. Over the past year, survival has been increased, which is asso-
ciated with a decrease in mortality through improved breast cancer therapy and early detection3. 
In Europe, breast cancer patients have a five-year survival of over 80%3, with rates exceeding 96% 
for stage I and 86% for stage II breast cancer4 5. Female sex, increasing age, reproductive factors, 
personal or family history of breast and/or ovarian disease, and genetic predisposition are estab-
lished risk factors for breast cancer6 7. A positive family history of breast cancer is the most widely 
recognized risk factor, particularly if it applies first-degree relatives diagnosed before the age of 
50 years8. This often reflects the inheritance of a pathogenic BRCA1 or BRCA2 gene mutation, 
which increases the lifetime risk of developing breast cancer up to, respectively, 81% and 85%9-11. 
Among women younger than 40 years sporadic breast cancer is relatively uncommon but increas-
es significantly thereafter12. The bimodal pattern of age, with a first peak at about 50 years and a 
second peak at 70 years, reflects the influence of age within the different subtypes; high-grade, 
poorly differentiated, disease tend to occur earlier, whereas slow-growing, hormone-sensitive, 
tumours tend to occur at a more advanced age. Today, due to improved diagnostic imaging, 
women are frequently diagnosed with non-invasive breast cancer (ductal or lobular carcinoma in 
situ) and early-stage invasive breast cancer (stage I-III). Since the latter are relatively small, mostly 
node-negative breast tumours, early-stage breast cancer is a potential curable disease and allows 
for less invasive treatment options. 
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1 Evolution of breast cancer workup
Nowadays, breast cancer workup includes a combination of clinical examination, imaging, and 
cytopathological and/or histopathological evaluation. Mainly early breast carcinomas are asymp-
tomatic. Breast cancer is often first detected on a mammogram. In case of a palpable mass or 
suggestive lesion on the mammogram, additional breast ultrasonography is performed, sometimes 
along with a biopsy to complete the diagnostics. If indicated additional imaging is performed to 
detect possible metastasis, such as ultrasonography of the (ipsilateral) axilla, breast MRI and/
or an FDG-PET or CT-scan of the thorax and abdomen in combination with bone scintigraphy. If 
chemotherapy is given prior to surgery the tumour response is evaluated using breast MRI. 
In general, non-metastasized breast cancer is treated by local surgical intervention. Breast cancer 
surgery has improved substantially over the past decades. Up to the 1980s, the standard treat-
ment was the (modified) radical mastectomy (i.e. removal of all breast tissue), regardless of the 
stage of the disease. Gradually, the question arose whether the breast could be preserved without 
compromising for survival. Several randomised trials trying to answer that question followed and 
have shown that breast-conserving therapy (BCT, i.e. breast-conserving surgery (BCS) followed 
by whole breast radiotherapy) is as effective as mastectomy for treatment of breast tumours <5 
cm13-17. Long-term results of these trials have shown equal survival rates for BCT and mastectomy 
in early-stage breast cancer patients18-21. A recent population-based study amongst T1-2N0-2M0 
breast cancer patients in the Netherlands has even shown a superior breast cancer-specific 
survival and overall survival for BCT patients compared to mastectomy (after correction for all 
identifiable confounders)22. Considering the at least comparable prognosis in early-stage breast 
cancer after BCT and mastectomy, quality of life should be a focus in treatment decision-making. 
To improve local control and survival, regional or locoregional radiotherapy, and/or (neoadjuvant) 
systemic therapy, including chemotherapy, antihormonal therapy or targeted therapy may be indi-
cated. Presently, breast reconstruction is considered an important step in breast cancer care as it 
not only creates a new breast but restores a woman’s body image and quality of life, while reducing 
the psychological anxiety that a mastectomy procedure causes23-25. Breast reconstruction is either 
applied at the time of mastectomy (immediate breast reconstruction), or at a given point in time 
after surgery (delayed breast reconstruction). The choice between immediate, delayed, and no 
breast reconstruction is determined by clinical and treatment characteristics as well as by patients’ 
preferences. 
International guidelines state that goals of breast cancer follow-up care are to detect recurrent 
disease or new malignancies at an early-stage and to detect and intervene in physical and psy-
chosocial (late) effects of therapy26-29. Schemes for detecting recurrences often comprise annual 
physical and mammographic examinations for at least five years, depending on the patient’s age, 
genetic predisposition, and tumour characteristics. Follow-up care also aims to detect and man-
age (late) effects of treatments28 29. 
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1Value-based healthcare and outcome measurement
Both the increased incidence of breast cancer and improved breast cancer survival rates have 
resulted in a rising prevalence of women with breast cancer. This brings new challenges to the 
medical community, as breast cancer and its treatment can negatively affect the physical-, psy-
chological- and social wellbeing of patients, both during treatment as well as in the long-term after 
treatment completion. Ideally, a patient-specific fit between patient and disease characteristics 
and the proposed treatment strategy should be strived for, choosing the least invasive therapy as 
possible while maintaining optimal cancer control. In this way, overtreatment, as well as under-
treatment, may be avoided. With the increased knowledge regarding specific treatment modalities 
for different sub-groups of patients, more personalized treatment of breast cancer patients can 
be achieved. Over recent years, a shift from a more generic approach of care towards a more 
patient-centred approach of care has been seen30. With patients-centred care, cancer care has 
become more focused on the individual needs of breast cancer patients, both in clinical as in 
personal values30. This patients-centred provision of care is the potential of the foundation of val-
ue-based healthcare (VBHC). VBHC aims to improve the quality of the care delivered by measuring 
and improving outcomes that reflect value instead of volume. Value of care is defined as health 
outcomes per total costs31. Since the value in healthcare depends on results, not inputs, value 
is measured by the outcomes achieved and not the volume of services delivered. Ideally, these 
outcomes reflect patient-orientated results instead of structure or process measures that do not 
always reflect the results obtained. In a VBHC-design, outcomes are both provider reported (i.e. 
breast cancer survival, complications, and hospitalization rates) and patient-reported (PROs)31. 
Inherently, these outcomes are disease-specific and multidimensional to reflect the total cycle 
of care and quality of life and disease burden in the long run32 33. To measure PROs, validated 
questionnaires can be used, called patient-reported outcome measures (PROMs). PROMs are 
targeted at either a diseased population in specific or at the population in general. The first is used 
in comparison across conditions, while the latter is more applicable to general aspects of health 
and wellbeing34. PROMs can be used to measure in absolute terms, such as patient’s ratings of 
the severity of pain, but can also be used to report changes from a previous measure such as a 
new onset of symptoms following chemotherapy. The patient perspective provides a more holistic 
interpretation and a comprehensive assessment of the benefits of the treatment when compared 
to survival rates and disease outcomes. For example, BCS followed by radiotherapy (BCT) may 
demonstrate good clinical outcomes in terms of locoregional control and breast cancer-free 
survival, while PROs may identify that breast cancer patients are non-compliant with BCT due to 
reported adverse side effects, intensity of the daily sessions of radiotherapy, and/or a poor quality 
of life. The effectiveness of therapy, therefore, has many dimensions, including clinical effective-
ness as well as the benefit felt by patients as a direct result of having that specific therapeutic 
intervention34. Specifically in the care for (early-stage) breast cancer patients, the importance of 
value is increasingly being recognized. Considering the excellent and comparable oncological 
outcomes and multiple locoregional strategies available, all with different outcomes and costs, 
there is an increasing need for outcome measurements that accurately differentiate between 
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1 treatment strategies. PROM results can be discussed at the outpatient clinic, during consultations, 
aiming to detect possible health problems that may require further attention. On the other hand, 
can PROMs also be applied for benchmarking, as routine PROM assessments can reflect the daily 
care delivered, giving an insight into the effectiveness of care. This insight into a health institution’s 
performance allows providers to improve their quality of care. In the era of increasing healthcare 
costs and stringent measures to lower costs, these outcomes could increase breast cancer care 
efficacy, and in addition, could add in future treatment decision-making and/or follow-up regimes.
OUTLINE OF THIS THESIS
The general aim of this thesis is to investigate facilities to obtain, measure and improve outcomes 
that matter most to breast cancer patients. In Part I the focus lies on a new and more patient 
friendly imaging tool used in the preoperative, neoadjuvant, setting. In Part II the focus lies on 
outcome measurement and improvement. Health-related quality of life outcomes regarding breast 
cancer and BRCA1 and BRCA2 gene mutation are evaluated using PROMs. Furthermore, the 
implementation of a VBHC-strategy is described. Part III focusses on shared decision-making in 
breast cancer follow-up care. To complete this section an overview is given of delayed breast re-
constructive surgery within the Netherlands using a population-based cohort. PROs and patients’ 
experiences were the main sources of information, putting the patient’s perspective at the heart 
of this thesis.
Part I – New breast imaging in tumour response evaluation
Part I of this thesis investigates three-dimensional ultrasonography in breast cancer diagnostics 
striving to implement diagnostic tools that are minimally burdensome for patients. In Chapter 2 
the Automated Breast Volume Scanner (ABVS – ACUSON S2000TM, Siemens Medical Solutions) 
is studied for its accuracy for the radiological tumour response evaluation in breast cancer patients 
who are treated with neoadjuvant chemotherapy (NAC). In this feasibility study, both tumour diam-
eter response and tumour volume responses were evaluated using the (3D) ABVS and compared 
to (3D) breast MRI, which is considered the gold standard. Additionally, patients’ acceptability for 
ABVS versus breast MRI was evaluated. 
Part II – Patient-reported outcome measures
Considering the at least equal oncological outcomes in early-stage breast cancer patients, irre-
spective of the type of surgery performed, outcomes reflecting the (long-term) quality of life are 
increasingly important in this group. Therefore the focus in this part lies particularly on early-stage 
breast cancer patients. Strategies to measure, interpret and improve PROs are evaluated striving 
to accurately differentiate between different locoregional therapies. The International Consortium 
for Health Outcomes Measurement (ICHOM) assembled a multidisciplinary international working 
group that developed a standard set of value-based patient-centred outcomes (PROMs) for breast 
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1cancer. Within this set PROMs are pivotal, accounting for 75% of outcomes. The other 25% is 
related to clinical outcomes. In Chapter 3 PROMs as proposed in the ICHOM standard set for 
breast cancer were administered to breast cancer patients through both regional and national 
patients’ advocate society. Satisfaction and applicability of PROMs were evaluated in addition. 
Chapter 4 describes the evaluation of PROMs in breast cancer patients surgically treated in the 
Erasmus MC Cancer Institute between January 2005 and August 2016. Striving to obtain reference 
scores for the PROMs used, the relation between PROM scores and patient-, tumour and treat-
ment characteristics were evaluated. Chapter 5 describes the way a value-based breast cancer 
strategy, including explicit and longitudinal PROMs, was implemented within the Academic Breast 
Cancer Centre of the Erasmus MC Cancer Institute. The outline describes both the development 
and implementation of this initiative, and is meant as a guide for future implementations. It is found 
that PROMs have been collected and advocated most often in breast cancer patients35. However, 
reviews focusing on methods of PROM administration in specifically breast cancer care has not 
been published. Therefore, a systematic review was performed. This review, described in Chapter 
6, provides an overview of PROM collection methods in breast cancer care, giving answer on how 
PROMs are administered and on what the impact of this administration is on patients, healthcare 
providers, and health services or processes. Moreover are facilitators and barriers influencing the 
integration of PROM collection in breast cancer clinical practice evaluated. Little has been done to 
predict PROs into the future. Therefore, the feasibility of predicting PROs following breast cancer 
surgery using machine learning techniques is explored in Chapter 7. 
VBHC embodies outcomes that are disease-specific and multidimensional and reflect the total 
cycle of care. Naturally, this also regards the women at risk. Women with a pathogenic mutation in 
the BRCA1 or BRCA 2 gene have a cumulative breast cancer risk to 80 years of 72% and 69% re-
spectively9. For managing breast cancer risk BRCA1/2 gene mutation carriers are offered intensive 
breast surveillance aimed at early detection of breast cancer, or bilateral prophylactic mastectomy 
(BPM) aimed at preventing breast cancer. It was hypothesized that PROs differ between women 
choosing for BPM and women choosing for breast surveillance. The aim in Chapter 8 was to 
explore (differences in) PROs of BRCA1/2 gene mutation carriers after either BPM followed by an 
immediate breast reconstruction or during breast surveillance to optimize shared decision-making 
in cancer risk management. In this pilot-study, PROs are collected amongst BRCA1/2 gene muta-
tion carriers diagnosed within the Erasmus MC Cancer Institute.
Part III – Follow-up care and delayed breast reconstructions
Within the last part of this thesis the focus lies on the period after the initial treatment of breast can-
cer. Further personalization of the follow-up care may be preferred to meet the individual patient’s 
needs. As treatment strategies depends on patient and tumour characteristics, it is expected 
that the prevalence and severity of treatment-related health problems vary between patients. To 
move towards more personalized follow-up care in breast cancer, in Chapter 9 the evidence on 
preferences-sensitive decisions and patient involvement in decisions about breast cancer follow-
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1 up is reviewed. Although most decisions about breast reconstructions are made before surgical 
treatment, sometimes this decision is delayed until after treatment. In Chapter 10 a nationwide 
population-based study is performed striving to provide an overview of the application of delayed 
breast reconstructions in patients with early-stage breast cancer in the Netherlands. 
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Accurate measurement of tumour response during and after neoadjuvant chemotherapy (NAC) is 
important and may influence treatment decisions in invasive breast cancer patients. Breast MRI 
forms the gold standard but is more burdensome, time consuming and costly. In this study re-
sponse measurement was done with 3-D ultrasound by Automated Breast Volume Scanner (ABVS) 
and compared to breast MRI. Moreover, patient satisfaction with both techniques was compared. 
Methods and materials 
A single-institution, prospective observational pilot study evaluating tumour response by ABVS 
in addition to breast MRI (standard care) was performed in 25 invasive breast cancer patients 
receiving NAC. Tumour response was evaluated comparing longest tumour diameters as well as 
tumour volumes at predefined time points using Bland-Altman analysis. Volume measurements 
for breast MRI were obtained using a fully immersive virtual reality system (a Barco I-Space) and 
V-Scope software. Same software was used to obtain ABVS volume measurements using an 
in-house developed desktop VR system. Inter- and intra-observer agreement was evaluated by 
Intraclass Correlation Coefficient (ICC). 
Results 
Twenty-five patients were eligible for baseline measurement, 20 for a mid-NAC response evalua-
tion, and five for a post-NAC response evaluation. MRI and ABVS showed absolute concordance 
in 73% of patients for the mid-NAC evaluation, with a ‘good’ correlation for the difference in long-
est diameter measurement (ICC 0.73, p<0.01) as compared to baseline assessment. Concerning 
difference in volume measurement in the mid-NAC response evaluation showed a ‘fair’ correlation 
(ICC 0.52, p<0.01) and in the post-NAC response evaluation an ‘excellent’ correlation (ICC 0.98, 
p<0.01). ‘Excellent’ inter- and intra-observer agreement was found (ICC 0.88, p<0.01) with com-
parable limits of agreement (LOA) for observer 1 and 2 in both diameter and volume measurement. 
Patient satisfaction was higher for ABVS compared to breast MRI, 93% versus 12% respectively. 
Conclusion
ABVS showed ‘good’ correlation with MRI tumour response evaluation in breast cancer patients 
during NAC with ‘excellent’ inter- and intra-observer agreement. ABVS has patients’ preference 
over breast MRI and could be considered as alternative to breast MRI, in case results on an 
on-going prospective trial confirm these results (NTR6799).
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2
INTRODUCTION
The use of neoadjuvant chemotherapy (NAC) for invasive breast cancer patients has increased in 
the Netherlands from 13% (6,262/49,073) in 2011-2014 to 20% in 20171. Systemic therapy can be 
administered preoperatively to downstage a tumour and allow for less extensive breast surgery. 
NAC generates the ability of in vivo response evaluation2. Tumour response evaluation therefore 
directly influences treatment decisions, i.e. immediate surgery or change of regime in case of 
progression. 
Internationally tumour response is evaluated according to ‘Response Evaluation Criteria in 
Solid Tumours’ (RECIST)3, stating that tumour responses should be evaluated by changes in the 
longest diameter of the (pre-specified) target lesion(s). Magnetic resonance imaging (MRI) is the 
preferred modality to evaluate longest tumour diameter and considered gold standard3. Reported 
concordance for tumour size measured by MRI or on histopathological specimen however varies 
in studies of breast cancer patients with2 4-7 and without NAC8 9. 
RECIST does not support handheld 2-D ultrasonography (US) response evaluation since it is an 
observer-dependent modality 3. Although currently not recommended, we hypothesized that whole 
breast ultrasound with standardized imaging, the Automated Breast Volume Scanner (ABVS), can 
be applied for breast cancer response evaluation.
ABVS is an observer-independent automated standardized ultrasound imaging technique with ac-
cess to images at any point in time10. ABVS was more accurate than handheld 2-D US in predicting 
histological tumour size10-13. ABVS has the opportunity to calculate volume using 3-D ABVS imag-
ing software, quite similar to MRI with 3-D MRI imaging software. A previous 3-D ABVS volume 
study within our institute showed an excellent association with histopathological tumour volume14. 
Multiple studies showed that tumour volume response (using 3-D MRI) mid and post NAC showed 
higher correlation with histopathologic tumour regression compared to diameter response15-17. We 
hypothesized that tumour volume response could be a more accurate than diameter response.
ABVS is known to be advantageous over breast MRI with regard to cost, time, ease of interpre-
tation by multiple clinicians, accessibility and avoidance of contrast agents18-20. We questioned 
whether the ABVS is as accurate as breast MRI and performed a feasibility study. Tumour diameter 
response as well as tumour volume response evaluation was done by ABVS and compared to 
breast MRI at predefined time points with two independent observers. Moreover, patient satisfac-
tion was measured. 




This prospective observational pilot study was conducted at the Academic Breast Cancer Centre/
Erasmus MC Cancer Institute, Rotterdam the Netherlands. Twenty-five patients were included from 
October 2015 to October 2017. Approval of the medical ethics committee was obtained prior to start 
of the study (MEC 2015-647). Women aged over 18 years, scheduled to undergo NAC and after writ-
ten informed consent were eligible. Patients with cT4 breast cancer were excluded, because lesions 
growing outside breast tissue (i.e. chest wall or skin) cannot be discriminated by ultrasonography 
precisely enough. Lesions were classified according to the TNM classification system (7th edition)21. 
Tumour differentiation grade was assessed at time of final histopathological evaluation or in pre-NAC 
biopsies in case of pathological complete response. Surrogate subtypes were defined according 
to the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer22.
Study procedures
Breast MRI and 3-D breast MRI
Dynamic contrast-enhanced breast MRI was performed on a 1.5 T system (Siemens Medical Solu-
tions – Erlangen, Germany), with the patient prone in a dedicated breast coil. Pre-contrast injection 
imaging protocol included a low resolution localizing sequence, a transversal T2-weighted fat-sup-
pressed (FS) sequence (TE/TR 42/67000, FOV 34 cm, slice thickness 5.0 mm, matrix 32 x 224). 
Than a pre- and post-contrast injection (with intravenous 7.5 cc Gadovist or 15 cc ProHance, 2 cc/s) 
VIBRANT (T1) transversal 3-D sequence were performed (TE/TR 1.0/34, FOV 34 cm, slice thickness 
2.2 mm, flip angle 10°, matrix 388 x 388), and a final post-contrast sagittal VIBRANT sequence (TE/
TR 1.0/34, FOV 34 cm, slice thickness 3 mm, flip angle 10°, matrix 388 x 388). All patients were in-
vestigated in prone position with breast pending in a dedicated double breast surface coil. Premeno-
pausal women were scanned on day 5-15 of the menstrual cycle. Subtraction images were obtained 
with the use of a software subtraction function. All MRI examinations were evaluated on a dedicated 
breast MRI workstation. Longest tumour diameter measurements were based on the dynamic T1 w 
sequences using digital rulers on the imaging workstation. For volume measurements on 3-D MRI 
a fully immersive virtual reality system (a Barco, Kuurne Belgium) I-Space was used. The Erasmus 
MC was the first university medical centre to install this system in which data can be visualized and 
manipulated using virtual reality, details of which have been described elsewhere23-25. The breast 
is projected as a hologram viewed with 3-D glasses and the observer can select the region of the 
breast with the targeted lesion. The selected image can be sized, turned and cropped with a wireless 
joystick (Online video I-Space)24. The driving V-scope software was developed by the department of 
Bioinformatics23 and enables calculation of volume based on differences in grey-levels25.
RESPONDER trial − 27
2
Using the V-scope software, specific thresholds for the grey-level of the voxels can be chosen to 
calculate the volume. Longest diameter measurements are obtained by measuring the distance 
between two specified points in a 3-D space. 
ABVS and 3-D ultrasonography
The ABVS (Siemens ACUSON S2000TM) is designed to acquire ultrasound images using a linear 
transducer that scans the entire breast in an automated fashion10. The resulting volume can be eval-
uated in three imaging-planes simultaneously (i.e. axial, coronal and sagittal plane) and measured 
repeatedly off-line. The transducer scans volume slabs while acquiring 0.5 mm thick images in the 
transverse plane10. The whole examination takes about 10 min. For ABVS, digital rulers were used to 
measure the longest tumour diameter, using the ABVS workstation. The measure the longest tumour 
diameter has to be obtained. The V-Scope software as used in the I-Space was also used for the 
3-D visualization of ABVS data on a desktop system (further defined as 3-D ABVS). Volume was 
measured based on differences in echogenicity similarly to the measurement in the 3-D MRI, Fig. 1.
Figure 1. Example of the ABVS used for response evaluation, compared to breast MRI.
a)  Transversal coupes of breast-MRI scans of the right breast. The left picture shows the tumour (coloured 
green) pre-NAC. The right picture shows the same patient mid-NAC with a smaller tumour (coloured green). 
b)  Frontal view (anterior-posterior) of the right breast. The left picture shows the tumour (upper left corner) pre-
NAC. The right picture shows the same patients mid-NAC with a smaller tumour (upper left corner). 
28 − Chapter 2
2
Response evaluation
According to standard care all patients underwent breast MRI prior to NAC and a second MRI 
following 3 courses of chemotherapy (mid-NAC), Fig. 2. If applicable a final MRI was obtained 
preoperatively after the completion of NAC (post-NAC) (Fig. 2). Only if the breast MRI showed 
residual tumour ABVS was applied. 
Figure 2. Flow chart patient inclusion and response evaluation.
NAC = Neo-adjuvant chemotherapy. US = ultrasonography
Response was calculated as percentage difference compared to baseline assessment (pre-NAC). 
Response was evaluated comparing the longest diameters using both breast MRI and ABVS. 
Additionally, response was evaluated by comparing the tumour volumes using both the 3-D MRI 
and 3-D ABVS. Changes in the RECIST criteria (Supplementary Table S1) were evaluated compar-
ing the longest diameter of the breast MRI to the longest diameter using ABVS. Response was 
measured mid-NAC and post-NAC (if applicable). 
Readings
Two observers performed repetitive measurements under identical conditions evaluating both 
tumour diameter and volume. The time-interval between two identical measurements was at least 
3 months. To evaluate the intra-observer and inter-observer agreement for both the mid-NAC and 
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post-NAC response evaluation all diameter responses were performed twice using the ABVS. 
Tumour diameter measurements on MRI were only evaluated by a radiologist. To evaluate the 
intra-observer and inter-observer agreement of the tumour volume response evaluation all meas-
urements were performed twice using the ABVS and the MRI.
Patient satisfaction
Patient satisfaction, i.e. acceptability for breast MRI and ABVS, was measured with the use of rat-
ing scale following the Likert Scale principle26 (Supplementary Fig. S1). Acceptability was scored 
on a 5-point scale (i.e. 5 resembles a ‘high acceptability’, 4 ‘acceptable’, 3 ‘neutral’, 2 ‘moderately 
acceptable’ and 1 being ‘not acceptable’). The acceptability questionnaire was administered to all 
patients during all the study visits. 
Statistical analysis 
Longest diameter response was scored based on the RECIST guidelines (PD >20% increase, SD 
<20% increase to < 30% decrease, PR >30% decrease in longest diameter and CR if no tumour 
is visible), see Supplementary Table S1. Response evaluations using (3-D) MRI were compared to 
(3-D) ABVS by calculating the Intraclass Correlation Coefficient (ICC), which determines the variation 
between the clusters as a proportion of the total variance. The level of clinical significance evidence of 
the ICC was judged according to Cichetti and colleagues; an ICC of <0.40 was rated as ‘Poor’, ICC of 
0.40-0.59 as ‘Fair’, ICC of 0.60-0.74 as ‘Good’ and ICC of 0.74-1.00 as ‘Excellent’27. The longest diam-
eter and volume response obtained by (3-D) MRI were compared to the longest diameter and volume 
response obtained by (3-D) ABVS (both in observer 1 and 2). Intra-observer agreement was evaluated 
comparing the first and second (3-D) ABVS measurement for longest diameter and tumour volume. 
Bland-Altman plots were used to graphically display the pairwise agreement in measuring the lesion 
size reduction (% longest diameter decrease) by breast MRI and ABVS. Agreement was expressed as 
the average difference in measurements together with 95% limits of agreement (LOA), i.e. the range of 
agreement within 95% of the difference between the measurements28. A p value ≤0.01 was considered 
statistically significant. Data analyses were performed using IBM SPSS Statistics (version 21).
RESULTS
Twenty-five patients undergoing NAC were eligible for participation in the study. In three patients 
the tumour was not visible on ultrasonography, resulting in 22 patients eligible for evaluation (Fig. 2). 
Patient and tumour characteristics are shown in Table 1. All carcinomas evaluated were invasive ductal 
carcinomas. MRI showed an average longest diameter of 27.5 mm, 17.0 mm and 17.0 mm for the 
pre-NAC, mid-NAC and post-NAC evaluation (Table 2). This was 21.6 mm, 14.4 mm and 23.5 mm re-
spectively using ABVS (observer 1). Tumour volume in MRI was 3.8 cm3, 0.7 cm3, 1.0 cm3 respectively 
for the first observer pre-NAC, mid-NAC and post-NAC (Table 2). Using 3-D ABVS tumour volume was 
2.5 cm3, 1.0 cm3 and 1.6 cm3 respectively for the first observer pre-NAC, mid-NAC and post-NAC.
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Table 1. Baseline characteristics of 25 eligible patients, n (%). 




Invasive ductal carcinoma 25 (100)






Luminal A 8 (32.0)
Luminal B 6 (24.0)









Not applicable* 7 (28.0)
ypT-stage










SNB = sentinel lymph node biopsy, itc = isolated tumour cells, 
pNstage = pathological nodal stage, ypTstage = histopathological 
tumour stage following NAC, ypNstage = histopathological nodal 
stage following NAC, micro = micro metastasis, 
*If by histopathological or cytopathological biopsy a lymph node me-
tastasis is diagnosed no pre-NAC SNB was performed.
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MRI (radiologist) 27.5 (18.8-34.0) 17.0 (10.0-28.5) 17.0 (9.0-29.0)
ABVS (observer 1) 21.6 (16.2-32.3) 14.4 (11.0-23.5) 23.5 (12.8-31.4)
ABVS (observer 2) 23.1 (16.0-32.1) 15.9 (11.1-23.5) 26.2 (14.0-32.9)
Tumour volume (cm3)
3-D MRI (observer 1) 3.8 (2.7-7.0) 0.7 (0.5-2.6) 1.0 (0.5-10.8)
3-D MRI (observer 2) 3.8 (2.8-7.0) 0.8 (0.5-2.6) 3.1 (0.5-10.5)
3-D US (observer 1) 2.5 (1.1-5.5) 1.0 (0.4-2.3) 1.6 (0.6-5.6)
3-D US (observer 2) 2.4 (1.1-5.1) 0.9 (0.4-2.2) 1.3 (0.4-5.3)
NAC = neoadjuvant chemotherapy
Mid-NAC response evaluation
MRI and ABVS (observer 1) showed an absolute concordance in 16/22 (73%) patients according 
to RECIST response (Table 3). Two patients showed a complete radiological response on MRI 
and were excluded for a diameter and volume response comparison. The Intraclass Correlation 
Coefficient (ICC) showed a significant and ‘good’ correlation for the longest diameter response 
for the MRI and ABVS, ICC 0.71 [95% CI (0.41-0.88)] and 0.73 (0.43-0.88), p<0.01 (Table 4). The 
inter- and intra-observer agreement for ABVS longest diameter response was ‘excellent’ with 
ICC 0.88 (0.73-0.95), 0.88 (0.73-0.95) and 0.85 (0.67-0.94) (p<0.01) respectively for observer 1 
and 2 (Table 4). Agreements for MRI with ABVS in diameter response evaluation are graphically 
displayed by Bland-Altman plots (Fig. 3). It is shown that the differences for the two examinations 
fall mainly between the limits of agreement except for one measurement (Fig. 3). The tumour 
volume response showed a ‘fair’ correlation when comparing the 3-D MRI with 3-D ABVS (Table 
5). Inter- and intra-observer agreement for ABVS tumour volume response evaluation was ‘good’ 
to ‘excellent’ (Table 5). 
Table 3. First response according to RECIST (n=22).
ABSV (1st observer)










t) Progressive disease 0 0 0 0
Stable disease 1 7^ 1 0
Partial response 0 3 8^ 0
Complete response 0 0 1 1^
MRI = Magnetic Resonance Imaging, ABVS = Automated Breast Volume Scanner
^Absolute concordance between MRI and ABVS RECIST response evaluation.
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Table 4. ICC (95% confidence interval) first diameter response (n=20).
MRI (radiologist) ABVS (observer 1) ABVS (observer 2)
MRI (radiologist) NA
ABVS (observer 1) 0.73 (0.43-0.88)* 0.88 (0.73-0.95)*§
ABVS (observer 2) 0.71 (0.41-0.88)* 0.88 (0.73-0.95)* 0.85 (0.67-0.94)*§
MRI = Magnetic Resonance Imaging, ABVS = Automated Breast Volume Scanner. 
§inter-observer agreement, *p-value <0.01.
Figure 3. Bland-Altman plots of differences longest diameter (mid-NAC) MRI versus ABVS in observer 
1 (Fig. 3a) and 2 (Fig. 3b).
Bland-Altman plots with representation of the mean difference (mean) and the limits of agreement (LOA), from 
-1.96s to +1.96s [a. LOA -38.8 to 27.5; b. LOA -41.3 to 32.0].
Table 5. ICC (95% Confidence Interval) first volume response (n=20).
3-D MRI  
(observer 1)
3-D MRI  
(observer 2)
3-D ABVS  
(observer 1)
3-D ABVS  
(observer 2)
3-D MRI (observer 2) 1.00 (0.99-1.00)*
3-D ABVS (observer 1) 0.52 (0.12-0.78)* 0.53 (0.13-0.78)* 0.95 (0.88-0.98)*§
3-D ABVS (observer 2) 0.48 (0.05-0.75) 0.49 (0.07-0.76) 0.93 (0.84-0.97)* 0.68 (0.35-0.86)*§
MRI = Magnetic Resonance Imaging, ABVS = Automated Breast Volume Scanner, 3-D = three-dimensional.
§inter-observer agreement, *p-value <0.01.
Post-NAC response evaluation
MRI and ABVS (observer 1) showed an absolute concordance in 5/8 (62.5%) patients according 
to RECIST response (Supplementary Table S2). Three patients showed a complete radiological 
response and were excluded for a diameter and volume response comparison. ICC showed 
non-significant correlations between longest diameter response on MRI and ABVS (Supplemen-
tary Table S3). Agreements for MRI with ABVS in diameter response evaluation are graphically 
displayed by Bland-Altman plots (Supplementary Fig. 2). It is shown that the differences for the 
two examinations fall mainly between the limits of agreement. Inter- and intra-observer agreement 
RESPONDER trial − 33
2
for ABVS longest diameter response was ‘excellent’ with ICC 0.99 (0.92-1.00)/1.00 (0.85-1.00), 
and 0.99 (0.87-1.00) respectively (p<0.01). In the five patients eligible for post-NAC evaluation 
longest diameter measured on both MRI and ABVS was compared with histopathological longest 
diameter. Concordance was seen in 4/5 (80%) patients. One patient showed pathological partial 
response (pPR) with <10% residual tumour (data not shown). The other, not concordant, patient 
showed pathological complete response (pCR), with absence of invasive cancer. Both breast MRI 
and ABVS however showed detectable surrounding cysts. Furthermore carcinoma in situ was 
found in histopathology (data not shown). 
Tumour volume response showed significant and ‘excellent’ correlation between MRI and ABVS, 
ICC 0.98 (0.85-1.00) and 1.00 (0.96-1.00) (p<0.01) respectively for MRI observer 1 and ABVS 
observer 1 and 2 (Supplementary Table S4). 
Patient satisfaction
Patients ranked ABVS as more acceptable than the breast MRI, 93% versus 12% respectively 
(Table 6). None of the patients reported the ABVS as ‘not acceptable’, in contrast to breast MRI 
(Table 6). Patients reported ABVS less invasive and time-consuming when compared to breast MRI 
(data not shown). 
Table 6. Patient satisfaction regarding breast MRI and ABVS in 27 patients, n (%). 
Acceptability MRI
Very acceptable 3 (12.0)
Acceptable 12 (46.0)
Neutral 6 (22.0)
Moderately acceptable 4 (15.0)
Not acceptable 2 (8.0)
Acceptability US






This is the first study showing the accuracy of (3-D) ABVS compared to (3-D) breast MRI in meas-
uring tumour response during and after NAC in breast cancer patients. 
In the 20 patients eligible for mid-NAC diameter evaluation we observed ‘good’ correlation for both 
observers using ABVS compared to MRI. Comparable ‘good’ results were found in the post-NAC 
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evaluation in five patients. Agreement with the RECIST response criteria was also high with an 
absolute concordance in 73% and 62.5%, mid- and post-NAC evaluation respectively. Bland Alt-
man plots, comparing MRI to ABVS, showed most measurements within the limits of agreement, 
which are relatively wide because of the small patient number. For both measurements, the line 
of equality was within the interval, meaning that there is no significant systematic error between 
breast MRI and ABVS according to the percentage response observed.
A strength of our study is that three-dimensional volume measurements were done in addition 
to diameter measurements, where other studies did not13 18. Studies assessing the feasibility of 
3-D US for volume calculation of solid breast lesions in patients suggest that 3-D US is a reliable 
method for the volumetric assessment19 20. A previous evaluation within our institute evaluating 
patients undergoing primary surgery showed a higher association for 3-D ABVS than 3-D MRI [ICC 
0.78 (95% CI 0.55-0.91) versus ICC 0.73 (0.44-0.88) respectively]14. These results in combination 
with operator-independency of the 3-D ABVS20 suggest 3-D ABVS to be a reliable and promising 
method for tumour volume measurements. 
Patients ranked ABVS much more acceptable as compared to breast MRI, which is an advantage 
of the ABVS. Patients found ABVS less invasive (less time-consuming, more comfortable, with 
avoidance of contrast agents) and appreciated the fact they could directly view the ultrasonogra-
phy images during the examination.
Another strength of the present study is the evaluation by two observers and therefore inter- and 
intra-observer agreement evaluation of ABVS, with ‘good’ to ‘excellent’ correlations for longest 
diameter response as well for the tumour volume response. Both observers were trained in analys-
ing ABVS data but had no previous experience in interpreting ABVS data, suggesting a short 
learning curve. 
We did not evaluate the inter- and intra-observer agreement of the breast MRI measurements, 
which is a limitation of our study. Another weakness of the present study is the small patient 
number especially in the post-NAC response evaluation. This is a consequence of the pilot-design. 
The ABVS could not be used for response evaluation in 3 patients as the tumour was not clearly 
visible on ultrasonography. In these patients the boundaries of the tumour could not be properly 
defined using ABVS. All had additional DCIS with a large diameter that, as expected29 30, enlarged 
the discrepancy since it is better (only) detected by MRI than by US. Presence of surrounding DCIS 
is a limitation of ABVS in the breast cancer tumour response evaluation. An additional limitation 
was that in 2 patients showing a complete radiological response at first MRI evaluation no ABVS 
was performed.
Differences in response evaluation can be possibly explained by different tumour visualization be-
tween ABVS and breast MRI. Ultrasound measurements are based on structural changes in breast 
tissue. Breast MRI on the other hand is contrast-enhanced. Malignant tumours are classified by the 
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kinetics of their contrast enrichment based on tumour angiogenesis31. Therapy causes an effect on 
neo-vascularisation presenting a decrease in contrast-intensity especially in the tumour periphery 
on MRI-images. Therefore, effect on response measurements are assumed larger with MRI than 
with ultrasonography. This hypothesis is supported by the ‘excellent’ correlation between 3-D 
MRI and 3-D ABVS in the volume response evaluation post-NAC. Since less decrease in contrast 
enhancement is seen and therefore differences between MRI and ABVS are smaller. Interestingly, 
ABVS showed larger lesions as compared to breast MRI post-NAC (23.5 mm and 17.0 mm respec-
tively). A marker placed in the target lesion prior to NAC may contribute to this longer diameter 
by the acoustic shadowing caused by the marker generating a signal void on the ultrasonography 
images. This cannot always be precisely differentiated from residual tumour. This can explain 
that three patients with complete response on MRI were scored as having partial response on 
ABVS post-NAC (data not shown). Histopathological specimen showed a complete pathological 
response (n=2) or a micro-invasion (n=1) component. Due to a limited patient numbers, no conclu-
sions can be drawn regarding the concordance with final histopathological evaluation. 
A pathological complete response (pCR; i.e. the absence of in situ and invasive residual tumour 
at histopathological specimen evaluation following the course of NAC) is an important predictor 
for long-term disease-free and overall survival 2 32 33. Over the years pCR-rates have increased, 
questioning the necessity to also perform breast surgery within these patients. Multiple studies 
are now undertaken to evaluate this necessity in patients showing pCR (for example NTR6120). In 
these studies patients are selected based on a radiological complete response diagnosed during 
or following the course of NAC. To increase the (future) applicability of the (3-D) ABVS for response 
evaluation not only the diameter or volume response, but also the accuracy for a prediction of a 
pCR during or following NAC should be investigated. 
Following this pilot study inclusion is continued in a larger prospective study; RESPONDER II 
(NTR6799). Based on the variance found for the mid-NAC evaluation using (3-D) ABVS compared 
to the (3-D) MRI a power analysis was conducted to estimate the number of patients needed to 
evaluate the accuracy of ABVS for response evaluation in breast cancer patients during NAC. 
Post-NAC (3-D) ABVS scans are being performed in all patients to evaluate the accuracy of ABVS 
in the post-NAC response and the concordance with histopathological response. 
CONCLUSIONS
ABVS showed ‘good’ correlation with MRI tumour response evaluation in breast cancer patients 
during NAC with ‘excellent’ inter- and intra-observer agreement. ABVS has patients’ preference 
over breast MRI and could be considered as alternative to breast MRI. Results of an ongoing 
prospective trial haves to be awaited. 
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SUPPLEMENTARY FILES CHAP TER 2
Supplementary Table S1. RECIST Tumour response criteria
Complete response (CR) Disappearance of all target lesions.
Partial response (PR) At least a 30% decrease in the sum of diameters 
Stable disease (SD) Neither sufficient shrinkage to qualify PR nor sufficient increase to qualify for PD
Progressive disease (PD) At least a 20% increase in the sum of diameters of target lesions. 
[In addition the sum must also demonstrate an absolute increase of at least 
5 mm. (Note; the appearance of one of more new lesions is also considered 
progressive disease)]




















t) Progressive disease 1^ 0 0 0
Stable disease 0 1^ 0 0
Partial response 0 0 3^ 0
Complete response 0 0 3 0
MRI = Magnetic Resonance Imaging, ABVS = Automated Breast Volume Scanner.
Supplementary Table S3. ICC (95% confidence interval) second diameter response (n=5)
MRI (radiologist) ABVS (observer 1) ABVS (observer 2)
MRI (radiologist) NA
ABVS (observer 1) 0.76 (-0.14-0.97) 0.99 (0.92-1.00)*§
ABVS (observer 2) 0.69 (-0.27-0.96) 0.99 (0.87-1.00)* 1.00 (0.85-1.00)*§
MRI = Magnetic Resonance Imaging, ABVS = Automated Breast Volume Scanner.
§inter-observer agreement, *p-value <0.01.
Supplementary Table S4. ICC (95% confidence interval) second volume response (n=5)
3-D MRI  
(observer 1)
3-D MRI  
(observer 2)
3-D ABVS  
(observer 1)
3-D ABVS  
(observer 2)
3-D MRI (observer 2) 0.98 (0.85-1.00)*
3-D ABVS (observer 1) 0.98 (0.79-1.00)* 0.94 (0.56-0.99)* 1.00 (0.98-1.00)§*
3-D ABVS (observer 2) 1.00 (0.96-1.00)* 0.97 (0.74-1.00)* 0.99 (0.92-1.00)* 1.00 (0.98-1.00)§*
MRI = Magnetic Resonance Imaging, ABVS = Automated Breast Volume Scanner, 3-D = three-dimensional. 
§inter-observer agreement, *p-value <0.01.
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Supplementary Figure S1. Ranking score acceptability breast MRI and ABVS
Supplementary Figure S2. Bland-Altman plots of difference longest diameter (post-NAC) MRI versus 
ABVS in observer 1 (Fig S2a) and 2 (Fig S2b)
Bland Altman plots with representation of the mean difference (mean) and the limits of agreement (LOA), from 
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In the International Consortium for Health Outcome Measures (ICHOM) breast cancer outcome set 
Patient Reported Outcome Measurements (PROMs) form an important but rather innovative part. 
Few data exist on scores per type of breast surgery and how to use scores in surgical practice. 
We evaluated PROM scores as well as satisfaction with and expectations of the use of PROMs in 
breast cancer patients using the national and local patient advocate society.
Methods
Through an online survey patients were asked to report age, type of breast cancer surgery (whether 
breast-conserving therapy (BCT), mastectomy, autologous or implant breast reconstruction) and 
time since surgery. PROMs (EORTC-QLQ-C30/BR23 and BREAST-Q postoperative modules) were 
compared for the different surgeries. Additional comparison was made with literature normative 
and reference scores. Three questions evaluated satisfaction with PROMs and expectations 
Results
496 patients completed all PROMs and 487 the satisfaction/expectation-questionnaire. Signifi-
cantly reduced physical functioning was reported following BCT as compared to other surgeries 
and literature reference values. Satisfaction scores were higher following autologous reconstruc-
tion and lower following implant reconstruction as compared to BCT. PRO scores were compara-
ble to normative scores and references scores except for the ‘physical functioning’ (BREAST-Q) 
scores that reported lower in the present study. Ninety-four percent of the participants was (highly) 
satisfied with future PROM use.
Conclusions
Statistical significant differences were found for PROMs following different types of breast surgery. 
The significance of these results should become clearer trough collection of future data. The great 
majority of participants considered PROMs as (highly) acceptable and reacted positively on their 
proposed future use.
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INTRODUCTION
Health outcomes embody the results of the healthcare delivered. Value in health care is defined as 
the health outcome per total cost1. Traditionally health outcome is reported by healthcare providers 
and consist for example of survival, recurrence or complication rates. Multiple outcomes are often 
used per medical condition in order to define and compare results of healthcare1. In value-based 
healthcare (VBHC) the value is defined based on outcomes important to the patient and therefore 
additionally consist of patient-reported outcome measures (PROMs). The International Consorti-
um for Health Outcomes Measurement (ICHOM) in collaboration with health care professionals 
of different international institutions developed standard sets of health outcome measures for 
specific medical conditions2. Breast cancer was among the first conditions covered by ICHOM3. 
It is expected that by reporting and comparing this ICHOM breast cancer set among patients and 
between institutions, the value of the care delivered can be improved1 3.
Especially for breast cancer patients in whom high survival rates are reached, patient-reported 
outcomes (PROs) are of great importance. Furthermore at least equal survival and recurrence rates 
are described in early-stage breast cancer patients when comparing breast-conserving therapy 
[(BCT) – breast-conserving surgery with additional radiation therapy of the breast] and mastectomy 
(with/without breast reconstruction)4-6. Surgical treatment decisions should therefore be focused 
on (long-term) health related quality of life. Especially the understanding of PROMs is expected to 
greatly improve this complex shared treatment decision-making by giving insight in quality of life 
and daily functioning after certain treatment decisions. Although these PROMs comprise around 
75% of the ICHOM breast cancer outcome set, not much data is available on ‘reference scores’ or 
expected scores per surgical treatment.
This study aimed to add knowledge on PROMs within a Dutch breast cancer population sample. 
Three breast cancer PROMs, as proposed in the ICHOM outcome set, were evaluated and com-
pared to normative scores (obtained in non-breast cancer patients) and reference scores (obtained 
in breast cancer patients) available in literature. Patients were additionally asked to give satisfac-
tion and expectation scores on the use of PROMS within clinical practice. 
METHODS
Study population
Participants were recruited via an online survey available from February 12th to March 13th 2017. 
The survey was available on the website of the Dutch breast cancer association7 and the social 
media page of our institute8. The Dutch breast cancer association has a strong national online 
forum of approximately 2,000 breast cancer patients 9. To evaluate the PROMs following surgery 
or active breast cancer treatment breast cancer patients that had not undergone surgery (yet) or 
that had undergone surgery <6 months were excluded.
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PROMs
All participants were asked to complete the PROMs as proposed in the international ICHOM 
breast cancer outcome set. The generic PROM EORTC-QLQ-C30 version 3, the disease specif-
ic-PROM EORTC-QLQ-BR23 version 1 and the BREAST-Q postoperative modules were used. 
Scores of the EORTC-QLQ-C30/BR23 range from 0-100. For the functional scales: ‘Global Health 
status’/ ‘Role functioning’/ ‘Physical functioning’/ ‘Emotional functioning’/ ‘Social functioning’ 
(EORTC-QLQ-C30) and the ‘Body Image’/ ‘Sexual functioning’ (EORTC-QLQ-BR23) higher 
scores represent a higher quality of life. Higher scores at the symptoms scales: ‘Pain’/ ‘Fatigue’ 
(EORTC-QLQ-C30) and ‘Breast symptoms’/ ‘Arm symptoms’ represent less functioning or more 
symptoms experienced by participants.
The modules in the BREAST-Q were dependent on type of surgery performed; the breast-conserv-
ing therapy module, mastectomy module or the reconstructive module. For all modules scores 
range from 0 to 100 in which higher scores represent higher functioning/quality of life. Differences 
as compared to the ICHOM breast cancer set were the use of the ‘Psychosocial, Physical and 
Sexual wellbeing’ modules of the postoperative BREAST-Q (i.e. not only ‘the satisfaction with 
breast’ module). PROM scores were calculated according to the questionnaires’ scoring protocol. 
Modules were judged as incomplete according to the questionnaires’ protocol10. Normative scores 
(i.e. scores obtained in the general population/non-breast cancer patients) or reference scores (i.e. 
scores obtained in breast cancer patients) were used to compare the PROM scores of the current 
survey. For the BREAST-Q normative scores reported by Mundy and colleagues were used11, who 
evaluated scores obtained using the preoperative modules in 1,201 participants. Normative scores 
of the EORTC-QLQ-C30 were based on an evaluation of 7,802 healthy participants12. Since no 
normative scores are available for the EORTC-QLQ-BR23 references scores (obtained in breast 
cancer patients) were used12. The reference scores available for the EORTC-QLQ-C30 were 
additionally compared to the current cohort by graphically displaying the means and standard 
deviations of the different populations.
Procedure
Participants recruited by the Dutch breast cancer association were redirected to the survey after 
completion of 6 questions introducing the VBHC-initiative (data shown in online forum B-force)9. 
Participants were asked to report their age, time since surgery and the type of surgery performed. 
The survey was ended if participants had not undergone breast cancer surgery (yet). All other 
participants were directed to the PROMs. Following the completion of the PROMs participants 
were asked to answer three additional (self-made) questions on their satisfaction with and expec-
tations of the routine use of PROMs (optional). The first questions asked if participants thought that 
PROMs used in the context of VBHC could aid in the care for future breast cancer patients (yes/
no). Second, participants were asked if they experienced the PROMs as helpful to gain insight in 
their current functioning (yes/no). Acceptability of the PROMs was scored as; ‘Very acceptable’/ 
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‘Acceptable’/ ‘Average’/ ‘Not acceptable’ or ‘Other’. Surveys were considered as complete when 
the questions regarding the respondents characteristics were completed and all 4 PROMs were 
activated.
Statistics
All data were analysed with SPSS version 21 (IBM). To compare the different surgeries (i.e. BCT, 
mastectomy alone, mastectomy followed by implant reconstruction and mastectomy followed 
by autologous reconstruction) with non-parametric continuous variables (age, duration ques-
tionnaire) the Kruskal-Wallis test was used. Surgical groups and categorical variables (time since 
surgery, ‘satisfaction and expectations’-questionnaire) were compared using the Chi-square test. 
The one-way ANOVA was used to compare parametric continuous variables (PROMs) between 
surgical groups. Post hoc analyses were performed with the two-sided Dunnett t-test using 
breast-conserving therapy as a control group. The correlation between PROMs was calculated 
using the Pearson correlation coefficient. A correlation coefficient (r) of <0.4 was rated as a ‘weak’ 
correlation, 0.4-0.59 as ‘moderate’ and ≥0.60 as a ‘strong’ correlation13. A p-value <0.05 was 
considered statistical significant. Additionally, the R2 statistic was calculated to evaluate the pro-
portion of variance explained by the correlation between PROMs evaluated. True correspondence 
was evaluated for scores present in the 4th (upper) quartile of the EORTC-QLQ-C30/BR23 and 
the BREAST-Q (number of participants/total participants per questionnaire with scores in the 4th 
quartile for both questionnaires). 
RESULTS
A total of 624 patients activated the online survey of which 72.6% and 27.4% respectively from the 
national and local patients advocate society (Fig. 1). Twenty-four (3.8%) questionnaires contained 
no data and were excluded. Additional exclusions were based on 21 (3.4%) participants that 
had not undergone breast cancer surgery (yet), 30 (4.8%) that had undergone breast surgery <6 
months and 53 (8.5%) that did not activate all 4 PROMs. Of the included participants 9 (1.8%) did 
not complete the ‘satisfaction and expectations with PROM’-questionnaire (Fig. 1). Median age 
of the participants was 54.0 years [Interquartile range (IQR) 49.0-61.0], median time since surgery 
was 5.0 years [IQR 3.0-7.0] (Table 1). The reported duration to complete all questionnaires was 
10 [IQR 9.0-15.0] minutes (Table 1). All baseline characteristics were comparable between the 
different surgical groups except for the time since surgery, see Supplementary Table S1.
PROM scores after different surgeries
Differences between the surgical groups were present in the EORTC-QLQ-BR23 (breast and arm 
symptoms) and the BREAST-Q (all modules except the Sexual functioning), see Table 2. 
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Of the 5 significantly different PROM scores 3 concerned symptom scales. Significantly less 
‘Breast symptoms’ (EORTC-QLQ-BR23) were reported following a mastectomy, autologous and/
or implant reconstruction as compared to BCT: -7.5 (p=0.001), -8.7 (p=0.034), -8.0 (p=0.007) (Table 
2 and supplementary Table S2). Mastectomy patients rated their ‘Arm symptoms’ 7.0 points worse 
than BCT patients (p=0.005). The mean ‘Physical functioning’ (BREAST-Q) was significantly bet-
ter following a mastectomy, autologous and/ implant reconstruction than following BCT: +22.2 
(p<0.001), +25.0 (p<0.001) and +21.3 (p<0.001) respectively. The mean ‘Satisfaction with breast’ 
(BREAST-Q) showed favourable scores +9.6 (p=0.014) following an autologous reconstruc-
tion and unfavourable scores -8.5 (p=0.004) following an implant reconstruction as compared 
to BCT. ‘Psychosocial functioning’ (BREAST-Q) was significantly lower in mastectomy patients 
compared to BCT patients, -5.6 (p=0.009). PROM scores gained did not differ from normative nor 
from reference scores of the EORTC-QLQ-C30 (Fig. 2) and from reference scores of the EORTC-
QLQ-BR23 (Fig. 3). PROMs were comparable to normative scores of the BREAST-Q except for 
the ‘Physical functioning’ scale which showed lower scores in the current cohort (Fig. 4). Overall 
‘moderate’ to ‘weak’ correlations were seen between the EORTC-QLQ-C30/BR23 and BREAST-Q 
(Supplementary Table S3). True correspondence for ratings within the 4th quartile showed absolute 
percentages of: 13.6% [‘Body Image’(EORTC-QLQ-BR23) versus ‘Q-satisfaction’], 12.2%, 11.2%, 
13.9% [‘Role, Emotional and Social functioning’ (EORTC-QLQ-C30) versus ‘Q-psychosocial’], 
6.6% [‘Physical functioning (EORTC-QLQ-C30) versus ‘Q-physical’] and 3.8% [‘Sexual functioning 
(EORTC-QLQ-BR23) versus ‘Q-sexual’] (data not shown).
Figure 1. Flow diagram participant inclusion.
BVN = Dutch abbreviation for Dutch breast cancer patients’ advocates society
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Patients’ experience and satisfaction with PROMs
A total of 222 (45.6%) participants scored the PROMs as ‘very acceptable’, 240 (49.3%) as ‘accept-
able’, 17 (3.5%) as ‘average’, 1 (0.2%) as ‘not acceptable’ and 7 (1.4%) as ‘other’ (Table 1). A total 
of respectively 434 (89.1%) and 398 (81.7%) of the participants responded positive when asked if 
1) they thought a structural use of the PROMs could improve the quality of care and 2) they thought 
the PROMs could be used as a ‘guidance tool for themselves’ in their individual care (Table 1). 
Participants’ experiences did not differ within the surgical groups (Supplementary Table S1). 
DISCUSSION
Early-stage breast cancer patients are faced with difficult treatment decisions following their 
diagnosis. Overall high15 and comparable survival and recurrence rates are reported in early-stage 
breast cancer patients following either BCT or a mastectomy4-6. Both strengthen the necessity 
to base treatment decisions on other outcomes than oncological outcomes alone focused on 
survivorship. The VBHC-initiative is expected to pave the way for shared-decision-making in sur-
gical treatment decisions. The ICHOM breast cancer outcome set consists for 75% of PROMs3. 
Table 1. Baseline characteristics (n=496).
Median age [years (IQR)] 55.0 (49.0-60.8)
Median time since surgery [years (IQR)] 5.0 (3.0-7.0)
Type of breast cancer surgery [n (%)]
Breast-conserving therapy 223 (45.0)
Mastectomy 162 (32.7)
Mastectomy with autologous reconstruction 38 (7.7)
Mastectomy with implant reconstruction 73 (14.7)
VBHC experiences (n=487)
Median duration PROM completion [minutes (IQR)] 10.0 (9.0-15.0)
Improvement breast cancer care [n (%)]
Yes 434 (89.1)
No 53 (10.9)
Tool for self-reflection [n (%)]
Yes 398 (81.7)
No 89 (18.3)
Acceptability PROMs [n (%)]
Very acceptable 222 (45.6)
Acceptable 240 (49.3)
Average 17 (3.5)
Not acceptable 1 (0.2)
Other 7 (1.4)
IQR = interquartile range, VBHC = value-based healthcare.
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Figure 2. EORTC-QLQ-C30 Survey scores versus 
normative and reference scores 12.
Mean scores with standard deviations (error bars) for 
EORTC scores. Higher scores represent better func-
tioning. ^Higher scores represent higher pain scores 
or more fatigue. #Reference and normative scores as 
based on 7,802 participants of the general population 
and 2,782 breast cancer patients respectively 12.
Figure 3. EORTC-QLQ-BR23 Survey scores 
versus reference scores.
Mean scores with standard deviations (error bars) 
for EORTC scores. Higher scores represent better 
functioning. ^Higher scores represent more symp-
toms. #Reference scores as based on 2,782 breast 
cancer patients 12.
Figure 4. BREAST-Q Survey scores versus 
normative reconstructive scores.
Mean scores with standard deviations (error bars) 
for Q-scores. Higher scores represent better func-
tioning. #Normative scores as calculated on 1,201 
14.
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Using an online survey the current study evaluated the PROMs (as proposed in the ICHOM set) 
within a Dutch breast cancer population sample and evaluated the participants’ satisfaction with 
and expectations of PROMs. We found statistical significant different results for PROMs following 
different types of breast surgery, which are important for future clinical decision-making. Most 
participants reacted positively on future use of PROMs in clinical practice. 
Post hoc analyses showed more ‘Arm symptoms’ (EORTC-QLQ-BR23) following a mastectomy 
compared to BCT. BCT patients showed more ‘Breast symptoms’ (EORTC-QLQ-BR23) and 
lower ‘Physical functioning’ (BREAST-Q) as compared to other surgeries. Higher ‘Satisfaction with 
breast’ (BREAST-Q) was reported following autologous reconstruction and lower scores following 
implant reconstruction as compared to BCT. Results for the ‘Satisfaction with breast’ scale are in 
line with previous studies showing favourable outcomes following autologous reconstruction14 16. 
Comparable satisfaction for BCT and autologous reconstruction are however also reported17. Us-
ing the BREAST-Q, Howes and colleagues also reported a reduced physical functioning following 
BCT18.
Table 2. Mean PROM scores (SD) for all participants and per type of surgery performed.
All BCT MAS REC A REC I p-value§
EORTC-QLQ-C30 (n=496) (n=223) (n=162) (n=38) (n=73)
Global health status 71.3 (18.8) 71.0 (19.3) 71.7 (18.2) 71.5 (17.0) 71.3 (19.6) 0.98
Role Functioning 74.4 (25.5) 76.5 (25.2) 71.5 (26.5) 72.8 (24.9) 74.9 (24.1) 0.28
Physical Functioning 80.7 (17.2) 81.4 (16.7) 78.9 (18.4) 81.1 (14.3) 82.6 (17.0) 0.38
Emotional Functioning 76.9 (23.0) 77.3 (22.3) 76.3 (24.2) 77.4 (20.7) 77.1 (24.2) 0.98
Social Functioning 77.5 (26.4) 78.1 (27.9) 77.6 (24.8) 76.3 (22.8) 76.3 (27.1) 0.95
Pain^ 27.0 (24.8) 26.6 (25.0) 27.6 (24.3) 31.1 (28.8) 24.9 (23.4) 0.63
Fatigue^ 34.7 (25.4) 34.9 (25.7) 34.6 (25.4) 41.8 (25.5) 30.3 (24.1) 0.16
EORTC-QLQ-BR23 (n=490) (n=221) (n=159) (n=37) (n=73)
Body image 75.9 (25.0) 78.9 (22.4) 73.2 (25.7) 76.3 (28.3) 72.4 (28.5) 0.09
Sexual Functioning 20.9 (19.6) 21.6 (19.5) 18.5 (19.6) 21.2 (18.3) 23.4 (20.3) 0.28
Breast symptoms^ 20.0 (19.7) 24.2 (21.8) 16.8 (26.8) 15.5 (20.1) 16.2 (16.3) <0.001
Arm symptoms^ 23.4 (21.7) 20.8 (20.5) 27.8 (22.8) 26.7 (23.6) 19.8 (20.0) 0.005
BREAST-Q (n=492) (n=222) (n=160) (n=38) (n=72)
Satisfaction with breast 60.9 (19.7) 62.3 (21.8) 59.5 (17.3) 71.9 (16.4) 53.8 (16.4) <0.001
Psychosocial functioning 64.7 (18.5) 66.5 (19.3) 60.9 (15.8) 72.7 (19.1) 63.5 (19.5) 0.001
Physical functioning 55.50 (19.7) 43.1 (16.5) 65.3 (15.5) 68.1 (16.6) 64.4 (17.3) <0.001
Sexual functioning 52.59 (18.6) 52.6 (17.1) 50.5 (19.3) 60.2 (19.8) 52.6 (19.4) 0.046
SD = standard deviation, BCT = breast-conserving therapy, REC A = Autologous reconstruction, REC I = Im-
plant reconstruction, §ANOVA.
Overall higher scores represent higher quality of life. ^Higher scores represent lower quality of life.
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Three out of 5 PROM modules differed significantly based on a reduced physical functioning/
more symptoms experienced following BCT. This was also present when comparing the results to 
normative scores showing a significantly decreased ‘Physical functioning’ (BREAST-Q) within our 
cohort. The significance of these possible differences in physical functioning or symptoms expe-
rienced following BCT should be explored in additional cohorts. The possible effect of radiation 
therapy (administered to all BCT participants) on physical function should be taken in consideration 
when evaluation future cohorts. It is however known that the high score (mean 91) found in the 
normative scores obtained by Mundy and colleagues can partly be explained by differences in the 
preoperative questionnaire (used to obtain the normative scores) and postoperative questionnaire 
(used to evaluate the current cohort) of the BREAST-Q11 14 19. Since PROMs are commonly used 
to evaluate an intervention, little data is available of non-interventional studies exploring PROMs 
following (surgical) breast cancer treatment. To adequately evaluate possible differences not only 
a statistical significance but also a clinical significance should be addressed. Clinically relevant dif-
ferences for the EORTC-QLQ-C30/BR23 and BREAST-Q are not well defined but in some literature 
defined this as half a standard deviation (0.5SD) difference14. For future VBHC-initiatives and trials 
a clinically relevant difference is of great importance and should be calculated based on different 
international cohorts.
An important strength of the current study lies in the evaluation of PROMs as proposed in the 
ICHOM set. This enabled a comparison of outcome scores for the different PROMs and a first 
‘patients’ satisfaction and expectations’ evaluation of the proposed ICHOM set. The availability 
of different PROMs within the same patient furthermore enabled a comparison of the correlation 
between the different PROMs in which the yes/no necessity for the different PROMs could be 
evaluated. When significant, all correlation present between the BREAST-Q and EORTC-QLQ-
C30/BR23 were ‘moderate’ to ‘weak’ suggesting that overall the PROMs are different and can 
generate different perspectives on the patients’ functioning. The relationship between the EORTC-
QLQ-C30/BR23 and the BREAST-Q only explained 0.1% minimum to maximum 65.7% of the 
variety. Absolute concordances for scores given in the upper (4th) quartile of comparable modules 
of the BREAST-Q and EORTC-QLQ-C30/BR23 was low, varying from 3.8% to 13.9%.
Limitations of the study were primarily a result of the study population analysed. PROM scores 
are dependent on the type of cohort evaluated and could be biased within this study. Patients 
within both patients’ advocates societies form a strong community that is actively involved in their 
personal care and that of other (future) breast cancer patients possibly influencing the experiences 
regarding the VBHC-initiative or influencing the PROM scores. Furthermore, a small absolute num-
ber of patients had undergone breast reconstruction (n=38 and n=73 respectively for autologous 
and implant reconstruction), limiting the statistical power to conclude specifically within this group. 
Data on the number of breast surgeries performed or bilateral breast cancer operations were 
unavailable and all data on breast operations were self-reported. PROM data were analysed as 
parametric data. A graphical inspection of the PROMs (all ranging from 0-100) showed that a 
normal distribution was present in most PROM modules. Skewed scores were however present 
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in some modules of the EORTC-QLQ-C30/BR23 that are in line with the skewed results found in 
the normative/ reference scores. Importantly, when analysing the PROM scores as non-parametric 
data no differences in the (non-)significance were seen (data not shown).
The significant differences detected by the BREAST-Q can be explained by the surgery-specific 
questions20. In the development of the BREAST-Q newer psychometric methods were used pos-
sibly improving the clinical utility as compared to the EORTC-QLQ-C30/BR2320. Furthermore, the 
BREAST-Q scores did show a parametric spread for all the outcome modules. The authors believe 
that all the modules of the BREAST-Q need to be used when evaluating breast cancer patients in 
future VBHC-initiatives and/or clinical trials. Although this is not proposed in the ICHOM breast 
cancer set this could increase the clinical utility and therefore facility of more adequate monitoring 
of patients. The overall ‘weak’ to ‘moderate’ correlations between the BREAST-Q and the EORTC-
QLQ-C30/BR23 are an additional argument to include the BREAST-Q.
A majority of the patients, 81.7% and 89.1% agreed that the PROMs could serve as a tool for 
self-reflection in time and expected the PROMs to lead to an improvement of the breast cancer 
care if used as a tool to guide treatment and discuss quality and functioning throughout care by 
physicians and nurses. The overall positive experiences (94.4% of participants rated the PROMs 
as (highly) acceptable) are supported by a recent evaluation in which PROMs are preferred over 
clinical outcomes or symptoms21 22. Positive results regarding VBHC and use of PROMs in clinical 
practice are also reported by randomized trials evaluating the use of PROMs as a tool to guide 
the individual care for breast cancer patients23 or cancer patients in general24 25. Kotronoulas and 
colleagues reviewed the use of PROMs within different studies and reported that overall positive 
effects were seen following the prospective and continues use of PROMs during cancer treatment 
or follow-up26. It is expected, however, that the success of the VBHC-initiative is partly dependent 
on the availability of reference scores for the different PROMs. A comparison of PROM scores 
with representative reference values enables an adequate evaluation of the care delivered or an 
intervention where needed which can then be evaluated. The comparison of our PROM data with 
normative scores for the EORTC-QLQ-C3012 and BREAST-Q14 but also reference scores for the 
EORTC-QLQ-C30/BR2312 forms an example of an initial evaluation of PROMs within a specific co-
hort. To properly access clinical significance ongoing future cohorts should focus on prospectively 
collected PROMs that enable an evaluation through time.
CONCLUSIONS
This is a first Dutch initiative to evaluate PROM scores of the ICHOM breast cancer set. Differences 
were found according to the type of surgery performed. Future studies should focus on obtaining 
reference values based on large patient cohorts in time aiming to improve the interpretation of 
the scores. Importantly the overall positive experiences reported by participants regarding these 
PROMs have further substantiated the value of the rising VBHC initiative.
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Median age  
[years (IQR)]
54 (48.0-61.0) 55.0 (49.0-61.0) 55.0 (50.0-60.0) 55 (46.5-60.0) 0.90
Median time since 
surgery [years (IQR)]
5.0 (3.0-7.0) 6.0 (4.0-7.0) 6.0 (4.0-7.0) 5.0. (3.0-7.0) 0.002
















Yes 199 (90.5) 140 (89.2) 32 (94.6) 60 (82.2)
No 21 (9.5) 17 (10.8) 2 (5.4) 13 (17.8)
Tool for self-reflection 0.09
Yes 188 (85.5) 119 (758) 29 (78.4) 62 (84.9)
No 32 (14.5) 38 (24.2) 8 (21.6) 11 (15.1)
Acceptability PROMs 0.90
Very acceptable 102 (46.4) 66 (42.0) 15 (40.5) 39 (53.4)
Acceptable 107 (48.6) 82 (52.2) 20 (54.1) 31 (42.5)
Average 8 (3.6) 5 (3.2) 2 (5.4) 2 (2.7)
Not acceptable 0 (.0) 1 (0.6) 0 (.0) 0 (.0)
Other 3 (1.4) 3 (1.9) 0 (.0) 1 (1.4)
BCT = breast-conserving therapy. ^^Kruskall-wallis test ¶Chi-square. REC A = Autologous reconstruction, REC 
I = Implant reconstruction
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Supplementary Table S2. Post hoc comparison significantly different PROM scores for surgical type.
Surgery vs BCT (reference) Mean difference P-value# 95% CI
EORTC-QLQ-BR23 
Breast symptoms^ Mastectomy -7.47 0.001 -12.28; -2.66
Autologous reconstruction -8.71 0.034 -16.9; -0.48
Prosthesis reconstruction -8.04 0.007 -14.28; -1.79
Arm symptoms^ Mastectomy 7.00 0.005 1.67; 12.32
Autologous reconstruction 5.90 0.31 -3.19; 15.01
Prosthesis reconstruction -1.00 0.97 -7.94; 5.89
BREAST-Q
Satisfaction with breast Mastectomy -2.81 0.39 -7.58; 1.96
Autologous reconstruction 9.60 0.014 1.52; 17.67
Prosthesis reconstruction -8.51 0.004 -14.74; -2.27
Psychosocial functioning Mastectomy -5.63 0.009 -10.13; -1.13
Autologous reconstruction 6.20 0.15 -1.44; 13.84
Prosthesis reconstruction -3.00 0.51 -8.88; 2.87
Physical functioning Mastectomy 22.21 <0.001 18.17; 26.24
Autologous reconstruction 25.04 <0.001 18.20; 31.87
Prosthesis reconstruction 21.31 <0.001 16.06; 26.58
Sexual functioning Mastectomy -2.06 0.66 -6.96; 2.83
Autologous reconstruction 7.61 0.06 -0.31; 15.52
Prosthesis reconstruction 0.01 1.0 -6.22; 6.24
CI = confidence interval. #Post hoc test Dunnett T (2-sided), the Dunnett T-test treat one group as a control and 
compares all other groups against it, the BCT group serves as a control group. 
Overall represent higher scores a higher quality of life. ^Higher scores represent lower quality of life. 
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Supplementary Table S3. Pearson correlation coefficient (r) and r2 for the different EORTC-QLQ-C30/
BR23 compared to the BREAST-Q.
BREAST-Q
Q-satisfaction 
with breast Q-Physical Q-psychosocial Q-sexual
r r2 r r2 r r2 r r2
EORTC-QLQ-C30
Global health status 0,292* 0.085 0,054 0.003 0,403* 0.162 0,243* 0.059
Physical functioning 0,256* 0.066 0,038 0.001 0,311* 0.097 0,126* 0.016
Role functioning 0,263* 0.069 0,032 0.001 0,328* 0.108 0,148* 0.022
Emotional functioning 0,237* 0.056 0,038 0.001 0,457* 0.209 0,308* 0.095
Social functioning 0,222* 0.049 0,047 0.002 0,372* 0.138 0,218* 0.047
Fatigue -0,200* 0.040 -0,060 0.004 -0,316* 0.100 -0,200* 0.040
Pain -0,262* 0.069 -0,031 0.001 -0,293* 0.086 -0,186* 0.035
EORTC-QLQ-BR23
Body Image 0,516* 0.267 0,004 0.000 0,657* 0.431 0,566* 0.320
Arm symptoms -0,242* 0.059 -0,013 0.000 -0,315* 0.099 -0,127* 0.016
Breast symptoms -0,272* 0.070 -0,089 0.008 -0,311* 0.097 -0,228* 0.052
Sexual functioning 0,132* 0.017 0,014 0.000 0,143* 0.021 0,344* 0.118
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Considering the comparable prognosis in early-stage breast cancer for breast-conserving therapy 
(BCT) and mastectomy, quality of life should be a focus in treatment decision(s). We retrospectively 
collected PROs and analysed differences per type of surgery delivered. We aimed to obtain refer-
ence values helpful in shared decision-making.
Methods
pTis-T3N0-3M0 patients operated between January 2005 and September 2016 were eligible if: 
1) no chemotherapy was administered <6 months prior to enrolment, and 2) identical surgeries 
were performed in case of bilateral surgery. After consent, EQ-5D-5L, EORTC-QLQ-C30/BR23, 
and BREAST-Q were administered. PROs were evaluated per baseline characteristics using mul-
tivariable linear regression models. Outcomes were compared for different surgeries as well as for 
primary (PBC) and second primary or recurrent (SBC) breast cancer patients using analyses of 
variance (ANOVAs).
Results
Response rate was 68%. PROs in 612 PBC patients were comparable to those in 152 SBC patients. 
Multivariable analyses showed increasing age to be associated with lower ‘Physical functioning’ 
[β -0.259, p<0.001] and ‘Sexual functioning’ [β -0.427, p<0.001] and increasing time since surgery 
with less ‘Fatique’ [β -1.083, p<0.001]. Mastectomy [β -13.596, p=0.003] and implant reconstruc-
tion [β -13.040, p=0.007] were associated with lower ‘Satisfaction with breast’ scores than BCT. 
Radiation therapy was associated with lower satisfaction scores than absence of radiotherapy.
Discussion 
PRO scores were associated with age, time since surgery, type of surgery and radiation therapy in 
breast cancer patients. The scores serve as a reference value for different types of surgery in the 
study population and enable prospective use of PROs in shared decision-making.
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INTRODUCTION
Breast cancer is the most frequently diagnosed cancer in women1. In the Netherlands, 1 in 7 
women are diagnosed with breast cancer2. Favourable high survival rates are reported eminently 
in early stages3. Survivorship as well as physical, sexual and psychosocial consequences of breast 
cancer therapies should therefore be accounted for in treatment decision-making. In early-stage 
breast cancer high survival rates are achieved irrespective of type of surgery whether breast-con-
serving therapy (BCT; breast-conserving surgery with breast radiation therapy) or mastectomy 
(with/without reconstruction)4-6. Consequently, anticipation of outcomes reflecting physical, sexual 
and psychosocial functioning is very important in treatment decision-making in these patients.
Value in healthcare is defined as the health outcome per total costs. Multiple health outcomes 
are often used for one medical condition to define this value7. In value-based healthcare (VBHC), 
the defined outcomes are patient orientated and therefore form a combination of more traditional 
clinical outcomes (for example, oncological outcome or complication rates) and patient-reported 
outcomes (PROs). Collaborations of the International Consortium for Health Outcomes Measure-
ment (ICHOM) with several other healthcare institutions worldwide resulted in the development 
of a standard breast cancer outcome set8. The incorporation of this set is expected to pave the 
way towards value-based breast cancer care with an impulse in shared decision-making as well 
as follow-up.
Patient-reported outcome measures (PROMs) are pivotal in the ICHOM breast cancer outcome 
set, accounting for approximately 75% of outcomes, the other 25% being related to clinical out-
comes. Little is known about PROM scores following different surgeries in relation to differences 
in patient, tumour and systemic or radiation treatment characteristics. Our institute implemented 
a breast cancer outcome set embedded in the institutional VBHC initiative in October 2015. At 
predetermined time points breast cancer patients received digitalized PRO questionnaires prior to 
their routine visit at the outpatient clinic. PROs were evaluated with the patient at the outpatient 
clinic and used to improve individual care9. Consequently, there was an urgent need to propose 
valid and meaningful reference scores. It was hypothesized that PROs differ between surgical 
treatments. The aim of this study was to assess the correlation between PROs and patient, tumour 
and treatment characteristics and to provide PRO reference values for different breast cancer 
surgeries. We therefore collected PROs amongst breast cancer patients operated in the last 10 
years within our institute.




Ethical approval was granted by the Institutional Review Board of the Erasmus Medical Centre 
(Erasmus MC), Rotterdam, the Netherlands (MEC-2015-669). Patients who had undergone breast 
cancer surgery between January 2005 and September 2016 were identified from the electronical 
patient files using operation codes. Women aged >18 years with pTis-3N0-3M0 breast cancer 
were deemed eligible. Patients were excluded if they had been treated with chemotherapy within 6 
months prior to the PRO assessment or had bilateral breast surgery with different types of surgery 
performed per side.
Procedures
This cross-sectional study retrospectively reviewed medical records to compile the following data: 
age, date and type of breast surgery, tumour morphology, Tumour, Node and Metastasis (TNM) 
staging according to TNM classification system (7th edition)10, hormonal receptor status, human 
epidermal growth factor receptor (HER2) status, BRCA1/2 status, local recurrence, second primary 
breast cancer, and details regarding chemotherapy and/or immunotherapy and endocrine therapy. 
Time since surgery was defined as time between first surgery and questionnaire completion. The 
respondents were categorized in ‘primary breast cancer’ (PBC) and ‘second primary or recurrent 
breast cancer’ (SBC). PBC patients represented women with primary unilateral or bilateral breast 
cancer, while SBC patients represented women with local recurrence or second primary breast 
cancer. In case of breast cancer recurrence or a second primary breast cancer, data regarding 
patient age, tumour morphology and TNM stage of the primary diagnosis was used. 
Operation types defined were: breast-conserving therapy (BCT), mastectomy alone (MAS), mastec-
tomy followed by immediate or delayed implant reconstruction (REC-I) and mastectomy followed by 
immediate or delayed autologous reconstruction (REC-A). Nodal stage at primary diagnosis was cat-
egorized as N0, N+ (N1-3), or unknown. Adjuvant systemic therapy was categorized as: 1) no systemic 
therapy, 2) chemotherapy and/or immunotherapy (CTx), 3) endocrine therapy (ETx), 4) chemotherapy/
immunotherapy & endocrine therapy (CTx & ETx) or 5) unknown. Radiotherapy was categorized as: 
1) radiation therapy following breast-conserving surgery, 2) no radiation therapy, or 3) thoracic wall 
radiotherapy in case of mastectomy and/or locoregional radiotherapy in case of mastectomy or BCT.
Eligible women were contacted by telephone to request their participation. Upon oral informed 
consent, details on adjuvant therapy and last breast surgery were verified. Patients who did not 
answer were called up to six times, after which participation was no longer pursued.
Following consent four questionnaires were administered; Euro-QoL 5D-5 L (EQ-5D-5 L version 
2.0)11, The European Organization of Research and Treatment of Cancer quality of life question-
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naires (EORTC-QLQ-C30 version 3.012 and EORTC-QLQ-BR23 version 1.013) and BREAST-Q 
(postoperative version 1.0)14. The questionnaires are proposed in the ICHOM breast cancer out-
come set to evaluate breast cancer patients undergoing locoregional treatment(s)8. The EORTC-
QLQ-C30 is a generic oncologic questionnaire containing 30 questions with 6 single-items scores, 
9 multiple-item scales, 3 symptom scales, and an additional global health status/quality of life 
(QoL) scale15. The EORTC-QLQ-BR23 is a breast cancer specific questionnaire of the EORTC QLG 
that contains 23 questions made up of 8 multiple-item scales and is considered an addition to 
the EORTC-QLQ-C30 specifically for breast cancer patients. The BREAST-Q is a surgery-specific 
questionnaire proposed in the ICHOM set to measure ‘Satisfaction with breast’ following breast 
cancer surgery. Multiple-item domains are, however, also available to evaluate ‘Satisfaction with 
overall outcome’, ‘Psychosocial wellbeing’, ‘Sexual wellbeing’, ‘Physical wellbeing’, and ‘Satisfac-
tion with care’14. In the current study, all modules of the BREAST-Q except ‘Satisfactions with 
overall outcome’ were used. 
Patients were given the choice for internet-based questionnaires sent by email or paper-based 
questionnaires sent by mail (with postage-paid return envelope). If the questionnaires remained 
uncompleted, a weekly reminder up to 3 weeks was sent by email (internet-based). After 4 weeks 
of no response, patients were contacted by telephone and requested to complete questionnaires 
(internet-based and paper-based). Thereafter, response was no longer actively pursued. PRO 
scores were calculated according to questionnaire scoring manual. PROs were evaluated for 
patients who completed at least the EORTC-QLQ-C30 questionnaire.
Study outcomes
The primary outcome was to obtain reference values for PROs following different surgical strat-
egies in relation to patient, tumour, and treatment characteristics of PBC patients. Additionally, 
PROs of SBC patients were evaluated and compared to PROs of PBC patients.
Statistical analysis
All analyses were performed in SPSS Statistics for Windows (version 21.0). Baseline characteristics 
were compared for responders versus nonresponders and PBC versus SBC patients. The different 
surgical groups were compared within both PBC and SBC using a one-way ANOVA. Post hoc 
analyses were performed to detect differences between specific groups. To evaluate the effect of 
patient, tumour and treatment on PROs, a multivariate linear regression was used in PBC patients. 
Factors evaluated were age, time since surgery, uni/bilateral breast cancer, BRCA mutation status, 
tumour stage, nodal stage, systemic therapy status and radiotherapy status. Beta coefficients 
(β) with corresponding p-values were calculated for the index value (EQ-5D-5L), ‘Global Health 
status’/ ‘Physical functioning’/ ‘Role functioning’ (EORTC-QLQ-C30), ‘Body image’/ ‘Sexual func-
tioning’ (EORTC-QLQ-BR23) and ‘Q-Satisfaction with breast’/ ‘Q-physical’/ ‘Q-psychosocial’ and 
‘Q-sexual’ (BREAST-Q). P-values ≤0.01 were considered statistically significant.
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RESULTS
Out of 1,850 patients identified, 1,230 (66.5%) had pTis-T3N0-3M0 breast cancer at primary 
diagnosis. A total of 1,116 (90.7%) was eligible for participation (Fig. 1). Out of eligible patients, 
764 (68.5%) responded. Of 352 non-responders, 114 (40.9%) could not be reached, 162 (46%) 
declined participation, and 46 (13.1%) did not complete the EORTC-QLQ-C30.
Figure 1. Flow chart study selection process.
T = tumour stage, N = nodal stage, PBC = primary breast cancer, SBC = second primary or recurrent breast 
cancer. 
Study population
Responders versus nonresponders 
Responders were significantly younger compared to non-responders (50.5 vs. 52.4 years, p = 
0.04). Significant differences were additionally found for type of surgery performed, T- stadium, 
systemic and radiation therapy (Supplementary Table S1).
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Responders: baseline characteristics and treatment 
A total of 612 (80.1%) responders had PBC (Table 1) and 152 (19.9%) women had SBC (Supple-
mentary Table S2). Of PBC patients, 257 (41.9%) underwent BCT, 162 (26.6%) mastectomy, 110 
(17.9%) implant reconstruction and 83 (13.5%) autologous reconstruction (Table 1). PBC patients 
showed significant differences between the surgical groups for age, time since surgery, unilateral/
bilateral surgery, T-stage, N-stage, systemic therapy, radiation therapy and BRCA mutation status 
(Table 1).










n = 83 p-value§



























Unilateral 475 (77.6) 251 (97.7) 133 (82.1) 51 (46.4) 40 (48.2)
Bilateral 137 (22.4) 6 (2.3) 29 (17.9) 59 (53.6) 43 (51.8)
Unknown .0 .0 .0 .0 .0
T stage < 0.001
T1 354 (57.8) 173 (67.3) 86 (53.1) 58 (52.7) 39 (47.0)
T2 128 (20.9) 42 (16.3) 51 (31.5) 14 (12.7) 21 (25.3)
T3 18 (2.9) .0 8 (4.9) 4 (3.6) 6 (7.2)
CIS 108 (18.0) 42 (16.3) 17 (10.5) 33 (30.0) 16 (19.3)
Unknown 2 (0.3) .0 .0 1 (0.9) 1 (1.2)
N stage < 0.001
N0 442 (72.2) 211(82.1) 91 (56.2) 90 (81.8) 50 (60.2)
N+ 170 (27.8) 46 (17.9) 71 (43.8) 20 (18.2) 33 (39.8)
Unknown .0 .0 .0 .0 .0
Systemic therapy < 0.001
None 256 (41.8) 130 (50.6) 46 (28.4) 53 (48.2) 27 (32.5)
CTx 88 (14.4) 26 (10.1) 20 (12.3) 16 (14.5) 25 (30.1)
ETx 95 (15.5) 49 (19.1) 34 (21.0) 10 (9.1) 2 (2.4)
CTx & ETx 173 (28.3) 52 (20.2) 62 (38.3) 31 (28.2) 29 (34.9)
Unknown .0 .0 .0 .0 .0
Radiation therapy < 0.001
RTx following BCS 233 (38.1) 233 (90.7) .0 .0 .0
No RTx 293 (47.9) 14 (5.4) 120 (74.1) 94 (85.5) 65 (78.3)
Thoracic-wall and/or 
locoregional RTx
85 (13.9) 9 (3.5) 42 (25.9) 16 (14.5) 18 (21.7)
Unknown 1 (0.2) 1 (0.4) .0 .0 .0
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Patient-reported outcomes
Completion rates for the individual PRO modules in respondents ranged between 88% and 
100%, with the exception of the Q-sexual module, which showed lower response rates (Table 
2). Statistically significant differences between surgical treatments were found in the PBC group 
in ‘Physical functioning’, ‘Sexual functioning’ and all Q-scores on univariate analyses (Table 2). 
Post hoc analyses showed that mastectomy patients overall reported significantly lower mean 
scores on ‘Physical functioning’ (80.1) compared to BCT (86.4, p=0.001), compared to implant 
(92.6, p<0.001) and compared to autologous reconstruction (87.5, p=0.006). ‘Body image’ was 
lower following mastectomy (75.7) compared to BCT (83.9, p=0.005). Significantly lower ‘Sexual 
functioning’ scores (EORTC-QLQ-BR23) were reported by BCT patients (24.2) compared to im-
plant (36.6, p<0.001) and autologous reconstruction (33.6, p=0.001) patients. Lower mean ‘Sexual 
functioning’ scores were also reported by mastectomy patients (20.6) compared to both implant 
and autologous reconstruction patients, p<0.001 and p=0.001 respectively. ‘Q-psychosocial’ was 
lower following mastectomy (65.8) compared to implant (74.1, p=0.004) and autologous recon-
struction (75.7, p<0.001). Mean ‘Q-satisfaction with breast’ reported by mastectomy patients 
(61.7) was significantly lower compared to BCT (65.7, p=0.006) and autologous reconstruction 











n = 83 p-value§
BRCA < 0.001
BRCA1/2 negative 399 (65.2) 179 (69.6) 113 (69.8) 58 (52.7) 49 (59.0)
BRCA1/2 positive 90 (14.7) 13 (5.1) 15 (9.3) 36 (32.7) 26 (31.3)
Unknown 123 (20.1) 65 (25.3) 34 (20.9) 16 (14.6) 8 (9.6)
Histological type 0.003
IDC 415 (67.8) 185 (72.0) 113 (69.8) 58 (52.7) 59 (71.1)
ILC 44 (7.2) 16 (6.2) 16 (9.9) 7 (6.4) 4 (4.8)
CIS 111 (18.2) 41 (16.0) 19 (11.7) 35 (31.8) 16 (19.3)
Other 35 (5.7) 15 (5.8) 12 (7.4) 7 (6.4) 2 (2.4)
Unknown 7 (1.1) .0 2 (1.2) 3 (2.7) 2 (2.4)
Differentiation grade^ <0.001
Grade 1 100 (16.3) 61 (23.7) 21 (13.0) 11 (10.0) 7 (8.4)
Grade 2 216 (35.3) 100 (38.9) 63 (38.9) 31 (28.2) 20 (24.1)
Grade 3 160 (26.1) 49 (19.1) 55 (34.0) 24 (21.8) 32 (38.6)
NA 113 (18.5) 44 (17.1) 19 (11.7) 35 (31.8) 16 (19.3)
Unknown 23 (3.8) 3 (1.2) 4 (2.5) 9 (8.2) 8 (9.6)
BCT = breast-conserving therapy, MAS = mastectomy, REC-I = mastectomy followed by (in-) direct implant 
reconstruction, REC-A = mastectomy followed by (in-)direct autologous reconstruction, CTx = chemotherapy 
and/or immunotherapy, ETx = endocrine therapy, RTx = radiation therapy.
§Chi square test. ¥Kruskall Wallis test.
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patients (70.5, p=0.004). No significant differences in outcome were found between the different 
surgeries in the SBC group (data not shown).
When evaluating PROs in multivariate analyses, increasing age was related to lower scores on 
‘Physical functioning’ (β -0.259, p<0.001) and ‘Sexual functioning’ (β -0.427, p<0.001) (Table 3). 
Longer time since surgery was associated with less ‘fatigue’ (β -1.083, p<0.001) (Table 3). ‘Q-
Satisfaction with breast’ was significantly lower for patients following mastectomy (β -13.596, 
p=0.003) and implant reconstruction (β -13.040, p=0.007) compared to BCT (Table 3). If patients 
had not undergone radiation therapy, ‘Q-satisfaction with breast’ was significantly better than 
following BCT (with consequent radiation therapy) (β 11.956, p<0.009) (Table 3).













(n = 83) p-value¥
EQ-5D-5L














79.5 (18.3) 79.2 (17.5) 0.86 79.7 (17.5) 76.2 (19.5) 82.6 (18.6) 81.3 (17.5) 0.026
Physical function° 86.0 (15.8) 83.9 (15.6) 0.16 86.4 (14.4) 80.1 (19.6) 92.6 (9.8) 87.5 (14.6) <0.001*
Role function° 83.1 (23.4) 79.8 (22.7) 0.11 85.0 (21.3) 78.0 (26.0) 86.2 (22.7) 83.7 (24.0) 0.01
Fatigue± 25.4 (24.5) 24.0 (22.1) 0.51 25.6 (25.0) 28.7 (24.1) 21.0 (23.0) 24.4 (25.3) 0.09





























































































PBC = primary breast cancer patients, SBC = second primary or recurrent breast cancer. 
EQ-5D-5L index-value: scale from -0.28 - 1.0. EORTC-QLQ-C30/BR23 and BREAST-Q scale 0 - 100. °Higher 
scores represent higher quality, ±Higher scores represent lower quality. [ ] percentages complete modules if not 
100%. §Unpaired T-test. ¥ANOVA. *Statistical significant differences.
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DISCUSSION
Breast cancer patients are faced with complex treatment decision(s) shortly after breast cancer 
diagnosis. Insights in not only prognosis but also quality of life or daily functioning resulting from 
these decisions could improve the shared decision-making process and ultimately the care de-
livered. Knowledge on QoL related to different surgical treatments is urgently needed. The aim 
of this study is to obtain and evaluate PROs in breast cancer patients according to the surgery 
performed. Collected PROs indeed showed statistically significant differences for the various 
surgeries performed. The collected PROs can serve as reference and ultimately pave the way for 
implementation of VBHC among future breast cancer patients at the outpatient clinic.
In primary breast cancer patients PRO scores in mastectomy patients were lower compared with 
BCT or breast reconstruction patients except for the ‘Q-physical’ and ‘Q-satisfaction with breast’. 
Both mastectomy patients and patients with an implant reconstruction reported significantly 
lower ‘Satisfaction with breast’ scores compared to BCT or autologous reconstruction patients. 
These results corroborate previous studies which showed lower satisfaction and impaired sexual 
functioning, psychosocial and physical functioning following mastectomy compared to BCT or 
breast reconstruction16 17. After adjustment for patient, tumour and treatment characteristics a 
significant effect of surgical treatment on ‘Q-Satisfaction with breast’ scores persisted. Compared 
to BCT, statistically significant lower ‘Q-Satisfaction with breast’ was reported by mastectomy 
and implant reconstruction patients. No statistically significant differences were found in PROs 
between autologous reconstruction and BCT when adjusting for patient, tumour and treatment 
characteristics. Contradictory results are found in literature, reporting comparable PRO scores18 
or scores in favour of autologous reconstruction techniques16. ‘No radiation therapy’ was associ-
ated with statistically significant higher ‘Q-Satisfaction with breast’ scores as compared to BCT 
patients. Thoracic wall radiation therapy (25.9%, 14.5% and 21.7% of mastectomy, REC-I and 
REC-A patients respectively) and locoregional radiotherapy in 3.5% of the BCT patients was as-
sociated with lower Q-satisfaction scores compared to patients that had not undergone radiation 
therapy. Radiation therapy is therefore an important independent factor for ‘Q-satisfaction with 
breast’ scores in addition to the type of surgery performed.
Strengths of the current study include the size of the study population and the response rate of 
68%. This enabled evaluation of 4 different PROMs, generating a detailed reflection of quality of 
life. To the best of the authors’ knowledge, this is the largest study to evaluate the complete set of 
PROs proposed in the ICHOM breast cancer set per type of surgery with adjustment for potential 
confounders. This is a pivotal step forward in the extensive use of PROMs in clinical research and 
practice for the implementation of VBHC. It furthermore enables a future international comparison. 
When both PROs and baseline characteristics are available, case-mix corrected comparison 
between centres can be performed to benchmark.
Limitations form the single-centre and retrospective design. Moreover, not all variables that pos-
sibly affect PROs were available for the current cohort such as socioeconomic status16. Large 
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multicentre initiatives are needed to obtain narrow reference scores as well as the possibility for 
benchmarking. Evaluation of PROs obtained in retrospect does however generate the necessary 
insights into factors possibly related to PRO scores. These data could be used to build models to 
perform case-mix analyses which could be validated in other cohorts.
The response rate for sexual functioning (EORTC-QLQ-BR23) was lower compared to other PROs 
except for patients with breast reconstruction. Therefore, scores for sexual functioning might have 
been biased. Previous studies on sexual health in breast cancer patients showed that 50-90% of 
women experience sexual dysfunction19 20 and that breast cancer surgery has a negative impact21. 
The VBHC initiative, with questions regarding sexual functioning, could possibly open the conver-
sation and future consultation on sexuality in breast cancer patients at the outpatient clinic. Data 
on sexual functioning are hampered by the lower response rate and the lack of longitudinal data, 
limiting the clinical applicability of these scores.
There were no statistically significant differences in PROs between PBC and SBC patients. This 
conclusion is hampered concerning the BREAST-Q questionnaire. In the SBC group, in which 
patients are more often operated on both breasts, the applicability of the BREAST-Q is lower, since 
it does not account for two operated breast or different types of breast surgery.
Measuring PROs during treatment has the potential to monitor and detect changes in physical or 
psychosocial problems at the outpatient clinic. Consequently, targeted supportive care concerning 
health-related QoL may be provided and possibly improve the care delivered9 22. This evaluation 
enables a first insight in PRO scores according to patient, tumour and treatment characteristics. 
Reference scores for the different PROs are pivotal when PROs are being used at the outpatient 
clinic to tailor and improve the care delivered. Knowledge on differences in satisfaction scores per 
type of breast cancer surgery performed can be used for shared decision-making16. However, it 
should be stressed that we cannot determine a causal relation between the different treatments 
and outcome yet. Effects of treatments in observational data are potentially biased by confounding 
by indication and selection should be interpreted with caution. Prospective and repeated evalua-
tions of PROs throughout care form the cornerstone of VBHC and potentially enable more patient-
centred breast cancer care with the possibility of improved shared treatment decision-making in 
breast cancer patients. 
CONCLUSIONS
PROs were evaluated in 764 historical patients according to patient, tumour and treatment 
characteristics in a single centre. ‘Satisfaction with breasts’ differed between type of surgery 
delivered. This knowledge as well as the collection of reference values could add value in shared 
decision-making concerning breast cancer surgery.
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(n = 22) p-value§

























Unilateral 35 (23.0) 2 (8.3) 28 (35.4) 2 (7.4) 3 (13.6)
Bilateral 117 (77.0) 22 (91.7) 51 (64.6) 25 (92.6) 19 (86.4)
Unknown .0 .0 .0 .0 .0
T -stage 0.35
T1 75 (49.3) 14 (58.3) 39 (49.4) 14 (51.9) 8 (36.4)
T2 31 (20.4) 3 (12.5) 14 (17.7) 6 (22.2) 8 (36.4)
T3 4 (2.6) 0 (0.0) 4 (5.1) 0 (0.0) .0
CIS 37 (24.3) 7 (29.2) 19 (24.1) 7 (25.9) 4 (18.2)
Unknown 5 (3.3) .0 3 (3.8) 0 (0.0) 2 (9.1)
N-stage 0.48
N0 121 (79.6) 20 (83.3) 59 (74.7) 24 (88.9) 18 (81.8)
N+ 30 (19.7) 4 (16.7) 19 (24.1) 3 (11.1) 4 (18.2)
Unknown 1 (0.7) .0 1 (1.2) 0 (0.0) 0 (0.0)
Systemic therapy 0.06
None 52 (34.2) 9 (37.5) 21 (26.6 13 (48.1) 9 (40.9)
CTx 30 (19.7) 2 (8.3) 15 (19.0) 8 (29.6) 5 (22.7)
ETx 22 (14.5) 7 (29.2) 13 (16.5) 1 (3.7) 1 (4.5)
CTx & ETx 48 (31.6) 6 (25.0) 30 (38.0) 5 (18.5) 7 (31.8)
Unknown .0 .0 .0 .0 .0
Radiation therapy <0.001
RTx by BCT 22 (14.5) 22 (91.7) .0 .0 .0
No RTx 58 (38.2) 1 (4.2) 35 (44.3) 13 (48.1) 9 (40.9)
Thoracic wall and/or 
locoregional RTx
72 (47.4) 1 (4.2) 44 (55.7) 14 (51.9) 13 (59.1)
Unknown .0 .0 .0 .0 .0
BRCA 0.07
BRCA1/2 negative 106 (69.7) 20 (83.4) 55 (69.6) 17 (63.0) 14 (63.6)
BRCA1/2 positive 33 (21.7) 2 (8.3) 14 (17.7) 9 (33.3) 8 (36.4)
Unknown 13 (8.6) 2 (8.3) 10 (12.7) 1 (3.7) .0
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Supplementary Table S2. Baseline characteristics 152 second primary or recurrent breast cancer 










(n = 22) p-value§
Histological type 0.58
IDL 88 (57.9) 14 (58.3) 43 (54.4) 15 (55.6) 16 (18.2)
ILC 10 (6.6) 0 (0.0) 8 (10.1) 1 (3.7) 1 (4..5)
CIS 36 (23.7) 7 (29.2) 18 (22.8) 7 (25.9) 4 (18.2)
Other 11 (7.2) 3 (12.5) 7 (8.9) 1 (3.7) .0
Unknown 7 (4.6) 0 (0.0) 3 (3.8) 3 (11.1) 1 (4.5)
Differentiation grade^ 0.017
Grade 1 16 (10.5) 5 (20.8) 7 (8.9) 4 (14.8) .0
Grade 2 28 (18.4) 8 (33.3) 11 (13.9) 5 (18.5) 4 (18.2)
Grade 3 32 (21.1) 3 (12.5) 14 (17.7) 5 (18.5) 10 (45.5)
NA 38 (25.0) 8 (33.3) 20 (25.3) 7 (25.9) 4 (18.2)
Unknown 38 (25.0) 0 (0.0) 27 (34.2) 6 (22.2) 4 (18.2)
BCT = breast-conserving therapy, MAS = mastectomy, REC-I = mastectomy followed by (in-) direct implant 
reconstruction, REC-A = mastectomy followed by (in-)direct autologous reconstruction, CTx = chemotherapy 
and/or immunotherapy, ETx = endocrine therapy, RTx = radiation therapy. §Chi square test. ¥Kruskall Wallis test
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Adding value of care to patients is crucial for all stakeholders. The use of both provider and patient 
reported outcome data was implemented in a single academic breast cancer centre. We describe 
the development of the outcomes set, data integration within electronical health records (EHR) 
and clinical use.
Methods
An Integrated Practice Unit (IPU) was constructed providing the full care cycle for breast can-
cer patients. Provider reported outcomes and patient reported outcomes (PROs) were defined, 
reflecting the entire cycle of care and long-term sustainability of quality of life. Multidisciplinary 
provider and patient perspectives were obtained via focus groups and surveys. Patient pathways 
were redesigned in order to identify suitable opportunities for data collection during the entire care 
cycle.
Results
A Standard Set for Breast Cancer Outcomes together with case-mix variables and timelines 
was agreed upon within the IPU. A secure electronic platform, directly linked to the EHR, was 
designed to measure PROs during the outpatient phase. First year evaluation showed a decrease 
of response rates over time, from 83.3% at baseline to 45.2% at 12 months after surgery. Patients 
reacted positively to the use of PROMs in daily clinical cancer care.
Conclusion
Assessment of patient reported as well as provider reported outcomes was implemented within 
our standard of breast cancer care. For this, dedicated resources, change of culture and practice, 
and improved knowledge and awareness about Value-based healthcare (VBHC) were essential. 
Our proposed framework aims to serve as a blueprint for implementation of VBHC in daily care.
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INTRODUCTION
Value-based healthcare (VBHC) aims to improve the quality of care delivered by measuring and improv-
ing outcomes that reflect value instead of volume1 2. Value of care is defined as health outcome per total 
costs1. Since value in healthcare depends on results, not inputs, value is measured by the outcomes 
achieved and not the volume of services delivered1. Ideally, these outcomes reflect patient-orientated 
results instead of structure or process measures that do not always reflect the results obtained1. Multiple 
health outcomes are often used to evaluate the care for a single medical condition. In a VBHC-design 
outcomes are both provider reported (i.e. breast cancer survival rates, complications, hospitalization 
rates) and patient reported (PROs)1. Inherently, these outcomes are disease specific and multidimen-
sional to reflect the total cycle of care and quality of life (QoL) and disease burden in the long run1 3. 
Specifically in the care for (early-stage) breast cancer patients the importance of value is increas-
ingly being recognized. High survival rates are achieved in early-stage breast cancer patients4 5 
irrespective of the type of surgery performed6-8. Considering these excellent and comparable on-
cological outcomes and the multiple locoregional strategies available in this setting (i.e. breast-
conserving therapy (BCT), mastectomy, whether or not followed by breast reconstructive surgery; 
all with differences in outcomes and costs), there is an increasing need for outcome measurements 
that accurately differentiate between treatment strategies. In the era of increasing healthcare costs 
and stringent measures to lower costs, these outcomes could increase breast cancer care efficacy 
(by improving outcomes against equal or lower costs). In addition, adequate outcome assessment 
could also add in future treatment decision-making and/or follow-up regimens. 
The Erasmus MC, a major academic healthcare institute within the Netherlands, initiated a VBHC-
strategy. With commitment from both the institution and different multidisciplinary disease teams, 
multiple outcome sets were defined and a data collection tool was developed to capture these 
outcomes. Following a pilot phase the concept was gradually rolled out and is now used in daily 
practice for 10 medical conditions amongst which breast cancer. The International Consortium for 
Health Outcome Measurements (ICHOM) has initiated efforts to develop standard sets of patient-
centred outcome measurements for various medical conditions amongst others breast cancer. 
As part of the ICHOM Working Groups, clinicians from the Erasmus MC have contributed to the 
development or implementation of multiple outcome sets on an international level9-13.
Value-based breast cancer care was designed in 2014 and initiated in October 2015 by the dedi-
cated multidisciplinary breast cancer team of the Erasmus MC Academic Breast Cancer Centre. A 
standardized outcomes set was created that encompassed both provider reported outcomes and 
PROs. Striving to implement value-based breast cancer care on a broader (inter)national scale, 
this article gives a step by step overview of the framework deployed for implementation of this 
outcome set and discusses the challenges within the implementation process. The description of 
our data collection tool that was linked to the electronic health records (EHRs) and the research 
performed during this implementation phase, is additionally aimed to serve as a guide for future 
implementations. Lastly, future steps are discussed needed to transform current breast cancer 
care towards a value-based breast cancer care.
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METHODS
Within the institute a breast cancer specific-strategy was developed to transform the current breast 
cancer care to value-based breast cancer care (Fig. 1)2 3. This step by step overview functions as 
a blueprint in the implementation process.
Figure 1. Erasmus MC’s blueprint, facilitate the teams on their journey towards VBHC.
VBHC, Value-based healthcare; IT, Information Technology
Institutional dedication 
Recently, the executive board of the Erasmus MC initiated a 5- year VBHC-strategy to transform 
the institute into a true value innovator. This institutional dedication is pivotal to enable a transfor-
mation of the current healthcare systems towards a VBHC-system. This institutional leadership 
ensures sufficient resources needed for this transformation14. We consulted the Institutional 
Review Board, who concluded that informed consent was not needed since the VBHC-strategy is 
considered standard of care in Erasmus MC.
Dedicated multidisciplinary team 
An integrated, and thus multidisciplinary breast cancer practice unit was already operative within 
our institute. The team is composed of oncological (breast)surgeons, medical oncologists, radi-
ation oncologist, radiologists, plastic & reconstructive surgeons, pathologists, specialist breast 
cancer nurses (all present at multidisciplinary board meetings), clinical geneticists, psychologists, 
gynaecologists, and thoracic surgeons (consulted upon indication). Within breast cancer care 
patient-reported outcome measures (PROMs) had already gained interest and participation in the 
institutional pilot phase was therefore seen as a unique opportunity. 
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Care pathway
Realigning services with patient needs is fundamental to deliver more efficient care2. For breast 
cancer, a ‘complex’ care pathway (involving many different disciplines), was first redesigned to 
serve as a starting-point for the design of other care-pathways: young women with (potentially 
hereditary) breast cancer who need neoadjuvant systemic treatment and afterwards undergo 
mastectomy with immediate (autologous) breast reconstruction. Within this redesign the time 
points when to visit several different physicians and when to evaluate different outcomes were 
determined (Supplementary Fig. S1).
Breast cancer outcomes set
Defining an outcomes set is an essential step within any VBHC-initiative which should occur before 
actual implementation. A first version of the outcomes set was composed by the multidisciplinary 
team after five 3-h work sessions. To ensure patients’ input in the outcomes selection, interviews 
and surveys were performed within breast cancer patients in different treatment phases. Validated 
questionnaires were searched capturing the intended outcomes. PROMs incorporated in the set 
were the EORTC-QLQ-Core (C30)15, EORTC-QLQ Breast Cancer (B23)16, BREAST-Q (both pre-
operative and postoperative modules)17, EQ-5D-5L18, Distress Thermometer19, the Reproductive 
Concerns Scale (RCS-NL)20, and the CarerQoL-7D21. All questionnaires were available in validated 
Dutch versions (Fig. 2).
Outcomes such as patient, tumour and treatment characteristics, survival rates and treatment-
related complications were defined by physicians considering patient input. These outcomes 
serve as either an outcome on its own (for example survival rates) or as a variable in multivariable 
or case-mix analyses used to evaluate outcome scores (Supplementary Table S1). 
The determined time points for data collection are equal to those in the, later developed, ICHOM 
set. Time points determined were: baseline (prior to treatment; T0), following the last course of 
neoadjuvant systemic therapy (T3), 6 months after surgery (T6) and annually thereafter (T12-60) 
(Fig. 2). To capture the period where patients might still be on endocrine therapy, follow-up was 
recommended up to 5-10 years in early breast cancer patients. Annual follow-up up to age 50 
years was recommended for young breast cancer patients. Annual follow-up for 10 years was 
recommended for patients with advance disease.
Data collection tool
An in-house developed open source electronical data collection tool was used and configured, 
which allowed the construction of data collection-forms and automatic distribution of PROMs. 
Emails are sent to the patients in order to activate the distribution of PROMs. After the right treat-
ment pathway is selected by the physician, all the following PROMs will be sent automatically by 
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the tool at the right time point. The tool was linked to the EHR enabling the review of the collected 
data for individual patients at the (outpatient) clinic. The secure platform is build up by two software 
programs, LimeSurvey22 and GemsTracker23. The development team simultaneously developed a 
user-friendly interface to display the collected data. Since the selected BREAST-Q questionnaire is 
surgery-specific, multiple pathways for data collection had to be build (i.e. BCT, mastectomy alone 
and mastectomy with breast reconstruction, either with implants or autologous). Longitudinal PRO 
data and data from the caregivers is collected in these pathways (Fig. 2).
RESULTS
During the institutional pilot-phase, in which a VBHC-strategy was implemented for six medical 
conditions, multiple institutional and regional (breast cancer specific) symposia were organized 
to update and include both physicians within the hospital, primary care givers, patient advocacy 
groups and other stakeholders in the ongoing initiative. Currently a VBHC-strategy is being used 
in the daily care for 10 other medical conditions other than breast cancer10-12.
Implementing value-based breast cancer care
An initial period of 3 months was used to test and evaluate the use of the different pathways. 
During this phase all emails (distributing the PROMs) were sent manually to patients by specialist 
nurses. This enabled proper insight in the functioning of
the pathways. The manual distribution consequently led to a reminder to discuss the initiative with 
patients or to follow-up on patients who had not responded. Currently, all postoperative modules 
are distributed automatically to patients (by the electronical data collection tool) 3 weeks before 
the scheduled consultation with 2 following weekly reminders. The preoperative surveys are dis-
tributed manually by specialist nurses considering their delicate timing of administration (directly 
following diagnosis and before surgery or start of neoadjuvant chemotherapy). An advantage of 
this continuous manual distribution is that it serves as a reminder to discuss the initiative with all 
patients (and caregivers) at the outpatient clinic. An additional change was made in the follow-up 
regimen, i.e. the PROs collection at the 6 month postoperative time point (T6) was considered 
mandatory instead of optional. The collected PROs at this time point were evaluated and dis-
cussed with the patient in the telephone consultation with the specialist nurse. A first consultation 
at the outpatient clinic was scheduled together with the (mammographic) follow-up visit. PRO 
scores were than evaluated and discussed with the patient in the consultation room. 
An average of 20 min per patient was needed to complete the PROMs of the outcome set at one 
specific time point24.
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^ Physician reported complications measured within 90 days postoperative
*
* Pre-operative PROMs
§ Only in case of neoadjuvant systemic therapy (NST)
§
Figure 2. Erasmus MC’s standard set for breast cancer.
a  All PROMs are collected at baseline (T0), 6 months (T6) after treatment, and then annually (T12-T60), except 
for the BREAST-Q-satisfaction with breast module, which is only collected at baseline (T0), 1 year (T12) and 2 
years (T24) after treatment. 
b  Collection of acute complications is recommended while the patient is undergoing treatment or within 90 days 
of treatment completion, except for complications of hormonal therapy, which are collected up to one year 
(T12). 
c  Survival and disease control. 
NST = neoadjuvant systemic therapy; PROMs = patient reported outcome measurements.
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First evaluation
We evaluated the first two years of our VBHC-initiative. Ethical approval for this evaluation was 
granted by the Institutional Review Board of the Erasmus MC (MEC-2018-1015). A total of 239 breast 
cancer patients, surgically treated at our institute, were enrolled between October 2015 and Decem-
ber 2017. A response rate of 83.3% (199/239 patients) was seen at baseline (T0), which decreased 
over time to 65.7% (157/239 patients) at 6 months postoperatively (T6) and 55.1% (108/196 patients) 
at 12 months postoperatively (T12). Looking at the different questionnaires it was found that not all 
questionnaires were completed at the several time points (T0, T6, and T12). For example, only the 
EORTC-QLQ-C30 and -B23 were completed and the BREAST-Q not, or otherwise (Fig. 3). Moreover, 
some time points were completely missed leaving all PROMs at that specific time point empty. 
The specialist nurse monitored whether patients completed the PROMs and asked patients about 
their reason not completing the questionnaire (if applicable). When no responses were received 
patients mostly stated that they had forgotten about the surveys (preoperatively) or had not under-
stood that they would be administered repeatedly (postoperatively). 
Ongoing efforts resulted in a user-friendly interface that directly displays the outcomes collected in a 
dashboard so they can be evaluated by both patients and physicians. Concerning feedback, PROs 
are filled in prior to outpatient clinic visits and discussed by the healthcare provider. If not filled in, 
the patient is asked to do so and a phone call is planned. Essential for the success of this VBHC-
initiative is the (direct) feedback of the PRO scores and/or the changes in the scores according to 
baseline values. An adequate interpretation of these (changes in) scores enables an appropriate 
change in care strategy or intervention. Reference scores are additionally needed to evaluate PROs 
scores in a broader perspective. In order to obtain useful reference scores applicable to our patient 
population, we evaluated PRO scores which were retrospectively assessed within our institute (all 
breast cancer patients treated over the last 10 years)25 and through the regional and national patient 
advocacy groups24. In addition, we evaluated the median PROs for the different PROM modules 
over time during the first year. As expected PRO scores decreased between baseline (T0) and 6 
months postoperatively (T6), but higher scores were seen at one year postoperatively (T12) com-
pared to T6, Fig. 4. Graphical visualization of the trend of PRO scores over time, during treatment 
and/or follow-up, facilitate a quick overview of a patient’s current state of health in the physiological, 
social, and physical areas and turn this information into a diagnostic tool. 
To evaluate whether patients were satisfied with our initiative, an experience survey was composed, 
asking patients (n ¼ 30) how satisfied they were with the number of PROMs, the content of the 
PROMs and the feedback of the PRO scores during hospital visits. Patients reported that PROMs 
were aligned with their treatment (86.3%), and they felt themselves more heard at T6 (64.3%) and 
at T12 (100%). The majority of the patients even reported that that completing the PROMs helped 
them to become more aware of their everyday functioning (60.0%), and contributed positively to 
their breast cancer treatment (80%) (Fig. 5).
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Figure 3. Percentage of breast cancer patients filled in the PROM questionnaires (n%) per time point 
during the first year.
Vertical axis shows the percentage (%) of patients who completed the PROM per time point. 
T0= baseline (prior to treatment), T6= six months after surgery, T12= twelve months after surgery
Figure 4. Spider plot representing the different PROM scores per time point (n=239).
T0= baseline (prior to treatment), T6= six months after surgery, T12= twelve months after surgery
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Figure 5. Experience survey (n=30)
DISCUSSION 
Value-based breast cancer care was implemented within our institution over a time-period of 
three years. First, standardized care pathways were developed by the dedicated multidisciplinary 
team. Second, a breast cancer outcomes set was developed in collaboration with breast cancer 
patients and regional patient advocacy groups. Third, the outcomes set was integrated in clinical 
practice by using a newly developed data collection tool which was linked to the electronic health 
records. Patients within our institute now receive PROs at baseline and at predetermined time 
points throughout their care cycle to discuss these outcomes with their healthcare providers and 
tailor their supportive therapies were necessary. 
The compliance during the first year was lower than expected. Possible explanations are patients’ 
unawareness or misunderstanding about the repeated administration of the PROMs. False or 
changing e-mail addresses was another issue which explains the lower compliance rate over time. 
In order to tackle these difficulties, a brochure to explain the VBHC-initiative and the different time 
point of survey-assessment was therefore created. 
Patients who have participated with the collection tool receiving and completing the PROMs have 
provided positive feedback about the initiative thus far. They stated that the use of PROMs helps 
them to prepare for the upcoming appointment, which makes it more tailored to their needs. 
Care providers at our institute reported similar benefits, additionally stating that with the use of 
PROMs a more complete view about the provided care can be obtained. Studies evaluating the 
use of a similar tool reported comparable positive feedback of both patients and care providers 
and identified several strengths26-28. The ability to prioritize topics for discussion at outpatient 
visits, symptom monitoring and management were well documented, as well as improved patient-
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provider communication leading to more shared decision-making. Clinicians found PRO data 
useful and not disruptive to their practice29-31. Several tools are available nowadays and successful 
implementations of outcomes sets by IT-systems integrated in the EHRs have been reported 28 32-34. 
Also, when enquiring about the expectations of breast cancer patients through the regional and 
national patient advocacy groups, positive answers were collected 24. Recently, a collaboration 
with eight hospitals in the Southwest region of the Netherlands aiming at the same outcomes set 
was started to expand the local value-based breast cancer-initiative. In this way transparency 
between hospitals can be driven in order to improve quality of regional breast cancer care by 
benchmarking outcomes. Comparing outcomes for quality monitoring requires implementation of 
identical outcomes sets. Regional and national, or even international, efforts to adapt an identical 
set creates the possibility for benchmarking and comparative effectiveness research. 
Both authors LK and MM were part of the ICHOM working group that established a consensus 
on the breast cancer outcome set13. The ICHOM breast cancer set was compared to the institu-
tional outcomes set and changes were made to obtain the highest resemblance. In addition to 
the ICHOM set the Erasmus MC outcomes set also includes the EQ-5D-5L-questionnaire and all 
modules of the BREAST-Q (i.e. not only the ‘satisfaction with breast’- module). This general health 
questionnaire was added mid-2016 within all VBHC-initiatives at the Erasmus MC in order to evalu-
ate the health status of all patients referred to our centre35. The BREAST-Q is a surgery specific 
questionnaire developed in 2009 with the use of modern psychometric methods17. It is expected 
to accurately differentiate satisfaction with cosmetic outcome per type of surgery performed36 37. 
An important advantage of early adaption to a value-based breast cancer care-initiative is that it 
generates the possibility to gain insights in the validity and applicability of PROMs used. 
Internationally, current payment systems are mostly based on the volume of services (fee-for-
service-model). Bundled-payment is a value-based model in which the basis for reimbursement 
is bundled care and value (results rather than services). Wang et al.38, examined the correlation 
of outcomes and medical expenditures by comparing a bundled-payment system to a fee for 
services-system in 17,940 breast cancer patients. With a range of 5-year follow-up, the medical 
payments of the bundled-payment group remained stable, whether the fee-for-service payments 
steadily increased. This suggests that bundled-payment systems may lead to better adherence 
to quality indicators, better outcomes, and more-effective cost-control over time38. Healthcare 
systems that already have a bundle-payment system could take advantage of the transformation 
made by breast cancer multidisciplinary teams towards a value-based breast cancer system. 
Although a VBHC-initiative is hard to translate to a fee-for-service model, it is expected that all 
stakeholders will benefit from such a transition to longer term bundles3. Not only in a fee-for-
service system but also in a bundled payment system sufficient research to gain insight in PROs 
validity and applicability is needed before PROs can be used to guide payments. 
Limitations seen within the implementation process should be rephrased into key lessons. 
Dedicated resources (human and financial) need to be established to make outcome measurement 
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core business. Changing culture as well as practice is a key part of the process and must be ac-
knowledged in the attempted changes. Healthcare providers therefore need to make active efforts 
to secure support for VBHC in daily practice. The development of our data collection tool was a 
significant milestone in the implementation process. Due to IT functional problems implementation 
slowed down, but true progress could be made after the data collection tool was functioning 
well. This went hand in hand with improved knowledge and awareness about VBHC and the data 
collection tool. Running pilots and educating both providers and patients are therefore essential 
for high compliance rates with provider outcomes and PROs. Lastly, to ensure continuous adapta-
tion and correction during the implementation process, small and incremental changes should be 
made instead of mass overhaul12. 
With breast cancer survival rates continuing to improve, the focus on survivorship issues and qual-
ity of life is increasingly becoming important. In the context of breast cancer care a value approach 
is expected to generate necessary insights in outcomes for the different surgical strategies and 
improve care efficiency (by improving outcomes and stabilizing or reducing costs). The VBHC-
initiative is expected to pave the way24. Our initiative has now grown beyond its own centre to 
support other breast cancer centres to implement the same set of outcomes, seeding the potential 
for learning and improvement initiatives on a much broader scale. At the moment we analyse a 
large dataset in order to develop prediction models for quality of life concerning certain therapies.
CONCLUSION
A value-based breast cancer strategy including explicit and longitudinal PRO scores was success-
fully implemented within our institute. Measurement of PROs as well as provider reported outcomes 
was implemented within our standard care. Structured measurements will create opportunities 
for performance improvement, shared treatment decision-making and benchmarking between 
different providers and healthcare systems, both on a regional and international scale. For this, 
dedicated resources, change of culture and practice, and improved knowledge and awareness 
about VBHC were essential. The outline described of both the development and implementation 
of this initiative is meant as a guide for future implementations.
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Supplementary Figure S1. Recalibration of the current pathway for young woman with hereditary 
breast cancer. 
The big squares show the previous pathway adapted to match the Erasmus MC standard set. The pathway in-
volves multidisciplinary specialty interaction at different time points, with – in the smaller squares – approxima-
tions of data collection time points used where necessary. For breast cancer patients treated with neoadjuvant 
chemotherapy an additional data collection point was added (T3). 
T0= baseline (prior to treatment), T3= following the last course of neoadjuvant chemotherapy or endocrine 
therapy, T6= six months after surgery T12= twelve months after surgery, and annually thereafter (T24-T60). 
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Supplementary Table S1. Case-mix and treatment variables, Erasmus MC’s breast cancer standard set.
Patient population Measure Data Sources
Demographic factors 








Body mass index Clinical 
Baseline clinical factors





All patients Date of histopathological diagnosis




Patients with NST Clinical TNM status§ Clinical
Patients with surgery Pathological TNM status§
Size of invasive component of tumour (mm)
Number of lymph nodes resected
Number of lymph nodes involved
Estrogen receptor status 
Progesterone receptor status 
Her-2-neu receptor status
Clinical







DCIS = ductal carcinoma in situ, Her-2-neu = human epidermal growth factor receptor 2, NST = neoadjuvant 
systemic therapy, TNM= Classification of Malignant Tumours (Tumour Node Metastasis).
^Breast-conserving therapy, mastectomy, reconstructive surgery (implant/ autologous), §American Joint com-
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Patient-reported outcome measures (PROMs) are increasingly being used to improve care delivery 
and are becoming part of routine clinical practice. This systematic review aims to give an over-
view of PROM administration methods and their facilitators and barriers in breast cancer clinical 
practice.
Study Design and Methods
A systematic literature search was conducted in Embase, MEDLINE, PsycINFO, Cochrane Central, 
CINAHL and Web of Science for potentially relevant articles from inception to November 2017. 
Reference lists of screened reviews were also checked. After inclusion of relevant articles, data 
was extracted and appraised by 2 investigators.
Results
A total of 2,311 articles were screened, of which 34 eligible articles were ultimately included. Meth-
od and frequency of PROM collection varied between studies. The majority of studies described a 
promising effect of PROM collection on patients (adherence, symptom distress, quality of life, ac-
ceptability and satisfaction), providers (willingness to comply, clinical decision-making, symptom 
management) and care process or system outcomes (referrals, patient-provider communication, 
hospital visits). A limited number of facilitators and barriers was identified, primarily of technical 
and behavioural nature.
Conclusion
Although interpreting the impact of PROM collection in breast cancer care is challenging owing 
to considerations of synergistic (multicomponent) interventions and generalizability issues, this 
review found that systematic PROM collection has a promising impact on patients, providers 
and care processes/systems. Further standardization and reporting on method and frequency of 
PROM collection might help increase the effectiveness of PROM intervention and is warranted to 
enhance their overall impact.
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INTRODUCTION
Breast cancer is the most common cancer affecting women worldwide1. With survival rates 
continuing to improve, the focus on quality of life is becoming increasingly important. Because 
healthcare is shifting toward a more value-based framework for quality of care improvement, more 
attention is being paid to patient-reported outcome (PROs)2. PROs are defined as feedback on 
a patient’s health condition (i.e. symptoms and quality of life) coming directly from the individual 
patient, thus without external interpretation3. 
PROMs are increasingly being collected and advocated in cancer care for aiding care management 
of the individual patient4-7. The use of PROMs has been associated with better patient satisfaction8, 
perceptions of quality of care9-11, health outcomes12-14, and higher patient acceptability12 15. Routine 
collection of PROMs can also have a positive impact on patient-provider communication, (shared) 
decision-making, and symptom management8 16 17. Challenges in collecting, storing, analysing, 
and reporting PROM scores in real time can impede the routine use in clinical practice5 making it 
important to identify these implementation issues. Howell et al.17 published a review of the factors 
of PROM implementation and use in cancer clinical practice and concluded that PROMs have 
been tested most often in the breast cancer population. However, reviews focusing on methods of 
PROM administration, specifically in breast cancer care, have not been published.
This review sought to provide an overview of PROM collection methods in breast cancer care 
answering the following questions: 1) how have PROMs been administered in breast cancer care; 
2) what is the impact of PROM administration on patients, care providers and healthcare services 
or processes; and 3) what are the facilitators and barriers that influence integration of PROM 
collection in routine breast cancer clinical practice?
METHODS
This systematic literature review was conducted according to the Preferred Reporting Items for 
Systematic Review and Meta-Analyses (PRISMA) model18 for reporting of systematic reviews. 
Literature Search Strategy
Six electronic databases were searched – Embase, MEDLINE, PsycINFO, Cochrane Central, 
CINAHL and Web of Science – from study inception to November 3, 2017. No restrictions to 
language or country of publication were applied to either the search strategy or study selection. 
The comprehensive search strategy was devised jointly with an experienced librarian and included 
a combination of keywords for breast cancer, which was searched in free text and as exploded 
medical subject headings where possible. Additional related terms were used to maximize the 
sensitivity of the search. The full search strategy is provided in the appendix (Supplementary S1). 
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Study Selection
Figure 1 shows the PRISMA flow diagram of the study selection process. Two investigators (AO 
and LE) independently screened titles and abstracts and identified potentially relevant articles. 
The reference lists of identified reviews were screened for other relevant publications. Studies were 
excluded if they: 1) did not include breast cancer patients, 2) had an irrelevant aim by focusing on 
PROMs as an evaluation method, endpoint or outcome for other interventions/ treatments, 3) had 
the following study design: case report, editorial, review, study protocol, 4) had an overlapping 
study population with another study (if relevant, the most recent article was included), and 5) were 
not published in full-text.
Remaining studies were reviewed in full-text by both authors using the same exclusion criteria. 
Disagreements on study eligibility were either resolved through discussion between both asses-
sors, or ultimately, through consultation with the whole research team. Subsequently included full-
text publications were listed in a taxonomy table that comprised of study descriptives (number of 
involved patients and healthcare providers, method and frequency of PROM collection, outcomes 
of PROM collection, and facilitators or barriers). 
Data Extraction & Quality Assessment
Data that were extracted included information on study aim and design, sample characteristics 
(for intervention and control groups, if applicable), and method or frequency of PROM collection. 
Outcomes described in the included studies were divided into 3 categories during data extraction: 
1) patient outcomes (i.e. adherence, symptoms, health outcomes, acceptability, and satisfaction), 
2) care provider outcomes (i.e. adherence, impact on clinical decision-making, acceptability, and 
satisfaction), and 3) care process/system outcomes (i.e. impact on referral (rates), communication, 
hospital visits, and usability). Acceptability was defined as the extent to which PRO collection was 
found pleasant by study participants. Satisfaction was defined as the extent to which the study 
participants enjoyed completing the PRO instruments19. 
Finally, described facilitators and barriers of routine PROM use in breast cancer care were also 
extracted. The Critical Appraisal Skills Programme (CASP) tool was used by both reviewers (AO 
and LE) to evaluate the quality of included studies (Supplementary Table S2). Discrepancies were 
discussed between both reviewers and supervisors until consensus was reached. There was no 
meta-analysis performed due to the heterogeneity among the included studies. 
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RESULTS
After the initial screening of titles and abstracts (n = 2,311), 58 remaining potentially relevant 
articles were retrieved (Fig. 1). These remaining manuscripts were checked for eligibility based on 
full-text assessment. Thirty-four studies met the inclusion criteria (Table 1).
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of rel-
evant article selection. 
Total Study Population
The total sum of patients across all selected studies was 14,083 of which 11,191 (79.5%) were 
breast cancer patients (range 13 – 8,359 patients). Sixteen of the 34 included articles exclusively 
involved breast cancer patients. In the remaining 18 studies, breast cancer patients were a sub-
group of study populations with various cancer types (prostate, lung, colon, gynaecologic, and 
genitourinary cancer, among others). Mean age was 54.68 years (± standard deviation [SD] 5.01). 
Implementation
The patient-reported outcome version of the Common Terminology Criteria of Adverse Events 
(PRO-CTCAE)19-24 was used most often, followed by the European Organization for research and 
Treatment of Cancer Quality of life Questionnaire (EORTC) modules QLQ-C30 and QLQ-B2325-34, 
M.D. Anderson Symptom Inventory (MDASI), EuroQol-5D questionnaire24 27 35 36, the Functional 
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Assessment of Cancer Therapy questionnaires (FACT-B, -F, -G)31 33 37 38, and the Hospital Anxiety & 
Depression Scale (HADS)26 30 39 respectively. 
PROMs were most often collected electronically (n=17). Web-based assessments were the primary 
method of data collection (n=7), both in and outside the clinic, followed by the use of a tablet 
(n=6), an (e-Health) application (n=2), email (n=1), and a software system (n=1) (Table 1). Four 
studies22 31 33 40 used both electronic and paper-based interventions to collect PROMs. A telephone-
based intervention was used in 9 studies, with 4 studies involving interactive voice response32 41-43, 
3 studies involving mobile applications20 44 45, and 2 studies involving semi-structured (computer-
assisted) telephone interviews or structured prompts of PRO domains26 28. One study used only a 
paper-based intervention27. Two qualitative studies involving patient focus groups did not include a 
PROM intervention46 47. One study48 did not specify the way PRO scores were collected. 
The frequency of PROM administration varied from once to daily during study time (Table 1). The 
duration of PROM interventions ranged from 1.5 months20 to 24 months48. Most interventions 
(n=14) provided PROMs only in the clinic, while 8 studies required patients to complete PROMs 
at home (all electronic- or telephone-based interventions), and in 3 studies either at home or in 
the clinic. PROMs were collected during treatment (n=22), during follow-up (n=3), or during both 
treatment and follow-up (n=9). One third of PROM interventions restricted assessments to only 
monitor a specific phase of breast cancer treatment, most commonly during chemotherapy. The 
most common reminder method was by e-mail or phone. 
In 4 studies11 21 29 43, the electronic PRO systems were directly integrated into the electronic health 
record (EHR). Some PROM interventions also provided patient education (n=9); one of these35 was 
administered through a module. Of 10 studies11 19 22 23 25 26 28 29 46 47 describing healthcare provider 
involvement (i.e. focus group, interviews, satisfaction or usability questionnaires), only 2 studies19 22 
described providers actually being part of the PROM intervention. Within the PROM intervention, 
patients’ providers could edit automatically generated care plans (based on PROM responses) to 
further tailor referrals and treatment recommendations. Once approved by providers, care plans were 
mailed to patients19 22. Outcomes were discussed by the treating clinician (n=9), nurse (practitioner) 
or physician assistant (n=5), or by a combination of these (n=7) (Table 1). Nearly one third of PROM 
interventions included alerts being sent to clinicians or patients. Alerts were typically sent by email 
or text message. In 18 studies, summary reports of PRO data were sent to prespecified providers.
Impact of PROMs on Patient Outcomes
Adherence. Among studies reporting on adherence (n=14), completion rates varied between 71%32 
and 100%48 (Table 1). The extent of adherence variation over time was rarely reported: Dean and 
Crittenden48 reported a decrease in compliance rate from 100% to 87.7% in 12 months, and Min et 
al.36 observed a decline from 100% to 13.3 % at 90 days. Other noteworthy observations were that 
noncompliers were slightly older43, that unemployed women had a higher compliance rate36, and that 
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higher rates were seen for monthly rather than for weekly adherence35. Snyder et al.11 reported that the 
proportion of missing PROM items was lower when PROMs were completed at home versus the clinic. 
Symptoms. Three randomized controlled trials (RCTs) evaluated the effect of PRO collection on 
symptom (severity) over time. All reported significantly decreasing symptom prevalence or symptom 
distress over time in the intervention arm versus controls32 39 49. Other studies26 41 43 45 also reported 
a reduction of symptoms postintervention when compared to baseline. More reporting of new or 
changing symptoms was observed when a PRO collection tool was used34. In addition, a (3-arm) 
RCT by Egbring et al.20 found that when PROs were administered through an application instead of 
paper-based questionnaires, there was a higher frequency of symptom reporting. There was also a 
higher tendency to report overall symptoms when patients were not supervised by care providers20. 
Health outcomes. Eleven studies evaluated the impact of PROM administration on patient wellbe-
ing (Table 1). Reduction of psychosocial distress was reported30, as was reduction of symptom 
distress or burden42 43, anxiety and depressive feelings26 41, and pain27 33. Furthermore, improved 
physical functioning and improved emotional and sexual wellbeing were found26 33 46 48. A sub-
stantial effect on health-related quality of life (HRQoL) over time between PROM intervention and 
control group was reported in 1 RCT (n=776), in addition to the significantly higher overall and 
quality-adjusted survival in the intervention group24. Two other RCTs26 30 also reported improved 
HRQoL scores, albeit not significantly improved. A qualitative study46, in which focus groups and 
one-on-one interviews were conducted, found that for women postmastectomy, PROMs focusing 
on emotional wellbeing, education, communication, and process of care (e.g. scheduling appoint-
ments and transition of care) were of greatest importance. 
Acceptability. Fifteen studies evaluated patients’ acceptability of PRO collection (Table 1). Patients 
were generally positive, reporting that the interventions were helpful. Four studies used a tablet 
computer to collect PROMs, and over 90% of their study populations found tablets (very) easy 
to use22 31 33 37. Similar results were reported for the use of applications45 50 and telephone-based 
interventions11 41 42. An online web-tool was used in 4 studies19 29 31 35, all of which reported an 
overall high acceptability. The majority of patients reported that the length and number of PROM 
questionnaires was acceptable19 22 37 43, the questionnaires were helpful in discussing health issues 
with their care providers during visits11 23 29 41 47 50, they were willing to answer additional questions23, 
and they liked being able to complete the questionnaires at home23 29 35 47. 
Satisfaction. Twelve studies reported the effect of PRO collection on patient satisfaction. A cohort study 
of 66 breast cancer patients that evaluated the use of a tablet computer for PROM collection found 
that 75% of patients were satisfied at baseline, and that percentage rose to 88% over time31. Of these 
patients, 84% to 94% were willing to recommend the PROM collection tool to other patients. In stud-
ies with a telephone-based PROM collection tool (n=4), patients reported a high satisfaction rate as 
well11 28 41 42. Comparable results were found for web-based collection tools with patients reporting them 
as helpful and enjoyable19 22. In 1 study, patients preferred the tablet computer over an online web-tool23. 
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Impact of PROMs on Provider Outcomes
Compliance. Knoerl et al.19 examined providers’ willingness to review PROMs: All providers (5 nurse 
practitioners and 1 physician assistant) created an account to a web-based platform (Carevive) 
for PROM collection and ultimately reviewed and finalized 81.3% of generated personalized care 
plans. However, only 20% of providers who completed all outcome assessments (n=5) reported 
that they consistently reviewed care plans with their patients19. 
Clinical decision-making. Care providers’ opinions were divided on whether PROM scores would 
influence their clinical decision-making. One study reported that none of the participating provid-
ers felt the PROM collection tool had led to different therapy decisions25, whereas another study 
reported one third of providers reporting that their clinical decisions were influenced by symptom 
alerts32. Providers’ email responses to symptom alerts were to maintain treatment strategies (46%), 
reassess the patient at the following clinic visit (33%), or alter the treatment (8%)32.
Acceptability. Five studies evaluated if PROMs were helpful to providers in identifying and controlling 
patient symptoms and other areas of need11 22 23 25 42. A prospective cohort study11 reported that 58% 
of providers were most likely to agree that a PROM intervention helped them to identify areas of 
concern. Stover et al.23, who implemented a web-based PRO screening system with 21 items as-
sessing symptoms and functional status, reported that providers found PRO summary reports most 
useful for reviewing symptoms (92%), and (very) helpful in changing the treatment plan (80%). Most 
providers (92%) also reported that discussing PRO results with patients during clinical visits did 
not lengthen the consultation time. Albert et al.25 evaluated an electronic PRO collection tool (QoL 
Profiles) and reported that providers (n=14) found the system understandable (100%), felt it provided 
more information (63%), helped them notice patients’ issues (25%), and found that the system cor-
responded to their own patient assessment (94%). Knoerl et al.19 also observed that care providers 
reported PROM collection being helpful in identifying appropriate areas of concern or need.
Impact of PROMs on Care Process/ System Outcomes
Referrals. There was limited evidence concerning the effects of monitoring or tracking PROMs on 
referral rates. Girgis et al.26 found a significant (p<0.0001) difference in the number of referral rec-
ommendations, as a response to PROM results, between nurses and clinicians with more referrals 
being recommended by nurses for unmet psychological, daily living, health service or information, 
and physical needs. Basch et al.24 demonstrated that 8% of severe symptom email alerts resulted 
in referrals, whereas the majority (77%) of email alerts prompted telephone counselling by nurses 
for symptom management.
Hospital visits. Only 2 studies looked specifically at the effect of PRO collection and screening 
on the rate of emergency room (ER) visits24 40. Basch et al.24 reported a significant 7% decrease 
(p=0.02) in ER visits between patients whose symptoms were electronically tracked and patients 
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who received usual care during active chemotherapy. Barbera et al.40 reported comparable results, 
with the number of ER visits being 43% lower in breast cancer patients who received routine PRO 
assessments prior to clinic visits during active chemotherapy as opposed to patients who did 
not. Effects of PROM interventions on hospitalizations were not significant: Basch et al.24 found a 
4% decrease in hospitalizations (p=0.08) in patients whose PROMs were monitored compared to 
patients with usual cancer care; Wheelock et al.34 did not find a difference between patients whose 
PROMs were electronically captured during breast cancer follow-up care compared to patients 
who did not receive the PROM intervention.
Communication. Regardless of study design, patients and providers were generally positive about 
the impact of systematic PROM collection on patient-provider communication20 25 26 31. Patients felt 
more encouraged after PRO assessment to discuss symptoms and issues with their providers that 
they otherwise would not have discussed31 and also felt more focused and taken seriously dur-
ing the consultation20. Although evidence was scarce, providers reported that reviewing PROMS 
encouraged clinical interactions between them and their patients19 and that this review also led to 
more specific questioning during the clinic visit25. 
Facilitators and Barriers
Facilitators. Technical facilitators of PROM implementation in routine breast cancer care were the 
most frequently described (Fig. 2). One article pointed out that technological methods of PROM 
Figure 2. Description of facilitators and barriers
PRO(M), Patient-Reported Outcome (Measurements); EHR, Electronic Health Record
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collection (e.g. web-based, smartphone applications, tablet computer) might be more acceptable32. 
Providers seem to prefer graphic presentations of PRO results above table reports, but they also 
valued addition of free-text comments by patients. Patient feedback included the recommendation 
of tailoring questions (through an interface) for individual patients and providing more information 
on PRO score results, which might enhance PRO collection and interpretation11 29. Email reminders 
to review PRO results could possibly increase care providers’ awareness of patient symptoms and 
problems and thus encourage symptom management32. Some patients expressed a preference 
to be notified when providers reviewed PRO reports29. One study found that the presence of a 
“change champion” was essential to facilitating PROM implementation by not only encouraging 
patients’ acceptance of the collection method (e.g. tablet computers), but also by guiding care 
providers through PRO reports and ensuring that appropriate actions are taken in response to 
significant patient issues31. 
Barriers. The clarity of PROM questions, including stating the (symptom) recall period, can be a 
hurdle for patients’ acceptability of the PROM intervention19 22. Providers also indicated that the 
lack of integration and synchronization of the PRO data system with the EHR was a significant 
barrier in routine PRO review, because it required logging into additional systems (with additional 
passwords) and compatible Internet browsers11 19 22 29. Some articles reported that patients found 
it confusing if the meaning of PRO summary scores were inconsistent, with higher scores alter-
natively indicating better or worse outcomes11 29. Conflicting providers’ opinions were reported 
regarding the timing of PROM review: Some providers indicated that most symptom alerts were 
received outside the hospital, thus impeding swift patient contact, whereas others reported that 
reviewing PROMs right before clinic appointments might disrupt the clinical practice flow owing to 
time constraints19 22 29 32. Another feasibility aspect was the burden to patients and staff: Not only 
can multiple PROMs become burdensome for patients over time, but reviewing and interpreting 
enormous amounts of patient data can also take its toll on providers 28 31 44.
DISCUSSION
This review studied implementation methods, impact, and facilitator and barriers of PROM col-
lection in breast cancer clinical practice. The PROM interventions were generally developed to 
improve symptom management, to identify psychosocial problems, to facilitate patient-centred 
care and treatment-specific monitoring during treatment phases, and to improve patient-provid-
er communication. Electronic PRO collection systems were most often used, which can allow 
patients to efficiently complete standardized assessments, can increase usability with a lower 
response burden, can lead to fewer missing data (when compared to paper-based PROMs), and 
can lead to higher satisfaction31 51 52. Electronic PROM collection can also provide a certain flexibil-
ity in assessment location (clinic vs home) and frequency, and can bridge treatment-specific and 
long-term PRO follow-up6. 
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An essential point is that some selected studies described the effects of a combined interven-
tion, which included not only a PROM collection component but also additional actions, such as 
enhanced care with patient education and coaching, proactive review of PROMs, and follow-up 
by providers. This makes it difficult, from a practical standpoint, to determine to which extent 
the observed impact of these multicomponent interventions can be attributed specifically to 
PROM collection and review. Then again, it might be unnecessary to separate the components, 
considering that complex interventions can lead to synergistic results and thus an accumulated 
impact. It might be more important to determine to what degree to which the individual parts 
of multicomponent strategies are implemented properly and according to the original proposed 
theory of the intervention53. 
Apart from differences in PROM collection methods across selected studies, there was also no-
table variety in the frequency (“intensity”) of the assessments: PRO assessments ranged from daily 
to once (for screening purposes). PRO collection tools were used to monitor specific treatment 
phases (e.g. adverse effects during chemotherapy or radiotherapy) or entire breast cancer care 
trajectories (from diagnosis to the end of follow-up). Successful implementation of routine PRO 
assessment should integrate both options and should combine them with the appropriate PROM 
to ensure optimal patient engagement and management of care. 
The heterogeneous study populations should be taken into account; more than half of the selected 
studies did not have a study population consisting entirely of breast cancer patients. In the studies 
included in our review, the percentage of breast cancer patients varied from 17.9% to 80%, with 
breast cancer patients being the majority in only 9 studies. Ruland et al.50 described the differences 
between breast and prostate cancer patients in their use of WebChoice, an interactive e-Health 
application designed to support cancer patients in illness management. Breast cancer patients 
used the application twice as often and asked significantly more often for help than prostate 
cancer patients. The gender-specific nature of different cancer types makes it difficult to identify 
attributes that could explain usage discrepancies. Nevertheless, the findings are consistent with 
previous research, which indicates that women seek more health-related information online than 
men do. In addition, the breast cancer patient population in the selected studies was overall 
younger than other cancer populations, and it is well known that younger people seek information 
online more often than older people do54 55. 
Another striking observation is the limited diversity in study populations across the selected articles. 
Most of the included study participants were overwhelmingly Caucasian11 19 22 23 28 29 31 33-35 38 41-43 46 56. 
There were only 2 studies in which PROM interventions were targeted at predominantly minority 
populations32 37. Limited diversity also applied to education levels of study participants across 
most included studies, with the majority of patients having a college degree or higher. As most 
of the interventions across the included studies required patients to be able to speak English, it 
became obvious that routine PROM collection was primarily executed in a select patient popula-
tion. Another important point is that most patients, across included articles were recruited in clinic 
112 − Chapter 6
6
waiting rooms by being asked if they were willing to participate. This could have introduced some 
selection bias if willingness itself has associations with better adherence to other care components. 
Naturally, this selectiveness in patient characteristics can affect the outcome results of PROM 
interventions. By striving to avoid “preselection” of patients to participate in PROM intervention 
studies, generalizability issues can also be (partially) circumvented in future research.
Numerous selected studies in this systematic review mentioned facilitators and barriers of the 
PROM interventions. It must be noted that nearly all selected studies did not identify these facilita-
tors and barriers after a thorough analysis because that was not the primary aim of the selected 
articles. The facilitators and barriers were mostly identified by observing the effects of PROM 
implementation in practice. Antunes et al.57 reported that substantial leadership is necessary to 
boost motivation in patients and care providers and educating them on the use, interpretation 
and advantages of routine PROM collection could increase adherence. Further research involving 
facilitator and barrier analysis should be conducted in order to provide more guidance during the 
design of PROM interventions.
Among 2,311 initially screened articles, 8 reviews were excluded based on irrelevant aims (see 
Methods). Their references, however, were also screened by title and abstract to ensure thorough-
ness of the literature search. Fourteen references12 15 58-69 were identified as potentially relevant but 
were not among the initial 2,311 articles. The apparent reason was that these articles were not 
indexed with breast cancer-related keywords or medical subject headings (e.g. “breast cancer”, 
“breast tumour”, “breast neoplasm”), probably because their study populations only contained a 
minimal proportion of breast cancer patients. So, it must be noted, for transparency reasons, that 
there could be some relevant articles that were not included because of their improper/incomplete 
indexing. These 14 articles did not provide any novel insights.
CONCLUSION
PROMs can be collected in a variety of methods, locations and frequencies. Although interpreting 
the impact of PROM interventions is challenging due to considerations of synergistic (multicom-
ponent) interventions and generalizability issues, this review found that the systematic PROM 
collection in routine breast cancer care has a promising impact on patients, providers and care 
processes/systems.
RECOMMENDATIONS
A major challenge in the implementation of value-based healthcare is standardizing PROMs that 
are meaningful to patients across different cultural and geographical settings70. Although there 
seems to be scepticism around the feasibility and effectiveness of standardized PROM collec-
tion as a part of breast cancer care, a number of PROMs (BREAST-Q, EORTC-QLQ-C30 and 
-B23, EQ-5D-5L, and the FACT-ES) have been validated within the breast cancer population71. 
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A breast cancer outcome set (including some of the aforementioned PROMs) was developed by 
the International Consortium for Health Outcomes Measurement (ICHOM), which recommended 
a timeline for PRO assessments in order to evaluate certain events (baseline, after neoadjuvant 
chemotherapy, surgery and follow-up) in breast cancer care71. If routine PROM collection is to be 
implemented in clinical practice, we recommend a standardized PROM set because it is one of the 
requirements for benchmarking treatments and healthcare providers. It could also ultimately allow 
comparisons of breast cancer outcomes across countries. By doing so, a major step will have 
been taken towards value-based healthcare.
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes.
Selected 
article Study objective Study design

















To determine feasibility 
and acceptability 
of tablet computers 
for administering 
standard assessment 
questionnaires, and for 
collecting patient-




66 breast cancer patients
Characteristics:
-  Mean age 54 years (± 
SD 12) 
-  Female 100%
-  Caucasian 77%
-  Metastatic 61%
-  College degree or 
higher 86%
“eTablet”, a tablet 
computer for PRO data 
collection 
-  Paper & electronic 
(tablet computer)
-  Clinic waiting room
-  4 times in 6 months
1.  FACT-G 2. FACT-B
3.  MDASI
4.  FACIT-F
5.  FACIT-Self-Efficacy 
Scale 
6.  PCM, an 86-item 
survey for common 
cancer- and treatment-
related symptoms
7.  Satisfaction & 
Acceptability survey
-  4 clinicians 
reviewed a printed 
PRO summary 
report 
-  1 (research) nurse 
included PRO 
reports to patient 
files after marking 
alarming items
6 Acceptability: 60/64 (94%) 
patients found “eTablets” 
very easy to use, 98% found 
it easy to respond to survey 
questions on eTablets, 94% 
found it easy to navigate, 77% 
found the eTablet’s weight very 
comfortable.
Satisfaction: 48/64 (75%) 
patients were satisfied with 
the eTablet for PRO collection 
at baseline, which increased 
to 88% at the 4th visit; 84% of 
patients would recommend 
it to others at 1st visit, which 
increased to 94% by the 4th visit. 
Other: 42/57 (74%) patients 
felt the PCM helped them 
recall experienced symptoms, 
which remained in 29/40 (73%) 
patients.
- Communication: 16/50 (32%) 
of patients, at the 1st visit, 
felt encouraged to address 
symptoms with clinicians that 
they otherwise wouldn’t have 
discussed, which increased to 
48% (16/33) patients) by the 
4th visit









24 breast cancer patients
Characteristics:
-  Median age 57 years 
(range 45-75) 
-  Female 100%
Individualized graphic 
QoL Profiles based on 
PROMs 
-  Electronic (software)
-  Clinic waiting room or 
doctor’s office
-  At each follow-up visit
1.  EORTC-QLQ-C30
2.  EORTC-QLQ-BR23
14 clinicians during 
follow-up care 
received mailed 
QoL profiles with 
discharge and most 
recent QoL scores
- - Compliance: 9/14 (64%) 
clinicians actively participated by 
completing most (67% response 
rate) routine surveys about 
usefulness of QoL profiles
Clinical decision-making: None 
of the clinicians felt that the QoL 
profiles led to different therapy 
decisions 
Acceptability: 
-  16/16 (100%) found the QoL 
profiles understandable, 63% 
felt that they provided more 
information, 25% felt they 
helped notice patient issues
-  94% felt that the profiles 
corresponded to their own 
patient assessment 
Communication: 7/16 (44%) 
clinicians felt the QoL profiles 
had an effect on the patient-
provider namely that more 
specific questions were being 
asked
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes.
Selected 
article Study objective Study design

















To determine feasibility 
and acceptability 
of tablet computers 
for administering 
standard assessment 
questionnaires, and for 
collecting patient-




66 breast cancer patients
Characteristics:
-  Mean age 54 years (± 
SD 12) 
-  Female 100%
-  Caucasian 77%
-  Metastatic 61%
-  College degree or 
higher 86%
“eTablet”, a tablet 
computer for PRO data 
collection 
-  Paper & electronic 
(tablet computer)
-  Clinic waiting room
-  4 times in 6 months
1.  FACT-G 2. FACT-B
3.  MDASI
4.  FACIT-F
5.  FACIT-Self-Efficacy 
Scale 
6.  PCM, an 86-item 
survey for common 
cancer- and treatment-
related symptoms
7.  Satisfaction & 
Acceptability survey
-  4 clinicians 
reviewed a printed 
PRO summary 
report 
-  1 (research) nurse 
included PRO 
reports to patient 
files after marking 
alarming items
6 Acceptability: 60/64 (94%) 
patients found “eTablets” 
very easy to use, 98% found 
it easy to respond to survey 
questions on eTablets, 94% 
found it easy to navigate, 77% 
found the eTablet’s weight very 
comfortable.
Satisfaction: 48/64 (75%) 
patients were satisfied with 
the eTablet for PRO collection 
at baseline, which increased 
to 88% at the 4th visit; 84% of 
patients would recommend 
it to others at 1st visit, which 
increased to 94% by the 4th visit. 
Other: 42/57 (74%) patients 
felt the PCM helped them 
recall experienced symptoms, 
which remained in 29/40 (73%) 
patients.
- Communication: 16/50 (32%) 
of patients, at the 1st visit, 
felt encouraged to address 
symptoms with clinicians that 
they otherwise wouldn’t have 
discussed, which increased to 
48% (16/33) patients) by the 
4th visit









24 breast cancer patients
Characteristics:
-  Median age 57 years 
(range 45-75) 
-  Female 100%
Individualized graphic 
QoL Profiles based on 
PROMs 
-  Electronic (software)
-  Clinic waiting room or 
doctor’s office
-  At each follow-up visit
1.  EORTC-QLQ-C30
2.  EORTC-QLQ-BR23
14 clinicians during 
follow-up care 
received mailed 
QoL profiles with 
discharge and most 
recent QoL scores
- - Compliance: 9/14 (64%) 
clinicians actively participated by 
completing most (67% response 
rate) routine surveys about 
usefulness of QoL profiles
Clinical decision-making: None 
of the clinicians felt that the QoL 
profiles led to different therapy 
decisions 
Acceptability: 
-  16/16 (100%) found the QoL 
profiles understandable, 63% 
felt that they provided more 
information, 25% felt they 
helped notice patient issues
-  94% felt that the profiles 
corresponded to their own 
patient assessment 
Communication: 7/16 (44%) 
clinicians felt the QoL profiles 
had an effect on the patient-
provider namely that more 
specific questions were being 
asked
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design
















al. (32), 2015 
To determine the 
feasibility and efficacy 
of an automated 
telephone-based 
intervention on pain and 
symptom improvement 
in minority patients
RCT 60 low-income breast 
cancer patients
Characteristics per group:
1) Intervention (n=31): 
-  Mean age 49.6 years 
(± 9.9)
-  Female 100%
-  Latina 58%
-  Metastatic 35%
-  Years of education 
10.6 years (± 4.1)
2) Control (n=29):
-  Mean age 50.5 years 
(± 11)
-  Female 100%
-  Latina 59%
-  Metastatic 41%
-  Years of education 10 
years (± 2.9)
Intervention: “Automated 
IVR” intervention for 
symptom reporting using 
dial-tone keypad for 
intensity rating
-  Telephone 
-  Home
-  2 times per week 
Control: 
Paper-based 
assessments at baseline 
and 2 follow-up points, 
without review by 
clinicians. Patients 
received usual symptom 
management, if indicated. 
1.  IVR-related pain and 
symptom list
2.  MDASI 3. BQ-II
4.  ECOG Performance 
Scale
5.  PMI 
PROMs (#2 - #5) were 
administered during clinic 
visits at two time points 








(pain score ≥ 5 on a 
0-10 scale) 
2 Adherence: 71% of IVR 
assessments were completed 
successfully. 
Symptoms: 
-  Proportion of patients with 
moderate to severe pain 
decreased from 86% to 43% 
(p=0.004). No significant de-
crease in control group (from 
80% to 56%). 
-  Proportion of patients in the 
intervention group with mod-
erate to severe symptoms 
(distress from 57% to 19%, 
sadness from 52% to 19%, 
drowsiness from 65% to 
30%) decreased significantly 
(p=0.008, p=0.04, p=0.04, 
respectively) over follow-up. 
Conversely, no significant 
changes were observed in the 
control group.
-  No significant difference in 
proportion moderate-severe 
symptoms between interven-
tion and control groups over 
time
Clinical decision-making: 
-  33.3% of clinicians disclosed 
that their clinical decisions 
were influenced by symptom 
alerts. 
-  Clinicians’ email response to 
symptom alerts were to main-
tain treatment course (46%), 
to assess the patient at the 
following clinic appointment 
(33%) or a new symptom 
treatment prescription (8%) 
Other: 
-  100% of symptom alerts were 
detected;
161/221 (73%) symptom alerts 
were acknowledged by clinicians 
through an email response to the 
research staff.
-  No significant difference 
between groups in proportion 
of patients receiving adequate 
analgesics (33% vs. 28%), as 
determined by the PMI
Barbera et al. 
(40), 2015 
To determine the impact 
of screening with ESAS 
on unplanned ER visit 




8359 breast cancer (stage 
I-III) patients receiving 
adjuvant chemotherapy 
within 6 months of 
diagnosis
Characteristics per group:
1) With ESAS screening 
(n=2541):
-Mean age 53.22 years (± 
SD 10.44)
2) Without ESAS 
screening (n=5818):
-Mean age 53.87 years (± 
SD 10.57)
Screening with ESAS 
instrument
-  Electronic (web-based) 
and paper-based 
-  Clinic waiting room
-  Each follow-up visit at 
cancer centre
1.  ESAS Clinical team 
received summary 
reports on symptom 





- Adherence: Median number 
of ESAS assessments was 3 
(IQR 1-5) for the 2541 patients 
that received at least one ESAS 
screening
- Hospital visits: 
-  ER visits were 43% lower in 
patients previously screened 
with ESAS compared to 
patients who were not. For 
each additional prior ESAS 
screening, there was a 17% 
decline in ER visits
-  Association of screening with 
ESAS on ER visits remained 
preventative even after adjust-
ing for other types of visits 
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design
















al. (32), 2015 
To determine the 
feasibility and efficacy 
of an automated 
telephone-based 
intervention on pain and 
symptom improvement 
in minority patients
RCT 60 low-income breast 
cancer patients
Characteristics per group:
1) Intervention (n=31): 
-  Mean age 49.6 years 
(± 9.9)
-  Female 100%
-  Latina 58%
-  Metastatic 35%
-  Years of education 
10.6 years (± 4.1)
2) Control (n=29):
-  Mean age 50.5 years 
(± 11)
-  Female 100%
-  Latina 59%
-  Metastatic 41%
-  Years of education 10 
years (± 2.9)
Intervention: “Automated 
IVR” intervention for 
symptom reporting using 
dial-tone keypad for 
intensity rating
-  Telephone 
-  Home
-  2 times per week 
Control: 
Paper-based 
assessments at baseline 
and 2 follow-up points, 
without review by 
clinicians. Patients 
received usual symptom 
management, if indicated. 
1.  IVR-related pain and 
symptom list
2.  MDASI 3. BQ-II
4.  ECOG Performance 
Scale
5.  PMI 
PROMs (#2 - #5) were 
administered during clinic 
visits at two time points 








(pain score ≥ 5 on a 
0-10 scale) 
2 Adherence: 71% of IVR 
assessments were completed 
successfully. 
Symptoms: 
-  Proportion of patients with 
moderate to severe pain 
decreased from 86% to 43% 
(p=0.004). No significant de-
crease in control group (from 
80% to 56%). 
-  Proportion of patients in the 
intervention group with mod-
erate to severe symptoms 
(distress from 57% to 19%, 
sadness from 52% to 19%, 
drowsiness from 65% to 
30%) decreased significantly 
(p=0.008, p=0.04, p=0.04, 
respectively) over follow-up. 
Conversely, no significant 
changes were observed in the 
control group.
-  No significant difference in 
proportion moderate-severe 
symptoms between interven-
tion and control groups over 
time
Clinical decision-making: 
-  33.3% of clinicians disclosed 
that their clinical decisions 
were influenced by symptom 
alerts. 
-  Clinicians’ email response to 
symptom alerts were to main-
tain treatment course (46%), 
to assess the patient at the 
following clinic appointment 
(33%) or a new symptom 
treatment prescription (8%) 
Other: 
-  100% of symptom alerts were 
detected;
161/221 (73%) symptom alerts 
were acknowledged by clinicians 
through an email response to the 
research staff.
-  No significant difference 
between groups in proportion 
of patients receiving adequate 
analgesics (33% vs. 28%), as 
determined by the PMI
Barbera et al. 
(40), 2015 
To determine the impact 
of screening with ESAS 
on unplanned ER visit 




8359 breast cancer (stage 
I-III) patients receiving 
adjuvant chemotherapy 
within 6 months of 
diagnosis
Characteristics per group:
1) With ESAS screening 
(n=2541):
-Mean age 53.22 years (± 
SD 10.44)
2) Without ESAS 
screening (n=5818):
-Mean age 53.87 years (± 
SD 10.57)
Screening with ESAS 
instrument
-  Electronic (web-based) 
and paper-based 
-  Clinic waiting room
-  Each follow-up visit at 
cancer centre
1.  ESAS Clinical team 
received summary 
reports on symptom 





- Adherence: Median number 
of ESAS assessments was 3 
(IQR 1-5) for the 2541 patients 
that received at least one ESAS 
screening
- Hospital visits: 
-  ER visits were 43% lower in 
patients previously screened 
with ESAS compared to 
patients who were not. For 
each additional prior ESAS 
screening, there was a 17% 
decline in ER visits
-  Association of screening with 
ESAS on ER visits remained 
preventative even after adjust-
ing for other types of visits 
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Basch et al. 
(24), 
2016 
To determine the effect 
of routine web-based 
collection of PROMs 
on HRQoL and clinical 
outcomes in patients 
receiving adjuvant 
chemotherapy
RCT 143/776 (18.4%) breast 
cancer patients receiving 
outpatient chemotherapy
Characteristics per group:
1) Intervention: 89/441 
(20%) breast cancer 
patients




2) Control: 54/325 (17%) 
breast cancer patients
-  19% computer-experi-
enced.
-  10% computer-inexpe-
rienced 
Intervention:
“STAR”, a web-based 
interface for symptom 
reporting
-  Electronic (web-based; 
tablet computer) 
-  Clinic and home 
(between-visit report)
-  Weekly email prompts 
to report symptoms
Control: Usual care
1.  CTCAE (adapted 
version) 
2.  EQ-5D 
-  Nurses received 
email alerts 
when symptoms 
progressed (by ≥ 2 
points or absolute 
score ≥ 3 on a 
0-5 scale) and 
responded directly 
-  Clinicians received 
a printed report of 
symptoms tracked 
at each clinic visit
Median 3.7 
(0.25-49)
Adherence: 73% of patients in 
the STAR arm completed a self-
report at any given clinic visit
Health outcomes:
-  HRQoL scores at 6 months 
improved in significantly more 
patients in the STAR group 
compared to control patients 
(34% vs. 18%, p<0.001)
-  EQ-5D subdomains mobility, 
self-care and anxiety/depres-
sion were significantly better 
in the STAR group compared 
to usual care (p=0.02, p=0.01 
and p=0.01, respectively); sig-
nificance was not reached for 
subdomains pain/ discomfort 
and usual activities
-  Overall survival at 12 months 
was higher in the STAR arm 
compared to the control arm 
(75% vs. 69%, p=0.05). Mean 
12-month quality-adjusted 
survival was also significantly 
higher in the STAR arm (8.7 
vs. 8 months, p=0.004)
Clinical decision-making: 
-  77% of alerts led to telephone 
counselling by nurses about 
symptom management, 12% 
of alerts led to start/change 
of supportive medication, 2% 
led to adjustment of chemo-
therapy dose
Referrals: 8% of alerts resulted 
in an ER/ hospital referral
Hospital visits: Proportion of 
patients visiting the ER was 
significantly less in the STAR 
arm compared to usual care 
(34% vs. 41%, p=0.02) at 12 
months A similar trend was 
observed for hospitalizations 
(45% vs. 49%, p=0.08)
Other: 
-  Patients in the STAR arm 
received significantly longer 
chemotherapy compared to 
the usual care group (8.2 vs. 
6.3 months, p=0.002)
-  No significant difference in the 
amount of nursing calls was 
observed between the STAR 
arm and usual care (mean 
12.8 vs. 12.9, p=0.93) 
Berry et al. 
(49), 
2014 
To determine the 
effect of a web-based 
PRO assessment and 
educational intervention 
on symptom distress 
during cancer treatment 
RCT 206/752 (27.4%) breast 
cancer patients
Characteristics per group:
1) Intervention: 109/374 
(30%) breast cancer 
patients






and a PRO assessment 
-  Electronic (web-based)
-  Home and clinic wait-
ing room
-  At least 4 times (study 
time points) and volun-
tary between visits
Control: Enhanced 
usual care with 4 PRO 
assessments with 
clinicians receiving a 
summary report






Clinicians could be 
called immediately 
if symptom levels 
were severe between 
clinic visits and they 
received summary 
reports at each visit
- Adherence: No significant 
difference in rates of outcome 
completion were observed 
between the intervention arm 
and usual care group (77.3% 
vs. 77.2%) 
Symptoms: 
-  Symptom distress was signifi-
cantly lower in the intervention 
arm vs. controls (mean 
change SDS-15 score -0.04 ± 
5.8 vs. 1.27 ± 6.7) 
-  A statistically significant 
reduction (average 1.93 score 
change in SDS-15, p=0.002) 
was observed in patients ≥ 50 
years within the intervention 
arm compared to usual care. 
No significant intervention ef-
fect was observed in patients 
<50 years.
- -
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Basch et al. 
(24), 
2016 
To determine the effect 
of routine web-based 
collection of PROMs 
on HRQoL and clinical 
outcomes in patients 
receiving adjuvant 
chemotherapy
RCT 143/776 (18.4%) breast 
cancer patients receiving 
outpatient chemotherapy
Characteristics per group:
1) Intervention: 89/441 
(20%) breast cancer 
patients




2) Control: 54/325 (17%) 
breast cancer patients
-  19% computer-experi-
enced.
-  10% computer-inexpe-
rienced 
Intervention:
“STAR”, a web-based 
interface for symptom 
reporting
-  Electronic (web-based; 
tablet computer) 
-  Clinic and home 
(between-visit report)
-  Weekly email prompts 
to report symptoms
Control: Usual care
1.  CTCAE (adapted 
version) 
2.  EQ-5D 
-  Nurses received 
email alerts 
when symptoms 
progressed (by ≥ 2 
points or absolute 
score ≥ 3 on a 
0-5 scale) and 
responded directly 
-  Clinicians received 
a printed report of 
symptoms tracked 
at each clinic visit
Median 3.7 
(0.25-49)
Adherence: 73% of patients in 
the STAR arm completed a self-
report at any given clinic visit
Health outcomes:
-  HRQoL scores at 6 months 
improved in significantly more 
patients in the STAR group 
compared to control patients 
(34% vs. 18%, p<0.001)
-  EQ-5D subdomains mobility, 
self-care and anxiety/depres-
sion were significantly better 
in the STAR group compared 
to usual care (p=0.02, p=0.01 
and p=0.01, respectively); sig-
nificance was not reached for 
subdomains pain/ discomfort 
and usual activities
-  Overall survival at 12 months 
was higher in the STAR arm 
compared to the control arm 
(75% vs. 69%, p=0.05). Mean 
12-month quality-adjusted 
survival was also significantly 
higher in the STAR arm (8.7 
vs. 8 months, p=0.004)
Clinical decision-making: 
-  77% of alerts led to telephone 
counselling by nurses about 
symptom management, 12% 
of alerts led to start/change 
of supportive medication, 2% 
led to adjustment of chemo-
therapy dose
Referrals: 8% of alerts resulted 
in an ER/ hospital referral
Hospital visits: Proportion of 
patients visiting the ER was 
significantly less in the STAR 
arm compared to usual care 
(34% vs. 41%, p=0.02) at 12 
months A similar trend was 
observed for hospitalizations 
(45% vs. 49%, p=0.08)
Other: 
-  Patients in the STAR arm 
received significantly longer 
chemotherapy compared to 
the usual care group (8.2 vs. 
6.3 months, p=0.002)
-  No significant difference in the 
amount of nursing calls was 
observed between the STAR 
arm and usual care (mean 
12.8 vs. 12.9, p=0.93) 
Berry et al. 
(49), 
2014 
To determine the 
effect of a web-based 
PRO assessment and 
educational intervention 
on symptom distress 
during cancer treatment 
RCT 206/752 (27.4%) breast 
cancer patients
Characteristics per group:
1) Intervention: 109/374 
(30%) breast cancer 
patients






and a PRO assessment 
-  Electronic (web-based)
-  Home and clinic wait-
ing room
-  At least 4 times (study 
time points) and volun-
tary between visits
Control: Enhanced 
usual care with 4 PRO 
assessments with 
clinicians receiving a 
summary report






Clinicians could be 
called immediately 
if symptom levels 
were severe between 
clinic visits and they 
received summary 
reports at each visit
- Adherence: No significant 
difference in rates of outcome 
completion were observed 
between the intervention arm 
and usual care group (77.3% 
vs. 77.2%) 
Symptoms: 
-  Symptom distress was signifi-
cantly lower in the intervention 
arm vs. controls (mean 
change SDS-15 score -0.04 ± 
5.8 vs. 1.27 ± 6.7) 
-  A statistically significant 
reduction (average 1.93 score 
change in SDS-15, p=0.002) 
was observed in patients ≥ 50 
years within the intervention 
arm compared to usual care. 
No significant intervention ef-
fect was observed in patients 
<50 years.
- -
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Bock et al. 
(56),
2012 
To determine the effect 
of an online health 







106 breast cancer 
patients
Characteristics:
-  Mean age 56.9 years 
(32-85)
-  Female 100%
-  Caucasian 87%
-  Metastatic 0%
Online questionnaire on 
symptoms (frequency, 
severity and associated 
distress) & health 
behavior
-  Electronic (web-based 
with/without tablet 
computer) 
-  Home or clinic waiting 
room
Unspecified PROM 
(symptoms and health 
history)
-  7 clinicians 
received patient-
reported symptom 
reports attached to 
the medical record 
prior to clinic visit 
-  3 nurse practitio-
ners
6 Symptoms: Number of patient-
reported symptoms (mean 3.8, 
range 0-13) was significantly 
(p<0.001) higher than number 
of clinician-reported (mean 1.8, 
range 0-7)
- Other: 
-  More than half of symptoms 
mentioned by both patients 
and clinicians are addressed, 
regardless of number of 
symptoms
-  Considerable discordance 
between patient and clinician 
documentation of exercise 
behavior (100% vs. 28%) and 
alcohol use (100% vs. 70%)
Børøsund et 
al. (39), 2014 
To determine the effects 
of an online illness 
management system, 
IPPC service, and 




RCT (3-arm) 167 breast cancer 
patients who underwent 
surgery or receiving other 
treatments (radiation, 
chemotherapy, hormone 
therapy or combinations) 





-  Mean age 51 years 
(37-79)
-  Female 100%
-  College degree or 
higher 63%
2) IPPC intervention: 
(n=45): 
-  Mean age 50 years 
(31-66)
-  Female 100%
-  College degree or 
higher 51%
3) Usual care (n=58):
-  Mean age 53 years 
(36-69)
-  Female 100%
-  College degree or 
higher 46%
Intervention 1: 







-  Electronic (web-based)
-  Home
-  Voluntary frequency
Control: Usual care
1.  Symptom list
2.  MSAS
3.  HADS
4.  CBI 
-  6 clinicians
-  11 nurses
-  3 social workers
IPPC messages were 
answered primarily 
by nurses through 
secure e-messages 
6 Adherence: 49/64 (77%) 
WebChoice users logged on at 
least once in 6 months. Of those 
who logged on at least twice, 
median was 7 times (range 
2-41).
Symptoms: 
-  Anxiety (mean difference 
-0.79, p=0.03) and depression 
(mean difference -0.79, 
p=0.03) were significantly 
lower in the WebChoice group 
vs. usual care group.
-  Symptom distress was 
significantly lower for patients 
in the WebChoice arm versus 
the usual care arm (mean 
difference -0.16, p=0.001). 
No difference was observed 
in symptom distress between 
IPPC and usual care. 
-  WebChoice participants had 
higher self-efficacy scores 
over time (mean difference 
8.81, p=0.08) than the usual 
care group
Adherence: 33/153 (22%) IPPC 
messages were answered by 
clinicians
-
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Bock et al. 
(56),
2012 
To determine the effect 
of an online health 







106 breast cancer 
patients
Characteristics:
-  Mean age 56.9 years 
(32-85)
-  Female 100%
-  Caucasian 87%
-  Metastatic 0%
Online questionnaire on 
symptoms (frequency, 
severity and associated 
distress) & health 
behavior
-  Electronic (web-based 
with/without tablet 
computer) 
-  Home or clinic waiting 
room
Unspecified PROM 
(symptoms and health 
history)
-  7 clinicians 
received patient-
reported symptom 
reports attached to 
the medical record 
prior to clinic visit 
-  3 nurse practitio-
ners
6 Symptoms: Number of patient-
reported symptoms (mean 3.8, 
range 0-13) was significantly 
(p<0.001) higher than number 
of clinician-reported (mean 1.8, 
range 0-7)
- Other: 
-  More than half of symptoms 
mentioned by both patients 
and clinicians are addressed, 
regardless of number of 
symptoms
-  Considerable discordance 
between patient and clinician 
documentation of exercise 
behavior (100% vs. 28%) and 
alcohol use (100% vs. 70%)
Børøsund et 
al. (39), 2014 
To determine the effects 
of an online illness 
management system, 
IPPC service, and 




RCT (3-arm) 167 breast cancer 
patients who underwent 
surgery or receiving other 
treatments (radiation, 
chemotherapy, hormone 
therapy or combinations) 





-  Mean age 51 years 
(37-79)
-  Female 100%
-  College degree or 
higher 63%
2) IPPC intervention: 
(n=45): 
-  Mean age 50 years 
(31-66)
-  Female 100%
-  College degree or 
higher 51%
3) Usual care (n=58):
-  Mean age 53 years 
(36-69)
-  Female 100%
-  College degree or 
higher 46%
Intervention 1: 







-  Electronic (web-based)
-  Home
-  Voluntary frequency
Control: Usual care
1.  Symptom list
2.  MSAS
3.  HADS
4.  CBI 
-  6 clinicians
-  11 nurses
-  3 social workers
IPPC messages were 
answered primarily 
by nurses through 
secure e-messages 
6 Adherence: 49/64 (77%) 
WebChoice users logged on at 
least once in 6 months. Of those 
who logged on at least twice, 
median was 7 times (range 
2-41).
Symptoms: 
-  Anxiety (mean difference 
-0.79, p=0.03) and depression 
(mean difference -0.79, 
p=0.03) were significantly 
lower in the WebChoice group 
vs. usual care group.
-  Symptom distress was 
significantly lower for patients 
in the WebChoice arm versus 
the usual care arm (mean 
difference -0.16, p=0.001). 
No difference was observed 
in symptom distress between 
IPPC and usual care. 
-  WebChoice participants had 
higher self-efficacy scores 
over time (mean difference 
8.81, p=0.08) than the usual 
care group
Adherence: 33/153 (22%) IPPC 
messages were answered by 
clinicians
-
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design
















al. (30), 2013 
To evaluate the short- 
and long-term effects 
of using a psychosocial 
screening instrument on 
psychological distress 
and HRQoL 
Cluster RCT 284/568 (50%) breast 
cancer patients receiving 
radiotherapy
Groups:









-  Mailed 
-  Home
-  2 times (at 3 and 12 
months follow-up)
Control: Usual care
1.  SIPP 
2.  HADS
3.  GHQ-12
4.  EORTC-QLQ-C30 
5.  VAS
7 clinicians reviewed 
the questionnaire 
scores to get 
an overview of 
psychosocial issues 
and patient needs/ 
preference for 
psychosocial care
12 Results for entire study 
population (n=568):
Adherence: >85% of patients 
completed the study. No 
difference in loss-to-follow rates 
between intervention and control 
arms.
Health outcomes: 
-  No significant intervention 
effects on prevalence and 
extent of psychological 
distress were observed on 
short and long terms
-  No significant intervention 
effects on HRQoL were 
observed on short and long 
terms.
- Other:
Significant interactions between 
trial arm, 3-month follow-up, and 
referral rate were found: anxiety 
symptoms ( β =2.16 and p = 
0.03), emotional functioning ( β 
= 15.16 and p = 0.02), appetite 
loss ( β =15.67 and p = 0.04) and 
financial problems ( β =11.39 
and p=0.01). These interactions 
imply that early referral might 
affect short-term HRQoL.
Dean et al. 
(48),
2016 
To determine the utility 
of the BREAST-Q as 




343 breast cancer 
patients 
Characteristics:
-  Median age 52 years 
(24-82)
Routine assessment with 
BREAST-Q instrument
-  Unspecified 
administration method 
-  Clinic waiting room
-  Ideally 5 times




the scores to the 
database
-  Clinic clerks 
entered 
questionnaire data
24 (range 1-58) Adherence: 
-  219/219 (100%) patients 
completed preoperative 
PROM prior to their first 
reconstructive procedure 
-  79/219 (36.1%) patients 
completed the PROM after 
undergoing all reconstructive 
procedures
-  68/106 (64.2%) patients 
completed the minimum of 
three BREAST-Q assessments 
(preoperative, postoperative 
≤ 3 months and post-
completion)
Health outcomes: At baseline 
(screening), patients with 
intact breasts had significantly 
(p<0.001) higher scores across 
all BREAST-Q domains than 
those with mastectomy defects.
Other: 
Completion of BREAST-Q by 
patient took approximately 10 
minutes
- Other: 
-  Data entry by clinic clerks of 
questionnaires took 3 minutes 
-  Nurse needed 5 minutes per 
questionnaire to score and 
transfer scores to a database
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design
















al. (30), 2013 
To evaluate the short- 
and long-term effects 
of using a psychosocial 
screening instrument on 
psychological distress 
and HRQoL 
Cluster RCT 284/568 (50%) breast 
cancer patients receiving 
radiotherapy
Groups:









-  Mailed 
-  Home
-  2 times (at 3 and 12 
months follow-up)
Control: Usual care
1.  SIPP 
2.  HADS
3.  GHQ-12
4.  EORTC-QLQ-C30 
5.  VAS
7 clinicians reviewed 
the questionnaire 
scores to get 
an overview of 
psychosocial issues 
and patient needs/ 
preference for 
psychosocial care
12 Results for entire study 
population (n=568):
Adherence: >85% of patients 
completed the study. No 
difference in loss-to-follow rates 
between intervention and control 
arms.
Health outcomes: 
-  No significant intervention 
effects on prevalence and 
extent of psychological 
distress were observed on 
short and long terms
-  No significant intervention 
effects on HRQoL were 
observed on short and long 
terms.
- Other:
Significant interactions between 
trial arm, 3-month follow-up, and 
referral rate were found: anxiety 
symptoms ( β =2.16 and p = 
0.03), emotional functioning ( β 
= 15.16 and p = 0.02), appetite 
loss ( β =15.67 and p = 0.04) and 
financial problems ( β =11.39 
and p=0.01). These interactions 
imply that early referral might 
affect short-term HRQoL.
Dean et al. 
(48),
2016 
To determine the utility 
of the BREAST-Q as 




343 breast cancer 
patients 
Characteristics:
-  Median age 52 years 
(24-82)
Routine assessment with 
BREAST-Q instrument
-  Unspecified 
administration method 
-  Clinic waiting room
-  Ideally 5 times




the scores to the 
database
-  Clinic clerks 
entered 
questionnaire data
24 (range 1-58) Adherence: 
-  219/219 (100%) patients 
completed preoperative 
PROM prior to their first 
reconstructive procedure 
-  79/219 (36.1%) patients 
completed the PROM after 
undergoing all reconstructive 
procedures
-  68/106 (64.2%) patients 
completed the minimum of 
three BREAST-Q assessments 
(preoperative, postoperative 
≤ 3 months and post-
completion)
Health outcomes: At baseline 
(screening), patients with 
intact breasts had significantly 
(p<0.001) higher scores across 
all BREAST-Q domains than 
those with mastectomy defects.
Other: 
Completion of BREAST-Q by 
patient took approximately 10 
minutes
- Other: 
-  Data entry by clinic clerks of 
questionnaires took 3 minutes 
-  Nurse needed 5 minutes per 
questionnaire to score and 
transfer scores to a database
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Decker et al. 
(41),
2009 
To develop and test 
an automated voice 
response system 




Cohort study 24/30 (80%) breast 
cancer patients receiving 
oral chemotherapy
Characteristics per group:
1) Adherence group 
(n=23, 77%):
-  Breast cancer patients 
74%
-  Age >71 years: 30.4% 
/ <70 years: 69.6%
-  Female 91.3%
-  Caucasian 95.7%
-  College degree or 
higher 34.8%
2) Non-adherence group 
(n=7, 23%):
-  Breast cancer patients 
100%
-Age <70 years: 100%
-  Female 100%
-  Caucasian 71.4%
-  College degree or 
higher 42.3%
AVR system and self-
help guide plus nursing 
intervention (for symptom 
management strategy) 
to monitor symptoms 
and oral chemotherapy 
adherence 
-  Telephone (automated 
system)
-  Home
-  8 times (weekly)




4.  Unspecified 
patient satisfaction 
questionnaire
Nurses would call 
patients when 
the AVR system 
indicated non-
adherence and/ or 
symptom severity (≥ 
4) for 3 consecutive 
weeks.
2.5 Symptoms: Difference in average 
sum of symptom severity before 
and after AVR intervention was a 
non-significant decrease of 4.35 
(p=0.21). 
Health outcomes: 
-  No significant differences in 
SF-12 items were observed 
between adherent and non-
adherent groups.
-  Patients in the adherent group 
had a lower CESD-20 scores 
than patients in the non-
adherent groups (8.67 vs. 11)
Acceptability: 60% of patients 
felt the intervention was helpful, 
30% felt that it was both 
burdensome and helpful and in 
10% not helpful.
Satisfaction: 17/17 (100%) 
patients that completed the 
questionnaire were either very 
satisfied or satisfied with the 
AVR system for monitoring 
symptoms. 
Other: 7/30 (23%) patients had 
confirmed nonadherence of 
chemotherapy
Other: Nurse interventions were 
especially indicated for fatigue 
and pain, the most commonly 
occurring symptoms with 
severity ≥4 for 3 consecutive 
weeks
Hospital visits: 4/30 (13%) 
patients had were admitted 
once to the hospital. 8/30 (27%) 
patients had primary care visits
Other: out-of-pocket expenses 
for oral chemotherapy agents 
was not significantly different 
between the adherent and the 
non-adherent group.
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Decker et al. 
(41),
2009 
To develop and test 
an automated voice 
response system 




Cohort study 24/30 (80%) breast 
cancer patients receiving 
oral chemotherapy
Characteristics per group:
1) Adherence group 
(n=23, 77%):
-  Breast cancer patients 
74%
-  Age >71 years: 30.4% 
/ <70 years: 69.6%
-  Female 91.3%
-  Caucasian 95.7%
-  College degree or 
higher 34.8%
2) Non-adherence group 
(n=7, 23%):
-  Breast cancer patients 
100%
-Age <70 years: 100%
-  Female 100%
-  Caucasian 71.4%
-  College degree or 
higher 42.3%
AVR system and self-
help guide plus nursing 
intervention (for symptom 
management strategy) 
to monitor symptoms 
and oral chemotherapy 
adherence 
-  Telephone (automated 
system)
-  Home
-  8 times (weekly)




4.  Unspecified 
patient satisfaction 
questionnaire
Nurses would call 
patients when 
the AVR system 
indicated non-
adherence and/ or 
symptom severity (≥ 
4) for 3 consecutive 
weeks.
2.5 Symptoms: Difference in average 
sum of symptom severity before 
and after AVR intervention was a 
non-significant decrease of 4.35 
(p=0.21). 
Health outcomes: 
-  No significant differences in 
SF-12 items were observed 
between adherent and non-
adherent groups.
-  Patients in the adherent group 
had a lower CESD-20 scores 
than patients in the non-
adherent groups (8.67 vs. 11)
Acceptability: 60% of patients 
felt the intervention was helpful, 
30% felt that it was both 
burdensome and helpful and in 
10% not helpful.
Satisfaction: 17/17 (100%) 
patients that completed the 
questionnaire were either very 
satisfied or satisfied with the 
AVR system for monitoring 
symptoms. 
Other: 7/30 (23%) patients had 
confirmed nonadherence of 
chemotherapy
Other: Nurse interventions were 
especially indicated for fatigue 
and pain, the most commonly 
occurring symptoms with 
severity ≥4 for 3 consecutive 
weeks
Hospital visits: 4/30 (13%) 
patients had were admitted 
once to the hospital. 8/30 (27%) 
patients had primary care visits
Other: out-of-pocket expenses 
for oral chemotherapy agents 
was not significantly different 
between the adherent and the 
non-adherent group.
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Egbring et al. 
(20), 2016 
To determine the 
impact of a mobile app 
on patient-reported 
daily functional activity 
between supervised and 
unsupervised breast 
cancer patients 




1) App use without 
physician review 
(unsupervised) (n=46):
-  Mean age 50 years (± 
SD 10)
-  Female 100%
-  Metastatic 0%
2) App use with physician 
review (supervised) 
(n=49): 
-  Mean age 53 years (± 
SD 12)
-  Female 100%
-  Metastatic 0%
3) Control group (n=44):
-  Mean age 56 years (± 
SD 15)
-  Female 100%
-  Metastatic 0%
Intervention 1:
Mobile app for symptom 
reporting without clinician 
review (unsupervised) 
Intervention 2: Mobile 
app for symptom 
reporting with clinician 
review (supervised)
-  Electronic (mobile app 




Control: Usual clinician 
support
1.  ECOG Performance 
Status
2.  CTCAE symptom list 
Clinicians reviewed 
reported symptom 
data and patient 
charts of only 
supervised patients
1.5 Symptoms: 
-  Both intervention groups 
reported more symptoms 
on the mobile app than the 
paper-based questionnaire 
(supervised: 1033 vs. 656 
symptoms; unsupervised 
852 vs. 823 symptoms) 
More overall symptoms were 
reported by unsupervised 
patients vs. supervised 
patients (4808 vs. 4463 
symptoms)
Health outcomes: 
-  Initially, all groups had a 
decline in functional activity 
scores from the 1st to the 2nd 
visit. Only supervised patients 
reported improvement of 
functional activity from the 2nd 
to 3rd visit. 
-  Overall, supervised patients 
had a stable functional activity 
over from the 1st to the 2nd 
(median 90.85 to median 
84.76, p=0.72)
Satisfaction: All supervised 
patients over time were satisfied 
with medical care
- Communication: Less patients 
in the supervised group had 
concentration problems during 
clinic visits than the other 
groups, all supervised patients 
felt they were taken seriously 
Fu et al. (45), 
2016 
To describe the 
development and 
testing of 






30 breast cancer patients
Characteristics:
-  Mean age 58.6 years 
(± SD 11.4)
-  Caucasian 73.3%
-  College degree or 
higher 86.6%
“TOLF” health IT system, 
an educational and 
behavioral self-care 
intervention including 
PROMs and symptom 
management
-  Electronic (mobile and 
web-based) 
1.  BCLE-SEI
2.  Perceived Ease of 
Use and Usefulness 
Questionnaire
3.  Post Study System 
Usability Questionnaire
- 3 Acceptability: 27/30 (90%) 
patients didn’t have major 
usability problems with TOLF
Symptoms: Patients reported 
significantly (p=0.022) less pain, 
tenderness, aching, soreness, 
and lymphedema at 12 weeks 
post-intervention compared to 
baseline
- -
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Egbring et al. 
(20), 2016 
To determine the 
impact of a mobile app 
on patient-reported 
daily functional activity 
between supervised and 
unsupervised breast 
cancer patients 




1) App use without 
physician review 
(unsupervised) (n=46):
-  Mean age 50 years (± 
SD 10)
-  Female 100%
-  Metastatic 0%
2) App use with physician 
review (supervised) 
(n=49): 
-  Mean age 53 years (± 
SD 12)
-  Female 100%
-  Metastatic 0%
3) Control group (n=44):
-  Mean age 56 years (± 
SD 15)
-  Female 100%
-  Metastatic 0%
Intervention 1:
Mobile app for symptom 
reporting without clinician 
review (unsupervised) 
Intervention 2: Mobile 
app for symptom 
reporting with clinician 
review (supervised)
-  Electronic (mobile app 




Control: Usual clinician 
support
1.  ECOG Performance 
Status
2.  CTCAE symptom list 
Clinicians reviewed 
reported symptom 
data and patient 
charts of only 
supervised patients
1.5 Symptoms: 
-  Both intervention groups 
reported more symptoms 
on the mobile app than the 
paper-based questionnaire 
(supervised: 1033 vs. 656 
symptoms; unsupervised 
852 vs. 823 symptoms) 
More overall symptoms were 
reported by unsupervised 
patients vs. supervised 
patients (4808 vs. 4463 
symptoms)
Health outcomes: 
-  Initially, all groups had a 
decline in functional activity 
scores from the 1st to the 2nd 
visit. Only supervised patients 
reported improvement of 
functional activity from the 2nd 
to 3rd visit. 
-  Overall, supervised patients 
had a stable functional activity 
over from the 1st to the 2nd 
(median 90.85 to median 
84.76, p=0.72)
Satisfaction: All supervised 
patients over time were satisfied 
with medical care
- Communication: Less patients 
in the supervised group had 
concentration problems during 
clinic visits than the other 
groups, all supervised patients 
felt they were taken seriously 
Fu et al. (45), 
2016 
To describe the 
development and 
testing of 






30 breast cancer patients
Characteristics:
-  Mean age 58.6 years 
(± SD 11.4)
-  Caucasian 73.3%
-  College degree or 
higher 86.6%
“TOLF” health IT system, 
an educational and 
behavioral self-care 
intervention including 
PROMs and symptom 
management
-  Electronic (mobile and 
web-based) 
1.  BCLE-SEI
2.  Perceived Ease of 
Use and Usefulness 
Questionnaire
3.  Post Study System 
Usability Questionnaire
- 3 Acceptability: 27/30 (90%) 
patients didn’t have major 
usability problems with TOLF
Symptoms: Patients reported 
significantly (p=0.022) less pain, 
tenderness, aching, soreness, 
and lymphedema at 12 weeks 
post-intervention compared to 
baseline
- -
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design


















To evaluate the effect of 
supportive care models 
on anxiety, depression, 
physical/ emotional 
functioning and unmet 
care needs
RCT 174/356 (49%) breast 
cancer patients
Characteristics per group:
1) CATI with an 
oncologist/ general 
practitioner intervention:
-  Breast cancer patients 
33%
-  Mean age 58.3 years 
(37-75)
-  Female 72.3 %
-  College degree or 
higher 39.5%
2) CATI with telephone 
caseworker:
-  Breast cancer patients 
34%
-  Mean age 57.8 years 
(33-75)
-  Female 72.5 %
-  College degree or 
higher 31.7%
3) Controls
-  Breast cancer patients 
33%
-  Mean age 57.4 years 
(28-75)
-  Female 71.8%
-  College degree or 
higher 37.6%
“Supportive care model” 
including CATI with a 
telephone caseworker 




-  Telephone 
-  Home
-  3 times (baseline, at 3- 
and 6-month intervals)
Control: Usual care
1.  HADS-14 
2.  EORTC-QLQ-C30
3.  SCNS-SF
4.  Needs Assessment 
for Advanced Cancer 
Patient Questionnaire
-  Clinicians received 
feedback reports 








-  No significant differences in 
prevalence of severe anxiety 
and depression between 
intervention and control 
groups. 
-  No overall intervention effect 
over time on anxiety and 
depression was observed 
between groups. Within 
the telephone caseworker 
group, there was a significant 
(p=0.01) decrease in elevated 
depression prevalence over 
time.
Health outcomes: 
-  Physical functioning was 
significantly (p=0.01) 
improved for patients in the 
telephone caseworker group.
-  No significant differences in 
QoL were observed between 
groups. QoL scores improved 
over time within groups, 
but there was no significant 
(p=0.88) overall intervention 
effect on QoL over time. 
-  No significant differences 
were observed between 
groups in emotional, 
cognitive, or social functioning
Other: 
-  A trend towards decreased 
unmet supportive care 
needs was observed in the 
telephone caseworker group 
at 6 months (p=0.07). 
-  No significant differences 
were seen in unmet needs 
between groups.
Compliance: Response to 
CATI feedback reports was 
significantly higher in the 
telephone caseworker group vs. 
oncologist/ general practitioner 
group (99.7% vs. 47.7%, 
p<0.0001)
Referrals: Referrals were 
significantly (p<0.0001) higher in 
the telephone caseworker group 
than the oncologist/ general 
practitioner group
Communication: Patients who 
did CATI’s with telephone 
caseworkers were significantly 
(p=0.0005) more inclined to 
strongly agree that study 
participation improved patient-
doctor communication
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design


















To evaluate the effect of 
supportive care models 
on anxiety, depression, 
physical/ emotional 
functioning and unmet 
care needs
RCT 174/356 (49%) breast 
cancer patients
Characteristics per group:
1) CATI with an 
oncologist/ general 
practitioner intervention:
-  Breast cancer patients 
33%
-  Mean age 58.3 years 
(37-75)
-  Female 72.3 %
-  College degree or 
higher 39.5%
2) CATI with telephone 
caseworker:
-  Breast cancer patients 
34%
-  Mean age 57.8 years 
(33-75)
-  Female 72.5 %
-  College degree or 
higher 31.7%
3) Controls
-  Breast cancer patients 
33%
-  Mean age 57.4 years 
(28-75)
-  Female 71.8%
-  College degree or 
higher 37.6%
“Supportive care model” 
including CATI with a 
telephone caseworker 




-  Telephone 
-  Home
-  3 times (baseline, at 3- 
and 6-month intervals)
Control: Usual care
1.  HADS-14 
2.  EORTC-QLQ-C30
3.  SCNS-SF
4.  Needs Assessment 
for Advanced Cancer 
Patient Questionnaire
-  Clinicians received 
feedback reports 








-  No significant differences in 
prevalence of severe anxiety 
and depression between 
intervention and control 
groups. 
-  No overall intervention effect 
over time on anxiety and 
depression was observed 
between groups. Within 
the telephone caseworker 
group, there was a significant 
(p=0.01) decrease in elevated 
depression prevalence over 
time.
Health outcomes: 
-  Physical functioning was 
significantly (p=0.01) 
improved for patients in the 
telephone caseworker group.
-  No significant differences in 
QoL were observed between 
groups. QoL scores improved 
over time within groups, 
but there was no significant 
(p=0.88) overall intervention 
effect on QoL over time. 
-  No significant differences 
were observed between 
groups in emotional, 
cognitive, or social functioning
Other: 
-  A trend towards decreased 
unmet supportive care 
needs was observed in the 
telephone caseworker group 
at 6 months (p=0.07). 
-  No significant differences 
were seen in unmet needs 
between groups.
Compliance: Response to 
CATI feedback reports was 
significantly higher in the 
telephone caseworker group vs. 
oncologist/ general practitioner 
group (99.7% vs. 47.7%, 
p<0.0001)
Referrals: Referrals were 
significantly (p<0.0001) higher in 
the telephone caseworker group 
than the oncologist/ general 
practitioner group
Communication: Patients who 
did CATI’s with telephone 
caseworkers were significantly 
(p=0.0005) more inclined to 
strongly agree that study 
participation improved patient-
doctor communication
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Graf et al. 
(27),
2016 
To identify variables that 
influence willingness of 
breast cancer patients 
to use electronic PROMs
Cross-sectional 
study
96 breast cancer patients
Characteristics (n=96):
-  Median age 56.68 
years (± SD 12.38)
-  Metastatic 68%
Three-part survey 
concerning SES, HRQoL, 
and attitude towards 
electronic PROMs 
-  Paper-based 
-  Once 
1.  EORTC-C30 2. EQ-5D-
5L/ EQ-VAS
3.  Validated partial 
questionnaires 
including modules of 
KPF-BK 
- - Health outcomes: Median EQ-
VAS 64.67 (± SD 18.15), median 
EORTC-C30 56.16 (± SD 23.56), 
overall QoL 58 (± SD 23.50). 
Acceptability: 
-  54% of patients welcomed 
electronic PROs 
-  47% of patients thought it 
would have a positive impact 
on care.
Other: Scores in computer skills 
differed; 35% had advanced 
computer skills, 34% used 
tablets
- -
Hahn et al. 
(37), 
2004 
To describe the use and 
testing of a multimedia 
program for QoL 
assessment in cancer 
patients withlow and 
high levels of literacy
Intervention 
study
50/126 (39.7%) breast 
cancer patients
Characteristics (n=126):
-  Mean age 50.9 years 
(± SD 13.7)
-  Female 69.8%
-  Caucasian 29.4%
-  College degree or 
higher 60.3%
“Talking Touchscreen”, a 
multimedia program





- - Adherence: Individual item 
response was nearly 100%;
Acceptability: 
-  95.2% reported that the 
touch-screen was easy-very 
easy to use, > 80% found the 
assessment not too long
-  64.4% preferred using the 
touchscreen rather than 
having an interviewer ask the 
question (P=0.172)
-  14.1% of patients would not 
be willing to do the survey 
each time when visiting the 
doctor
- Other: Average PROM 
completion time differed 
significantly for low and high 
literacy patients (33 vs. 28 
minutes, p=0.041)
Holch et al. 
(21), 
2017 
To describe the 
development of 
eRAPID, a system for 
patient-report and 





2/13 (15.4%) breast 
cancer patients
Characteristics (n=13):
-  Mean age 53 years 
(35-69)
-  College degree or 
higher 84.6%
9 patient advocates from 
PRO group 
“eRAPID”, a system 
with an integrated web 
application interface and 
an online questionnaire 
builder (QTool)
-  Electronic (web-based)
1.  PRAE, with responses 
being allocated to 
scores corresponding 
with the CTCAE 
severity grade and 
UKONS
19 clinicians receive 
email alerts when 
severe symptoms are 
reported, and can 
respond to alerts by 
viewing reports in the 
EHR.
- Adherence: Patient compliance 
is monitored by tracking 
website visits and questionnaire 
completions. Adherence was 
encouraged by the system 
through weekly generated 
reminders (email/ text message)
Other: Patients can securely 
report AEs online from home
- Other: 
-  Automated tailored AE 
management advice for 
patients was generated by 
the system (from clinical 
algorithms)
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Graf et al. 
(27),
2016 
To identify variables that 
influence willingness of 
breast cancer patients 
to use electronic PROMs
Cross-sectional 
study
96 breast cancer patients
Characteristics (n=96):
-  Median age 56.68 
years (± SD 12.38)
-  Metastatic 68%
Three-part survey 
concerning SES, HRQoL, 
and attitude towards 
electronic PROMs 
-  Paper-based 
-  Once 
1.  EORTC-C30 2. EQ-5D-
5L/ EQ-VAS
3.  Validated partial 
questionnaires 
including modules of 
KPF-BK 
- - Health outcomes: Median EQ-
VAS 64.67 (± SD 18.15), median 
EORTC-C30 56.16 (± SD 23.56), 
overall QoL 58 (± SD 23.50). 
Acceptability: 
-  54% of patients welcomed 
electronic PROs 
-  47% of patients thought it 
would have a positive impact 
on care.
Other: Scores in computer skills 
differed; 35% had advanced 
computer skills, 34% used 
tablets
- -
Hahn et al. 
(37), 
2004 
To describe the use and 
testing of a multimedia 
program for QoL 
assessment in cancer 
patients withlow and 
high levels of literacy
Intervention 
study
50/126 (39.7%) breast 
cancer patients
Characteristics (n=126):
-  Mean age 50.9 years 
(± SD 13.7)
-  Female 69.8%
-  Caucasian 29.4%
-  College degree or 
higher 60.3%
“Talking Touchscreen”, a 
multimedia program





- - Adherence: Individual item 
response was nearly 100%;
Acceptability: 
-  95.2% reported that the 
touch-screen was easy-very 
easy to use, > 80% found the 
assessment not too long
-  64.4% preferred using the 
touchscreen rather than 
having an interviewer ask the 
question (P=0.172)
-  14.1% of patients would not 
be willing to do the survey 
each time when visiting the 
doctor
- Other: Average PROM 
completion time differed 
significantly for low and high 
literacy patients (33 vs. 28 
minutes, p=0.041)
Holch et al. 
(21), 
2017 
To describe the 
development of 
eRAPID, a system for 
patient-report and 





2/13 (15.4%) breast 
cancer patients
Characteristics (n=13):
-  Mean age 53 years 
(35-69)
-  College degree or 
higher 84.6%
9 patient advocates from 
PRO group 
“eRAPID”, a system 
with an integrated web 
application interface and 
an online questionnaire 
builder (QTool)
-  Electronic (web-based)
1.  PRAE, with responses 
being allocated to 
scores corresponding 
with the CTCAE 
severity grade and 
UKONS
19 clinicians receive 
email alerts when 
severe symptoms are 
reported, and can 
respond to alerts by 
viewing reports in the 
EHR.
- Adherence: Patient compliance 
is monitored by tracking 
website visits and questionnaire 
completions. Adherence was 
encouraged by the system 
through weekly generated 
reminders (email/ text message)
Other: Patients can securely 
report AEs online from home
- Other: 
-  Automated tailored AE 
management advice for 
patients was generated by 
the system (from clinical 
algorithms)
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Javid et al. 
(46),
2016 
To assess breast 
cancer patients’ and 
clinicians’ perspective 
on measurement tools, 





patients participated in 
focus groups or one-on-
one interviews 
Characteristics:
-  Caucasian 85%
-  College degree or 
higher 69%
25 surgeons completed 
the prioritization 
questionnaire and 
participated in a web 
conference
A Stakeholder Advisory 
Panel (12 clinicians and 
5 patients) reviewed 
input from patients and 
clinicians about breast 
surgery PRO collection.
Intervention: -
-  Other (focus groups)





online surveys about 
PRO domains
1.  Prioritization 
questionnaires about 
PRO domains across 
key time periods
2.  Focus groups and 
1-on-1 interviews, or 
web conference
- 12 Health outcomes: 
-  HRQoL (including concerns 
about treatment, treatment 
complications, treatment 
decision satisfaction, 
impact on family/friends) 
was consistently ranked the 
highest domain, while sexual 
function was the lowest. 
-  Treatment-decision-making 
and physical function were 
ranked highly preoperative 
and short-term postoperative. 
-  Emotional wellbeing 
subdomains (fear of 
recurrence and impact 
on family and career) was 
prioritized highly in long-term 
postoperative period.
Other: 
-  HRQoL domain (concerns 
about treatment, 
complications and decision 
satisfaction/regret) was 
prioritized highly in the 
preoperative and short-term 
postoperative period on 
family and friends, fear of 
recurrences was deemed 
most important in the long-
term postoperative period. 
-  In the late-term postoperative 
phase, providers also deemed 
emotional wellbeing (coping 
issues, distress feelings, 
personal relationships, 
support groups) a priority. 
Communication: Communication 
was prioritized highly during the 
preoperative and short-term 
postoperative period
Other: Care process themes 
that came up during discussions 
were scheduling clinic 
appointments, team-based 
care, transition of care, nurse 
navigation, and continuity of 
care.
Judson et al. 
(35), 2013 
To determine long-term 
patient adherence rate 





within larger (3- 
arm) RCT 
72/286 (25%) breast 
cancer patients receiving 
chemotherapy
Characteristics (n=286):
-  Mean age 58 years 
(30-85)
-  Female 64%
-  Caucasian 88%
-  College degree or 
higher 85%
“STAR”, a web-based 
interface for symptomatic 
toxicity reporting
-  Electronic (web-based)
-  Home 
1.  CTCAE
3.  EQ-5D-5L
4.  Performance status
-  Clinician received 
printed patients’ 
STAR reports to 
review at each 
clinic visit
-  Nurse received 
triggered 
automated email 
alerts in case 






-  In total, patients logged into 
STAR 8690 times, of which 
71% from home (between 
visits) and 29% at the clinic 
-  Average monthly compliance 
83%, while average weekly 
compliance was 62%
-  Self-reported reasons for 
non-adherence were: 73% of 
patients said they forgot, were 
too busy, or did not feel like 
it, 11% experienced technical 
and illness-related barriers 
-  Older age at baseline, 
Caucasian and higher 
education level were 




al. (33), 2016 
To determine how 
PROs of self-efficacy 
for selected symptoms 
were associated with 
symptom severity, and 




65/178 (36.5%) breast 
cancer patients
Characteristics (n=65):
-  Mean age 54.6 years
-  Caucasian 78%
-  Metastasis 60%
Multiple PROMs
-  Electronic (tablet) and 
paper-based
-  Clinic waiting room 
-  Once
1.  Arthritis Self-Efficacy 
Scale (modified 
version)
2.  Chronic Pain Self-
Efficacy Scale
3.  MDASI (“pain” item)
4.  FACT-G
5.  Electronic PRO-
Satisfaction
- - Health outcomes: Self-efficacy 
for functioning, pain and other 
symptoms was associated with 
their reported outcomes of pain, 
FACT-G sub-scales and MDASI 
scales. 
Acceptability: Patients felt the 
tablet computer was easy to 
read, to use, to navigate, and 
comfortable to use
Satisfaction: Mean satisfaction 
score was 19.9 (± SD 1.55), out 
of a possible score of 20
- Other: No differences in 
patients’ responses were found 
between methods of PROM 
administration (electronic vs. 
paper-based)
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Javid et al. 
(46),
2016 
To assess breast 
cancer patients’ and 
clinicians’ perspective 
on measurement tools, 





patients participated in 
focus groups or one-on-
one interviews 
Characteristics:
-  Caucasian 85%
-  College degree or 
higher 69%
25 surgeons completed 
the prioritization 
questionnaire and 
participated in a web 
conference
A Stakeholder Advisory 
Panel (12 clinicians and 
5 patients) reviewed 
input from patients and 
clinicians about breast 
surgery PRO collection.
Intervention: -
-  Other (focus groups)





online surveys about 
PRO domains
1.  Prioritization 
questionnaires about 
PRO domains across 
key time periods
2.  Focus groups and 
1-on-1 interviews, or 
web conference
- 12 Health outcomes: 
-  HRQoL (including concerns 
about treatment, treatment 
complications, treatment 
decision satisfaction, 
impact on family/friends) 
was consistently ranked the 
highest domain, while sexual 
function was the lowest. 
-  Treatment-decision-making 
and physical function were 
ranked highly preoperative 
and short-term postoperative. 
-  Emotional wellbeing 
subdomains (fear of 
recurrence and impact 
on family and career) was 
prioritized highly in long-term 
postoperative period.
Other: 
-  HRQoL domain (concerns 
about treatment, 
complications and decision 
satisfaction/regret) was 
prioritized highly in the 
preoperative and short-term 
postoperative period on 
family and friends, fear of 
recurrences was deemed 
most important in the long-
term postoperative period. 
-  In the late-term postoperative 
phase, providers also deemed 
emotional wellbeing (coping 
issues, distress feelings, 
personal relationships, 
support groups) a priority. 
Communication: Communication 
was prioritized highly during the 
preoperative and short-term 
postoperative period
Other: Care process themes 
that came up during discussions 
were scheduling clinic 
appointments, team-based 
care, transition of care, nurse 
navigation, and continuity of 
care.
Judson et al. 
(35), 2013 
To determine long-term 
patient adherence rate 





within larger (3- 
arm) RCT 
72/286 (25%) breast 
cancer patients receiving 
chemotherapy
Characteristics (n=286):
-  Mean age 58 years 
(30-85)
-  Female 64%
-  Caucasian 88%
-  College degree or 
higher 85%
“STAR”, a web-based 
interface for symptomatic 
toxicity reporting
-  Electronic (web-based)
-  Home 
1.  CTCAE
3.  EQ-5D-5L
4.  Performance status
-  Clinician received 
printed patients’ 
STAR reports to 
review at each 
clinic visit
-  Nurse received 
triggered 
automated email 
alerts in case 






-  In total, patients logged into 
STAR 8690 times, of which 
71% from home (between 
visits) and 29% at the clinic 
-  Average monthly compliance 
83%, while average weekly 
compliance was 62%
-  Self-reported reasons for 
non-adherence were: 73% of 
patients said they forgot, were 
too busy, or did not feel like 
it, 11% experienced technical 
and illness-related barriers 
-  Older age at baseline, 
Caucasian and higher 
education level were 




al. (33), 2016 
To determine how 
PROs of self-efficacy 
for selected symptoms 
were associated with 
symptom severity, and 




65/178 (36.5%) breast 
cancer patients
Characteristics (n=65):
-  Mean age 54.6 years
-  Caucasian 78%
-  Metastasis 60%
Multiple PROMs
-  Electronic (tablet) and 
paper-based
-  Clinic waiting room 
-  Once
1.  Arthritis Self-Efficacy 
Scale (modified 
version)
2.  Chronic Pain Self-
Efficacy Scale
3.  MDASI (“pain” item)
4.  FACT-G
5.  Electronic PRO-
Satisfaction
- - Health outcomes: Self-efficacy 
for functioning, pain and other 
symptoms was associated with 
their reported outcomes of pain, 
FACT-G sub-scales and MDASI 
scales. 
Acceptability: Patients felt the 
tablet computer was easy to 
read, to use, to navigate, and 
comfortable to use
Satisfaction: Mean satisfaction 
score was 19.9 (± SD 1.55), out 
of a possible score of 20
- Other: No differences in 
patients’ responses were found 
between methods of PROM 
administration (electronic vs. 
paper-based)
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Kim et al. 
(44), 
2016 
To determine if a mobile 
mental-health tracker 
can potentially indicate 
depression, and to 
examine adherence on 
accuracy in depression 
screening 
Cohort study 78 breast cancer patients 
Characteristics: 
-  Mean age 44.35 years 
(± SD 7.01)
-  College degree or 
higher 52.6%
“Pit-a-Pat”, a smartphone 
app for collecting PROs
-Telephone 
(mobile app)
-  Daily (mental health) 
and biweekly (PHQ-9)
1.  Mental health items: 




-  Lower adherence (n=58) 
group reported 208/497 
(42%) observations, while 
the higher adherence (n=20) 
group reported 289/497 (58%) 
observations (p<0.001)
-  Self-report adherence was 
associated with an increase 
in the accuracy of depression 
screening, with all AUC’s of 
the higher adherence group 
being statistically higher 
(p<0.01) than those of the 
lower adherence group 
Symptoms: 
Depression screening 
performance of mobile mental-
health trackers is comparable 
to the traditional method, 
administration of a PHQ-9 test, 
in the clinical setting
- Other: Screening accuracy 
with all three approaches 
(ratio, average, and frequency 
measurement of daily mental-
health ratings) was statistically 
higher (p<0.05) for patients in 
the higher adherence group than 
the lower adherence group
Knoerl et al. 
(19), 
2017 
To pilot test and 
determine the feasibility, 
acceptability, usability 
and satisfaction of the 
“Carevive Planning 
System” among breast 






25 breast cancer patients 
planned for or receiving 
neurotoxic chemotherapy
Characteristics (n=25):
-  Female 100%
-  Caucasian 80%
-  Metastatic 36%
-  College degree 88%
“CPS”, a web-based 
platform for collecting 
patient-reported 
CIPN symptoms to 
generate a customized 
symptom care plan
-  Electronic (web-based 
platform) for symptoms 
-  Clinic waiting room
-  3 times (before clinic 
visit)
1.  PRO-CTCAE 
2.  EORTC-QLQ-CIPN20 
3.  System Usability Scale
4.  Adapted Acceptability 
E-scale 
Providers (n=6)
-  5 nurse 
practitioner
-  1 physician 
assistant
Characteristics:
-  Female 100%





plans based on 
patients’ response 
to PROMs and could 






-25/25 (100%) patients created 
a CPS account
-  All patients completed 74/75 
(98.6%) questionnaires over 3 
clinic visits
Acceptability: 
-  Easy to use 4.90 (± SD 0.29) 
(range 4-5)
-  Helpfulness of CPS 4.08 (± 
SD 0.93) (range 2-5)
-  Understandability of questions 
4.75 (± SD 0.53) (range 3-5)
-  Acceptability of time required 
for PROM completion 4.58 (± 
SD 0.58) (range 3-5)
-  Overall acceptability ranged 
from 4.08 (± SD 0.93) to 4.90 
(± SD 0.29) (range 1-5) (n=24)
Satisfaction:
-  Enjoyment of CPS 4.19 (± SD 
0.73) (range 3-5)
-  Overall satisfaction 4.56 (± SD 
0.65) (range 3-5)
Other: 
-  Usability score 85.00 (± SD 
11.54) (range 62-100)
Adherence:
-  6/6 (100%) providers created 
a CPS account
-  61/75 (81.3%) patient care 
plans were reviewed 
-  20% of providers reviewed 
care plans consistently with 
patients
Acceptability: 
-  Ability of CPS to identify 
appropriate issues of concern 
3.20 (± SD 0.84) (range 2-4)
-  Ability to identify symptoms or 
areas of need 2.40 (± SD 1.14) 
(range 1-4)
-  Overall acceptability ranged 
from 1.60 (± SD 0.89) to 3.20 
(± SD 0.84) (range 1-5) (n=5) 
Other:
-  Usability score 33.50 (± SD 
17.19) (range 12.50-57.50)
-  100% of CIPN care plan 
recommendations were 
accepted by providers
-  35% of tasks associated with 
treatment recommendations 
were accepted at visit 1 and 
53% of tasks were accepted 
at visit 3
Communication:
-  Helpfulness of CPS in guiding 
clinical conversations with 
patients 1.80 ± SD 1.10 (1-3)
-  Helpfulness in patient-
provider communication 
improvement 1.60 ± SD 0.89 
(1-3)
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Kim et al. 
(44), 
2016 
To determine if a mobile 
mental-health tracker 
can potentially indicate 
depression, and to 
examine adherence on 
accuracy in depression 
screening 
Cohort study 78 breast cancer patients 
Characteristics: 
-  Mean age 44.35 years 
(± SD 7.01)
-  College degree or 
higher 52.6%
“Pit-a-Pat”, a smartphone 
app for collecting PROs
-Telephone 
(mobile app)
-  Daily (mental health) 
and biweekly (PHQ-9)
1.  Mental health items: 




-  Lower adherence (n=58) 
group reported 208/497 
(42%) observations, while 
the higher adherence (n=20) 
group reported 289/497 (58%) 
observations (p<0.001)
-  Self-report adherence was 
associated with an increase 
in the accuracy of depression 
screening, with all AUC’s of 
the higher adherence group 
being statistically higher 
(p<0.01) than those of the 
lower adherence group 
Symptoms: 
Depression screening 
performance of mobile mental-
health trackers is comparable 
to the traditional method, 
administration of a PHQ-9 test, 
in the clinical setting
- Other: Screening accuracy 
with all three approaches 
(ratio, average, and frequency 
measurement of daily mental-
health ratings) was statistically 
higher (p<0.05) for patients in 
the higher adherence group than 
the lower adherence group
Knoerl et al. 
(19), 
2017 
To pilot test and 
determine the feasibility, 
acceptability, usability 
and satisfaction of the 
“Carevive Planning 
System” among breast 






25 breast cancer patients 
planned for or receiving 
neurotoxic chemotherapy
Characteristics (n=25):
-  Female 100%
-  Caucasian 80%
-  Metastatic 36%
-  College degree 88%
“CPS”, a web-based 
platform for collecting 
patient-reported 
CIPN symptoms to 
generate a customized 
symptom care plan
-  Electronic (web-based 
platform) for symptoms 
-  Clinic waiting room
-  3 times (before clinic 
visit)
1.  PRO-CTCAE 
2.  EORTC-QLQ-CIPN20 
3.  System Usability Scale
4.  Adapted Acceptability 
E-scale 
Providers (n=6)
-  5 nurse 
practitioner
-  1 physician 
assistant
Characteristics:
-  Female 100%





plans based on 
patients’ response 
to PROMs and could 






-25/25 (100%) patients created 
a CPS account
-  All patients completed 74/75 
(98.6%) questionnaires over 3 
clinic visits
Acceptability: 
-  Easy to use 4.90 (± SD 0.29) 
(range 4-5)
-  Helpfulness of CPS 4.08 (± 
SD 0.93) (range 2-5)
-  Understandability of questions 
4.75 (± SD 0.53) (range 3-5)
-  Acceptability of time required 
for PROM completion 4.58 (± 
SD 0.58) (range 3-5)
-  Overall acceptability ranged 
from 4.08 (± SD 0.93) to 4.90 
(± SD 0.29) (range 1-5) (n=24)
Satisfaction:
-  Enjoyment of CPS 4.19 (± SD 
0.73) (range 3-5)
-  Overall satisfaction 4.56 (± SD 
0.65) (range 3-5)
Other: 
-  Usability score 85.00 (± SD 
11.54) (range 62-100)
Adherence:
-  6/6 (100%) providers created 
a CPS account
-  61/75 (81.3%) patient care 
plans were reviewed 
-  20% of providers reviewed 
care plans consistently with 
patients
Acceptability: 
-  Ability of CPS to identify 
appropriate issues of concern 
3.20 (± SD 0.84) (range 2-4)
-  Ability to identify symptoms or 
areas of need 2.40 (± SD 1.14) 
(range 1-4)
-  Overall acceptability ranged 
from 1.60 (± SD 0.89) to 3.20 
(± SD 0.84) (range 1-5) (n=5) 
Other:
-  Usability score 33.50 (± SD 
17.19) (range 12.50-57.50)
-  100% of CIPN care plan 
recommendations were 
accepted by providers
-  35% of tasks associated with 
treatment recommendations 
were accepted at visit 1 and 
53% of tasks were accepted 
at visit 3
Communication:
-  Helpfulness of CPS in guiding 
clinical conversations with 
patients 1.80 ± SD 1.10 (1-3)
-  Helpfulness in patient-
provider communication 
improvement 1.60 ± SD 0.89 
(1-3)
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Knoerl et al. 
(22), 
2017 
To determine if CPS 
can encourage patient 









75 breast cancer patients 
planned for or receiving 
neurotoxic chemotherapy
Characteristics:
-  Mean age 51.93 years 
(25-82)
-  Female 100%
-  Caucasian 88% 
-  Metastatic 13.3%
“CPS”, a web-based 
platform for collecting 
patient-reported CIPN 
symptoms to generate a 
customized care plan
-  Electronic (tablet 
computer) and paper-
based (only PAM)
-  Clinic waiting room
-  3 clinic visits
NB. also a pencil/paper 
version of the PAM at the 
first and third visit
1.  PRO-CTCAE (visit 1-3)
2.  QLQ-CIPN20 (visit 1-3)
3.  PAM (visit 1 and 3)
4.  System Usability Scale 
(visit 3)
5.  Adapted Acceptability 
E-scale (visit 3)
Providers (n=6)
-  5 nurse 
practitioners
-  1 physician 
assistant
Characteristics:
-  Female 100%





-  Mean QLQ-CIPN20 sensory 
and motor severity scores 
remained low across 3 study 
visits, ranging from 6.28 to 
17.68 (scale 0–100)
-  Mean PRO-CTCAE numbness 
and tingling severity and 
interference scores also 
remained low, ranging from 
0.32 to 1.07 (range 0–4)
Acceptability:
-  Easy to use 4.49 (± SD 0.94) 
(range 1-5) 
Other:
-  85% of patients possessed 
high (level III-IV) patient 
activation at baseline. PAM 
scores improved significantly 
(p=0.02) from baseline to final 
clinic visit from 67.15 (± SD 
13.5) to 69.29 (SD ± 16.18) 
-  Helpfulness of CPS 3.75 (± 
SD 1.10) (range 1-5)
-  Understandability of questions 
4.27 (± SD 1.0) (range 1-5)
-  Acceptability of time required 
for PROM completion 4.03 (± 
SD 1.14) (range 1-5)
-  Overall acceptability ranged 
from 3.63 (± SD 1.18) to 4.49 
(± SD 0.94) (range 1-5)
Satisfaction:
-Enjoyment of CPS 3.63 (± SD 
1.18) (range1-5)
-  Overall satisfaction 4.11 (± SD 
1.04) (range 1-5)
Other:
-  Usability was highly rated with 
a mean score of 76.18 (± SD 
21.93) (range 0-100)
Acceptability:
Providers reported several 
barriers to reviewing the care
plans with the patients: 
-  lack of time to review 
-  not finding CIPN management 
recommendations useful
-  difficulty logging into Carevive 
website due to password and/
or software operational errors
Other:
60/67 (89.6%) patients received 
at least 1 care plan, while only 
37/67 (55.2%) patients received 
all 3 care plans during the study 
period
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Knoerl et al. 
(22), 
2017 
To determine if CPS 
can encourage patient 









75 breast cancer patients 
planned for or receiving 
neurotoxic chemotherapy
Characteristics:
-  Mean age 51.93 years 
(25-82)
-  Female 100%
-  Caucasian 88% 
-  Metastatic 13.3%
“CPS”, a web-based 
platform for collecting 
patient-reported CIPN 
symptoms to generate a 
customized care plan
-  Electronic (tablet 
computer) and paper-
based (only PAM)
-  Clinic waiting room
-  3 clinic visits
NB. also a pencil/paper 
version of the PAM at the 
first and third visit
1.  PRO-CTCAE (visit 1-3)
2.  QLQ-CIPN20 (visit 1-3)
3.  PAM (visit 1 and 3)
4.  System Usability Scale 
(visit 3)
5.  Adapted Acceptability 
E-scale (visit 3)
Providers (n=6)
-  5 nurse 
practitioners
-  1 physician 
assistant
Characteristics:
-  Female 100%





-  Mean QLQ-CIPN20 sensory 
and motor severity scores 
remained low across 3 study 
visits, ranging from 6.28 to 
17.68 (scale 0–100)
-  Mean PRO-CTCAE numbness 
and tingling severity and 
interference scores also 
remained low, ranging from 
0.32 to 1.07 (range 0–4)
Acceptability:
-  Easy to use 4.49 (± SD 0.94) 
(range 1-5) 
Other:
-  85% of patients possessed 
high (level III-IV) patient 
activation at baseline. PAM 
scores improved significantly 
(p=0.02) from baseline to final 
clinic visit from 67.15 (± SD 
13.5) to 69.29 (SD ± 16.18) 
-  Helpfulness of CPS 3.75 (± 
SD 1.10) (range 1-5)
-  Understandability of questions 
4.27 (± SD 1.0) (range 1-5)
-  Acceptability of time required 
for PROM completion 4.03 (± 
SD 1.14) (range 1-5)
-  Overall acceptability ranged 
from 3.63 (± SD 1.18) to 4.49 
(± SD 0.94) (range 1-5)
Satisfaction:
-Enjoyment of CPS 3.63 (± SD 
1.18) (range1-5)
-  Overall satisfaction 4.11 (± SD 
1.04) (range 1-5)
Other:
-  Usability was highly rated with 
a mean score of 76.18 (± SD 
21.93) (range 0-100)
Acceptability:
Providers reported several 
barriers to reviewing the care
plans with the patients: 
-  lack of time to review 
-  not finding CIPN management 
recommendations useful
-  difficulty logging into Carevive 
website due to password and/
or software operational errors
Other:
60/67 (89.6%) patients received 
at least 1 care plan, while only 
37/67 (55.2%) patients received 
all 3 care plans during the study 
period
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design
















al. (47), 2015 
To assess cancer 
survivors’ and care 
providers’ expectations 
of potential attributes 
of an interactive portal 




21/34 (61.8%) breast 
cancer survivors 
Characteristics:
Breast cancer survivors 
(n=21):
-  Mean age 52.9 years 
(range 27-76)
-  Female 100%




-  Mean age 45.5 years 
(range 24-62)
-  Medical n=7
-  Paramedical n=10
-  Psychosocial n=14
Interactive portal 
including PROs with 
feedback, among others.
-  Other (focus groups)
-  Once
Focus group discussion 
on expectations’ 
concerning an interactive 
portal 
- - Other:
-  Patients indicated that the 
information from completing 
PROMs could increase the 
knowledge about their health 
status
-  Patients had doubts about 
care providers’ incentives 
to review PROs due to time 
constraints
Other: 
-  Care providers expected an 
increase in knowledge of 
patients’ health status 
-  Care providers had their 
doubts about who the 
responsibility, for PRO review 
and feedback, would fall onto 
Communication:
-  Both patients and care 
providers expected that 
the patient-provider 
communication would 
improve through PRO 
feedback by providers (and 
thus better preparedness for 
appointment)





CAT for fatigue and 
sleep-disturbance items 
Cohort study 60/336 (17.9%) breast 
cancer patients 
Characteristics (n=336):
-  Mean age 57.44 years 
(± SD 15.71)
-  Female 54.8%
-  Caucasian 74.6%
-  Metastatic 30%
PROMIS CAT of cancer-
related fatigue and other 
sleep-disturbance items
-  Electronic (tablet) 
-  During clinic visits
1.  PROMIS CAT 3 domain 
item banks
2.  FACIT-F 
3.  ISI
4.  Acceptability survey
- - Acceptability:
-  >98% indicated that 
symptom screening was not 
burdensome
-  65% were willing to complete 
survey at every visit
Other:
-  67% thought PRO results 
were useful for clinicians
- Other:
-  Average number of items 
completed of ISI was 5.36 
(±SD 2.16) for sleep-
disturbance, and 4.51 (± SD 
1.59) for FACIT-F (score range 
0-52) for fatigue
-  Overall time 15-20 minutes 
per patient to complete all 
measures











30 patients completed 
the study
Characteristics (n=30):
-  Mean age 45 years 
(36-65)
-  Lymph node 
metastasis 77%
-  College degree or 
higher 47%
“Pit-a-Pat”, a smartphone 
app for collecting PROs 
-  Electronic (mobile app)
-  30-minute interview at 
admission
-  Daily 
30-minute interview (app 
use) +
1.  EQ5D-3L 
2.  BDI
3.  Sleep disturbance 
symptoms
4.  Acute symptomatic 
chemotherapy-related 
toxicity
5.  Medication ‘diary’
Clinicians could 
review the data in the 
EHR as the database 
was integrated in it. 
3 Adherence:
-  Overall compliance rate 45%
-  Longitudinal compliance 
curve decreased from 100% 
(day 1) to 50% (day 34) to 
13.3% (day 90)
-  Cumulative compliance rate 
decreased steadily from 50% 
(day 70) to 45% (day 90)
-  Unemployed women were 
associated with a higher rate 
of compliance (p=.03)
-  Rate of self-reporting in 
the jobless subgroup was 
significantly higher compared 
to employed patients (55% 
± SD 25.7 vs. 30.7% ± 19.2, 
p=.006)
Acceptability: Reasons that 
patients gave for not self-
reporting were that the app 
did not work (38% of patients), 
forgetting to (29%), finding the 
app not useful (21%), feeling 
too sick to self-report (8%), not 
feeling like it (4%)
- The rate self-reporting was 
higher in the subgroup with 
a 1-day lag time (self-report 
immediately after enrollment) 
than in patients that had a lag-
time of ≥ 2 days (51.6% ± SD 24 
vs. 29.6% ± 25.3, p=0.03) 
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design
















al. (47), 2015 
To assess cancer 
survivors’ and care 
providers’ expectations 
of potential attributes 
of an interactive portal 




21/34 (61.8%) breast 
cancer survivors 
Characteristics:
Breast cancer survivors 
(n=21):
-  Mean age 52.9 years 
(range 27-76)
-  Female 100%




-  Mean age 45.5 years 
(range 24-62)
-  Medical n=7
-  Paramedical n=10
-  Psychosocial n=14
Interactive portal 
including PROs with 
feedback, among others.
-  Other (focus groups)
-  Once
Focus group discussion 
on expectations’ 
concerning an interactive 
portal 
- - Other:
-  Patients indicated that the 
information from completing 
PROMs could increase the 
knowledge about their health 
status
-  Patients had doubts about 
care providers’ incentives 
to review PROs due to time 
constraints
Other: 
-  Care providers expected an 
increase in knowledge of 
patients’ health status 
-  Care providers had their 
doubts about who the 
responsibility, for PRO review 
and feedback, would fall onto 
Communication:
-  Both patients and care 
providers expected that 
the patient-provider 
communication would 
improve through PRO 
feedback by providers (and 
thus better preparedness for 
appointment)





CAT for fatigue and 
sleep-disturbance items 
Cohort study 60/336 (17.9%) breast 
cancer patients 
Characteristics (n=336):
-  Mean age 57.44 years 
(± SD 15.71)
-  Female 54.8%
-  Caucasian 74.6%
-  Metastatic 30%
PROMIS CAT of cancer-
related fatigue and other 
sleep-disturbance items
-  Electronic (tablet) 
-  During clinic visits
1.  PROMIS CAT 3 domain 
item banks
2.  FACIT-F 
3.  ISI
4.  Acceptability survey
- - Acceptability:
-  >98% indicated that 
symptom screening was not 
burdensome
-  65% were willing to complete 
survey at every visit
Other:
-  67% thought PRO results 
were useful for clinicians
- Other:
-  Average number of items 
completed of ISI was 5.36 
(±SD 2.16) for sleep-
disturbance, and 4.51 (± SD 
1.59) for FACIT-F (score range 
0-52) for fatigue
-  Overall time 15-20 minutes 
per patient to complete all 
measures











30 patients completed 
the study
Characteristics (n=30):
-  Mean age 45 years 
(36-65)
-  Lymph node 
metastasis 77%
-  College degree or 
higher 47%
“Pit-a-Pat”, a smartphone 
app for collecting PROs 
-  Electronic (mobile app)
-  30-minute interview at 
admission
-  Daily 
30-minute interview (app 
use) +
1.  EQ5D-3L 
2.  BDI
3.  Sleep disturbance 
symptoms
4.  Acute symptomatic 
chemotherapy-related 
toxicity
5.  Medication ‘diary’
Clinicians could 
review the data in the 
EHR as the database 
was integrated in it. 
3 Adherence:
-  Overall compliance rate 45%
-  Longitudinal compliance 
curve decreased from 100% 
(day 1) to 50% (day 34) to 
13.3% (day 90)
-  Cumulative compliance rate 
decreased steadily from 50% 
(day 70) to 45% (day 90)
-  Unemployed women were 
associated with a higher rate 
of compliance (p=.03)
-  Rate of self-reporting in 
the jobless subgroup was 
significantly higher compared 
to employed patients (55% 
± SD 25.7 vs. 30.7% ± 19.2, 
p=.006)
Acceptability: Reasons that 
patients gave for not self-
reporting were that the app 
did not work (38% of patients), 
forgetting to (29%), finding the 
app not useful (21%), feeling 
too sick to self-report (8%), not 
feeling like it (4%)
- The rate self-reporting was 
higher in the subgroup with 
a 1-day lag time (self-report 
immediately after enrollment) 
than in patients that had a lag-
time of ≥ 2 days (51.6% ± SD 24 
vs. 29.6% ± 25.3, p=0.03) 
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design
















al. (42), 2014 
To determine whether 
timely emailed 





and thus lead to better 
symptom outcomes 
RCT 99/250 (39.6%) breast 




-  Breast cancer patients 
n=63 (48.8%)
-  Mean age 55.2 years 
(21-86)
-  Female 82.2%
-  Caucasian 89.6%
2) Control (n=121):
-  Breast cancer patients 
n=36 (29.8%)
-  Mean age 55.8 years 
(19-81)
-  Female 69.4%




reporting system, with 
symptom alerts (if 
moderate-to-severe 
levels) being sent to care 
providers








10 symptoms (pain, 
fatigue,
nausea/ vomiting, fever, 
insomnia, anxiety, 
depression, mouth 
sores, diarrhea, and 
constipation) 
An oncology 
physician and nurse 
received automated 
alerts of unrelieved 
symptoms
1.5 Adherence: 
-  Overall daily call adherence 
was 65% of expected days 
-  No difference in average days 
called between intervention 
and control groups (28.72 ± 
15.62 days vs. 29.69 ± 16.78 
days, p=0.66)
Symptoms:
-  Most frequent moderate-
severe symptoms in both 
groups were fatigue (89.2% 
of patients), trouble sleeping 
(74.9%) and pain (70.4%).
-  Severe levels were 
significantly (p<0.001) more
common in the treatment group 
-  Less talking about symptoms 
at patient-initiated contacts in 
intervention group (62 % vs. 
73%, P=0.19)
Health outcomes: 
-  No significant difference 
between symptom severity 
or distress scores between 
arms (mean difference=0.06, 
p=0.58)
Acceptability:
-  94% quiet or very easy to use
-  91% call length acceptable
-  61% very much or quite 
helpful in keep track of their 
symptoms
-  52% system helped them feel 
like participating in their care
-  79% quiet or very confident 
the system notified their 
oncology providers of their 
symptoms
-  25% agreed the system 
helped their doctor/nurse 
decrease their symptoms 
Satisfaction:
-  77% quite or very satisfied 
with using the system
Acceptability:
-  100% found the alert reports 
to be timely
-  89% found the system easy 
to interpret
-  82% found it useful
-  0% reported technical 
difficulties
Satisfaction:
-  11/13 (85%) providers were 
somewhat to very satisfied 
with the system
Hospital visits:
-  No difference between 
intervention and control group 
in number of times an alert 
was generated (p=0.80) 
-  No difference in frequency 
of patient- and/or provider-
initiated unscheduled 
contacts (p=0.73)
-  No difference in patient- vs. 
provider-initiated
unscheduled contacts (p=0.14)
-  More provider-initiated 
contacts in intervention group 
than the control group (18 vs. 
10 contacts) 
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design
















al. (42), 2014 
To determine whether 
timely emailed 





and thus lead to better 
symptom outcomes 
RCT 99/250 (39.6%) breast 




-  Breast cancer patients 
n=63 (48.8%)
-  Mean age 55.2 years 
(21-86)
-  Female 82.2%
-  Caucasian 89.6%
2) Control (n=121):
-  Breast cancer patients 
n=36 (29.8%)
-  Mean age 55.8 years 
(19-81)
-  Female 69.4%




reporting system, with 
symptom alerts (if 
moderate-to-severe 
levels) being sent to care 
providers








10 symptoms (pain, 
fatigue,
nausea/ vomiting, fever, 
insomnia, anxiety, 
depression, mouth 
sores, diarrhea, and 
constipation) 
An oncology 
physician and nurse 
received automated 
alerts of unrelieved 
symptoms
1.5 Adherence: 
-  Overall daily call adherence 
was 65% of expected days 
-  No difference in average days 
called between intervention 
and control groups (28.72 ± 
15.62 days vs. 29.69 ± 16.78 
days, p=0.66)
Symptoms:
-  Most frequent moderate-
severe symptoms in both 
groups were fatigue (89.2% 
of patients), trouble sleeping 
(74.9%) and pain (70.4%).
-  Severe levels were 
significantly (p<0.001) more
common in the treatment group 
-  Less talking about symptoms 
at patient-initiated contacts in 
intervention group (62 % vs. 
73%, P=0.19)
Health outcomes: 
-  No significant difference 
between symptom severity 
or distress scores between 
arms (mean difference=0.06, 
p=0.58)
Acceptability:
-  94% quiet or very easy to use
-  91% call length acceptable
-  61% very much or quite 
helpful in keep track of their 
symptoms
-  52% system helped them feel 
like participating in their care
-  79% quiet or very confident 
the system notified their 
oncology providers of their 
symptoms
-  25% agreed the system 
helped their doctor/nurse 
decrease their symptoms 
Satisfaction:
-  77% quite or very satisfied 
with using the system
Acceptability:
-  100% found the alert reports 
to be timely
-  89% found the system easy 
to interpret
-  82% found it useful
-  0% reported technical 
difficulties
Satisfaction:
-  11/13 (85%) providers were 
somewhat to very satisfied 
with the system
Hospital visits:
-  No difference between 
intervention and control group 
in number of times an alert 
was generated (p=0.80) 
-  No difference in frequency 
of patient- and/or provider-
initiated unscheduled 
contacts (p=0.73)
-  No difference in patient- vs. 
provider-initiated
unscheduled contacts (p=0.14)
-  More provider-initiated 
contacts in intervention group 
than the control group (18 vs. 
10 contacts) 
142 − Chapter 6
6
Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design
















al. (43), 2017 
To determine the 
efficacy of an automated 
symptom management 
system in reducing 
chemotherapy side-
effects as vs. enhanced 
usual care
RCT 156/358 (43.6%) breast 
cancer patients, starting 
chemotherapy with at 
least 3 planned cycles
Characteristics per group 
(n=358)
1) Intervention (n=180):
-  Mean age 54.77 years 
(±12.17)
-  Female 75%
-  Caucasian 80%
-  College degree or 
higher 69%
2) Controls (n=178):
-  Mean age 56.79 years 
(± 10.54)
-  Female 76%
-  Caucasian 86%
-  College degree or 
higher 69%
Intervention: “Symptom 
Care at Home” system, 
a combined intervention 





-  Telephone 
-  Home
-  Daily 
Control: Enhanced usual 
care with daily symptom 
reporting without review 
by care providers
11 symptoms (fatigue, 
insomnia, nausea/
vomiting, pain, numbness 
or tingling, depression,
anxiety, distress over 
appearance, diarrhea,
mouth sore, and trouble 
thinking/concentrating)
Nurse practitioners 
responded to alerts 
indicating symptom 
severity exceeding 
present thresholds by 
calling intervention 
patients to provide 
guideline-based 
symptom care







-  Daily call adherence was high 
and not significantly (p=0.80) 
different between intervention 
and control arms 
-  12% voluntary withdrawal 
was recorded but the 
difference between groups 
was not significant; non-
compliant patients (SCH 25 
patients; UC 27 patients) were 
slightly older (58.45 vs. 55.08 
years, p=0.02)
Symptoms:
-  Most prevalent symptoms 
with moderate-severe levels 
were fatigue (reported by 86% 
of patients), pain (80% of 
patients), sleep troubles (78% 
of patients) and nausea (60% 
of patients)
-  10/11 reported symptoms 
were significantly lower for 
intervention patients (p<0.001 
- 0.025) than control patients
Health outcomes: 
-  Post-baseline symptom 
burden reduction (treatment 
impact) for intervention 
patients was 3.59 severity 
points (p < 0.001), roughly 
43% of the control group
-  Intervention patients had 3 
times fewer (67% less) severe 
days (p<0.001) and 1.65 times 
fewer (39% less) moderate 
days (p=0.001) than control 
patients; intervention patients 
had 39% more mild days 
(p=0.016) and 25% more ‘no 
symptom’ days (p=0.006) 
than control patients 
Other: Intervention patients 
reported alerting symptoms only 
on 19% of calls, while control 
patients alerted on 37% of calls
- -
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design
















al. (43), 2017 
To determine the 
efficacy of an automated 
symptom management 
system in reducing 
chemotherapy side-
effects as vs. enhanced 
usual care
RCT 156/358 (43.6%) breast 
cancer patients, starting 
chemotherapy with at 
least 3 planned cycles
Characteristics per group 
(n=358)
1) Intervention (n=180):
-  Mean age 54.77 years 
(±12.17)
-  Female 75%
-  Caucasian 80%
-  College degree or 
higher 69%
2) Controls (n=178):
-  Mean age 56.79 years 
(± 10.54)
-  Female 76%
-  Caucasian 86%
-  College degree or 
higher 69%
Intervention: “Symptom 
Care at Home” system, 
a combined intervention 





-  Telephone 
-  Home
-  Daily 
Control: Enhanced usual 
care with daily symptom 
reporting without review 
by care providers
11 symptoms (fatigue, 
insomnia, nausea/
vomiting, pain, numbness 
or tingling, depression,
anxiety, distress over 
appearance, diarrhea,
mouth sore, and trouble 
thinking/concentrating)
Nurse practitioners 
responded to alerts 
indicating symptom 
severity exceeding 
present thresholds by 
calling intervention 
patients to provide 
guideline-based 
symptom care







-  Daily call adherence was high 
and not significantly (p=0.80) 
different between intervention 
and control arms 
-  12% voluntary withdrawal 
was recorded but the 
difference between groups 
was not significant; non-
compliant patients (SCH 25 
patients; UC 27 patients) were 
slightly older (58.45 vs. 55.08 
years, p=0.02)
Symptoms:
-  Most prevalent symptoms 
with moderate-severe levels 
were fatigue (reported by 86% 
of patients), pain (80% of 
patients), sleep troubles (78% 
of patients) and nausea (60% 
of patients)
-  10/11 reported symptoms 
were significantly lower for 
intervention patients (p<0.001 
- 0.025) than control patients
Health outcomes: 
-  Post-baseline symptom 
burden reduction (treatment 
impact) for intervention 
patients was 3.59 severity 
points (p < 0.001), roughly 
43% of the control group
-  Intervention patients had 3 
times fewer (67% less) severe 
days (p<0.001) and 1.65 times 
fewer (39% less) moderate 
days (p=0.001) than control 
patients; intervention patients 
had 39% more mild days 
(p=0.016) and 25% more ‘no 
symptom’ days (p=0.006) 
than control patients 
Other: Intervention patients 
reported alerting symptoms only 
on 19% of calls, while control 
patients alerted on 37% of calls
- -
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Ruland et al. 
(50), 2013 
To report patients’ use 
of WebChoice, a multi-
component application 
for disease management 







56/103 (54%) breast 
cancer patients, who had 
access to WebChoice 
(intervention) and had 
logged on at least 2 times
Characteristics:
-  Mean age 51 years (± 
SD 7.1)
-  Metastatic 17.7%











with nurses, and a patient 
discussion forum. 
-Electronic (web-based)





and personal email 
messages to a nurse. 
2.  Diary (personal notes) 




the accuracy of 
posts in the patient 
discussion forum, 
and also posted 
helpful advice 
6 Adherence:
-  System was used 4153 times 
(median=13.5 times, range 
2-892 log-ons) 
-  216 personal messages to 
nurse (median=1 time)
-  Discussion forum most used 
of WebChoice with 374 posts 
by breast cancer patients, 
which was significantly 
(p=0.01) higher compared to 
132 posts by prostate cancer 
patients 
-  291 vs. 209 (p=0.54) self-
assessments were made by 
breast cancer and prostate 
cancer patients, respectively.
-  93/103 (90%) of usefulness 
questionnaires were returned
Acceptability:
-  Most useful section of 
WebChoice, considered by 
patients, was receiving an 
answer from the nurse (score 
7.6, range 3-9)
-  Most common reasons for 
using each section were: “get 
help with a problem” (75% 
of breast cancer patients), 
“get information about a 
problem”(77%), compare 
experiences with other 
patients (81%) and “prepare 
communication with health 
personnel” (29%) 
- -
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Ruland et al. 
(50), 2013 
To report patients’ use 
of WebChoice, a multi-
component application 
for disease management 







56/103 (54%) breast 
cancer patients, who had 
access to WebChoice 
(intervention) and had 
logged on at least 2 times
Characteristics:
-  Mean age 51 years (± 
SD 7.1)
-  Metastatic 17.7%











with nurses, and a patient 
discussion forum. 
-Electronic (web-based)





and personal email 
messages to a nurse. 
2.  Diary (personal notes) 




the accuracy of 
posts in the patient 
discussion forum, 
and also posted 
helpful advice 
6 Adherence:
-  System was used 4153 times 
(median=13.5 times, range 
2-892 log-ons) 
-  216 personal messages to 
nurse (median=1 time)
-  Discussion forum most used 
of WebChoice with 374 posts 
by breast cancer patients, 
which was significantly 
(p=0.01) higher compared to 
132 posts by prostate cancer 
patients 
-  291 vs. 209 (p=0.54) self-
assessments were made by 
breast cancer and prostate 
cancer patients, respectively.
-  93/103 (90%) of usefulness 
questionnaires were returned
Acceptability:
-  Most useful section of 
WebChoice, considered by 
patients, was receiving an 
answer from the nurse (score 
7.6, range 3-9)
-  Most common reasons for 
using each section were: “get 
help with a problem” (75% 
of breast cancer patients), 
“get information about a 
problem”(77%), compare 
experiences with other 
patients (81%) and “prepare 
communication with health 
personnel” (29%) 
- -
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Snyder et al. 
(28), 2010 
To identify the topics 
that patients and 
clinicians report as being 
relevant in a PROM for 
use in clinical practice
Cross-sectional 
study
 21/41 (51.2%) breast 
cancer patients
Characteristics (n=41):
-  Mean age 63.8 years 
(± SD 12.56)
-  Female 51.12%
-  Caucasian 68.3%
-  College degree or 
higher 65.9%
Semi-structured 
interviews with patients 
and clinicians regarding 
prioritizing issues/ 










-  67% of breast cancer patients 
preferred questions about 
whether it is an issue they 
want to have addressed
-  Slight preference for a 
categorical assessment and 
reporting of results
Other:
-  2 domains discussed by 
>70% of breast cancer 
patients were pain and 
information needs
-  7 domains discussed 
by <50% of all patients 
(n=41): cognitive function, 




-  >70% of breast cancer 
patients reported physical 
function, role function, pain, 
fatigue and information needs, 
to be relevant for inclusion in 
a PROM
Acceptability:
-  83% of breast cancer 
clinicians (n=6) preferred 
questions about how 
bothered the patient is
Other:
-  9 domains discussed by 
>70% of clinicians (n=15): 
physical function, nausea/ 
vomiting, role function, 
diarrhea, information needs, 
pain, fatigue, constipation, 
and
sexual function.
-  3 domains discussed by 
<50% of clinicians: cognitive 
function, social function, and 
sleep problems.
-  >70% of clinicians reported 6 
domains (information needs, 
cognitive function, emotional 
function, role function, sexual 
function, fatigue, fatigue) to 
be relevant for inclusion in a 
questionnaire
-
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Snyder et al. 
(28), 2010 
To identify the topics 
that patients and 
clinicians report as being 
relevant in a PROM for 
use in clinical practice
Cross-sectional 
study
 21/41 (51.2%) breast 
cancer patients
Characteristics (n=41):
-  Mean age 63.8 years 
(± SD 12.56)
-  Female 51.12%
-  Caucasian 68.3%
-  College degree or 
higher 65.9%
Semi-structured 
interviews with patients 
and clinicians regarding 
prioritizing issues/ 










-  67% of breast cancer patients 
preferred questions about 
whether it is an issue they 
want to have addressed
-  Slight preference for a 
categorical assessment and 
reporting of results
Other:
-  2 domains discussed by 
>70% of breast cancer 
patients were pain and 
information needs
-  7 domains discussed 
by <50% of all patients 
(n=41): cognitive function, 




-  >70% of breast cancer 
patients reported physical 
function, role function, pain, 
fatigue and information needs, 
to be relevant for inclusion in 
a PROM
Acceptability:
-  83% of breast cancer 
clinicians (n=6) preferred 
questions about how 
bothered the patient is
Other:
-  9 domains discussed by 
>70% of clinicians (n=15): 
physical function, nausea/ 
vomiting, role function, 
diarrhea, information needs, 
pain, fatigue, constipation, 
and
sexual function.
-  3 domains discussed by 
<50% of clinicians: cognitive 
function, social function, and 
sleep problems.
-  >70% of clinicians reported 6 
domains (information needs, 
cognitive function, emotional 
function, role function, sexual 
function, fatigue, fatigue) to 
be relevant for inclusion in a 
questionnaire
-
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes




use, usefulness, & 










-  Mean age 57 years 
(range 28-80) 
-  Caucasian 79%
-  Metastatic 52%
-  College degree or 
higher 73%
“PatientViewpoint”, a 
webtool for administering 
PRO surveys at intervals 
and to generate those in 
graphical score reports 
-  Electronic (web-based; 
integrated in EHR)
-  Home or clinic 
-  Every 2 weeks 
(regardless of visit 
frequency) 
1.  6 PROMIS short forms 
(physical function, 
pain interference, 
satisfaction with social 
roles, fatigue, anxiety, 
& depression) 
2.  EORTC-QLQ-BR23
3.  15-item feedback form 
on PatientViewPoint
Clinicians could 
choose how to 
review PROM results: 
in paper report, on 
the website, in the 
EHR, or not at all.
- Adherence: 
-  87% of questionnaires was 
completed offsite
-  3/47 (60%) patients only 
completed PROMs in the 
clinic; 28/47 (60%) patients 
completed PROMs only at 
offset
-  84% no missing items on 
PROMIS questionnaires when 
completed at home vs. 67% 
at the clinic
Symptoms: Among breast 
cancer patients, most prevalent 
domains were systemic therapy 
including symptoms and/or 
side effects (53%), and sexual 
function (50%)
Acceptability:
-  Patients were generally 
positive with >90% indicating 
“strong” usability
-  46% reported clinicians used 
the reported information
-  39% reported care quality 
improved
Satisfaction: 
-  Patients reported the webtool 
to be well organized and 
laid-out, and that it allowed 
opportunities to discuss 
issues that would otherwise 
have not been
-  Patients also mentioned that 
they questioned whether their 
care providers reviewed the 
PROM results
Clinical decision-making:
-  Most likely to discuss 
systematic therapy (89%), 
pain interference (80%), 
fatigue (80%), and sexual 
function (6%)
-  Most common actions taken 
in response to identified 
issues were providing 
information and/or advice
Acceptability:
-  PROM results of 24/47 (51%) 
patients were reviewed by 
clinicians in the HER, while in 
17% of patients the results 
were reviewed on the paper 
report. Results of 15/47 (32%) 
patients were reviewed in 
PatientViewpoint or not at all
-  On 10/47 (21%) feedback 
forms, clinicians reported not 
using the PRO information. 
Clinicians reported the 
following reasons for 
questionnaire use: it provided 
additional information 
(51%), it confirmed 
knowledge of patients’ 
problems (49%), it provided 
an overall assessment 
(43%), it identified issues 
for discussion (38%), it 
contributed to patient 
management (30%)
-  On 27/47 (58%) feedback 
forms, clinicians reported that 
the questionnaire assisted 
them in identifying areas of 
concern, and that it improved 
quality of care (54%)
Acceptability:
-  Clinicians strongly preferred 
graphical PROM results 
in PatientViewPoint but 
preferred plain-text score 
reports in the HER
-  More explanation about 
PRO item content and score 
meaning was desired
Other:
-  PROMIS completion: median 
6 minutes (2-12) 
-  EORTC-QLQ-BR23 
completion: median 3 minutes 
(1-11)
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes




use, usefulness, & 










-  Mean age 57 years 
(range 28-80) 
-  Caucasian 79%
-  Metastatic 52%
-  College degree or 
higher 73%
“PatientViewpoint”, a 
webtool for administering 
PRO surveys at intervals 
and to generate those in 
graphical score reports 
-  Electronic (web-based; 
integrated in EHR)
-  Home or clinic 
-  Every 2 weeks 
(regardless of visit 
frequency) 
1.  6 PROMIS short forms 
(physical function, 
pain interference, 
satisfaction with social 
roles, fatigue, anxiety, 
& depression) 
2.  EORTC-QLQ-BR23
3.  15-item feedback form 
on PatientViewPoint
Clinicians could 
choose how to 
review PROM results: 
in paper report, on 
the website, in the 
EHR, or not at all.
- Adherence: 
-  87% of questionnaires was 
completed offsite
-  3/47 (60%) patients only 
completed PROMs in the 
clinic; 28/47 (60%) patients 
completed PROMs only at 
offset
-  84% no missing items on 
PROMIS questionnaires when 
completed at home vs. 67% 
at the clinic
Symptoms: Among breast 
cancer patients, most prevalent 
domains were systemic therapy 
including symptoms and/or 
side effects (53%), and sexual 
function (50%)
Acceptability:
-  Patients were generally 
positive with >90% indicating 
“strong” usability
-  46% reported clinicians used 
the reported information
-  39% reported care quality 
improved
Satisfaction: 
-  Patients reported the webtool 
to be well organized and 
laid-out, and that it allowed 
opportunities to discuss 
issues that would otherwise 
have not been
-  Patients also mentioned that 
they questioned whether their 
care providers reviewed the 
PROM results
Clinical decision-making:
-  Most likely to discuss 
systematic therapy (89%), 
pain interference (80%), 
fatigue (80%), and sexual 
function (6%)
-  Most common actions taken 
in response to identified 
issues were providing 
information and/or advice
Acceptability:
-  PROM results of 24/47 (51%) 
patients were reviewed by 
clinicians in the HER, while in 
17% of patients the results 
were reviewed on the paper 
report. Results of 15/47 (32%) 
patients were reviewed in 
PatientViewpoint or not at all
-  On 10/47 (21%) feedback 
forms, clinicians reported not 
using the PRO information. 
Clinicians reported the 
following reasons for 
questionnaire use: it provided 
additional information 
(51%), it confirmed 
knowledge of patients’ 
problems (49%), it provided 
an overall assessment 
(43%), it identified issues 
for discussion (38%), it 
contributed to patient 
management (30%)
-  On 27/47 (58%) feedback 
forms, clinicians reported that 
the questionnaire assisted 
them in identifying areas of 
concern, and that it improved 
quality of care (54%)
Acceptability:
-  Clinicians strongly preferred 
graphical PROM results 
in PatientViewPoint but 
preferred plain-text score 
reports in the HER
-  More explanation about 
PRO item content and score 
meaning was desired
Other:
-  PROMIS completion: median 
6 minutes (2-12) 
-  EORTC-QLQ-BR23 
completion: median 3 minutes 
(1-11)
150 − Chapter 6
6
Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Stover et al. 
(23), 
2015 
To develop a web-based 
PRO screening system 
through cognitive 
interviews with cancer 
patients, and to assess 
patients’ and clinicians’ 
acceptability and value 













the clinic (10 
breast cancer 
patients)
19/74 breast cancer 
patients (26%) receiving 
chemotherapy
Characteristics (n=74):
-  Age > 60 43%
-  Female 50%
-  Caucasian 66%





-  Electronic (web-based/
tablet)
-  Clinic waiting room
1.  PRO-CTCAE 
2.  PROMIS- Global 
Health scale
3.  2 items written by 
the authors (“agenda 
setting” & “other 
unlisted symptoms”)
A summarized report 
of most severe 
to least severe 
symptoms, was 
generated and given 
to both patients and 
clinicians prior to the 
appointment.
- Acceptability:
-  92% of patients found it 
helpful in discussing health 
issues
-  82% wanted to review PRO 
results with clinicians during 
future appointments 
-  87% would recommend the 
system to other patients 
-  64% reported screening 
questions were helpful in 
discussing medical issues 
with provider that might have 
been missed otherwise
-  80% chose to make an 
agenda for discussion during 
the visit
-  92% were willing to answer 
additional questions
-  82% were willing to do the 
survey at home
Satisfaction: 
-  High satisfaction with the 
web-based screening tool and 
summarized PRO report . 
-  Patients recommended the 
use of the tablet computer.
Acceptability: 
-  83% of clinicians found 
summarized PRO report easy 
to interpret
-  67% found it helpful for 
communicating with patients
-  92% would recommend it to 
future patients
-  92% found the PRO 
summarized report most 
useful for reviewing symptoms
-  80% (4/5) felt that the PRO 
summary was (very) helpful in 
changing the treatment plan
-  92% reported that discussing 
the summarized PRO report 
with their patient during the 
clinic appointment did not 




al. (34), 2015 
To integrate and 
determine the use of 
SIS.NET, a multi-
component intervention, 
in the follow-up of breast 
cancer survivors 
RCT 100 breast cancer 
patients (TNM stages 
I-III), who completed 
and recovered from 
acute treatment 
(surgery, chemo- and/




-  Mean age 54.78 years 
(± SD 8.66)
-  Caucasian 69.5%
2) Control (n=41):
-  Mean age 53.32 years 
(± SD 10.79)
-  Caucasian 78.1%
Intervention: “SIS.NET”, 
a combined intervention 
with routine online health 
surveys, generated 
summary reports with 
highlighted concerning 
symptoms, review by 
nurse practitioners, 
and tailored automated 
referrals, and additional 
patient requests for 
interim health surveys 
and appointments 
-  Electronic (web-based)
-  Before clinic visit 
-  4 times (3-month 
intervals)
Control: Standard 
care with similar 
online question-
naires with generated 
summary reports for 




3.  MSAS 
Nurse practitioners 
received notifications 




18 Adherence: No significant 
difference in proportion of 
questionnaires completed 
between intervention (average 
50%) and control arms (average 
62.5%)
Symptoms: Significant difference 
in the number of changed or 
new symptoms between SIS.
NET and control arm (mean 7.36 
vs. mean 3.2, p=0.00445)
- Hospital visits: No significant 
differences between intervention 
and control arms in number of 
appointments with clinicians 
(10.8 ± SD 8.2 vs. 9.6 ± SD 7.3, 
p=0.45) or number of breast 
cancer visits (4.2 ± SD 2.3 vs. 
4.1 ± SD 1.8, p=0.78)
Other: No significant difference 
in number of medical tests 
between SIS.NET and control 
arm (average 3.5 ± SD 2.2 vs. 
3.8 ± SD 2.4, p=0.51)
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Stover et al. 
(23), 
2015 
To develop a web-based 
PRO screening system 
through cognitive 
interviews with cancer 
patients, and to assess 
patients’ and clinicians’ 
acceptability and value 













the clinic (10 
breast cancer 
patients)
19/74 breast cancer 
patients (26%) receiving 
chemotherapy
Characteristics (n=74):
-  Age > 60 43%
-  Female 50%
-  Caucasian 66%





-  Electronic (web-based/
tablet)
-  Clinic waiting room
1.  PRO-CTCAE 
2.  PROMIS- Global 
Health scale
3.  2 items written by 
the authors (“agenda 
setting” & “other 
unlisted symptoms”)
A summarized report 
of most severe 
to least severe 
symptoms, was 
generated and given 
to both patients and 
clinicians prior to the 
appointment.
- Acceptability:
-  92% of patients found it 
helpful in discussing health 
issues
-  82% wanted to review PRO 
results with clinicians during 
future appointments 
-  87% would recommend the 
system to other patients 
-  64% reported screening 
questions were helpful in 
discussing medical issues 
with provider that might have 
been missed otherwise
-  80% chose to make an 
agenda for discussion during 
the visit
-  92% were willing to answer 
additional questions
-  82% were willing to do the 
survey at home
Satisfaction: 
-  High satisfaction with the 
web-based screening tool and 
summarized PRO report . 
-  Patients recommended the 
use of the tablet computer.
Acceptability: 
-  83% of clinicians found 
summarized PRO report easy 
to interpret
-  67% found it helpful for 
communicating with patients
-  92% would recommend it to 
future patients
-  92% found the PRO 
summarized report most 
useful for reviewing symptoms
-  80% (4/5) felt that the PRO 
summary was (very) helpful in 
changing the treatment plan
-  92% reported that discussing 
the summarized PRO report 
with their patient during the 
clinic appointment did not 




al. (34), 2015 
To integrate and 
determine the use of 
SIS.NET, a multi-
component intervention, 
in the follow-up of breast 
cancer survivors 
RCT 100 breast cancer 
patients (TNM stages 
I-III), who completed 
and recovered from 
acute treatment 
(surgery, chemo- and/




-  Mean age 54.78 years 
(± SD 8.66)
-  Caucasian 69.5%
2) Control (n=41):
-  Mean age 53.32 years 
(± SD 10.79)
-  Caucasian 78.1%
Intervention: “SIS.NET”, 
a combined intervention 
with routine online health 
surveys, generated 
summary reports with 
highlighted concerning 
symptoms, review by 
nurse practitioners, 
and tailored automated 
referrals, and additional 
patient requests for 
interim health surveys 
and appointments 
-  Electronic (web-based)
-  Before clinic visit 
-  4 times (3-month 
intervals)
Control: Standard 
care with similar 
online question-
naires with generated 
summary reports for 




3.  MSAS 
Nurse practitioners 
received notifications 




18 Adherence: No significant 
difference in proportion of 
questionnaires completed 
between intervention (average 
50%) and control arms (average 
62.5%)
Symptoms: Significant difference 
in the number of changed or 
new symptoms between SIS.
NET and control arm (mean 7.36 
vs. mean 3.2, p=0.00445)
- Hospital visits: No significant 
differences between intervention 
and control arms in number of 
appointments with clinicians 
(10.8 ± SD 8.2 vs. 9.6 ± SD 7.3, 
p=0.45) or number of breast 
cancer visits (4.2 ± SD 2.3 vs. 
4.1 ± SD 1.8, p=0.78)
Other: No significant difference 
in number of medical tests 
between SIS.NET and control 
arm (average 3.5 ± SD 2.2 vs. 
3.8 ± SD 2.4, p=0.51)
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Table 1. PROMs scored and their impact on patient-, clinician- and process/system-level outcomes. (continued)
Selected 
article Study objective Study design












(months) Patient outcomes Provider outcome
Care process/system 
outcomes
Wu et al. 
(29), 
2016 
To assess patients’ and 
clinicians’ perspectives 
on the usability of 
PatientViewpoint, a 
webtool to incorporate 





17/42 (40.5%) breast 
cancer patients 
Characteristics (n=42):
-  Mean age 65 years 
(32-83)
-  Metastatic 30%
-  Caucasian 81%
-  College degree or 
higher 69%
“PatientViewpoint”, a 
webtool that allows 
clinicians to assign 
PROMs to patients, that 
collects PROM data, 
links it to the EHR, and 
displays it in graphical 
reports
-  Electronic (web-based) 
-  Clinic or home or 
elsewhere 
-  Every 2 weeks 




3.  PROMIS short forms
Clinicians could 
review in the EHR 
an automatically 
generated graphical 
report of PROM 




Strengths of the webtool:
-  Notifications/ reminders to 
complete questionnaires
-  Possibility of filling out 
questionnaires at home
-  Discussing issues with 
clinicians that they otherwise 
would not have
-  Free-text comments for 
additional details
-  Possibility of tracking scores 
over time 
Recommendations:
-  Sufficient reminders about 
survey
-  Tailoring questions 
-  Additional information on PRO 
results including consistent 
score meanings
-  Clinicians’ responsibility 
to review scores, discuss 
abnormal results, and act on 
them
Acceptability: 
All clinicians reported that it 
could be helpful
Concerns:
-  Limited time to review PRO 
results if they were filled in just 
before the appointment 
-  Rather face-to-face 
interaction than looking at 
graphical reports in EHR
Wanted:
-  Email reminders
-  Graphical presentation is 
preferred above tables
-  Clearer and consistent score 
meanings for interpretation 
-  Full integration into her
-  No additional login to access 
system
-
Table 1 Legend: PRO(M) = Patient Reported Outcome (Measure); SD = Standard Deviation; QoL = Quality of Life; FACT-G = 
Functional Assessment of Cancer Therapy – General; FACT-B = Functional Assessment of Cancer Therapy – Breast Cancer; 
MDASI = MD Anderson Symptom Inventory; FACIT-F = Functional Assessment of Chronic Illness Therapy – Fatigue Scale; 
FACIT-Self-Efficacy Scale = Functional Assessment of Chronic Illness Therapy – Self Efficacy Scale; PCM = Patient Care Monitor; 
EORTC-QLQ-C30 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire of Cancer pa-
tients, 30-item; EORTC-QLQ-BR23 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 
of Breast, 23-items; RCT = Randomized Controlled Trial; IVR = Interactive Voice Response; BQ-II = Barriers Questionnaire-II; 
ECOG = Eastern Cooperative Oncology Group, PMI = Pain Management Index; ESAS = Edmonton Symptom Assessment Scale; 
ER = Emergency Room; IQR = Inter-Quartile Range; HRQoL = Health-Related Quality of Life; STAR = Symptom Tracking and 
Reporting; CTCAE = Common Terminology Criteria for Adverse Events; EQ-5D = EuroQol 5-Dimension; ESRA-C = Electronic 
Self-Report Assessment-Cancer, SDS-15 = Symptom Distress Scale-15, PHQ-9 = Patient Health Questionnaire, 9-items; IPPC 
= Internet-based Patient-Provider Communication Service; MSAS = Memorial Symptom Assessment Scale, HADS = Hospital 
Anxiety and Depression Scale, CBI = Cancer Behavioral Inventory, SIPP = Dutch Screening Inventory of Psychosocial Problems, 
GHQ-12 = Goldberg’s General Health Questionnaire-12, VAS = Visual Analogue Scale, BREAST-Q = Breast-Questionnaire, AVR 
= Automated Voice Response, CESD-20 = Centre for Epidemiologic Studies Depression Scale-20; SF-12 = Short Form-12; TOLF 
= The-Optimal-Lymph-Flow health IT system; BCLE-SEI = Breast Cancer and Lymphedema - Symptom Experience Index; CATI 
= Computer-Assisted Telephone Interviews; SCNS-SF = Supportive Care Needs Survey; SES = Socio-Economic Status; EQ-
VAS = EuroQol-Visual Analogue Scale; KPF-BK = Kölner Patientenfragebogen für Brustkrebs; SF-36 = Short Form-36; SGUQ = 
Standard Gamble Utility Questionnaire; eRAPID = electronic patient self-Reporting of Adverse-events: Patient Information and 
aDvice; PRAE = Patient-Reported AE adaptation of the gold standard CTCAE; UKONS = United Kingdom Oncology Nursing 
Society; HER = Electronic Health Record; CPS = Carevive Planning System; CIPN-20 = Chemotherapy-Induced Polyneuropathy 
Questionnaire-20 item; PAM = Patient Activation Measure; PROMIS = Patient-Reported Outcomes Measurement Information 
System; CAT = Computerized Adaptive Testing; FACIT-F = Functional Assessment of Chronic Illness Therapy; ISI = Insomnia 
Severity Index; BDI = Beck Depression Inventory; SCH = Symptom Care at Home; UC = Usual Care; SIS.NET = System for 
Individualized Survivorship Care; TNM = Tumour Node Metastasis
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SUPPLEMENTARY FILES CHAP TER 6
Supplementary S1: Search Strategy: Literature Search Terms for Embase
(‘breast tumour’/exp OR ‘mastectomy’/exp OR (((breast* OR mamma*) NEAR/3 (cancer* OR tumour* OR tu-
mour* OR carcino* OR neoplas* OR oncolog* OR malignan* OR resection* OR amputat*)) OR mammacarcinom* 
OR mastectom* OR mammectom* OR postmastectom*):ab,ti) AND (‘patient-reported outcome’/de OR ‘patient 
reported outcome measure’/de OR ((‘self report’/de) AND (‘outcome assessment’/de OR ‘quality of life’/exp 
OR ‘quality of life assessment’/exp OR ‘complication’/de OR ‘symptom’/de OR ‘wellbeing’/de OR ‘psycho-
logical well-being’/de OR ‘health status’/de )) OR (((patient* OR self) NEAR/3 (report* OR based OR centreed 
OR centred OR rate OR rating OR rated OR questionnaire* OR assess* OR survey* OR index OR indices OR 
instrument*) NEAR/6 (outcome* OR measur* OR quality-of-life OR qol OR hrqol OR hrql OR ql OR symptom* OR 
complication* OR psychosocial OR ‘well-being’ OR wellbeing OR functioning OR disabil* OR ‘health status’)) 
OR ((patientreport* OR selfreport* OR patientcent*) NEXT/2 (outcome* OR factor* OR measur*)) OR PROM OR 
PROMs):ab,ti) AND (‘health care quality’/de OR ‘quality of care’/de OR ‘clinical effectiveness’/de OR ‘clinical 
practice’/de OR ‘health care’/de OR ‘nursing care’/exp OR (care OR ((clinical OR nursing) NEXT/2 (effective-
ness* OR practice* ))):ab,ti)
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Qualitative study:
1) Was there a clear statement of the aims of the 
research? 
2) Is a qualitative/ quantitative methodology 
appropriate? 
3) Was the research design appropriate to 
address the aims of the search? 
4) Was the recruitment strategy appropriate to the 
aims of the research? 
5) Was the data collected in a way that addressed 
the research issue? 
6) Has the relationship between researcher and 
participants adequately considered? 
7) Have ethical issues been taken into 
consideration? 
8) Was the data analysis sufficiently rigorous?
9) Is there a clear statement of findings? 
10) How valuable is the research?
Randomized controlled trail (RCT):
1) Did the trial address a clearly focused issue? 
2) Was the assignment of patients to treatments 
randomized?
3) Were all of the patients who entered the trial 
properly accounted for at its conclusion? 
4) Were patients, health workers and study personnel 
‘blind’ to treatment? 
5) Were the groups similar at the start of the trial? 
6) Aside from the experimental intervention, were the 
groups treated equally?
7) How large was the treatment effect?
8) How precise was the estimate of the treatment 
effect? 
9) Can the results be applied to the local population, 
or in your context?
10) Were all clinically important outcomes 
considered?
11) Are the benefits worth the harms and costs?
Cohort study:
1) Did the study address a clearly focused issue? 
2) Was the cohort recruited in an acceptable way?
3) Was the exposure accurately measured to 
minimize bias? 
4) Was the outcome accurately measured to 
minimize bias? 
5) A. Have the authors identified all important 
confounding factors? B. Have they taken 
account of the confounding factors in the 
design and/or analysis? 
6) A. Was the follow up of subjects complete 
enough? B. Was the follow-up of subjects long 
enough? 
7) What are the results of this study? 
8) How precise are the results? 
9) Do you believe the results? 
10) Can the results be applied to the local 
population? 
11) Do the results of this study fit with other 
available evidence? 
12) What are the implications of this study for 
practice? 
Cross-sectional study:
1) Did the study address a clearly focused question / 
issue?
2) Is the research method (study design) appropriate 
for answering the research question?
3) Is the method of selection of the subjects 
(employees, teams, divisions, organizations) 
clearly described?
4) Could the way the sample was obtained introduce 
(selection)bias?
5) Was the sample of subjects representative with 
regard to the population to which the findings will 
be referred?
6) Was the sample size based on pre-study 
considerations of statistical power?
7) Was a satisfactory response rate achieved?
8) Are the measurements (questionnaires) likely to be 
valid and reliable?
9) Was the statistical significance assessed?
10) Are confidence intervals given for the main 
results?
11) Could there be confounding factors that haven’t 
been accounted for?
12) Can the results be applied to your organization?
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ABSTRACT
As high breast cancer survival rates are achieved nowadays, irrespective of type of surgery per-
formed, prediction of long-term physical, sexual, and psychosocial outcomes is very important 
in treatment decision-making. Patient-reported outcomes (PROs) can help facilitate this shared 
decision-making. Given the significance of more personalized medicine and the growing trend 
on the application of machine learning techniques, we are striving to develop an algorithm using 
machine learning techniques to predict PROs in breast cancer patients treated with breast surgery. 
This short communication describes the bottlenecks in our attempt to predict PROs. 
SHORT COMMUNICATION
Improvement in early detection and treatment of breast cancer has resulted in increased long-term 
breast cancer survivors1. The cornerstone of breast cancer management still is surgery. In breast 
cancer surgery, equal survival rates are achieved, irrespective of type of surgery performed2-4. 
However, breast cancer surgery can adversely affect women’s psychological health and health-re-
lated quality of life (HRQoL). Prediction of long-term physical, sexual, and psychosocial outcomes 
is therefore very important in treatment decision-making. 
Patient reported outcomes (PROs) come directly from the patient without interpretation by 
a healthcare provider and reflect aspects of health, quality of life, and related constructs5. The 
routine collection of PROs has been implemented in many health institutions6-10, and it is clear 
that PROs have an important role in today’s clinical practice. Collaboration of the International 
Consortium for Health Outcomes Measurement (ICHOM) with several other healthcare institutions 
worldwide has resulted in the development of a Standard Set for breast cancer outcomes10. Within 
this outcome set, patient-reported outcome measures (PROMs) are pivotal and accounting for 
75% of the outcomes evaluated10. 
PROs can help facilitate in shared decision-making through informing treatment decisions and 
settings expectations. The ability for patients to understand what other patients with breast cancer 
experienced after surgery is thereby vital.
Predictive modelling is not new to medicine. In clinical medicine, a multivariable prediction model 
combines information from multiple predictors to predict the probability of or risk for a specific 
disease or outcome11. Predictive modelling has the purpose of informing patients and guiding 
clinicians in decision-making on treatment decisions. The majority contains prediction of patient 
outcomes focused on cancer survival and risk of cancer recurrence or local control12-14, but little 
has been done to predict PROs into the future. Moreover, to our knowledge, there are no tools 
available focusing on predicting HRQoL outcomes after breast surgery into the future. Given the 
significance of more personalized medicine and the growing trend on the application of machine 
learning techniques, our breast cancer team is striving to develop an algorithm using machine 
learning techniques to predict PROs in breast cancer patients treated with breast surgery.
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We aimed to develop and validate a simple prediction model for improvement of HRQoL after 
breast cancer surgery using data from 3 PRO questionnaires as proposed in the ICHOM Standard 
Set for Breast Cancer, namely the EORTC QLQ-C30 and EORTC QLQ-B23, and the BREAST-Q 
(postoperative modules). To this end, a retrospective cohort collected and described previously6 
was used. This cohort contained 764 female patients with breast cancer (pTis-3N0-3M0) who 
underwent breast cancer surgery between January 2005 and September 2016 at Erasmus MC 
Academic Breast Cancer Centre, Rotterdam, the Netherlands. Data on patient characteristics, 
age, date and type of surgery, tumour morphology, TNM staging (7th edition15), hormonal status, 
HER2 status, BRCA 1/2 gene mutation status, local recurrence, second primary breast cancer, 
details regarding chemotherapy and/or immunotherapy and endocrine therapy, radiotherapy and 
follow-up were available. Machine learning (i.e. General Linear Model regression (GLM), Support 
Vector Machines (SVM), single-layer Artificial Neural Networks (ANN), and Deep Learning (DL))16, 
was used to jointly study presurgical prognostic variables relating to age, medical status, tumour 
characteristics, and possible (neo)adjuvant treatment indications/treatment characteristics. 
Unfortunately, a lack of relationship was found between outcome variables and their predictors, 
meaning that the accuracy reflected just the population prevalence of the outcomes. Machine 
learning models have an immense number of parameters that must be either learned using data 
or set manually by the researcher17. By combining variables in a reduced number of dimensions, 
we tried to help the analysis, but this did not yield substantial changes and required days of 
computational time. 
During the process some crucial obstacles were identified, which stagnated the development 
of a machine learning model in this data set. This included the cross-sectional design, the lack 
of baseline PROs and the relative small sample size. Given the increase in the use of machine 
learning techniques in medical research and the, worldwide, desire to predict and influence PROs 
after breast surgery, we believe it is important to draw attention to our findings.
Machine learning describes the use of computer algorithms that learn nonlinear associations 
retrospectively from the data to estimate risk of a specific outcome. Even though machine learn-
ing is increasingly used in medical research18-20, success is not always guaranteed. As with any 
method, a good understanding of the problem and an appreciation of the limitations of the dataset 
is important. Also crucial is an understanding of the assumptions and limitations of the algorithms 
being applied. If a machine learning experiment is properly designed, with correctly implementa-
tion and validated results, there usually is a good chance of success. 
Although we used patient and treatment characteristics, and outcomes of interest to both patients 
and clinician (i.e. validated PROMs as proposed in the ICHOM Standard Set for Breast Cancer) 
there were some important limitations in using the existing dataset6. With 764 breast cancer pa-
tients, the study was relatively large, although for machine learning techniques probably not large 
enough. The size of the dataset is one of the most common limitations noted in studies reporting 
machine learning techniques14. The dataset needs to be sufficiently large, which allows sufficient 
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partitioning into training and testing sets, leading to reasonable validation of the estimators14 in 
order to enhance the generalizability of the predictive model. 
The most important limitation however is the cross-sectional design of the dataset, meaning the 
absence of baseline PROs. Traditional methods for evaluating PROMs look at the change over 
time, using the baseline compared to the endpoint. Enabling comparison with preoperative PROs 
is expected to reflect the influence of different treatments on HRQoL outcomes better than a 
single score obtained following treatment. One explanation probably is the fact that not every 
individual patient will score their breasts to the highest possible level at baseline. Although preop-
erative PROs were not available, all known other potential predictors were assessed, except for 
socioeconomic status (which cannot be easily obtained in the Netherlands for privacy reasons). 
The next step toward further validation of this approach to prediction would be to work with a 
more complete dataset, including baseline PROs and lifestyle measures. The research team has 
secured a prospective data set over a longer time frame, but this dataset currently consists of a 
small number of patients. Since PROM collection is considered standard of care at our institute 
nowadays9, in combination with a regional and international collaboration, this cohort will be 
progressively enlarged over time. There are plans in place to develop and test the performance of 
the machine learning techniques in this dataset in the near future. However, the above-described 
study was a valuable first step towards modelling PROMs data for use in breast cancer surgery. 
Once developed, the model could have potential for use outside breast surgery because similar 
sets are used in other diseases. But, as also suggested by Beam et al.17, the challenges and 
obstacles to reproducibility of machine learning techniques must be carefully considered to ensure 
the validation, safety and effectivity of these new class of prediction tools. 
In conclusion, using machine learning methods, we endeavoured to develop a clinical predic-
tion model for PROs after breast surgery. Clinicians could use information on the level of patient 
HRQoL outcome improvement, when counselling patients about the (prognostic) outcomes of 
breast cancer surgery, allowing patients to be more involved in their treatment decision. To actually 
realize an effective clinical prediction model, information regarding patients starting position is cru-
cial. This emphasize the urgent need of collecting PROMs at baseline, leading to the opportunity 
of predictive modelling on PROMs in breast cancer surgery in the future. 
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The aim of this study was to compare patient-reported outcomes (PROs) of BRCA1/2 mutation 
carriers, either after bilateral prophylactic mastectomy (BPM) or during breast surveillance, to 
improve shared decision-making in their cancer risk management. 
Methods
Unaffected BRCA1/2 mutation carriers at least one year after BPM followed by immediate breast 
reconstruction (BPM-IBR) or one year under surveillance were eligible. After informed consent, the 
Hospital Anxiety and Depression Scale (HADS) and BREAST-Q were administered and compared 
between the different strategies. PROs were also compared to available normative data. 
Results
Ninety-six participants were analysed in this study and showed significant differences between 
strategies in age, age at genetic testing, and time since BPM or starting breast surveillance. All 
HADS scores were below 8 suggesting no signs of anxiety or depression in both groups. Higher 
mean ‘Q-physical wellbeing’ scores were reported by the surveillance group (81.78 [CI 76.99 – 
86.57]) than the BPM group (76.96 [CI 73.16 – 80.75]; p= 0.011). Overall, for both questionnaires 
better scores were seen when compared to age-matched normative data.
Conclusions
No signs of anxiety or depression were seen in the surveillance or BPM-IBR group. Slightly better 
mean BREAST-Q scores were seen for the surveillance group in comparison to BPM-IBR, except 
for ‘Q-psychological wellbeing’. The difference in ‘Q-physical wellbeing’ was significantly worse 
for BPM-IBR. Approaches to obtain longitudinal PROs and reference values should be explored 
in the future, which could add value to shared-decision-making in regards to breast cancer risk 
management in this specific patient population. 
Patient-reported outcomes in BRCA 1/2 mutation carriers − 175
8
INTRODUCTION
A woman’s lifetime risk of developing breast cancer is greatly increased when she inherits a 
BRCA1 or BRCA2 gene mutation. While the general population has a lifetime risk of 12%1, BRCA1 
and BRCA2 mutation carriers have a cumulative breast cancer risk of, respectively, 72% and 69%2 
till 80 years of age. 
Breast cancer risk management for BRCA1/2 mutation carriers encompass the possibility of 
intensive breast surveillance aimed at early detection, or bilateral prophylactic mastectomy (BPM). 
BPM has shown a risk reduction up to 95%3-7 and is associated with decreased general and 
cancer-related distress8 9. As BPM is a major, elective and irreversible procedure, however, it is also 
associated with a negative impact on health-related quality of life (HRQoL) outcomes such as body 
image, psychosocial-, psychosexual-, and physical wellbeing8 10 11. 
The alternative is intensive breast surveillance, consisting of annually alternating mammography 
and breast MRI, and semi-annual clinical breast examination commencing at 25 years of age12. 
Carriers who choose surveillance might have fewer problems with body image in the psychoso-
cial- and psychosexual area, but will be confronted with difficulties concerning cancer-related 
distress and the risk of breast cancer13.
Since BPM, either followed by immediate breast reconstruction (BPM-IBR) or not, and surveillance 
are both validated options with high survival rates14, the choice between them is dependent on 
the individual woman’s preferences. To facilitate decision-making, it is important to fully explain 
the pros and cons of both options, especially when considering preference-based care for which 
there exists more than one clinically appropriate treatment option15. Therefore, women considering 
BPM(-IBR) should be informed about the impact of prophylactic surgery on not only survival and 
the risk of cancer but on the expected HRQoL outcomes as well8 15-18. 
According to value-based healthcare principles, these HRQoL outcomes can be both provider-
reported as well as patient-reported outcomes (PROs). Since PROs are direct assessments from 
patients, typically collected through validated questionnaires (i.e. PROMs = patient-reported 
outcome measurements), they reflect patients’ quality of life or functional status. PRO data is 
incredibly valuable to get insight into long-term HRQoL and can be used as a guide for BRCA1/2 
mutation carriers in their decision-making process in regard to their breast cancer risk manage-
ment. However, little is known about PROs following the choice for either BPM or surveillance in 
BRCA1/2 mutation carriers. 
It was hypothesized that PROs differ between women choosing BPM(-IBR) and women opting 
for breast surveillance. This study aimed to compare PROs between BRCA1/2 mutation carriers 
following their choice for either BPM-IBR or breast surveillance. 




A total of 96 unaffected BRCA1/2 mutation carriers, diagnosed at the Academic Breast Cancer 
Centre of the Erasmus MC between 2014 and 2017, were included. Female BRCA1/2 mutation 
carriers, aged over 18 years and with an adequate understanding of the Dutch language, were 
deemed eligible. Mutation carriers who were at least 1 year post-BPM-IBR (autologous or im-
plants) were identified from the electronic health records using operation and diagnosis codes. 
Mutation carriers scheduled for at least 1 year of breast surveillance were approached at the 
surgical oncology outpatient clinic. Mutation carriers were asked to participate until at least 50 
participants were enrolled in each group. Women with a past history of (in situ) breast cancer were 
excluded. Ethical approval was granted by the Institutional Review Board of the Erasmus Medical 
Centre, Rotterdam, The Netherlands (MEC-2018-1601).
Procedures
In this cross-sectional study, medical records were retrospectively reviewed to collect the following 
data: BRCA1/2 mutation status and date of genetic testing, age at genetic testing, family history of 
breast cancer, comorbidities, smoking status, family status, time since start breast surveillance, or 
time since surgery, and – if applicable – type of surgery performed. Missing data was handled by 
contacting the participant via telephone. For the BPM-IBR group, eligible women were recruited 
by telephone or mail. Women in the surveillance group were asked to participate at the outpatient 
clinic. Following informed consent, two PROM questionnaires were administered: the Hospital 
Anxiety and Depression Scale (HADS)19 and the BREAST-Q version 1.0 (pre-mastectomy module 
for the surveillance group and the post-reconstruction module for BPM-IBR)20. Both PROMs were 
web-based questionnaires and administered through the software program “GemsTracker”21, an 
online system for distributing and collecting surveys. If the questionnaires remained uncompleted, 
a weekly reminder was sent by the system. If patients had not responded in 4 weeks, participants 
were contacted by telephone and asked to complete the questionnaires. PROM scores were 
calculated according to the questionnaires’ scoring manuals.
Statistical analysis
All analyses were performed using Statistical Package for Social Sciences (SPSS), Version 24.0 
(IBM Corporation, Armonk, NY, USA). Baseline characteristics were compared between women 
who underwent BPM-IBR versus those who chose breast surveillance. Comparisons across both 
groups were made using the Mann-Whitney U test for continuous variables, and Fisher’s exact 
test or the Chi-squared test, as appropriate, for categorical variables. Two-sided p value <0.05 
was considered statistically significant. In addition, PROM scores were compared to normative 
scores22-24. 




Between October 2018 and May 2019, 168 women were contacted via telephone, mail or at the 
outpatient clinic (Fig. 1). Of the eligible participants, 143 (85%) women responded. Eight (5.6%) 
responders declined participation. Of the surveillance group, 22 (25.3%) responders did not reply 
despite verbal consent being obtained at the outpatient clinic. After informed consent, 55 (63.2%) 
women participated in the surveillance group and 53 (67%) in the BPM-IBR group. Three women 
were excluded from the BPM-IBR group: one woman underwent a delayed breast reconstruction 
and the other two due to the absence of a BRCA1/2 gene mutation. 
Figure 1. Flowchart of study selection process. 
BPM-IBR, bilateral prophylactic mastectomy followed by immediate breast reconstruction
Characteristics 
A total of 96 participants were included for analysis: 47 BPM-IBR and 49 breast surveillance partic-
ipants (Table 1). Statistically significant differences were seen between both groups in age at study 
enrolment, age at genetic testing, and time since surveillance start or since BPM-IBR. Overall, the 
study population was relatively young: 43% of the surveillance group and 45% of the BPM-IBR 
group were aged below 35 years. Approximately 60% of both groups had a positive family history 
for breast cancer in two or more relatives. Risk-reducing bilateral salpingo-oophorectomy (RRSO) 
or prophylactic tubectomy were performed in, respectively, 45% and 11% of the study population. 
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 (n=47) p value
Mean (SD) age (years)§ 42.4 (10.7) 44.5 (12.0) 40.2 (8.8) 0.046
Mean (SD) age (years) at genetic testing§ 36.6 (10.3) 38.7 (10.6) 34.3 (9.6) 0.039
Mutation type¥ 0.969
BRCA1 57 (59) 29 (59) 28 (60) 
BRCA2 39 (41) 20 (41) 19 (40) 
Mean (SD) age (years) at start cancer risk management§ 37.9 (9.8) 38.7 (10.7) 37.1 (8.7) 0.447
Mean (SD) time (years) since start of cancer risk management§ 4.7 (3.7) 6.1 (4.7) 3.1 (1.2) 0.002
Family history¥ 0.723
0 13 (14) 7 (14) 6 (13) 
1 24 (25) 10 (20) 14 (30) 
>2 57 (59) 30 (61) 29 (62) 
Unknown 2 (2) 2 (4) .0 
First degree family history¥ 0.176
0 66 (69) 30 (61) 36 (77) 
1 28 (29) 17 (35) 11 (23) 
>2 .0 .0 .0 
Unknown 2 (2) 2 (4) .0 
Second degree family history¥ 0.229
0 63 (66) 32 (65) 31 (66) 
1 28 (29) 15 (31) 13 (28) 
>2 .0 .0 3 (6) 
Unknown 2 (2) 2 (4) .0 
Third degree family history¥ 0.617
0 32 (33) 16 (33) 16 (34) 
1 31 (32) 14 (29) 17 (36) 
>2 31 (32) 17 (35) 14 (30) 
Unknown 2 (2) 2 (4) .0 
Marital status¥ 0.079
Single 8 (8) 1 (2) 7 (15) 
Relationship 21 (22) 11 (22) 10 (21) 
Married 58 (60) 30 (61) 28 (60) 
Unknown  9 (9) 7 (14) 2 (4) 
Parity, mean (SD)§ 1.4 (1.0) 1.4 (0.9) 1.5 (1.07) 0.461
Ovarian status¥ 0.147
In situ 31 (32) 16 (33) 15 (32) 
RRSO 45 (47) 27 (55) 18 (38) 
Tubectomy 11 (11) 3 (6) 8 (17) 
Unknown 9 (9) 3 (6) 6 (13) 
Smoking status¥ 0.910
Yes 9 (9) 4 (8) 5 (11) 
No 73 (76) 31 (63) 42 (89) 
Unknown 14 (15) 14 (29) .0 
BPM-IBR, bilateral prophylactic mastectomy followed by immediate breast reconstruction; RRSO, risk-reduc-
ing bilateral salpingo-oophorectomy;
¥ Chi squared test. § Mann-Whitney U test.
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PROMs
Table 2 gives an overview of the PROM scores. For both groups, all individual HADS scores were 
below 8, which was defined as the upper limit of normal22. Slightly better mean BREAST-Q scores 
were seen in the surveillance group as compared to the BPM-IBR group, except for the domain 
‘Q-psychological wellbeing’. In contrast, only the difference in ‘Q-physical wellbeing’ was signif-
icantly higher in the surveillance group (81.78; CI 76.99 – 86.57) than the BPM-IBR group (76.96; 
CI 73.16 – 80.75; p = 0.011). 
Obtained HADS scores were compared to normative data22, demonstrating lower scores on both 
the anxiety and the depression scale in both groups (Fig. 2a). As the mean age of our cohort was 
42.4 years, normative data of the female age category 40 – 44 years was used for comparison. 
The normative data of the preoperative reconstruction module was used for the comparison with 
BREAST-Q scores of both groups in our cohort23 24. PROMs were comparable to normative scores 
of the BREAST-Q except for the ‘Q-physical wellbeing’ scale, which showed lower scores in the 
current cohort (Fig. 2b). 








p value¥Mean (95% CI) Mean (95% CI) Mean (95% CI)
















































BPM-IBR, bilateral prophylactic mastectomy followed by immediate breast reconstruction; HADS, Hospital 
Anxiety and Depression Scale HADS index value: scale from 0-21; BREAST-Q scale from 0 to 100.
° Higher scores represent lower quality. § Higher scores represent higher quality. 
¥ Mann-Whitney U test 
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DISCUSSION
BRCA1/2 mutation carriers are faced with complex decisions within breast (and ovary) cancer risk 
management. Insights into not only cancer risk but also into HRQoL or daily functioning as a result 
of these decisions could improve the shared decision-making process and ultimately the care 
delivered. Therefore, this study aimed to obtain and evaluate PROs in BRCA1/2 mutation carriers 
according to their choice of breast cancer risk management (BPM-IBR versus breast surveillance). 
The PROMs in this study have succeeded in providing valuable insights into HRQoL in BRCA1/2 
mutation carriers, in both the BPM-IBR and the breast surveillance group. The interpretation of 
these data was done both separately and in comparison to available normative data22-24. 
HADS demonstrated no scores outside normal cut-off values on the two scales. Moreover, mean scores 
observed for both groups were quite similar and all reported scores were below the upper limit. These 
observations indicate that none of the mutation carriers in the present study reported anxiety or depres-
sion that reached clinically relevant levels. In addition, no significant differences in anxiety or depression 
outcomes were observed between women in the surveillance group and the BPM-IBR group.
Overall, slightly better BREAST-Q scores were seen for the surveillance group compared to BPM-
IBR. The surveillance group scored lower on ‘Q-psychological wellbeing’, albeit not statistically 
significant. This difference was expected since previous studies have already shown elevated 
levels of psychological distress in women at increased risk of developing breast cancer8 13. Only 
the difference in ‘Q-physical wellbeing’ was statistically significant, which can be explained by the 
Figure 2: Comparison of PROM scores with normative scores. 
2a]  HADS survey scores versus normative scores22. Mean scores with standard deviations (error bars) for 
HADS-scores. 
 HADS index value: scale from 0-21. Higher scores represent lower quality. 
  *Normative scores as based on 486 patients (anxiety subscale) and 489 patients (depression subscale)22, 
presented by gender and age (i.e. female and 5-year age group 40-44 years).
2b]   BREAST-Q survey scores versus normative reconstructive scores23. Mean scores with standard deviations 
(error bars) for Q-scores. 
 BREAST-Q scale from 0 to 100. Higher scores represent better functioning. 
 ^Normative scores as based on 1201 participants of the general population23. 
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surgical procedure these women have undergone. However, it has been acknowledged that not 
only the statistical significance of the differences in QoL questionnaires is important but the clinical 
relevance of them as well25. Although there is no consensus yet on clinically relevant BREAST-Q 
scores, it is generally accepted that a difference of 5 points should be considered as a small clinical 
difference, 10 points as moderate, and 20 points as a very clinically important difference26. There 
was a difference of 5 – 10 points for all BREAST-Q modules except for ‘Q-sexual wellbeing’, which 
suggests a small clinical difference between both groups. PROs should be collected longitudinally 
in order to evaluate the clinical differences in PROM scores over time within both groups.
Of all BREAST-Q subscales, the lowest scores were reported for ‘Q-sexual wellbeing’ by both 
BPM-IBR and breast surveillance women. Previous studies have shown that breast cancer surgery 
may have a negative impact on sexual health27 28. The low ‘Q-sexual wellbeing’ scores might also 
be explained by the high proportion of women with a risk-reducing ovarian cancer intervention 
(RRSO or tubectomy). Since RRSO substantially decreases the levels of oestrogen and testos-
terone, it has an effect on quality of life and sexual functioning, among other domains, at an early 
age29 30. However, we also compared mean ’Q-sexual wellbeing’ scores between women with and 
without RRSO/tubectomy and found slightly higher mean scores in the RRSO/tubectomy group 
(i.e. 65.04 [60.01 – 70.07] and 55.90 [49.43 – 62.38], respectively). This emphasizes our rationale 
of the impact that breast surgery can have on a woman’s sexual health, which is in line with 
our previous publication also showing low ‘Q-sexual wellbeing’-scores in surgical treated breast 
cancer patients (without a BRCA1/2 mutation)31. Also noteworthy is that only 33.9% of the women 
were treated with hormone replacement therapy (n=8 in the BMP-IBR and n=11 in the surveillance 
group) (data not shown). 
Available normative data for the HADS were derived from the Epidemiology of Functional Disorders 
(EpiFunD) Study22 and normative data for the BREAST-Q from the Army of Women community23. 
When comparing the PROM scores of our cohort with the normative data, one must take into 
account that the normative data were obtained in the United Kingdom (HADS) and the United 
States (BREAST-Q). Due to cultural differences between these countries and the Netherlands, this 
data does not entirely reflect normative scores for Dutch women. However, similar Q-scores were 
seen when comparing the current cohort with Dutch cohorts27 32; i.e. overall better scores except 
for ‘Q-psychical wellbeing’. HADS scores were not available within these cohorts.
Significant differences in patient characteristics existed between both groups, suggesting a 
possible treatment indication bias. Available data on the impact of patient characteristics on a 
woman’s decision to undergo BPM vary. Most studies show that age at genetic testing does not 
significantly affect the choice for BPM8 13 15 33, which is in opposition to our findings. On the other 
hand, no significant differences in family history, ovarian status, marital status and parity existed 
between both groups, in contrast to other studies showing that these factors do have a significant 
impact on the choice for BPM10 13 33-35. However, due to the retrospective design of this pilot study, 
baseline (anxiety) scores could not be obtained. Women may experience physical- and psycho-
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logical trauma associated with being diagnosed with a BRCA1/2 mutation, which will affect their 
HRQoL. Thus, changes in PROs before and after diagnosis are to be expected, which emphasizes 
the necessity of PRO collection at baseline.
The significant differences in age at study enrolment, age at genetic testing, and the time since 
BPM-IBR or starting breast surveillance could be explained by the manner in which women were 
selected. Eligible participants for the BPM-IBR group were found through a search in the electronic 
health record. The search was thereby limited by year of surgery, namely between 2014 and 2017. 
Gene mutation carriers scheduled for breast surveillance were asked to participate at the outpatient 
clinic. No limitations on patient inclusion was set for this group and could, therefore, be completed 
before 2014. Although the duration of the inclusion period was over 6 months and all BRCA1/2 
mutation carriers were scheduled for follow-up every 6 months during their surveillance, a potential 
selection bias could have been introduced. Moreover, the time since the start of cancer risk man-
agement significantly differed between both groups (6.1 years for surveillance versus 3.1 years for 
BPM-IBR, p=0.002), and time since BMP-IBR was relatively short. Previous studies have shown 
that psychological outcomes as well as coping strategies change over time8 13 13. Coping strategies 
represent cognitive and behavioural efforts to deal with stressful encounters36. Effects of coping can 
differ depending on the duration and controllability of the stress factor. As women in our cohort did 
not have a history of breast cancer (consistently favourable results during their surveillance), long-
term breast cancer-related distress might decrease as a consequence of ‘underestimating’ their 
breast cancer risk13. This observation may be a possible explanation for the low distress and anxiety 
levels in our cohort. Another possible explanation for the low scores is potential selection bias, as the 
women who experienced increased levels of depression might have been less likely to participate. 
We did not find that women in the BMP-IBR group were more likely to have a first-degree relative 
with a history of breast cancer (35% surveillance versus 23% BPM-IBR, p=0.176), which is in 
contrast to what others have reported33 37. 
Intuitively, it would seem that women with a BRCA1 mutation would most likely be the ones to 
consider BPM as they have a higher breast cancer risk than BRCA2 mutations2. Moreover, a 
previous study with 5,889 Dutch BRCA1/2 mutation carriers showed that, compared to breast 
surveillance, BPM was associated with lower mortality for BRCA1 mutation carriers, whereas for 
BRCA2 mutation carriers breast cancer-specific survival rates were similar between BPM and 
breast surveillance38. In our cohort, however, there were no differences in the percentage of 
BRCA1 carriers in the BPM-IBR group compared to the surveillance group. The observations that 
BPM was associated with lower mortality rates than surveillance for BRCA1 and similar breast 
cancer-specific survival for BRCA2, underscore the importance of counselling BRCA1/2 mutation 
carriers on their choice between breast surveillance and BPM. Knowledge of patient-reported 
HRQoL outcomes can be valuable in facilitating this choice.
Limitations include the relatively small sample size and the retrospective study design. The power was 
limited due to the small study population. Longitudinal PRO collection and comparison with baseline 
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PROM scores are needed when striving to showcase the influence of different risk management 
strategies13 15. However, the retrospective evaluation of PROs does provide the necessary insight 
into (case-mix) factors possibly associated to PROs, and their inclusion for predictive modelling. 
Multiple PROM instruments are available nowadays. Only two questionnaires were selected in this 
study. HADS was chosen since it is a short questionnaire and the most extensively validated scale 
for screening emotional distress in cancer patients39, while BREAST-Q was chosen since it is a 
validated breast-specific instrument that is used worldwide. Razdan et al.15 evaluated PROs after 
BPM and concluded that generic instruments were not sensitive enough to measure physical and 
mental changes related to specifically BPM, either followed by (immediate) breast reconstruction 
or not. The use of a breast-specific instrument (e.g. BREAST-Q) was recommended. We support 
this recommendation combined with the standardization of PROMs, since this will provide results 
that are comparable with other similar studies. 
Several initiatives of longitudinal PRO collection in breast cancer patients have proven to be helpful 
in daily practice and are appreciated by both patients and providers40 41. The present study pro-
vides a first insight into PROs in BRCA1/2 mutation carriers following their choice for either breast 
surveillance or BPM-IBR. Collected PROs can serve to pave the way for the implementation of a 
value-based healthcare strategy among future BRCA1/2 mutation carriers at the outpatient clinic. 
Interpretability of the important differences in PRO(M)s is the cornerstone to its successful use 
in individual clinical care, comparative effectiveness research, and regulatory efforts. Knowledge 
about differences in HRQoL outcomes between BPM and surveillance can be used to facilitate 
shared decision-making. Informing BRCA1/2 mutation carriers about both positive and negative 
consequences of either BPM-IBR or breast surveillance is of great importance for building up real-
istic expectations9. Measuring PROs in BRCA1/2 mutation carriers from gene mutation diagnosis 
to the subsequent trajectory has the potential to monitor and detect changes in psychosocial or 
physical problems over time. Reference PROM scores for the different strategies are then essential 
for the use of PROs at the outpatient clinic to personalize and improve the care delivered. Large 
multicentre initiatives and prospective PRO collections are, therefore, needed to obtain (and nar-
row down) these reference scores. Such an initiative is currently pending at our institution. 
CONCLUSION
Patient-reported HRQoL outcomes were evaluated in unaffected BRCA1/2 mutation carriers who 
underwent either breast surveillance or BPM-IBR. No signs of anxiety or depression were seen 
in both groups. Slightly better mean BREAST-Q scores were seen for the surveillance group in 
comparison to BPM-IBR except for ‘Q-psychological wellbeing’; the difference in ‘Q-physical well-
being’ was significantly worse for BPM-IBR. A first step was made towards value-based healthcare 
for BRCA1/2 mutation carriers. Future possibilities should be explored to obtain reference PROM 
values, which could add value to the shared decision-making process in regard to cancer risk 
management in this specific population. 
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Current follow-up arrangements for breast cancer do not optimally meet the needs of individual 
patients. We therefore reviewed the evidence on preferences and patient involvement in decisions 
about breast cancer follow-up to explore the potential for personalised care. 
Methods 
Studies published between 2008 and 2017 were extracted from MEDLINE, PsycINFO, and EM-
BASE. We then identified decision categories related to content and form of follow-up. Criteria for 
preference sensitiveness and patient involvement were compiled and applied to determine the 
extent to which decisions were sensitive to patient preferences and patients were involved. 
Results
Forty-one studies were included in the full-text analysis. Four decision categories were identified: 
‘surveillance for recurrent/secondary breast cancer; consultations for physical and psychosocial 
effects; recurrence-risk reduction by anti-hormonal treatment, and improving quality of life after 
breast cancer’. There was little evidence that physicians treated decisions about anti-hormonal 
treatment, menopausal symptoms, and follow-up consultations as sensitive to patient preferences. 
Decisions about breast reconstruction were considered as very sensitive to patient preferences, 
and patients were usually involved. 
Conclusion
Patients are currently not involved in all decisions that affect them during follow-up, indicating a 
need for improvements. Personalised follow-up care could improve resource allocation and the 
value of care for patients. 
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BACKGROUND
Breast cancer is the most common form of cancer among women worldwide1. The five-year rela-
tive survival for early-stage breast cancer is high, with rates exceeding 96% for stage I and 86% 
for stage II disease2 3. International guidelines state that the goals of breast cancer follow-up care 
are to detect recurrent disease or new malignancies at an early stage, and to inform and counsel 
patients about the physical and psychosocial (late) effects of therapy4-7. Schemes for detecting 
recurrences often comprise annual physical and mammographic examinations for at least five 
years, depending on the patient’s age, genetic predisposition, and/or tumour characteristics. 
Consultations that seek to detect physical and psychosocial effects are often linked to the visits 
for recurrence detection, and are most frequently planned during the first year of follow-up4 6. 
At present, arrangements for follow-up suboptimally meet the needs of patients with breast 
cancer, and there is concurrently a growing demand for personalised care planning within cancer 
follow-up care8-11. Such personalised follow-up care could be based on the patient’s individual risk 
of recurrence for the length and/or frequency of surveillance12 13, or on the type of treatment, and 
therefore, the management of treatment-induced (late) effects and complaints4 6. Moreover, cancer 
survivors might experience very different psychosocial consequences after the disease and treat-
ment, including fear of recurrence, sleeping difficulties, cognitive issues, fatigue, and sexual is-
sues14. Each of these effects require a personalized follow-up strategy. Patient-preferences about 
the preferred form and content of the follow-up care have been reported in previous studies15 16. 
Since the advent of value-based healthcare, there have been ongoing efforts to improve care qual-
ity by adding value throughout an individual patient’s journey from diagnosis, through treatment, 
and to follow-up care17. A way to meet this goal of personalised care is to include patients and their 
preferences in the decision-making process. For example, in the shared decision-making (SDM) 
process, decisions are based on both the best available (medical) evidence and the patients’ 
needs and values. Preference sensitive care involves making treatment decisions with significant 
trade-offs that should reflect a patient’s personal values and preferences. Besides, only when 
patients have enough information to make an informed choice, a decision can be made18. This 
means that the quality of this SDM process might affect the eventual effect on the value of care, in 
terms of outcomes, costs, and organizational effort19. 
In the present study, we hypothesised that decisions about breast cancer follow-up are sensitive to 
patient preferences, and that it is an option to include SDM in the follow-up care of these patients. 
Thus, we aimed to discover the potential for personalising follow-up care among patients with 
breast cancer by exploring the evidence on preferences for, and patient involvement in, decisions 
about breast cancer follow-up care. 
METHODS
The review was registered in PROSPERO (reference No.: CRD42018082501)20.
194 − Chapter 9
9
Search strategy
Three research questions were posed: (1) ‘what decisions are made during follow-up about con-
tent or form of follow-up care for breast cancer survivors?’; (2) ‘to what extent are these decisions 
sensitive to patient preferences?’, and (3) ‘to what extent and how are patients with breast cancer 
involved in making these decisions?’. The literature was searched separately for each question, 
between 18th July and 25th September 2017, in the MEDLINE (accessed through PubMed), Psy-
cINFO (accessed through Ovid), and EMBASE databases (Table 1). We included any study that 
discussed decisions made or interventions applied during follow-up for breast cancer, provided it 
was written in English and published in the last 10 years (2008-2017). The time restriction was set 
because breast cancer care and treatment have changed significantly over previous decades. The 
follow-up period was defined as the time period after surgery for breast cancer. 
After removing duplicates, study titles and abstracts were screened by two independent screeners 
(KdL and LvE). Studies were excluded if they did not include patients with breast cancer, did 
not discuss follow-up, did not describe actual decision-making, or did not describe the patients’ 
roles in decision-making. Studies were also excluded if they included patients receiving palliative 
treatment. Full texts were retrieved for the remaining studies. Those without full text articles were 
excluded after attempt to contact the corresponding authors to access the text. EndNote21 was 
used to manage all search results.
Quality assessment
The quality of the included studies was assessed by the Critical Appraisal Skills Programme 
checklist, comprising criteria for qualitative studies, randomised controlled trails, cohort studies, 
and systematic reviews. Criteria could be scored with a positive or negative response; when 
criteria were not applicable or unknown/unable to be assessed, this was recorded as well 22. First, 
we determined the study design for each included study, provided this was not already described 
in the study’s method section. Studies were deemed of sufficient quality when half or more of the 
criteria could be scored positive, provided there was a clear aim or research question. 
Analyses
First, we identified the decisions were made or could be made about content or form of follow-up 
care delivered to breast cancer patients. Second, criteria were compiled to determine whether 
decisions were sensitive to patient preferences and whether patients were involved in making the 
decisions. Third, these criteria, in turn, were used to assess the degree to which decisions were 
sensitive to patient preferences and the extent to which patients were involved in making these 
decisions. 
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Criteria for preference sensitiveness (PS0-5) were based on the definition by Van der Weijden et al. 
23. Decisions were considered preference-sensitive if the following criteria were met:
0. There were multiple options available (PS0); and
1. Options had potential favourable and unfavourable outcomes, leading to an individual trade-
off (PS1); or
2. Options did not differ in terms of favourability of the outcomes, or (un)favourable outcomes 
were equally (un)desirable (PS2); or
3. There was insufficient evidence about favourable or unfavourable outcomes to determine the 
best option (PS3); or
4. The potential risks of an option were high, regardless the potential benefits of this option (PS4); 
or
5. The outcomes were highly dependent on patient cooperation, or the actions required for the 
preferred option had high impact on the patient’s lifestyle (PS5). 
Criteria for the extent of patient-involvement (SDM1-7) were based on the conditions set by Légaré 
et al. 18 and the components described by Coulter and Collins. 24: 
1. The decision was preference sensitive (SDM1); and
2. There was sufficient time to make a decision (SDM2); and/or
3. The patient was capable and sufficiently informed to make a decision (SDM3); and/or
4. There was a belief that SDM would lead to better patient outcomes (SDM4); and/or
5. The physician was motivated for SDM and clarified the options and preferences (SDM5); and/
or
6. There was a belief that SDM will lead to better clinical outcomes (SDM6); and/or
7. There was a system for recording, communicating, and implementing the patient’s preferences 
(SDM7).
RESULTS
Figure 1 summarises the selection process according to the PRISMA scheme. In total, 3,077 
records were screened after removing duplicates (n = 2,539, 28, 1,058 per research question). 
After screening titles, abstracts, and full-texts, we finally included 41 studies. 
Within the screened records, ‘follow-up’ often referred to the study design rather than the post-
treatment period, and ‘preference-sensitive’ was used little or infrequently, only appearing as a key 
word in 21 records. Studies also generally described gaps in patient involvement rather than care 
that was already well-organized. Moreover, we excluded many studies (n=2871) that could not be 
related to the SDM criteria because they did not describe decision-making about the content or 
form of follow-up care. Another 11 studies were excluded because the full texts were not available. 
These were mainly studies published as conference abstracts, dissertations, or books. Contact 
details were available for only five of the corresponding authors of these abstracts, and only one 
responded.
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All included studies (n=41) were rated as valuable in the quality assessment (Supplementary Table 
2). Most studies employed a design with surveys (n=11) or interviews (n=16; comprising focus 
groups, needs assessments, and semi-structured/directed/open-ended interviews. The survey-
based studies included larger samples (n=5-41), whereas the interview-based studies included 
smaller groups (n=5–41). Less common methods included studies of electronic health records 
(n=1) and internet fora (n=1). Randomised Controlled Trials (RCT) designs were used for studies 
about life style interventions (n=2) and SDM-related tools about breast reconstruction (n=3).  
Table 2 summarizes the preference-sensitive aspects (criterion PS) and aspects of patient involve-
ment (criterion SDM) for each decision about the content or form of follow-up care. Decisions 
were classified into those concerning (1) ‘surveillance for recurrent or secondary breast cancer’; (2) 
‘consultations for physical and psychosocial (late) effects’; (3) ‘recurrence-risk reduction by anti-
hormonal treatment’; and (4) ‘improving quality of life after breast cancer’. Results are described in 
more detail below. Supplementary Table S1 summarizes the included studies.
Figure 1. PRISMA flow chart of study inclusion
Opportunities for personalised follow-up care among patients with breast cancer − 197
9
(1) Surveillance for recurrent or secondary breast cancer 
Follow-up aims to detect recurrent disease or new associated malignancies at an early-stage 
through surveillance imaging (mammography and/or MRI) and physical examination4-7. Two includ-
ed studies discussed decisions about the form and frequency of surveillance imaging (PS0)25 26. 
Klaassen et al.25 assessed the needs of Dutch patients and physicians with regard to an aftercare 
decision-aid. Brandzel et al.26 then described the experiences and preferences for breast imaging 
among breast cancer survivors in the United States. The main form of surveillance tended to 
be mammography, though some also received MRI; however, the authors did not specify who 
received what type of surveillance imaging or the reasons for the differences. If their breast cancer 
initially was missed on mammography, patients sometimes lost trust in this method, and preferred 
other imaging modalities. Furthermore, many patients received surveillance mammography more 
often than the recommended annual frequency without clinical indication26. Patients preferred this 
higher frequency because it reassured them about the absence of recurrences25 26. However, breast 
imaging also caused anxiety and was considered uncomfortable for many patients26, suggesting 
scope for a trade-off between burdens and benefits of surveillance imaging (PS1). Surveillance 
preferences were also affected by financial costs and insurance coverage26, and therefore, the 
patient’s willingness to bear these costs (PS5).
Little evidence was found for patient involvement in surveillance-related decisions. Brandzel et 
al.26 found that physicians typically determined the imaging type and frequency of surveillance 
(SDM5), despite the opposing preferences and trade-offs expressed by patients. The patient’s 
understanding of the goal of surveillance could be improved here: patients felt confused about 
the options for the type of surveillance imaging and frequency of surveillance imaging, and ex-
pressed a need for information about the transition from treatment to surveillance care (SDM3). 
The aftercare decision-aid produced by Klaassen et al.25 provides an overview of follow-up options 
(SDM7), and could reduce information needs before initiating follow-up. Surveillance length was 
not discussed in the literature. 
Hereditary testing is most often performed during breast cancer diagnosis and may be less rel-
evant during follow-up4. However, Rini et al.27 described hereditary testing in women with a history 
of breast cancer. Hereditary testing leads to information about the risk of secondary breast cancer, 
and/or risk of breast cancer or ovarian cancer in family members. This can affect surveillance 
schemes or preventative options, such as contralateral prophylactic mastectomy (PS0). 
(2) Consultations for physical and psychosocial (late) effects 
A second goal of follow-up is informing and counselling patients about the physical and psycho-
social (late) effects of treatment4-7. Two studies described decision-making regarding the form, 
frequency, and length of follow-up consultations within follow-up care (PS0). Patients preferred 
more personal attention from their physician and a higher frequency of oncology-led aftercare than 
was offered (current situation not defined), which gave them more security about their health25. 
Regarding the length of follow-up consultation, all USA-based participants in a study by Hudson 
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et al. had received follow-up care from a cancer specialist within the previous year, even though 
the time since their last active cancer treatment ranged from three to seventeen years; however, 
decisions about length were not discussed further28. Regarding the form of consultations, patients 
preferred consultations by a breast cancer specialist, possibly alternated with nurse consultations 
(PS1)25. Regardless of these preferences, patients were rarely offered options about the frequency, 
form, or length of consultations, indicating low patient-involvement. 
By contrast, most physicians stated that SDM was common practice in their healthcare facilities 
and in their own work, and reported that using SDM made the patients feel positively involved in 
decisions related to follow-up (SDM5)25. Referral to other medical specialists or care providers dur-
ing follow-up was not specifically described. However, 24% of patients sought care from multiple 
providers, including a primary care provider, general internist, or gynaecologist28.
(3) Recurrence risk reduction by anti-hormonal treatment
Seven studies described treatment decisions about anti-hormonal therapy29-35. This consisted of 
tamoxifen or aromatase-inhibitor use to increase locoregional tumour control and survival, given 
for a minimum of five consecutive years, and continuing during follow-up4. Respectively, there 
were two and five studies on decisions regarding therapy initiation30 35 and therapy adherence29-32 34. 
Within the literature, therapy initiation was rarely regarded as a preference sensitive decision: one 
study described that 96% of patients were steered towards anti-hormonal therapy, irrespective of 
the expected benefit33; in another study, patients felt obliged to take the therapy (PS0)30. However, 
the decision about anti-hormonal therapy is not an one-off decision: four studies described that the 
decision to adhere to anti-hormonal therapy leads to patients making an ongoing risk-versus-ben-
efit trade-off between the risk-reducing effect of treatment and the severity of treatment-induced 
side-effects (PS4)29-32 34. Nonadherent patients in two studies felt unable to cope with side-effects 
that severely affected their lives (PS5)30 31. Three studies reported that professional guidance or 
support from physicians for managing these side effects could be improved29 31 32. Such guidance is 
important, because patients can better persevere with side effects if they have a high belief in their 
ability to manage and control their medication and side effects (PS1)32. However, four studies report-
ed gaps in providing information about expected side effects29 30 33 or their management (SDM3)30 31. 
Frequently reported effects of anti-hormonal therapy were menopausal symptoms and joint pain, 
with cognitive decline and cardiac distress also occurring, but less frequently30. Two studies spe-
cifically discussed the identification and treatment of treatment-induced menopausal symptoms 
(PS0)36 37, such as hot flashes, weight gain, loss of sexuality, and increased osteoporosis. Symptom 
treatment was considered a preference sensitive decision because hormone replacement therapy 
is the customary and most effective option, even though it increases the risk of recurrence and 
should be avoided in patients with breast cancer (PS4)36 37. However, there are few alternatives 
(PS2), with these limited to various lifestyle changes, pharmaceutical options, and complementary 
treatments (e.g. mind-body therapies and natural health products)36. As both studies reported, a 
lack of reliable and unambiguous information about these options makes it difficult to select the 
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best option (PS3). Concerning this dilemma, patients were frustrated by the lack of conclusive 
information, particularly about complementary therapies, and by an inability to differentiate be-
tween credible and non-credible information sources (SDM3). Balneaves et al.36 suggested using 
an SDM-tool that could summarise credible information about accepted options and thus facilitate 
decision-making (SDM7). Two-third of patients in this study still used complementary therapy to 
manage symptoms, despite the lack of information36.
(4) Improving quality of life after breast cancer treatment 
This topic was subdivided into three subtopics. Sixteen studies focused on delayed breast recon-
struction, two on lifestyle changes, and four on getting pregnant after breast cancer. 
Breast reconstruction yields positive psychosocial effects38-41 and may contribute to the patients 
wellbeing after breast cancer. Although some, if not most decisions about breast reconstruction are 
made before surgical treatment, resulting in immediate breast reconstruction, some patients and/
or clinicians delay the decision about breast reconstruction until after treatment. Patients must then 
first decide whether to undergo delayed breast reconstruction, and when they do, decide which 
reconstruction technique should be used (PS0). Decisions about delayed breast reconstruction 
can remain relevant years after tumour surgery42 43 and have been recognised as highly preference 
sensitive in three studies38 44 45. Furthermore, seven studies indicated that breast reconstruction 
yields positive psychosocial effects38-41 and that it is an important option for patients who have 
undergone mastectomy42 46 47. In three studies, common reasons for opting to delay breast recon-
struction rather than undergoing breast reconstruction were reported, and it was concluded that 
either patients wanted to focus on other treatment modalities first39 42, or that the desired technique 
was not available at their facility45. Patients generally refused breast reconstruction if they felt it 
was not important, urgent42, or necessary, or feared undergoing further surgery39. Thus, apart from 
medical contra-indications, decisions about undergoing breast reconstruction were affected by 
its timing and individual decisions about trade-offs (PS1). Regardless of the potential for positive 
psychosocial effects38-41, risks of breast reconstruction can be high (PS4). Indeed, it is a major and 
invasive surgery38 39 42 47 48, and patients have reported concerns about surgical complications, and 
interference with cancer surveillance42, or postmastectomy radiotherapy39. There are also multiple 
options, such as autologous or implant-based breast reconstruction (PS0), with each associated 
with to different outcomes (PS1)38 40 43 49. 
Current patient involvement in decisions about breast reconstruction appeared to be high: 
fifteen studies described elements of patient-involvement or SDM38-48 50-52, and patients in two 
studies specifically reported feeling involved in decision-making (SDM5)51 52. SDM about breast 
reconstruction led to less conflict around decisions and to more satisfaction with the information 
provided (SDM4)43. By contrast, four studies reported that patients experienced decision-making 
uncertainty41-43 47 and eight studies recommended further improvement of information provision 
(SDM3)38 40 42 45 47 48 50 52. This could be addressed by using one of four decision aids that have been 
developed (SDM7)38 43 49 50. 
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In younger patients, breast cancer treatment can interfere with the desire to have a family. Four 
studies described the decision to get pregnant after treatment for breast cancer 29 53-55. Although 
this decision may feel like a risk, there is consensus that pregnancy following breast cancer is 
safe53. Nevertheless, both patients and physicians have expressed concerns about the poten-
tial for pregnancy to increase recurrence risk in patients with hormone-sensitive breast cancer 
(PS4)53-55. Patients not only felt under informed (SDM3)53, but also, patients worried whether breast 
cancer and its treatment would negatively affect the health of a future child (PS4)53 55. In general, 
there was a wide variety in the level of concern about fertility and getting pregnant. The importance 
of family building depended on personal circumstances, values, and expectations53-55. In a study 
of Chinese breast cancer survivors, social and cultural perceptions about having children were 
important motives (PS1)55. Although all three included studies described patient involvement in 
decisions about fertility management, it was also noted that the information provided could be 
improved (SDM3). 
Anti-hormonal therapy may cause infertility in premenopausal patients. Those on anti-hormonal 
therapy may therefore have to wait to the end of the treatment period (i.e. five years), while may 
be accompanied by an age-related decline in fertility (PS1). In some patients, oncologists were 
willing to discuss the option of a reduced duration of anti-hormonal treatment53. Another study 
recognised the need to counsel patients about family-building periodically during anti-hormonal 
treatment29. Indeed, fertility counselling may remain important throughout follow-up because 
treatment-affected fertility may have negative psychosocial consequences54 55. 
Chemotherapy treatment can also lead to reduced fertility. Therefore, patients should have the 
option to choose from a range of artificial reproductive techniques, including ovarian stimulation, 
and oocyte or embryo cryopreservation, before treatment (PS0)53. These decisions will also affect 
decision-making during follow up, for instance, patients who have opted for artificial reproductive 
techniques before treatment will have to decide on what to do with their preserved oocytes or 
embryos after treatment (PS0). All patients in a study by Corney and Swinglehurst53 indicated that 
they would not use the embryos or oocytes if they were able to conceive naturally, leading to moral 
decision about what to do with the oocytes or embryos. 
Quality of life improvements after cancer may be found by implementing lifestyle changes. Two 
RCTs described a lifestyle intervention and the reasons why patients did and did not participate 
(PS0)56 57. Shtaynberger and Krebs57 described how decisions about physical activities and fruit 
and vegetable intake were based on an individual weighing the pros and cons of making a change 
(the so-called decisional balance) (PS1). Carter et al.56 described the reasons for cancer patients to 
participate in either of two physical activity programmes (walking or ‘dragon boat’ rowing’) offered 
in their RCT. They reported that decisions were based on physical (health benefits), social (meeting 
new people, learning new skills), and practical (time investment, scheduling) considerations, but 
did not state whether the decision was discussed with a physician.
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DISCUSSION
In this study, we aimed to assess the potential to personalise follow-up care for patients after breast 
cancer treatment, by exploring the evidence on patient preferences for, and patient involvement 
in decisions about follow-up care. We identified many decisions that needed to be made during 
follow-up, including those related to surveillance imaging, follow-up consultations, anti-hormonal 
treatment, treatment-induced menopausal symptoms, and lifestyle changes. Moreover, we iden-
tified decisions that were made during treatment, but that required additional decisions during 
follow-up, such as delayed breast reconstruction, hereditary testing, and pregnancy. The literature 
revealed that there was a large variety in the degree of preference sensitiveness and patient in-
volvement with each decision during follow-up. Decisions about delayed breast reconstruction, 
for instance, were among those shown to be highly preference sensitive and for which many 
indications for patient-involvement existed. Equally, however, decisions were identified for which 
patients exhibited preferences, but for which they were not necessarily involved. Notably, this 
included decisions about the form, frequency, and length of surveillance imaging and follow-up 
consultations. Some decisions were not currently regarded as preference sensitive with a low 
recognition of the need for patient involvement, such as decisions about anti-hormonal therapy 
and the management of treatment-induced menopausal symptoms. 
Notably, the data indicated that the patient’s role and involvement should be improved for several 
decisions. First, regarding the form, frequency, and length of surveillance imaging, patients desired 
more frequent25 26 and intensive26 surveillance; continuity of care and more frequent or longer 
appointments were preferences expressed in other studies already15 16. Despite these strong 
preferences, patients were rarely involved in making decisions, with physicians typically setting 
the imaging type and frequency26. However, this is probably a legitimate approach because guide-
lines provide clear, evidence-based recommendations about surveillance schemes and imaging 
modalities4-7. We suspect that the identified preferences were primarily based on the patient’s 
need for reassurance25 26 58, and that they may be unaware that more intensive surveillance has no 
evidence base59, or that increased exposure might even be harmful60 61. Efforts should be made to 
improve patient understanding of the goals of surveillance62, specifically at the point of transition 
from treatment to follow-up26 63. Furthermore, the frequency and length of surveillance could be 
determined by recurrence risk stratification61, based on data from nomograms or risk-calculators. 
Although Rabin et al.64 reviewed 22 cancer prognostic tools, of which 8 focussed on breast cancer, 
patient-involvement with these tools was not discussed. The authors found only limited evidence 
reporting actual use of these in practice. 
Issues also existed for follow-up consultations aimed at the physical and psychosocial effects of 
treatment. The available research indicated that patients preferred more frequent consultations 
than was recommended, that these should be led by specialised oncology-providers25, and that 
these should be provided over a longer period of time28. As literature described unmet needs in 
information provision about follow-up, health promotion, late and long term-effects, or emotional 
and social needs63 65-68, these preferences may be the result of these unmet needs. Moreover, 24% 
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of patients sought care from multiple other providers28, suggesting that referral for personalised 
care may sometimes be more appropriate than providing general oncology-led follow-up. We 
expect that using patient-reported outcome measures (PROMs) would help to identify patients’ 
needs regarding specific forms of care69. PROMs can include symptom-specific scales about, for 
instance, physical impairments, sexuality problems, psychosocial problems, and body image70 71. 
Patients and physicians would be able to discuss the results and subsequently ensure appropriate 
referrals to physiotherapists, sexologists, gynaecologists, medical social workers, psychologists, 
or plastic surgeons, as necessary. 
Decisions about anti-hormonal treatment had little recognition as preference sensitive decisions 
among physicians, which is somewhat consistent with the 2015 European Society for Medical 
Oncology guideline. Although this guideline states that follow-up care should seek to motivate 
patients to continue anti-hormonal treatment6, we should remember that patients must suffer 
many side-effects over a long period of time29-32 34, and that this often occurs without proper 
counselling29 31 32. This leaves patients struggling to cope with difficult symptoms with minimal 
support 31. Given that therapy-adherence depends on perseverance despite side-effects30 31, the 
needs and preferences of patients require more personalised attention in the long-term. This may 
be challenging, particularly for patients confronted with menopausal symptoms, for whom safe 
and effective evidence-based options for symptom relief are scarce36 37. Finally, treatment-affected 
fertility in young premenopausal women may conflict with the desire to build a family, producing 
negative long term psychosocial effects29 54 55. These issues necessitate explicit information provi-
sion, counselling, and ongoing support to ensure treatment compliance and management of side 
effects67 72 73.
Strengths and limitations
Several limitations should be kept in mind when interpreting the results of this study. In the inter-
view and focus-group studies, the samples included in these studies were small, which may limit 
the generalizability of the data. However, all the included studies were rated as valuable in the 
quality assessment. 
We considered that the effectiveness of patient involvement or SDM is a separate research topic. 
Shay and Lafaya74 concluded that evidence about the association between empirical measures of 
SDM and patient behavioural and health outcomes is lacking. Given that SDM is not associated 
with improved outcomes, it should not be considered a goal in itself. However, because outcomes 
do tend to improve with personalised care, SDM may moderate some other factor74. 
Practice implications and recommendations
Currently, there is an international trend towards increased SDM in the diagnosis and treatment of 
all disease, based on the value-based healthcare initiative17. Further personalisation of follow-up 
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care may lead to care that is not only of greater value for the individual patient, but also to care 
that is more appropriate from a financial perspective, potentially leading to more responsible use 
of available healthcare services as well. The process used when deciding on breast reconstruction 
may be considered an example of best-practise for other decisions about follow-up. Eight studies 
recommended improvement in information provision38 40 42 45 47 48 50 52, and four reported on decision 
aids to address these information gaps38 43 49 50. Although patient-involvement seemed to be more 
straightforward when making elective decisions about breast reconstruction, true involvement in 
the decision-making process requires that patients be given the best available evidence, including 
details of the risks and benefits18. When the evidence for a certain decision is low, such as when 
making decisions about relieving menopausal symptoms, this uncertainty should be outlined by 
physicians75.
CONCLUSION
We identified a variety of decisions that can be made about the content or form of follow-up care 
for patients with breast cancer. We grouped these into four categories: surveillance for recurrent 
or secondary breast cancer, consultations for physical and psychosocial (late) effects, recurrence 
risk reduction by anti-hormonal treatment, and improving quality of life. More attention should be 
given to the patient’s role and the involvement in decisions where their input is both relevant and 
possible. Further personalisation of follow-up care may lead to care of greater relevance and value 
to individual patients.
214 − Chapter 9
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Current clinical practice and determinants of the use of 
delayed breast reconstruction in the Netherlands
LSE van Egdom, KM de Ligt, L de Munck, LB Koppert,  
MAM Mureau, HA Rakhorst, S Siesling
Submitted
SUMMARY
Delayed breast reconstruction (DBR) is a valid option for postmastectomy breast cancer patients 
who did not undergo immediate breast reconstruction (IBR). The objective of this study was to 
investigate the clinical practice and determinants of the use of DBR in the Netherlands. Stage I-III 
breast cancer patients diagnosed between January and March 2012 and treated with mastec-
tomy were selected from the Netherlands Cancer Registry. Routinely collected patient, tumour, 
treatment and hospital characteristics were complemented with data about DBR up to 2018. Mul-
tivariable logistic regression analyses were performed to identify factors independently associated 
with postmastectomy DBR. Factors associated with time to DBR were identified through Cox 
regression analyses. 
Of all patients who underwent mastectomy (N=1,415), 13.7% underwent IBR, 10.2% DBR, and 
76.1% mastectomy alone. DBR patients more often received autologous reconstruction compared 
to IBR patients (37.5% vs 6.2%, p<0.001). Age below 50 years (OR 4.3) and neoadjuvant and 
adjuvant chemotherapy (OR 2.99 and OR 2.85, respectively) were significantly associated with 
DBR. Mean time to DBR was 2.4 years [range 1-6 years]. Time to DBR was significantly associated 
with radiotherapy (HR 0.61) and adjuvant chemotherapy (HR 0.53). 
The use of DBR after mastectomy could not be fully explained by age below 50 years and chemo-
therapy. Treatment with radiotherapy and adjuvant chemotherapy increased time to DBR. More in-
formation about patient preferences is needed to understand the use and timing of reconstruction.
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INTRODUCTION
In breast cancer treatment, decisions about surgery are part of a continuum of treatment decisions 
rather than stand-alone decisions. Although breast-conserving therapy (BCT, breast-conserving 
surgery followed by radiotherapy) has become the central component of surgical breast cancer 
treatment1, many women still elect to undergo mastectomy2, despite possible negative effects on 
body image and psychosocial wellbeing3 4. Postmastectomy breast reconstruction is considered 
an important treatment modality in breast cancer care, as it not only restores the breast contour 
but also provides psychological, psychosocial and functional improvement, including body image 
and sexuality4-7. Patients treated with mastectomy may opt for breast reconstruction, which is 
either performed during mastectomy as an immediate breast reconstruction (IBR) or as delayed 
breast reconstruction (DBR) at any given point in time following mastectomy8.
Multiple factors may affect the timing of breast reconstruction, including both tumour and treatment 
characteristics as clinical cancer stage, tumour size and localization, comorbidity, smoking, as well 
as individual patient’s and surgeon’s preferences8 9. From a clinical perspective, DBR is considered 
a good option for patients with a high risk of postmastectomy radiotherapy, typically with stage 
II or III breast cancer. While IBR is not absolutely contraindicated in patients indicated for radio-
therapy, the general clinical believe within the Netherlands is that patients who are scheduled for 
postmastectomy radiotherapy are better served by DBR. Reasons are that radiotherapy following 
IBR may not only increase the chance of implant loss, reconstruction failure, or poorer aesthetic 
outcomes10 11, but that IBR may also negatively affect the quality of radiotherapy, specifically if tis-
sue expanders with integrated valves are used12-15. Furthermore, in Dutch clinical practice, tumour 
resection is done by oncological surgeons, while breast reconstruction is typically performed by 
plastic surgeons. Presumably, differences exist between hospitals and regions in local ‘in-house 
styles’ and organization of care.
From a patient perspective, common reasons or preferences for choosing DBR over IBR range 
from a preference to focus on oncological treatment first16 17 to the unavailability of the desired 
technique in the facility of breast cancer treatment18. Also, patients may feel it is unimportant, 
unnecessary, nor urgent16, or they choose to undergo limited surgery as the first procedure17. 
Ultimately, decisions regarding DBR may be relevant from pre-treatment up to years after breast 
cancer surgery19.
Trends in IBR have been evaluated extensively, both nationally20 21 and internationally2 22 23. Com-
pared to IBR, where data can be easily studied as IBR is linked to the mastectomy performed, 
proper collection of DBR-data is more challenging since DBR can be performed years after mas-
tectomy. Consequently, reliable information regarding the current clinical practice of DBR from a 
national perspective is lacking. Therefore, the objective of the present study was to investigate the 
clinical practice of the use of DBR in stage I-III breast cancer patients in the Netherlands and the 
factors affecting its use.




As DBR may remain relevant years after breast cancer surgery19, we selected breast cancer patients 
diagnosed between January and March 2012 from the Netherlands Cancer Registry (NCR) for our 
nationwide population-based study. Patients with stage I-III disease, treated with a mastectomy, 
were included. The NCR records data for all newly diagnosed malignancies in the Netherlands 
since 1989 and incorporates data on patient, tumour and treatment characteristics. Data about 
breast reconstruction is only routinely collected for IBR, therefore, information regarding DBR was 
manually and retrospectively retrieved for our cohort. Patients’ electronic health records were 
checked in 2018, leading to a follow-up period of about five years after diagnosis. 
Tumour stage was classified according to the AJCC TNM Classification for Breast Cancer (7th Edi-
tion). Topography, morphology, and grade were coded according to the International Classification 
of Diseases for Oncology, using tumour, node, and metastasis classification system (ICD-O, 3rd 
edition). Data about recurrent disease was available up to five years after diagnosis.
This study was approved by the Privacy Review Board of the NCR. 
Construction of variables
The primary study outcome was DBR, defined as any reconstruction performed at any other date 
after mastectomy; other treatment groups were patients treated with IBR (defined as any recon-
struction on the same date as mastectomy) and patients treated with mastectomy only. 
Hospitals were grouped according to hospital of oncologic surgery and hospital of reconstruction. 
The surgical volume of a hospital was defined as the annual number of breast cancer patients in 
2012, divided into low-volume <175 (n=51), mid-range volume 175-245 (n=29), and high-volume 
>245 (n=19). Hospitals were categorized as either academic hospitals (including cancer centres, 
n=8), teaching hospitals (n=44) and general hospitals (n=51). Both academic and teaching hos-
pitals provide medical training to surgical residents. Plastic surgery training is provided in a more 
limited number of specific hospitals. 
Statistical analyses
Patient, tumour, treatment and hospital characteristics were summarized per treatment group and 
compared using Pearson Chi-square tests (two-sided). Multivariable logistic regression analyses 
were used to determine factors that were independently associated with use of DBR in contrast to 
mastectomy alone, controlled for patient, tumour, and treatment characteristics that had a signifi-
cant relationship with DBR in univariable analyses (significance level p<0.10). To determine factors 
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influencing the time between mastectomy and DBR, a Cox regression analysis was performed 
controlled for patient, tumour, and treatment characteristics that had a significant relationship 
with DBR in univariable analyses (significance level p<0.10). Variables were selected based on 
literature8 9 and included age at time of surgery, clinical tumour and nodal stage, morphology, 
differentiation grade, chemotherapy, radiotherapy, hospital type, and hospital volume. Conditions 
of proportionality were analyzed graphically. In multivariable analyses, P-values <0.05 were con-
sidered as statistically significant. All analysis was performed using STATA (version 14)24.
Sample size
To enable regression analyses, Harris’ rule of thumb (1985) prescribes a minimum of 10 partici-
pants per predictor variable in equations including six or more variables25. We expected to include 
10-15 independent variables in our multivariable regression, requiring a minimum of 150 DBR 
patients. In a similar cohort study performed in Denmark, that has an identical nationwide cancer 
registry, 10.1% of women received DBR in the years following diagnosis (1999-2006, follow-up to 
2009)26. By including 1500 patients treated with mastectomy, about a quarter of annually newly 
diagnosed breast cancer patients treated with mastectomy in the Netherlands, we expected to 
include enough DBR patients. In 2012, quarterly rates of mastectomy and IBR were constant, 
suggesting generalizability of DBR-rates over a similar period. 
RESULTS
Patients characteristics
Of all patients diagnosed with stage I-III breast cancer between January and March 2012, 36% of 
patients (n=1,415) had been surgically treated with mastectomy (Table 1). Of these patients, 194 
(13.7%) patients received IBR, 144 (10.2%) DBR, and 1,077 (76.1%) mastectomy without any 
reconstructive procedures in the years following resection. DBR patients had a significantly lower 
mean age than IBR patients (47.4 [range 25.1 – 74.9] years versus 51.1 [range 26.7 – 78.8] years, 
respectively, p<0.001). DBR patients were significantly more often diagnosed with higher clinical 
stage (stage III: 11.8%; T2-stage: 40.3% or T3-stage: 13.2%) and nodal involvement (57.6%; 
p<0.05) compared to IBR-patients. Statistically significant differences were found between all 
groups for treatment characteristics, including radiotherapy and chemotherapy (p<0.001), as well 
as for hospital type (p<0.001) and hospital volume (p<0.006, Table 1). 
Figure 1 shows a flowchart of the treatment characteristics for all breast reconstruction patients 
following mastectomy. Most patients who had undergone breast reconstruction (either IBR or 
DBR) were not treated with adjuvant radiotherapy.
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Table 1: Patient, tumour, treatment, and hospital characteristics for patients treated with mastectomy (n=1415), 








Age in years 
(at diagnosis)
<35 19 9.8% 22 15.3% 18 1.7% <0.001
35-49 73 37.6% 73 50.7% 169 15.7%
50-75 99 51.0% 49 34.0% 609 56.5%
75+ 3 1.5% 0 0.0% 281 26.1%
Median 
(range)
51.1 26.7-78.8 47.4 25.1-74.9 64.5 26.3-96.5 n/a
Tumour characteristics
Stage (clinical) I 93 47.9% 43 29.9% 336 31.2% <0.001
II 81 41.8% 78 54.2% 585 54.3%
III 5 2.6% 17 11.8% 112 10.4%
Unknown 15 7.7% 6 4.2% 44 4.1%
Clinical tumour size 
(cT)
0/IS 2 1.0% 0 0.0% 2 0.2% <0.001
cT1 99 51.0% 58 40.3% 401 37.2%
cT2 69 35.6% 58 40.3% 473 43.9%
cT3 10 5.2% 19 13.2% 98 9.1%
cT4 0 0.0% 2 1.4% 55 5.1%
Missing 14 7.2% 7 4.9% 48 4.5%
Grade Grade I 38 19.6% 15 10.4% 145 13.5% 0.090
Grade II 79 40.7% 60 41.7% 446 41.4%
Grade III 46 23.7% 48 33.3% 345 32.0%
Unknown 31 16.0% 21 14.6% 141 13.1%
HER2 status Positive 146 80.2% 112 79.4% 877 82.4% 0.393
Negative 3 1.6% 0 0.0% 16 1.5%
Unclear 33 18.1% 29 20.6% 171 16.1%
Hormone receptor 
status
Positive 127 68.6% 99 68.8% 654 61.1% 0.053
Mixed 28 15.1% 15 10.4% 201 18.8%
Negative 30 16.2% 30 20.8% 215 20.1%
ER statusa Negative 31 16.8% 31 21.5% 221 20.7% 0.438
Positive 154 83.2% 113 78.5% 849 79.3%
PR statusa Negative 57 30.8% 44 30.6% 410 38.3% 0.043
Positive 128 69.2% 100 69.4% 660 61.7%
Multifocality No 129 69.7% 91 63.2% 745 69.6% 0.447
Yes 56 30.3% 52 36.1% 318 29.7%
Lymph node status N0 132 68.0% 61 42.4% 491 45.6% <0.001
>N1 58 29.9% 83 57.6% 552 51.3%
Not 
applicable
4 2.1% 0 0.0% 34 3.2%
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Table 1: Patient, tumour, treatment, and hospital characteristics for patients treated with mastectomy 








Recurrent cancer  
(5 yeas follow-up)
Yes 10 5.4% 13 8.8% 221 8.0% 0.416
Mean time to 
recurrence (in days) 
Mean (SD) 1012 466 1070 428 884 447 n/a
Type of recurrence Local 4 2.2 4 2.7 40 1.5 n/a
Regional 3 1.6 4 2.7 57 2.1
Metastasis 7 3.8 10 6.8 196 7.1
Treatment characteristics
Chemotherapy Yes 120 61.9% 120 83.3% 522 48.5% <0.001
Neoadjuvant 89 74.2% 94 78.3% 390 74.7% 0.758
Adjuvant 27 22.5% 23 19.2% 122 23.4%
Both 4 3.3% 3 2.5% 10 1.9%
Endocrine therapy Yes 121 62.4% 102 70.8% 707 65.6% 0.267
Radiotherapy Yes 28 14.5% 52 36.1% 359 33.3% <0.001
Before BR 0 0.0% 48 92.0% n/a n/a <0.001








56 28.9% 60 41.7% 385 35.7% <0.001
Teaching 
hospital
111 57.2% 76 52.8% 631 58.6%
Academic 
hospital 
27 13.9% 8 5.6% 61 5.7%
Hospital 





55 28.4% 42 30.4% n/a n/a 0.796
Teaching 
hospital
112 57.7% 80 58.0% n/a n/a
Academic 
hospital 





Low 48 24.7% 50 34.7% 380 35.3% 0.006
Middle 60 30.9% 46 31.9% 361 33.5%
High 86 44.3% 48 33.3% 336 31.2%
IBR, mastectomy with immediate breast reconstruction; DBR, mastectomy with delayed breast reconstruction
*Chi-square tested
a Only available if hormone receptor status was tested
b Hospitals were categorized as either general, teaching, or academic hospitals. Cancer-specialized centres 
were included in the category of academic hospitals. 
c Number of surgical treated non-metastatic breast cancer patients in 2012, categorized as low (≤175), medium 
(175<245), and high (>=245) volume.
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Figure 1. Treatment characteristics for surgical treated patients diagnosed between January and 
March 2012
IBR, mastectomy with immediate breast reconstruction; DBR, mastectomy with delayed breast reconstruction.
Percentages compared to population of patients treated with mastectomy (n=1415).
Absolute numbers of type of reconstruction are reported at the end of the corresponding bar.
Delayed breast reconstruction
DBR patients significantly more often received mastectomy at general hospitals compared to 
IBR patients (41.7% versus 28.9%, respectively, p<0.001). Implant-based DBR was performed 
most frequently (n=70, 48.6%), followed by autologous DBR (n=54, 37.5%; Table 2). However, 
autologous reconstructions were performed significantly more often in DBR patients than in IBR 
patients (6.2%), where implant-based reconstructions were leading (82.1%). 
Mean time to DBR was 710 days (Table 1). In Fig. 2, time to DBR was categorized by TNM-staging. 
With an increasing tumour stage, DBR was performed later in time, starting >1 year following 
mastectomy (p=0.019). Patients treated with radiotherapy received DBR approximately one year 
later than patients without radiotherapy, with a mean time between diagnosis and DBR of 2.9 years 
(SD 1.26) versus 2.1 years (SD 1.23), respectively (p=0.002; results not shown in Fig. 2). 
Table 2. Type of breast reconstruction for immediate and delayed breast reconstructions (n,%) for 





Autologous 12 6.2% 54 37.5% <0.001b
Combined autologous and implants 11 5.7% 10 6.9%
Implants 169 82.1% 70 48.6%
Not specified 2 1.0% 10 6.9%
IBR, mastectomy with immediate breast reconstruction; DBR, mastectomy with delayed breast 
reconstruction.
*Chi-square tested
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Figure 2. Time (in years) between mastectomy and DBR per TNM-stage; cumulative number of DBR 
(n=144).
DBR, mastectomy with delayed breast reconstruction.
Absolute cumulative numbers of patients with DBR are reported per year over each line.
Factors associated with the use of DBR
The following variables were significantly related to the use of DBR in univariable analyses and 
therefore included in the multivariable analyses: age, clinical T-stage and N-stage, grade, chemo-
therapy, radiotherapy, endocrine therapy, hospital type, and hospital volume. In the multivariable 
logistic regression analyses, the use of DBR was significantly and positively associated with age 
<35 years (OR 15.55, CI 8.37–28.93, p<0.001), age 35-49 (OR 4.18, CI 2.84–6.17, p<0.001), and 
receiving chemotherapy, either neoadjuvant chemotherapy (OR 2.59, CI 1.39–4.84, p<0.001) or 
adjuvant chemotherapy (OR 2.83, CI 1.75–4.56, p <0.001; Table 3).
As part of a sensitivity analysis, we performed a multivariable logistic regression for the factors 
related to any breast reconstruction (including both IBR and DBR) in contrast to mastectomy 
alone. Additionally to chemotherapy, radiotherapy was also associated with receiving breast 
reconstruction (OR 0.07, p<0.001), as were hospital type and volume (Table 4). 
Factors associated with the time between mastectomy and DBR
The following variables were significantly related to time between mastectomy and DBR in 
univariable Cox regression analyses, and therefore included in the multivariable analyses: age, 
chemotherapy, radiotherapy, and endocrine therapy. In the multivariable analyses, a longer time 
between mastectomy and DBR was significantly associated with radiotherapy (HR 0.61, CI 
0.42–0.89, p=0.011), and adjuvant chemotherapy (HR 0.53, CI 0.30–0.93, p=0.028; Table 5). Based 
on graphical investigation, proportionality was assumed for all variables. 
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Table 3. Logistic regression for the odds of delayed breast reconstruction versus mastectomy alone.
n=1221
Univariable Multivariable p-value*
OR 95% CI OR 95% CI
Patient characteristics
Age <35 33 12.9 6.15 - 27.1 14.65 7.49 – 28.66 <0.001
35-49 245 5.56 3.75 – 8.26 4.30 2.93 – 6.34 <0.001
50-75 657 ref
75+ 286 1 omitted omitted
Tumour characteristics
Clinical stage T0 2 omitted omitted
T1 459 Ref Ref
T2 531 0.85 0.58 – 1.25 - - -
T3 117 1.34 0.76 – 2.35 - - -
Lymph node status N0 552 Ref Ref
>N1 635 1.21 0.85 - 1.72 - - -
Not applicable 34 1 omitted - - -
Grade Grade I 160 ref ref
Grade II 506 1.30 0.72 – 2.36 - - -
Grade III 393 1.35 0.73 – 2.48 - - -
Unknown 162 1.44 0.71 – 2.90 - - -
Treatment characteristics
Chemotherapy No 579 Ref Ref
Yes, adjuvant 484 5.57 3.50 – 8.89 2.99 1.84 – 4.85 <0.001
Yes, neoadjuvant 145 4.36 2.38 – 7.98 2.85 1.52 – 5.35 0.001
Radiotherapy No 810 Ref Ref
Yes 411 1.13 0.79 – 1.62 - - -
Endocrine therapy No 412 Ref Ref
Yes 809 1.27 0.87 – 1.86 - - -
Hospital factors
Hospital type 
(hospital of oncologic 
treatment)a
General hospital 445 ref ref
Teaching hospital 707 0.77 0.54 – 1.11 - - -
Academic hospital 69 0.84 0.38 – 1.85 - - -
Hospital type 
(hospital of DBR)a
General hospital 43 ref ref
Teaching hospital 81 1 omitted - - -
Academic hospital 16 1 omitted - - -
Hospital volume 
(hospital of oncologic 
treatment)b
Low 430 ref ref
Middle 407 0.97 0.63 – 1.48 - - -
high 484 1.09 0.71 – 1.66 - - -
Goodness-of-fit Prob > chi2 = 0.5925
Area under ROC curve 0.7704
DBR, mastectomy with delayed breast reconstruction; cT, clinical tumour-stage.
*Chi-square tested.
a Hospitals were categorized as either general, teaching, or academic hospitals. Cancer-specialized centres 
were included in the category of academic hospitals.
b Number of surgical treated non-metastatic breast cancer patients in 2012, categorized as low (≤175), 
medium (175-245), or high (>245) volume.
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Table 4. Univariable and multivariable logistic regression for the odds of breast reconstruction (either 
IBR or DBR) versus mastectomy alone.
n=1221
Univariable Multivariable p-value*
OR 95% CI OR 95% CI
Patient characteristics
Age <35 46 7.59 4.03 – 14.28 15.64 7.93 – 30.86 <0.001
35-49 323 3.73 2.82 – 4.95 4.39 3.21 – 6.01 <0.001
50-75 757 ref ref
75+ 289 0.04 0.01 – 0.13 0.06 0.02 – 0.21 <0.001
Tumour characteristics
Clinical stage T0 4 2.55 0.36 – 18.29 8.28 0.43 – 158.0 0.160
T1 558 Ref Ref
T2 600 0.69 0.52 – 0.90 0.91 0.67 – 1.24 0.569
T3 127 0.76 0.48 – 1.19 1.62 0.90 – 2.91 0.108
Lymph node status N0 684 Ref Ref
>N1 693 0.65 0.51 – 0.83 1.14 0.84 – 1.53 0.407
Not applicable 38 0.30 0.10 – 0.85 0.24 0.06 – 0.96 0.044
Grade Grade I 198 ref ref
Grade II 585 0.85 0.59 – 1.23 - - -
Grade III 439 0.75 0.51 – 1.10 - - -




No 653 Ref Ref
Yes, adjuvant 573 2.66 2.01 – 3.51 1.59 1.12 – 2.26 0.010
Yes, neoadjuvant 172 2.32 1.57 – 3.44 2.47 1.45 – 2.23 0.001
Radiotherapy No 976 Ref Ref
Yes 439 0.62 0.47 – 0.82 0.07 0.05 – 0.10 <0.001
Anti-hormonal therapy No 485 Ref Ref




General hospital 501 ref ref
Teaching hospital 818 0.98 0.76 – 1.28 0.72 0.49 – 1.05 0.090
Academic hospital 96 1.90 1.20 – 3.03 1.76 1.03 – 2.99 0.036
Hospital volumeb Low 478 ref ref
Middle 467 1.14 0.83 – 1.55 1.66 1.12 – 2.45 0.011
high 470 1.55 1.15 – 2.08 2.24 1.46 – 3.45 <0.001
Goodness-of-fit Prob > chi2 = 0.0383
Area under ROC curve 0.89
IBR, mastectomy with immediate breast reconstruction; DBR, mastectomy with delayed breast 
reconstruction; cT, clinical tumour-stage; MDT, multidisciplinary team meeting. 
*Chi-square tested.
a Hospitals were categorized as either general, teaching, or academic hospitals. Cancer-specialized centres 
were included in the category of academic hospitals.
b Number of surgical treated non-metastatic breast cancer patients in 2012, categorized as low (≤175), 
medium (175-245), or high (>245) volume.
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Table 5. Cox regression for the time between mastectomy and delayed breast reconstruction (DBR).
n=144
Univariable Multivariable p-value*
HR 95% CI HR 95% CI
Patient characteristics
Age <35 17 1.95 1.09 – 3.49 1.77 0.95 – 3.32 0.074
35-49 77 1.08 0.75 – 1.55 1.47 0.99 - 2.20 0.058
50-75 50 ref ref
75+ 0 omitted omitted
Tumour characteristics
Clinical stage T0 58 omitted omitted
T1 58 Ref Ref
T2 19 0.73 0.50 – 1.06 - - -
T3 9 1.16 0.67 – 1.99 - - -
Lymph node status N0 61 Ref Ref
>N1 83 0.81 0.57 – 1.13 - - -
Not applicable 0 omitted omitted
Grade Grade I 15 ref ref
Grade II 60 0.63 0.35 – 1.12 - - -
Grade III 48 0.75 0.42 – 1.34 - - -
Unknown 21 0.92 0.47 – 1.80 - - -
Treatment characteristics
Chemotherapy No 24 Ref Ref
Yes, adjuvant 94 0.59 0.37 – 0.94 0.53 0.30 – 0.93 0.028
Yes, neoadjuvant 23 0.85 0.47 – 1.53 0.85 0.44 – 1.66 0.644
Radiotherapy No 92 Ref Ref
Yes 52 0.73 0.51 – 1.04 0.61 0.42 - 0.89 0.011
Endocrine therapy No 42 Ref Ref
Yes 102 0.71 0.49 – 1.02 0.94 0.63 – 1.41 0.778
Hospital factors
Hospital type (hospital of 
oncologic treatment)a
General hospital 60 ref ref
Teaching hospital 76 0.91 - - -
Academic hospital 8 1.24 0.64 – 1.28 - - -
Hospital type 
(hospital of DBR)a
General hospital 43 ref 0.56 – 2.74 ref
Teaching hospital 81 0.86 0.57 – 1.30 - - -
Academic hospital 16 1.30 0.87 – 1.94 - - -
Hospital volume (hospital of 
oncologic treatment)b
Low 50 ref ref
Middle 46 0.81 0.56 – 1.18 - - -
high 48 0.85 0.47 – 1.54 - - -
DBR, mastectomy with delayed breast reconstruction; cT, clinical tumour-stage. 
*Chi-square tested.
a Hospitals were categorized as either general, teaching, or academic hospitals. Cancer-specialized centres 
were included in the category of academic hospitals.
b Number of surgical treated non-metastatic breast cancer patients in 2012, categorized as low (≤175), 
medium (175-245), or high (>245) volume.
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DISCUSSION
The objective of the current study was to investigate the breast cancer patient population opt-
ing for DBR in the Netherlands. Based on one quarter of newly diagnosed patients treated with 
mastectomy in 2012, DBR was performed in 10.2% (144/1,415) of patients, which is consistent 
with DBR rates of 9.3–13% from European literature (Denmark, the UK; 1999-2009)26 27. Breast 
cancer patients with DBR significantly differed from patients with IBR or mastectomy alone. DBR 
patients were significantly younger, were more often diagnosed with stage II breast cancer and 
axillary lymph node metastases and were more often treated with chemotherapy or radiotherapy. 
This corresponds with the rationale that patients who are considered eligible for IBR are generally 
diagnosed with stage I breast cancer, with a good prognosis and a negative sentinel lymph node 
without the indication for axillary lymphadenectomy or radiotherapy14. In addition, most DBR and 
mastectomy alone patients were treated at teaching or general hospitals, whereas IBR was mostly 
performed at academic or teaching hospitals20 28. This corroborates the findings of Alderman et 
al.29, who demonstrated that breast reconstruction rates were most probably higher in breast 
cancer specialized centres and hospitals with a high clinical breast surgery volume, because of 
high referrals to plastic surgeons.
Although not exclusively explaining the use of DBR, age below 50 years and treatment with 
(neoadjuvant) chemotherapy were significantly associated with DBR. This is in contrast to current 
literature. Initiation of adjuvant chemotherapy is recommended within 6-12 weeks after mastec-
tomy8 30-32, and a recent large Dutch population-based study found that IBR did not reduce the 
likelihood of receiving adjuvant chemotherapy within 9 or 12 weeks following mastectomy33. This 
suggests that IBR does not delay the initiation of adjuvant chemotherapy to a clinically relevant 
extent33, and thus DBR is not per se preferred over IBR when chemotherapy is indicated. Further-
more, literature has shown younger age is mainly related to higher IBR-rates20 28 34, not to DBR-
rates, and IBR-rates decrease significantly with increasing age35. Therefore, both associations may 
seem unexpected. However, our results could be explained by the following. 
First, the decisions for IBR and DBR are interdependent, or as stated in our introduction section, 
part of a continuum of decisions. There are several reasons to prefer IBR over DBR, including 
cosmetic result and organizational benefits6 8 19. Patients who prefer a reconstruction but have a 
contra-indication for IBR, will most likely opt for DBR. The decision for DBR is therefore conditional 
to the decision regarding IBR, which may explain why we found no significant association of 
radiotherapy with DBR. This is illustrated by our sensitivity analysis. Radiotherapy was strongly 
negatively associated with receiving any breast reconstruction (IBR or DBR) in contrast to mastec-
tomy alone (Table 4); a result from adding IBR patients to the regression analyses as reported in 
Table 3. Radiotherapy is reported as the most common reason to delay breast reconstruction until 
the acute side-effects of radiotherapy have been resolved, preferring DBR over IBR8 12 14 15. Our Cox 
regression analysis demonstrated that the time between mastectomy and DBR was significantly 
longer when radiotherapy was given; most patients were scheduled for DBR at least 2 years after 
radiotherapy completion. 
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The same may apply for age. Of all patients with a contra-indication for IBR, young patients may 
still opt for DBR, whereas older patients may be satisfied with mastectomy alone. This is partly 
explained by both patients’ preferences and clinicians’ beliefs. As older patients are more likely 
to have significant comorbidities, clinicians may find younger patients more eligible to undergo 
breast reconstruction35. Moreover, one may speculate that older patients more easily accept the 
loss of their breast(s) or may not want to undergo major surgery. Younger patients in contrast may 
be more aware of breast reconstruction possibilities20 and may be more assertive to discuss this 
option with their physician19. 
Second, treatment practice has changed since 2012. Chemotherapy may be a proxy for disease 
severity and the prognosis of recurrence risk: DBR patients significantly more often had stage III 
disease and larger pre-treatment tumours. Therefore, reluctancy towards IBR may have caused 
physicians to advice DBR instead. At that time, IBR was more cautiously offered to patients in-
dicated for chemotherapy36, while current evidence-based guidelines state chemotherapy is not 
a contra-indication for IBR33 37. In our study we revealed a longer time between DBR in case of 
chemotherapy. The reason for this is not clear but could be patients were initially reluctant to 
undergo yet another stressful treatment in the hospital.
Implant-based breast reconstruction was the most frequently used technique (82.1% IBR; 48.6% 
DBR) in our cohort. Nowadays, however, autologous reconstructions are increasingly recom-
mended8, as lower rates of total reconstruction failure and better long-term patient satisfaction 
with aesthetic outcome compared to implant reconstruction have been reported8 38. In our radiated 
sub-population, the majority had received autologous breast reconstruction. The Dutch evidence-
based guideline for breast reconstruction (2018) states that for DBR after radiotherapy it is prefer-
able not to perform reconstruction with an implant only due to the high risk of implant loss8, but 
rather add non-irradiated tissue to cover the implant or perform a full autologous reconstruction. 
The nationwide and population-based character is a major strength of our study. However, the 
data obtained for this study was restricted to the time period between January and March 2012. 
Although this limits the size of our sample, our sample size calculation substantiates the number 
of included patients in our cohort. Because DBR is not routinely registered in the NCR, data had to 
be manually collected retrospectively over a time period of five years of follow-up. Still, within this 
quarter, patients who received DBR in a hospital different from were mastectomy was performed, 
may have been lost to follow-up. Patients may have decided independently for DBR at another 
hospital, leaving no paper trail at the hospital where the mastectomy was performed. These refer-
ral patterns are not easily identified by NCR’s registrars, especially when time since diagnosis 
passes, probably resulting in a somewhat smaller number of identified DBR patients. In a study 
on IBR a 5% hospital transfer was seen39, which implies little incompleteness in our study. Active 
follow-up for all patients in the NCR is advisable. 
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Several latent variables may have accounted for the reduced explanatory power of our multivari-
able logistic regression model for the use of DBR. Factors as patients’ preferences and behaviour 
(smoking, BMI), surgeons’ beliefs or hospital organizational factors probably also affect the use 
of DBR, as they do in IBR20, but are not collected in detail in the NCR. For IBR patients, multiple 
hospital organizational factors were identified that could possibly also affect the use of DBR after 
mastectomy for stage I-III breast cancer in the Netherlands, including hospital type and volume, 
employment of a plastic surgeon, referral to a plastic surgeon, and the structural attendance of a 
plastic surgeon at the MDT20.
The present study provides an overview of the use of DBR within the Dutch population of breast 
cancer patients treated with mastectomy within the last five years. Studies with long-term events 
since cancer treatment as primary outcome, such as recurrent disease, face the fact that clinical 
practice usually has changed over time since diagnosis because of improvements in cancer treat-
ments. Similarly, this should be kept in mind when interpreting conclusions about DBR. Currently, 
BCT is considered at least equally safe as mastectomy1. Furthermore, IBR-rates in mastectomy 
patients have increased over the past years (from 14.8% in 2011 to 26.7% in 2015)21. Regarding 
which type of breast reconstruction is used, recent concerns about the association between the 
use of breast implants and anaplastic large cell lymphoma (ALCL)40 could potentially further shift 
the preference to autologous reconstructions. 
Our study is a starting point for future practice evaluation. In order to answer aforementioned 
questions, data on DBR should be registered on regular basis similar to IBR, taking into account 
the fact that DBR can be performed until years after the mastectomy. Future research is needed to 
identify the trend of DBR within the Netherlands over de last years, the variation between hospitals 
in performing DBR after mastectomy, and the effects of patients’ and surgeons’ preferences. 
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In all parts of this thesis new diagnostic techniques, outcome measures and patients’ preferences 
were evaluated with the overarching goal to evaluate, measure and improve the breast cancer 
care currently delivered. By evaluating outcomes that matter most to patients, this thesis strives 
towards a value-based and patient-centred breast cancer care. 
NEW BREAST IMAGING IN TUMOUR RESPONSE EVALUATION 
To improve diagnostic techniques and minimize the burden to breast cancer patients in the pre-
operative setting, during neoadjuvant chemotherapy (NAC), we aimed to extend the applicability 
of (three-dimensional) breast ultrasonography. The Automated Breast Volume Scanner (ABVS – 
ACUSON S2000TM, Siemens Medical Solutions) is an observer-independent automated breast 
ultrasound technique that automatically scans the breast using a linear transducer. In Chapter 
2, we performed the first study that evaluated the accuracy of the ABVS compared to breast 
MRI in measuring tumour response during and after completion of NAC in invasive breast cancer 
patients. A good correlation was found in the longest diameter for both the mid-NAC and post-
NAC evaluation. In contrast to other studies1 2, were three-dimensional volume measurements 
obtained and compared to longest diameter measurements. For volume measurements, a fair 
correlation was found in the mid-NAC evaluation and an excellent correlation in the post-NAC 
evaluation. Agreement with the RECIST response criteria was high with an absolute concordance 
in respectively 73% and 62.5% for mid-NAC and post-NAC response evaluation. Strengths of the 
study are the evaluation by two observers, showing an excellent intra-observer and inter-observer 
agreement for (3-D) ABVS measurements, and the evaluation of the acceptability for ABVS and 
breast MRI. Patients ranked the ABVS as much more acceptable as compared to breast MRI and 
appreciated the fact they could directly view the ultrasonography images during the examination. 
The study was however limited by its sample size and the availability of mainly tumour response 
evaluation measurements performed mid-NAC and not post-NAC (due to a considerable amount 
of (near) complete responses mid-NAC and no indication for post-NAC MRI). Consequently, the 
ability to compare the radiological response post-NAC with the pathological tumour response was 
limited. As the ABVS has proven to be advantageous over breast MRI with regard to cost, time, 
ease of interpretation by multiple clinicians, accessibility, avoidance of contrast agents, and with a 
diminished burden for patients and a high patient satisfaction rate, further evaluation is warranted. 
A second, larger, trial (RESPONDER II, NL6615) is, therefore, ongoing that compares the ABVS and 
MRI tumour response both during NAC and also post-NAC. The results of this larger sample size 
will be again compared with the pathological tumour response. 
Future perspectives
As the effectiveness of systemic therapies improves, the rate of pathological complete response 
(pCR) in the neoadjuvant setting will increase. Assessment of pCR is thereby of valuable infor-
mation, since the eradication of disease, from both breast and lymph nodes, is associated with 
improved survival when compared to the presence of residual disease3. Patients with chemother-
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apy-sensitive tumours have an excellent outcome, such that additional systemic therapy may not 
be necessary4. This highlights one of the advantages of NAC, as it provides outcome information 
to physicians and patients in an early phase of treatment which may result in an opportunity to 
tailor treatment recommendations based on tumour response. Studies are now evaluating the role 
of additional systemic and/or locoregional therapy in both chemotherapy-sensitive and chemo-
therapy-resistant tumours5 6. For these trials, as well as in clinical practice, an accurate prediction 
of pCR becomes more important. Moreover, demanding a better radiological prediction of pCR 
than is currently achieved may prevent patients from unnecessary biopsies post-NAC7 8. Future 
research, including RESPONDER II, must indicate the role of the ABVS in this field. 
The ABVS can also be used for purposes other than tumour response evaluation. The fundamental 
balance between a cleaner resection and a better aesthetic outcome is a key issue in breast-
conserving surgery (BCS) and still very difficult to evaluate due to the lack of a reliable evaluation 
method. A previous study by Lagendijk et al., performed within our institute, has shown that 3-D 
ultrasonography measurements can be used as a preoperative tool to predict aesthetic outcome9. 
Using the ABVS it is shown that both breast volume and tumour volume have a significant and 
high association with the gold standard; i.e. water displacement method for the preoperative as-
sessment of breast volume and the histopathological measurements of tumour volume9. Breast 
volume and tumour volume could be important for the aesthetic outcome prediction of breast-
conserving therapy (BCT). Vos et al.10 have shown that the tumour volume in relation to breast 
volume is a precise and independent predictor for the aesthetic result, and developed a decision 
model to compare the quality of life after BCT and mastectomy11. This model includes breast 
volume, tumour volume and the quadrant of the breast in which the tumour is located to predict 
the aesthetic outcome. Following these promising results, the ABVS was implemented in an ongo-
ing randomized controlled trial: TURACOS trial12. In this trial, the ABVS is used to measure both 
breast volume and tumour volume in early-stage breast cancer patients opting for BCT. By using 
the decision model as developed by Vos et al., the objective of this trial is to provide evidence that 
a good aesthetic outcome following BCT can be predicted12. The trial enables us to evaluate the 
agreement between the aesthetic outcome as measured using patient-reported outcome mea-
sures (PROMs), and the objective aesthetic outcome as evaluated by an independent panel, as 
well as by digitalized measurement using BCCT.core software13. Combining both aforementioned 
study-subjects into one, this prediction model might be even helpful in predicting the odds that 
BCT is feasible after the completion of NAC. 
PATIENT-REPORTED OUTCOME MEASURES
Considering comparable disease-specific outcomes and survival rates for both BCT and mas-
tectomy, whether or not followed by breast reconstruction, evaluation of experiences and quality 
of life of women who have had breast surgery is needed to inform the decision-making process 
and to optimize the long-term health of those who are facing a new breast cancer diagnosis. The 
assessment of patients’ quality of life and experiences using validated, clinically relevant, PROMs 
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is thereby critical. The studies presented in Chapter 3 and Chapter 4 were performed to gain 
insights into patient-reported outcomes (PROs) following breast cancer surgery amongst Dutch 
breast cancer patients and moreover, to provide reference scores for the comparison between 
surgical populations. PROMs, as proposed in the ICHOM outcome set for breast cancer14, were 
collected in collaboration with the regional and national patients’ advocate society (Chapter 3), 
and amongst breast cancer patients from the Erasmus MC Cancer Institute surgically treated 
between 2005 and 2016 (Chapter 4). The different results for PROMs following different types of 
breast surgery are in line with other studies, showing lower PROM scores in mastectomy patients 
and those who have had an implant-based breast reconstruction compared to patients undergo-
ing BCT or autologous breast reconstruction15-17. Comparing PROs between BCT and autologous 
reconstruction, PROs are either comparable between both procedures or in favour of autologous 
reconstructions. Reference scores, as obtained in Chapter 3 and Chapter 4, are pivotal when 
PROs are being used at the outpatient clinic to tailor and improve the care delivered. The data 
can be used to help guide personal choice with a candid discussion of all treatment options. Both 
studies were, thereby, the first studies to evaluate the complete set of PROMs as proposed in the 
ICHOM outcome set per type of breast surgery. However, these studies were both retrospective in 
nature and represented only a snapshot in time. A prospective evaluation of PROs along several 
designated time points would provide a more accurate comparison of the surgical procedures. En-
abling comparison with baseline PROs will reflect the influence of different treatments better than 
a single score obtained. Measuring PROs during treatment has thereby the potential to monitor 
and detect changes in physical or psychological problems at the outpatient clinic. For example, 
an important finding when evaluating PROs in our patient population were the low response rates 
on the questions regarding sexual wellbeing, along with the low scores on the sexual wellbeing 
domain. Since the data on sexual functioning are hampered by the lower response rate and the 
lack of longitudinal data, the clinical applicability of these scores is limited. However, previous 
studies on sexual health in breast cancer patients have shown that 50-90% of women experience 
sexual dysfunction18 19 and that breast cancer surgery has a negative impact20. Longitudinally 
PROM collection, with questions regarding sexual functioning, could open up the conversation 
and future consultation on sexuality in breast cancer patients at the outpatient clinic. Obtaining, 
and narrow, PROM reference scores for the different treatment strategies are then indispensable. 
It would also be interesting to evaluate the role of the patient’s partner within this topic, as well as 
the will or the ease of discussing sexuality in the consultation room by the care provider, as both 
may influence the outcomes on sexual wellbeing. 
As the majority of the patients in Chapter 3 agreed that PROs could add in improving the current 
breast cancer care delivered, these findings highlight the value of the initiatives undertaken, seek-
ing to enhance the quality of surgical care by taking a more patient-centric approach. Herewith, 
an important step towards extensive use of PROMs in clinical practice and the implementation 
of value-based healthcare (VBHC) within Erasmus MC’s breast cancer care was made. Driven by 
the raised desire for longitudinal PRO collection and evaluation, our value-based breast cancer 
care strategy was then implemented. This strategy, as described in Chapter 5, is based on the 
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principle to create value for our breast cancer patients by the measurement of (patient-reported) 
health outcomes. Herewith the focus lies on outcome-measures not on volume-measures that 
only facilitate processes but do not reflect outcome. A breast cancer outcomes set that is in line 
with the ICHOM standard set was integrated into our clinical practice by using an adapted data 
collection tool that is linked to our electronic health record (EHR). Patients within our institute 
now receive PROMs at baseline and at predetermined time points throughout their care cycle to 
discuss these outcomes with their healthcare providers and tailor their supportive therapies where 
necessary. The PROMs used in this set are all validated questionnaires, specific to the questions 
at hand. Positive feedback about the initiative was obtained from both patients and healthcare 
providers. PROs add in information provision, giving a more complete view about the patient, 
the provided care, and the impact of the treatment given on patients’ health-related quality of 
life (HRQoL) outcomes. The ability to prioritize topics for discussion at the outpatient visits and 
to monitor and manage symptoms consequently improved patient-provider communication and 
enhanced shared-decision-making. 
Several tools for PRO collection are available nowadays and used in clinical breast cancer care, of 
which we have provided an overview in Chapter 6. PROM administration methods and their facili-
tators and barriers were studied, as well as the impact of PRO collection on patients, providers, and 
care processes. In line with our own experiences with PRO collection (Chapter 5), we have found 
that PROM interventions were generally developed to improve symptom management, to identify 
psychosocial problems, to facilitate patient-centred care and treatment-specific monitoring during 
treatment phases, and to improve patient-provider communication. The advantages of the use 
of electronic PRO collection systems were found, which strengthen the way our VBHC-strategy 
was implemented and integrated into the patient’s EHR. Collecting PROs electronically provides 
a certain flexibility in assessment location (clinic versus home), frequency and duration of PRO 
follow-up21. Consequently, the usability increases, along with a lower response burden, higher 
completion-rates, and thus fewer missing data (when compared to paper-based PROMs). All the 
aforementioned findings in turn can lead to better PROM scores and higher patient satisfaction22-24. 
In Chapter 6 it was also found that most PROM collection tools either focused on monitoring a 
specific treatment phase or on the entire breast cancer trajectory. In our opinion should routine 
PROM assessment integrate both and, moreover, be combined with the appropriate PROM to en-
sure optimal patient engagement and management of care. Within our outcome set, we included 
an additional time point for breast cancer patients treated with neoadjuvant systemic therapy to 
measure the degree of chemotherapy-induced peripheral neuropathy. Besides, as we collect a 
surgery-specific PROM as the BREAST-Q, the PRO collection is based on the individual patient’s 
treatment pathway (i.e. type of surgery performed). 
Following the successful implementation of a standardized outcome set that encompassed both 
provider- and patient-reported outcomes (Chapter 5), we strive towards expanding our initiative 
amongst the women at risk for breast cancer. In Chapter 8 we compared PROs of BRCA1/2 muta-
tion carries after either bilateral prophylactic mastectomy followed by immediate breast reconstruc-
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tion (BPM-IBR) or during breast surveillance to optimize shared-decision-making in their breast 
cancer risk management. The Hospital Anxiety and Depression Scale (HADS) and the BREAST-Q 
were administered amongst unaffected BRCA1/2 mutation carriers. With all HADS scores below 
the upper limit of normal, no signs of anxiety or depression were seen in both the surveillance and 
the BPM-IBR group. For the BREAST-Q questionnaire, slightly better mean scores were seen for 
the surveillance group as compared to BPM-IBR, except for the psychological wellbeing module. 
Moreover, the difference in physical wellbeing with chest module was significantly worse for BPM-
IBR. As baseline scores were not available due to the cross-sectional retrospective design of this 
study, initial anxiety levels for developing breast cancer were not available. Being diagnosed with a 
BRCA1/2 mutation is however associated with physical and psychological trauma, and (amongst 
others) patient’s (psychosocial) characteristics, coping, and type of risk management strategy 
chosen are of influence on PROs. Changes in PROM scores over time are thus expected. This, 
again, emphasizes the necessity of longitudinal PRO collection starting at baseline. Moreover, 
given the results of a previous study within our institute25, future possibilities should be explored 
to obtain reference values which could add value in shared decision-making concerning breast 
cancer risk management in this population. Within this study, it was shown that for BRCA1 BPM 
was associated with lower mortality-rates than surveillance and that for BRCA2 surveillance was 
as effective as BPM regarding breast cancer-specific survival25. This underscores the importance 
of adequate counselling BRCA1/2 mutation carriers regarding their choice between breast surveil-
lance and BPM. Knowledge of PROM outcomes concerning the quality of life after this choice is 
thereby of great value.
Pressures as aging populations, increasing numbers of people with (multiple) chronic conditions, 
and high survival rates following breast cancer surgery, along with the greater focus on patient-
centred care, have raised the demand for VBHC26. However, defining VBHC is still a challenge. The 
concept of VBHC-delivery, as envisioned by Porter, is a structure for rebuilding global healthcare 
systems with the overarching goal of value for patients27. To establish this indisputable goal of 
improving value for patients, outcomes of importance to patients and their costs should be mea-
sured and these results should be compared to others inside and outside the organisation. This 
creates the possibility to compare the care delivered within a single healthcare institute as well 
as between different institutes, on both national and international levels. A challenge in this is 
standardizing PROMs that are meaningful to patients across different cultural and geographical 
settings. If routine PROM collection is to be implemented in clinical practice, it is recommended 
to implement a standardized outcome set, such as the ICHOM standard sets28, because it is one 
of the requirements for benchmarking treatments and healthcare providers. Regional, national, or 
even international efforts to adopt an identical outcome set creates the possibility for benchmark-
ing and comparative research on a much broader scale. 
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Future perspectives
Quality of life is an important endpoint of breast cancer treatment, and the effects of various 
interventions on a woman’s quality of life are of major interest. As our surgical techniques are 
becoming more sophisticated, we need to be able to look at them with a much more sophisticated 
lens in terms of research. PROMs could be used as a tool to facilitate comparisons of different 
surgical techniques from a patient perspective. PROMs make it then able to learn from patients, 
from their point of view, whether or not one approach is better than the other for that individ-
ual patient in terms of HRQoL endpoints. We, therefore, desire reliable prognostic information 
tailored to the individual patient; i.e. practical data that can help surgeons and patients tease 
out the optimal surgical approach and help to set reasonable expectations in anticipation of the 
specific surgical procedure selected. Predictive modelling has the purpose of informing patients 
and guiding clinicians in decision-making on treatment decisions. Given the growing trend in the 
application of machine learning methodologies, we investigated the possibility of developing an 
algorithm to predict patient-reported HRQoL endpoints in breast cancer patients treated with 
surgery (Chapter 7). To this extent, we used the dataset as described in Chapter 4. Unfortunately, 
in this dataset, we were not successful because of the lack of baseline scores and the, for machine 
learning, a relatively small sample size. To realize an effective clinical prediction model, information 
regarding patients’ starting position is crucial. The lack of preoperative psychological profiles or 
PROM scores is, however, a weakness in various other studies or healthcare institutes. This em-
phasizes, even more, the urgent need of collecting PROMs at baseline. A prospective comparison 
of preoperative and postoperative PROs might be able to give more definite answers. The next 
step toward further validation of this approach to the prediction of HRQoL endpoints would be to 
work with a more complete dataset, including baseline PROs and lifestyle measures. Since PRO 
collection is considered standard of care at our institute (Chapter 5), a prospective dataset is 
nowadays gathered, which will grow progressively over time. This prospective dataset, including 
baseline PROs and longitudinal PROs for a period of at least 5 years, should be used to further test 
the possibilities of developing a predictive tool. 
Furthermore, due to the introduction of oncoplastic surgery techniques into the breast-conserving 
surgery area, a significant number of new surgeries have been generalized. There is an almost 
absolute lack of knowledge of the aesthetic outcome of these surgeries as well as its impact on a 
woman’s HRQoL. The correlation of the aesthetic outcome with patients’ HRQoL is not standard-
ized and very difficult to evaluate anyway. Although several challenges impede bringing aesthetic 
evaluation into daily clinical practice now, it is expected to be a critical component in future breast 
cancer management workflows43. As artificial intelligence breakthroughs are achieved in current re-
search, the next logical step is to improve the overall aesthetic evaluation also resorting to machine 
learning. The introduction of objective methods to measure the aesthetic outcome like BCCT.core13, 
brings possibilities to adapt machine learning methodologies to integrated disparate measures 
into a global assessment of the aesthetic result. Using machine learning it is possible to extract 
predesigned features from the patients photograph29. For example, the most relevant anatomical 
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landmarks as the incisura jugularis, nipples, and breast contours, with particular emphasis in the 
endpoints. The algorithm can learn to compute features directly form the photograph, including the 
best set of attributes (distances, textural differences, etc.), and to use those features in the analysis 
of the aesthetic outcome. The first incursion in explaining the automatic aesthetic assessment has 
already been made29 30, promising accountability for the future. However, there is still a lack of big 
data and extensive international studies. An sizeable repository of photographs of locoregional 
treated breast cancer patients will enable the development, testing and validation of machine learn-
ing based methodologies to improve aesthetic evaluation and overall quality of life follow-up. These 
methodologies enables us to build on top of the present efforts for locoregional surgeries, adapting 
the models for the aesthetic evaluation of the vast offer of breast cancer treatments. Finally, the 
current journey towards more objective methods excluded patients self-assessment from the 
evaluation process. It seems fundamental to unite these two perspectives of HRQoL, researching 
methods for the evaluation of the aesthetic outcomes of breast cancer treatments integrating ob-
jective methods and significant factors derived from patients’ input. The aforementioned, currently 
ongoing, TURACOS trial is an example of such a trial. This prediction model may add information 
in the conflict between obtaining tumour free resection margins for oncologic control and conserv-
ing breast symmetry and aesthetics. But moreover will the PROs obtained inform us whether or 
not women choose BCT over other surgical techniques in terms of the patient’s self-esteem and 
HRQoL. Ultimately are patients’ preferences, if obtained in multiple cohorts, expected to enable an 
improved objective shared-decision-making in future breast cancer patients
FOLLOW-UP CARE AND DELAYED BREAST RECONSTRUCTIONS
Most patients should be allowed to make their decisions based on their psychological state, values, 
and preferences, with the proviso that it is oncologically safe. For patients, it is vital to be fully 
informed about the pros and cons of the different approaches and have realistic expectations about 
what a specific treatment can achieve. Only when a patient has enough information to make an 
informed choice, a decision can be made31. The quality of the shared-decision-making process, 
therefore, might affect the eventual effect on the value of the care delivered, in terms of outcomes, 
costs and organizational efforts32. Currently, the arrangements for follow-up care meet the needs 
of breast cancer patients suboptimally33-35. This is also reflected in the literature study described in 
Chapter 9. By exploring the evidence on preferences for and patient involvement in decisions about 
breast cancer follow-up care, the potential for personalising follow-up care among breast cancer pa-
tients was evaluated. The decisions described concerned subjects as surveillance for recurrence or 
the development of secondary breast cancer, recurrence-risk reduction by anti-hormonal treatment, 
consultations relating to physical and psychological (late) effects and improving the HRQoL after 
breast cancer. It was found that patients are currently not involved in all decisions about the content 
of the form of follow-up that affect them during follow-up, nor it was optimally acknowledged they 
had preferences towards these decisions. Decisions about follow-up consultations, anti-hormonal 
treatment, and menopausal symptoms were considered not to be sensitive to patient preferences. 
Decisions about breast reconstructions in turn were regarded to be very sensitive to patient pref-
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erences. Moreover, were patients usually involved in breast reconstruction decision-making. These 
findings resulted in the recommendation to further personalise breast cancer follow-up care, as it is 
expected to lead to care that is of greater relevance and value to individual patients. 
Breast cancer patients who undergo a mastectomy as part of their treatment can face a potentially 
life-changing decision, namely whether or not to have their breast reconstructed, and if so, what 
kind of reconstruction. For patients receiving radiotherapy to reduce the risk of local recurrence, 
this decision becomes even more challenging. As identified in Chapter 9 were decisions regard-
ing breast reconstructive surgery considered sensitive to patient preferences, and were patients 
usually involved in breast reconstruction decision-making. Considering the enormous value that 
a breast reconstruction can bring, including the rebuilding of the breast and restoring a woman’s 
body image and her HRQoL, decisions regarding breast reconstruction are vitally important within 
breast cancer care. To make a deliberate decision it is crucial to be fully informed about the dif-
ferent methods available. As information regarding immediate breast reconstructions (IBR, i.e. re-
construction applied during the mastectomy) is widely available in the Netherlands36-38, partly due 
to systematic recording of all surgically treated breast cancer patients by the Netherlands Cancer 
Registry (NCR), the focus within the last part of this thesis lays on delayed breast reconstructions 
(DBR, i.e. reconstruction applied at a given point in time after the mastectomy). Besides, decisions 
regarding DBR are more often made after a mastectomy is performed and can remain relevant until 
years after the initial surgical procedure. In Chapter 10 it was found that DBR was performed in 
about 10% of the patients curatively treated with mastectomy for stage I-III breast cancer. Within 
this cohort, DBR patients were significantly younger, were most often diagnosed with stadium II 
breast cancer, with nodal involvement, were treated with chemotherapy and/or radiotherapy, and 
were more often treated at a teaching hospital. The mean time between mastectomy and DBR 
was 2.4 years (range 1 – 6 years). Age and chemotherapy were identified as predictive factors, as 
they increased the probability of receiving DBR. Implant-based reconstructions were performed 
most often, followed by autologous reconstructions, despite treatment with postmastectomy 
radiotherapy. As for the effect of radiotherapy on the type of DBR: in our radiated sub-population, 
the largest group had autologous reconstructions. When radiotherapy or adjuvant chemotherapy 
was performed the time between mastectomy and DBR was extended. The information provided 
can be helpful in future shared decision-making about breast reconstructive options. Further 
research is needed to identify the trend of DBR within the Netherlands over de last couple of 
years, the variation in hospitals in performing DBR after mastectomy, and patients’ and surgeon’s 
preferences. Patients who are facing the decision about breast reconstructive surgery may benefit 
greatly from the perspective of patients who have had the procedures. 
Future perspectives
Multiple (patient-reported) treatment-related health problems are identified up to five years after the 
breast cancer diagnosis, variating per treatment modality (i.e. (neoadjuvant) systemic therapy, type 
of (reconstructive) breast surgery, and radiotherapy)39-41. It is difficult to predict which patients will 
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encounter medical, physical, and psychological late effects of breast cancer and its treatment43. 
One gap in knowledge we are now striving to fill, is the one regards (late) effects of radiotherapy, 
because whether or not to receive radiotherapy has a major influence on treatment outcomes. 
Although in general BCT is associated with good aesthetic outcomes, up to 30% of patients are 
affected by a severe form of radiation induced fibrosis (RIF) of the radiated breast44-46. Moreover, 
symptoms after RIF as skin induration and thickening, loss of elasticity, lymphoedema, limited 
joint mobility, pain and an impaired aesthetic outcome, have a negative impact on a woman’s 
HRQoL and a marked effect on the subsequent psychological outcome47. Preoperative insight 
into which women will and which women will not be affected by radiation toxicity gives a woman 
with a high risk of RIF the possibility to deviate from breast-conserving therapy and opt for a mas-
tectomy (whether or not followed by (immediate) breast reconstruction) that does not necessarily 
requires radiotherapy. However, there is a large patient-to-patient variability and the severity of RIF 
is known to be affected by differences in treatment characteristics as maximum radiation dose, 
boost treatment, and intrinsic radiosensitivity48 49. The latter is characterized by patient related 
factors such as age, breast volume, smoking and/or profound biological differences46 50 51. How-
ever, the determination of an individual’s normal tissue radiosensitivity is seldom possible before 
treatment. Current practice standard therefore commonly prescribe radiation dose according to 
clinical scenarios, without regard to the genotype or phenotype of the individual being irradiated. 
An important biological difference, which can explain the differences in individual radiosensitivity, 
is the presence of senescence in cells (i.e. permanent arrest state of cell division), which can be 
induced by ionizing radiotherapy in fibroblasts and other cellular types52. It is suggested that by 
analysing characteristic features of senescence, the individual radiosensitivity, and thus the risk of 
RIF, can be predicted52 53. Since RIF is expected to negatively affect the aesthetic outcome and a 
woman’s HRQoL, the multivariable adjusted association between senescence and RIF after BCT 
should be further explored. In addition, it is relevant to measure the impact of RIF from patients’ 
point of view. PROMs specific for RIF in breast cancer patients will illustrate the clinical relevance 
of developing a prediction tool for RIF, but has not been properly evaluated yet. Future trial should 
therefore not focus on predicting individual radiosensitivity only54, but should include PROMs as 
well. If developing RIF indeed decreases the patient-reported HRQoL substantially, it would be 
clinically relevant to use cell senescence measurements in the shared decision-making process of 
the choice of breast cancer treatment.
It is plausible that follow-up could be more personalized by predicting which health symptoms 
may occur in patients. Follow-up care could also become more effective by targeting those health 
symptoms for which the biggest impact on the patient’s life is expected. Successful management 
of these symptoms would have a large effect on breast cancer survivorship. Again, PROMs could 
be used for symptom monitoring and management, and to identify other health-related actualities. 
Prospective PRO collection, starting at baseline and continued during treatment until after treat-
ment completion, is therefore recommended. 
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Based on the VBHC-initiative, there is an international trend towards increased shared-decision-
making in diagnosis and treatment. PROM scores and patients’ preferences, as obtained within 
this thesis, helps us to manage and improve health-related outcomes. In addition, PROs can 
contribute to the evaluation of the clinical relevance of outcome prediction. Further personalisa-
tion of (follow-up) care may lead to care that is of great value for the individual patient, with the 
possible consequence of reducing overtreatment and / or undertreatment. However, it needs to be 
emphasized that treatment and follow-up choices must be made within proven clinical guidelines.
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In alle delen van dit proefschrift worden nieuwe diagnostische technieken, uitkomstmaten en voor-
keuren van patiënten geëvalueerd, met het overkoepelende doel om de huidige borstkankerzorg 
te meten, te sturen en te verbeteren. Door zorg uitkomsten te evalueren die het meest belangrijk 
worden geacht voor borstkankerpatiënten, wordt in dit proefschrift gestreefd naar een waardege-
dreven borstkankerzorg waarbij de patiënt centraal staat.
NIEUWE BEELDVORMENDE TECHNIEK IN DE TUMORRESPONS EVALUATIE
Met het doel de belasting voor borstkankerpatiënten in de preoperatieve behandelfase te mi-
nimaliseren, wordt in het eerste deel van dit proefschrift gekeken naar de mogelijkheden om 
diagnostische technieken te verbeteren. 
In hoofdstuk 2 wordt de eerste studie beschreven die de nauwkeurigheid van de Automated 
Breast Volume Scanner (ABVS) evalueert in het meten van de tumorrespons tijdens en na 
voltooiing van neoadjuvante chemotherapie (NAC) bij patiënten met invasieve borstkanker. De 
resultaten van de ABVS werden vergeleken met die van de borst-MRI (gouden standaard). Er 
werd een goede correlatie gevonden in de langste diameter respons voor zowel de tussentijdse 
evaluatie (mid-NAC) als de evaluatie na het voltooien van NAC (post-NAC). Een sterk punt van 
dit onderzoek is dat, in tegenstelling tot andere studies1 2, ook driedimensionale volumemetingen 
uitgevoerd werden naast de diametermetingen. Voor volumemetingen werd een redelijke correlatie 
gevonden tussen de ABVS en de MRI in de mid-NAC evaluatie, en een uitstekende correlatie 
in de post-NAC evaluatie. De overeenstemming met de RECIST-responscriteria was eveneens 
hoog, met een absolute overeenstemming van, respectievelijk, 73% en 62,5% voor de mid-NAC 
evaluatie en post-NAC-respons. Andere sterke punten zijn de evaluatie door twee onafhankelijke 
onderzoekers werd verricht, met een uitstekende overeenkomst tussen beide onderzoekers, en 
de evaluatie van de patiënttevredenheid ten aanzien van de MRI en ABVS. In tegenstellig tot de 
MRI werd de ABVS als zeer acceptabel beoordeeld. Patiënten waardeerden daarnaast het feit 
dat de echografiebeelden direct konden worden bekeken tijdens het onderzoek. De studie was 
echter beperkt door de steekproefomvang en de beschikbaarheid van voornamelijk tumorres-
ponsevaluatiemetingen mid-NAC en niet post-NAC. Dit laatste was een gevolg van de complete 
radiologische tumorrespons die bij het merendeel van de patiënten gezien werd bij de mid-NAC 
evaluatie, waardoor er geen indicatie bestond voor het herhalen van de MRI post-NAC. Derhalve 
werd de ABVS post-NAC ook achterwegen gelaten en was het vermogen om de radiologische 
respons post-NAC te vergelijken met de histopathologische tumorrespons beperkt. Aangezien de 
ABVS voordelig is gebleken ten opzichte van borst-MRI met betrekking tot kosten, tijd, interpreta-
tiegemak door meerdere clinici, toegankelijkheid, het vermijden van contrastmiddelen met tevens 
een hoge patiënttevredenheid, is verdere evaluatie gerechtvaardigd. Daarom is er een tweede, 
grotere studie (RESPONDER II, NL6615) opgezet die de ABVS- en MRI-tumorrespons vergelijkt, 
zowel mid-NAC als ook post-NAC. In deze studie worden eveneens de resultaten vergeleken met 
de histopathologische tumorrespons.
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PATIËNT- GERAPPORTEERDE UITKOMSTMATEN
Gezien heden ten dage vergelijkbare ziekte specifieke-uitkomsten en overlevingspercentages voor 
zowel mammasparende therapie (MST) als voor mastectomie worden bereikt, kan evaluatie van 
de kwaliteit van leven en patiënttevredenheid van reeds behandelde patiënten bijdragen aan het 
besluitvormingsproces en lange termijn uitkomsten van diegene die in de toekomst geconfron-
teerd zullen worden met de diagnose borstkanker. De beoordeling van de kwaliteit van leven en 
ervaringen van patiënten met behulp van gevalideerde, klinisch relevante vragenlijsten, is daarbij 
van cruciaal belang. 
De studies gepresenteerd in hoofdstuk 3 en hoofdstuk 4 zijn uitgevoerd om inzicht te krijgen in 
door patiënten gerapporteerde uitkomsten (PROs) na borstkankeroperaties bij Nederlandse borst-
kankerpatiënten. Met behulp van deze uitkomsten streven we er eveneens naar referentiescores 
te verkrijgen om met behulp van PROs de vergelijking tussen verschillende chirurgische populaties 
te kunnen maken (i.e. MST, mastectomie en borstreconstructie, autoloog of met behulp van im-
plantaten). Patiënt-gerapporteerde uitkomstmaten (PROMs), overeenkomend met de ICHOM-uit-
komstenset voor borstkanker3, werden verzameld in samenwerking met de regionale en nationale 
patiëntenverenigingen (hoofdstuk 3) en onder alle borstkankerpatiënten van het Erasmus MC 
Kanker Instituut welke chirurgisch werden behandeld tussen 2005 en 2016 (hoofdstuk 4). De 
verkregen PROs, per type borstchirurgie, komen overeen met resultaten van andere studies en to-
nen lagere PROM-scores bij borstkankerpatiënten die een mastectomie of een borstreconstructie 
met implantaten ondergingen. Dit is in tegenstelling tot MST of een autologe borstreconstructie, 
waar juist hogere scores worden gerapporteerd4-6. Wanneer we PROs vergelijken tussen MST en 
autologe reconstructies, zijn PROs of vergelijkbaar tussen beide procedures of in het voordeel van 
autologe reconstructies. Referentiescores, zoals verkregen in hoofdstuk 3 en hoofdstuk 4, zijn 
cruciaal wanneer PROs worden ingezet tijdens poliklinische controles om de geleverde zorg te 
meten, te sturen en te verbeteren. De gegevens kunnen worden gebruikt om de persoonlijke keuze 
te begeleiden bij het bespreken van alle behandelingsopties. 
Beide studies waren daarbij de eerste studies die de complete set van PROMs evalueren zoals 
voorgesteld in de ICHOM-uitkomstenset per type borstchirurgie. Deze studies waren echter beide 
retrospectief van aard en vormden slechts een momentopname. Een prospectieve evaluatie 
van PROs op verschillende tijdstippen gedurende de behandeling en follow-up zou een meer 
nauwkeurige vergelijking van de chirurgische procedures bieden. Een vergelijking met baseline 
PROs zal daarbij nog beter de invloed van verschillende behandelingen weergeven dan een enkele 
score. Het meten van PROs tijdens de behandeling kan veranderingen in fysieke of psychische 
problemen detecteren, welke vervolgens poliklinisch kunnen worden opgepakt en vervolgd. Een 
belangrijke bevinding bij het evalueren van PROs in onze patiëntenpopulatie waren de lage res-
ponspercentages op de vragen over seksueel welzijn, samen met de lage PROM-scores op het 
domein van seksueel welzijn. Omdat de gegevens over seksueel functioneren worden gekleurd 
door de lagere respons en het ontbreken van longitudinale gegevens, is de klinische toepasbaar-
heid van deze scores beperkend. Eerdere onderzoeken naar seksuele gezondheid bij borstkanker-
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patiënten hebben echter aangetoond dat 50-90% van de vrouwen seksuele disfunctie ervaart7 8 
en dat borstkankeroperaties een negatief effect hebben9. Longitudinale PROM-verzameling, met 
vragen over seksueel functioneren, zal het gesprek over seksualiteit bij borstkankerpatiënten in 
de polikliniek kunnen openen. Het verkrijgen van PROM-referentiescores voor de verschillende 
behandelstrategieën is dan onontbeerlijk. Daarnaast zou het ook interessant zijn om de rol van 
de partner van de patiënt binnen dit onderwerp te evalueren, evenals de wil of het gemak van het 
bespreken van seksualiteit in de spreekkamer door de zorgverlener, omdat beide de uitkomsten 
van seksueel welzijn mogelijk beïnvloeden. 
De meerderheid van de patiënten in hoofdstuk 3 vond dat PROs zouden kunnen bijdragen aan de 
verbetering van de huidige geleverde borstkankerzorg. Dit benadrukt de waarde van de genomen 
initiatieven, die erop gericht zijn de kwaliteit van de chirurgische zorg te verbeteren door een meer 
patiëntgerichte benadering te volgen. Hiermee is een belangrijke stap gezet in de richting van het 
gebruik van PROMs in de kliniek en de implementatie van waardegedreven zorg (value-based 
healthcare, VBHC) binnen de borstkankerzorg van het Erasmus MC. Gedreven door de wens 
voor longitudinale PRO-verzameling en PRO-evaluatie, werd een strategie voor waardegedreven 
borstkankerzorg geïmplementeerd. Deze strategie, zoals beschreven in hoofdstuk 5, is gebaseerd 
op het principe om waarde te creëren voor onze borstkankerpatiënten door het meten van (door de 
patiënt gerapporteerde) gezondheidsresultaten. Hierbij ligt de focus op uitkomstmaten, en niet op 
volumemetingen die alleen processen weergeven maar geen uitkomst weerspiegelen. Een set van 
uitkomstmaten voor borstkanker, die in overeenstemming is met de ICHOM-uitkomstenset, werd 
in onze klinische praktijk geïntegreerd met behulp van een nieuw ontwikkelde tool voor gegevens-
verzameling die is gekoppeld aan het elektronische patiëntendossier (EPD). Borstkankerpatiënten 
binnen ons instituut ontvangen nu PROMs bij aanvang en op vooraf bepaalde tijdstippen gedu-
rende hun gehele behandeltraject en de bijbehorende follow-up. De PROM-resultaten worden 
poliklinisch met de behandeld arts besproken en zo kan, waar nodig, ondersteunende therapie 
worden aangeboden. De PROMs die in deze set worden gebruikt, zijn allen gevalideerde vragen-
lijsten, specifiek voor het betreffende zorgpad waar de patiënt zich in bevindt. Zowel patiënten 
als zorgverleners gaven positieve feedback ten aanzien van het initiatief. PROs geven meer infor-
matievoorziening, met een vollediger beeld van de patiënt, de geboden zorg en de impact van de 
behandeling op de gezondheid gerelateerde kwaliteit van leven van de patiënt. De mogelijkheid 
om prioriteit te geven aan onderwerpen voor discussie tijdens de poliklinische bezoeken en om de 
symptomen te monitoren en te beheren, verbeterde de communicatie tussen de patiënt en de arts 
en verbeterde tevens de gezamenlijke besluitvorming.
In hoofdstuk 6 wordt een overzicht gegeven van de verschillende tools voor PRO-verzameling 
die heden ten dagen beschikbaar zijn en gebruikt worden in de borstkankerzorg. PROM-ver-
zamelmethoden en hun facilitators en belemmeringen werden bestudeerd, evenals de impact 
van PRO-verzameling op patiënten, zorgverleners en zorgprocessen. In overeenstemming met 
onze eigen ervaringen met PRO-verzameling (hoofdstuk 5), hebben we geconstateerd dat 
PROM-interventies over het algemeen werden ontwikkeld om de symptoomdetectie te verbeteren, 
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psychosociale problemen te identificeren, patiëntgerichte zorg en behandeling specifieke moni-
toring tijdens bepaalde behandelingsfasen te vergemakkelijken, en om de communicatie tussen 
patiënt en zorgverlener te verbeteren. Gevonden werd dat, met name, het gebruik van elektro-
nische PRO-verzamelsystemen voordelen heeft. Dit spreekt voor de manier waarop onze eigen 
VBHC-strategie werd geïmplementeerd en geïntegreerd in het EPD van de borstkankerpatiënt. 
Het elektronisch verzamelen van PROs biedt namelijk een zekere flexibiliteit in de locatie waar de 
PROMs kunnen worden ingevuld (kliniek versus thuis), en in de frequentie en duur van PRO-follow-
up10. Dit leidt tot een betere bruikbaarheid, en samen met een lagere responslast tot een hoger vol-
tooiingspercentages en dus minder ontbrekende gegevens (in vergelijking met papieren PROMs). 
Alle bovengenoemde bevindingen kunnen op hun beurt weer leiden tot verbeterde PROM-scores 
en een hogere patiënttevredenheid11-13. Tevens werd in hoofdstuk 6 gevonden dat de meeste 
PROM-verzamelingstools zich ofwel op het monitoren van een specifieke behandelingsfase of-
wel op het gehele borstkankertraject concentreerden. Naar onze mening moeten routinematige 
PROM-collectie beide integreren en bovendien worden gecombineerd met de juiste PROM om 
een  optimale patiëntbetrokkenheid en zorgmanagement te waarborgen. In onze uitkomstenset 
namen we een extra collectiemoment op voor borstkankerpatiënten die werden behandeld met 
neoadjuvante systemische therapie om de mate van door chemotherapie geïnduceerde perifere 
neuropathie te meten. Bovendien, aangezien we chirurgie-specifieke PROMs afnemen (namelijk 
de BREAST-Q), is de PRO-collectie gebaseerd op het behandeltraject van de individuele patiënt 
(d.w.z. het type chirurgie dat wordt uitgevoerd).
Na de succesvolle implementatie van een gestandaardiseerde uitkomstenset die zowel harde 
uitkomstmaten als door de patiënt gerapporteerde uitkomsten omvat (hoofdstuk 5), streven we 
ernaar ons initiatief uit te breiden onder de vrouwen met een verhoogd risico op borstkanker. 
In hoofdstuk 8 hebben we PROs van BRCA1 en BRCA2 genmutatiedraagsters vergeleken die 
een bilaterale profylactische mastectomie gevolgd door een directe borstreconstructie (BPM-IBR) 
hadden ondergaan met genmutatiedraagsters die borstkankerscreening (surveillance) ondergaan, 
met het doel de gedeelde besluitvorming rondom borstkankerrisico-reducerende opties te opti-
maliseren. De Hospital Anxiety and Depression Scale (HADS) en de BREAST-Q werden afgenomen 
onder BRCA1 en BRCA2 genmutatiedragers. Met alle HADS-scores onder de 8, de bovengrens 
van normaal, werden geen tekenen van angst of depressie gezien in zowel de surveillance als de 
BPM-IBR-groep. Voor de BREAST-Q-vragenlijst werden iets betere gemiddelde scores gezien voor 
de surveillancegroep in vergelijking met BPM-IBR, behalve voor de module voor psychologisch 
welzijn. Bovendien was het verschil in de module voor fysiek welzijn (borsttevredenheid) aanzienlijk 
slechter voor BPM-IBR. Omdat baselinescores niet beschikbaar waren vanwege het retrospec-
tieve, cross-sectionele, studiedesign, waren aanvankelijke angstniveaus voor het ontwikkelen 
van borstkanker niet beschikbaar. Gediagnosticeerd worden met een BRCA1/2-mutatie wordt 
echter geassocieerd met fysiek en psychologisch trauma. De (psychosociale) kenmerken, coping 
en de gekozen borstkankerrisico-reducerende strategie hebben invloed op PROs. Veranderingen 
in PROM-scores in de loop van de tijd mogen dus worden verwacht. Dit benadrukt nogmaals 
de noodzaak van longitudinale PRO-verzameling vanaf het moment van diagnose. Bovendien 
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moeten, mede gebaseerd op de resultaten van een eerdere studie binnen ons instituut14, mogelijk-
heden worden onderzocht om referentiewaarden te verkrijgen die van toegevoegde waarde zijn in 
de gedeelde besluitvorming rondom borstkankerrisico-reducerende strategieën in deze populatie. 
Binnen deze studie14 werd aangetoond dat voor een BRCA1 genmutatie BPM geassocieerd was 
met lagere sterftecijfers dan surveillance, en dat voor BRCA2 surveillance even effectief was als 
BPM wat betreft borstkanker-specifieke overleving. Deze resultaten onderstrepen het belang van 
adequate begeleiding van BRCA1/2 genmutatiedragers met betrekking tot hun keuze tussen 
surveillance en BPM(-IBR). Kennis van PROs met betrekking tot de kwaliteit van leven na deze 
keuze is daarbij van grote waarde.
Predictiemodellen hebben tot doel patiënten te informeren en clinici te begeleiden bij de besluit-
vorming rondom behandelingen. Gezien de groeiende trend in de toepassing van machine learning 
voor predictie, hebben we in hoofdstuk 7 de mogelijkheid onderzocht om een  algoritme te ontwik-
kelen om patiënten gerapporteerde kwaliteit van leven-eindpunten te voorspellen bij chirurgisch 
behandelde borstkankerpatiënten. Hiertoe hebben we de dataset gebruikt zoals beschreven in 
hoofdstuk 4. Helaas waren we met deze dataset niet succesvol vanwege het ontbreken van 
baselinescores en de, voor machine learning, relatief kleine steekproefomvang. Om een  effectief 
klinisch predictiemodel te realiseren, is informatie over de startpositie van patiënten cruciaal. Het 
ontbreken van preoperatieve psychologische profielen en/of PROM-scores is echter eveneens een 
zwakte in verschillende andere studies of zorginstellingen. Dit benadrukt nog meer de dringende 
behoefte om PROs bij aanvang te verzamelen. Een prospectieve vergelijking van preoperatieve 
en postoperatieve PROs kan wellicht meer definitieve antwoorden geven. De volgende stap in 
de richting van verdere validatie van deze benadering voor de voorspelling van kwaliteit van 
leven-eindpunten zou zijn om te werken met een completere dataset, inclusief baseline PROs en 
levensstijlgegevens. Omdat PRO-verzameling wordt beschouwd als standaardzorg in ons instituut 
(hoofdstuk 5), wordt momenteel een prospectieve dataset verzameld, die in de loop van de tijd 
geleidelijk zal worden uitgebreid. Met behulp van deze dataset hopen we de ontwikkeling een 
dergelijk predictiemodel in de nabije toekomst te kunnen realiseren.
NAZORG EN UITGESTELDE BORSTRECONSTRUCTIES
Hoewel sommige patiënten geen keuze hebben wat betreft de behandelingsstrategie berustend 
op de tumorkenmerken en -stadium, dient er wel rekening worden gehouden met de autonomie en 
wensen en voorkeuren van de patiënt. Uiteraard zolang het oncologisch veilig is. Voor patiënten is 
het uiterst belangrijk om volledig op de hoogte te zijn van de voor- en nadelen van de verschillende 
behandelstrategieën en om realistische verwachtingen te hebben over wat een specifieke behan-
deling kan bereiken. Alleen wanneer een patiënt voldoende informatie heeft om een  geïnformeerde 
keuze te maken, kan een beslissing worden genomen15. De kwaliteit van het gedeelde besluitvor-
mingsproces kan daarom van invloed zijn op het uiteindelijke effect op de waarde van de geleverde 
zorg, in termen van resultaten, kosten en organisatorische inspanningen16. Momenteel voldoen de 
regelingen voor de nazorg aan de behoeften van borstkankerpatiënten suboptimaal17-19. Dit komt 
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eveneens naar voren in de literatuurstudie die is beschreven in hoofdstuk 9. In deze studie werd 
de preferentie-sensitiviteit van en de patiëntbetrokkenheid bij beslissingen rondom de borstkanker 
nazorg geëvalueerd. Tevens werd het potentieel voor het personaliseren van nazorg bij borst-
kankerpatiënten onderzocht. Dit betrof onderwerpen als surveillance (recidief dan wel secundaire 
borstkanker), vermindering van het recidiefrisico door anti-hormonale behandeling, consultaties in 
het kader van fysieke en psychologische (late) effecten, en verbetering van de kwaliteit van leven 
na borstkanker. Er werd vastgesteld dat borstkankerpatiënten momenteel niet altijd betrokken zijn 
bij beslissingen rondom de inhoud en de vorm van de follow-up die op hen van toepassing is, 
noch werd optimaal erkend dat patiënten voorkeuren hebben voor de manier waarop hun nazorg 
wordt ingericht. Beslissingen over poliklinische follow-up afspraken, anti-hormonale behandeling 
en symptomen van de menopauze werden niet preferentie-sensitief geacht. Beslissingen over 
borstreconstructies werden op hun beurt als zeer preferentie-sensitief beschouwd Bovendien wa-
ren patiënten meestal betrokken bij de besluitvorming over borstreconstructie. Deze bevindingen 
resulteerden in de aanbeveling om de nazorg voor borstkanker verder te personaliseren, omdat 
dit naar verwachting zal leiden tot zorg die van grotere relevantie en waarde is voor individuele 
patiënten.
Patiënten met borstkanker die een mastectomie ondergaan als onderdeel van hun behandeling, 
kunnen voor de, potentieel leven veranderende, vraag komen te staan al dan de borst te laten re-
construeren, en zo ja, wat voor reconstructie. Voor patiënten die radiotherapie krijgen om het risico 
op lokaal recidief te verminderen, wordt deze beslissing nog uitdagender. Zoals geïdentificeerd 
in hoofdstuk 9 werden beslissingen met betrekking tot borstreconstructie preferentie-sensitief 
beschouwd en waren borstkankerpatiënten meestal ook betrokken bij de besluitvorming rondom 
borstreconstructie. Gezien de enorme waarde die een borstreconstructie kan opleveren, namelijk 
het reconstrueren van een borst en het herstellen van het lichaamsbeeld van een vrouw en haar 
gezondheid gerelateerde kwaliteit van leven, zijn beslissingen met betrekking tot borstreconstruc-
tie van vitaal belang binnen borstkankerbehandeling. Om een  weloverwogen beslissing te kunnen 
nemen, is het cruciaal om volledig op de hoogte te zijn van de verschillende beschikbare methoden. 
Aangezien informatie over directe borstreconstructies (IBR, reconstructie ten tijde van de mastec-
tomie) algemeen beschikbaar is in Nederland20-22, deels als gevolg van systematische registratie 
van alle chirurgisch behandelde borstkankerpatiënten door de Nederlandse Kankerregistratie 
(NCR), ligt de focus in het laatste deel van dit proefschrift op uitgestelde borstreconstructies (DBR). 
Beslissingen met betrekking tot DBR worden vaker genomen nadat een mastectomie is uitgevoerd 
en kunnen daarom relevant blijven tot jaren na de initiële chirurgische procedure. In hoofdstuk 10 
werd gevonden dat DBR werd uitgevoerd bij ongeveer 10% van de patiënten die curatief werden 
behandeld met mastectomie voor stadium I-III borstkanker. Binnen dit cohort waren DBR-patiënten 
aanzienlijk jonger, meestal gediagnostiseerd met stadium-II borstkanker, met aanwezigheid van 
lymfekliermetastasen, werden ze behandeld met chemotherapie en/of radiotherapie en werden ze 
vaker behandeld in een perifeer (opleidings-)ziekenhuis. De gemiddelde tijd tussen mastectomie 
en DBR was 2,4 jaar (range 1 - 6 jaar). Adjuvante behandeling met radiotherapie of chemotherapie 
verlengde de tijd tussen mastectomie en DBR. Leeftijd onder de 50 jaar en chemotherapie werden 
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geïdentificeerd als voorspellende factoren, omdat ze de kans op DBR verhoogden. Implantaat-re-
constructies werden het vaakst uitgevoerd, gevolgd door autologe reconstructies. Wat betreft 
het effect van radiotherapie op het type DBR: in onze bestraalde subpopulatie had de grootste 
groep autologe reconstructies. De verkregen informatie kan nuttig zijn bij toekomstige gedeelde 
besluitvorming over reconstructieve opties voor borsten. Patiënten die worden geconfronteerd 
met beslissingen over reconstructieve borstoperaties kunnen veel baat hebben bij het perspectief 
van patiënten die een dergelijke procedures hebben gehad. Verder onderzoek is nodig om de trend 
van DBR in Nederland over de afgelopen jaren, de variatie in ziekenhuizen bij het uitvoeren van 
DBR na mastectomie en de voorkeuren van patiënten en chirurgen te identificeren. 
Mede dankzij het VBHC-initiatief is er een internationale trend naar meer gedeelde besluitvorming 
bij de behandeling van, onder andere, borstkanker. PROM-scores en voorkeuren van patiënten, 
zoals verkregen binnen dit proefschrift helpen ons bij het beheren en verbeteren van gezond-
heidsgerelateerde resultaten. Bovendien kunnen PROs bijdragen aan de evaluatie van de klinische 
relevantie van het ontwikkelen van predictie modellen. Verdere personalisatie van (na)zorg kan 
leiden tot zorg die van grote waarde is voor de individuele patiënt, en mogelijk zelfs leiden tot 
minder over- dan wel onderbehandeling. Echter, het moet worden benadrukt dat behandelings- en 
vervolgkeuzes moeten worden blijven gemaakt binnen de bewezen klinische richtlijnen.
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